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Introduction
At the beginning of a new life, one totipotent stem cell gives rise to the development of 
all kinds of tissues which ultimately form the human being. Later in life, multipotent stem 
cells maintain the normal turnover of regenerative organs, such as blood, skin and intestinal 
tissues. The key features of stem cells are that they have the ability to differentiate into 
diverse specialized cell types and can self-renew to produce more stem cells. Hematopoietic 
stem cells reside in the bone marrow and are necessary for maintaining the cellular 
components of the blood. The myeloid stem cell is the precursor cell for the erythrocytes, 
neutrophils, monocytes and platelets, the lymphoid precursor cell gives rise to B, T and NK 
cells [1]. 
Acute myeloid leukemia (AML) is a cancer of the white blood cells (WBC) in which myeloid 
precursor or stem cells transform into leukemic cells that display uncontrolled growth 
and lack of differentiation into mature cells. In case of AML, leukemic cells accumulate 
in the bone marrow and hamper the production of normal blood cells. This will result in 
low numbers of erythrocytes (anemia) and low numbers of platelets (thrombopenia) and 
hence increased risk of bleeding. Furthermore, reduction in the numbers of functionally 
normal neutrophils (neutropenia) is associated with an increased risk of infection. AML is 
a rare disease (2-3 per 100.000 men and women per year in the Netherlands); however, 
since its incidence increases with age and due to aging of the population, the incidence 
is increasing. If left untreated AML will result in death within weeks to months [2]. This 
aggressive nature warrants intensive treatment with high dose chemotherapy, such as 
cytarabine and anthracyclins such as daunorubicin [3]. After obtaining complete remission, 
that is, no more leukemic cells are detectable by morphology, additional (chemo)therapy is 
needed to prevent relapse of the disease. This so-called post remission therapy can include 
allogeneic stem cell therapy in poor prognostic cases. Complete remission is achieved in 
70-80% of patients below the age of 60. Unfortunately, despite intensive treatment, 30-40% 
overall survival rates are accomplished [4].
PART I: Classification of AML
Transformation of a normal myeloid progenitor cell into a malignant cell can happen at 
every stage of differentiation along the myeloid lineages. These differences in differentiation 
stages can be examined by morphology and define their subclasses, for example: minimally 
differentiated AML, acute myelomonoblastic leukemia and acute megakaryoblastic leukemia. 
In addition, classification based on chromosomal aberrancies indicates an acute leukemia 
as AML with recurrent genetic abnormalities. For instance, rearrangement of parts of 
chromosome 8 and chromosome 21 (called translocation t(8;21)) will result in the formation 
of a fusion protein: RUNX1-RUNX1T1 . Presence of RUNX1-RUNX1T1  classifies an acute 
leukemia as AML with recurrent genetic abnormalities and implicates a good chance for 
survival after treatment [5]. However, not all AML cases can be classified on morphology or 
chromosomal aberrancies. In that case classification is based on other cell specific features 
such as proteins present on the cell membrane or in the cytoplasm. Based on various 
combinations of these proteins, differentiation between maturation stage along the myeloid 
lineages can be made. Leukemic cells express different proteins compared with their non-
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malignant counterparts, the so called aberrant markers. For instance myeloid leukemias 
can express aberrant lymphoid markers such as CD7 or CD19. Even more, sometimes it 
is not clear-cut whether a particular leukemia originates from the lymphoid or myeloid 
lineage; these cases are called mixed phenotype acute leukemia (MPAL) [6]. For therapy 
decision making discrimination between the predominant lineage, myeloid or lymphoid, is 
necessary: acute myeloid leukemia warrants different treatment schemes compared to B 
and T lymphoblastic leukemia. However, for MPAL the predominant lineage preference is 
unclear. In PART I we discuss the role of immunophenotyping in diagnosing MPAL cases and 
we further investigate how new immunodiagnostic approaches might help in deciphering 
the myeloid or lymphoid lineage predominance of an acute leukemia of ambiguous lineage.
PART II: The immune system and AML
In general, both myeloid and lymphoid cells protect the human being against pathogens and 
tumor cells. To do so, cells of the immune system have the capacity to distinguish non-self 
antigens from self antigens. Cells of the innate immune systems recognize these non-self 
antigens in a generic, relatively non-specific manner, but do not induce long-lived immunity. 
Cells responsible for innate immunity are mainly derived from the myeloid lineage, for 
instance neutrophils and macrophages. For long-lived immunity, activation of cells of 
the adaptive immune system is necessary and involves activation of T and B cells. After 
recognition of a specific antigen, naïve B and T lymphocytes will transform into activated 
B and T cells. B cells transform into plasma cells which secrete antigen-specific antibodies; 
these antibodies function as flags for the other cells of the immune system, such as Natural 
Killer (NK) cells and granulocytes to clear away these target cells. In contrast to B cells, 
activated cytotoxic (CD8+) T cells, a subpopulation of T cells, are able to recognize and kill 
their target cells directly. Recognition of antigens by T cells also occurs in a specific manner: 
CD8+ and CD4+ T cells only recognize antigens presented by the Major Histocompatibility 
Complex (MHC) associated molecules which are found in most vertebrates; the human 
counterpart is called the human leukocyte antigen (HLA) molecule. HLA class I molecules are 
presented by all nucleated cells of the human body, HLA class II molecules can be found on 
antigen presenting cells (APC). Activation of T cells happens through APC, such as dendritic 
cells (DC), macrophages and B cells. APC are able to engulf infected cells (or part of cells) 
and present processed antigens onto their HLA class I and/or II molecules. Furthermore, 
APC have co-stimulatory molecules on their cell surface which ensure activation of CD8+ T 
and CD4+ T cells and subsequent outgrowth of memory/effector cytotoxic T cells or T helper 
cells, respectively. B cells and cytotoxic T cells receive help from a second group of T cells: 
CD4+ T helper cells. T helper cells are activated in more or less the same manner as CD8+ T 
cells; however, they recognize peptides presented in HLA class II molecules [7]. 
Presentation of antigens onto HLA class I molecules involves various steps: intracellular 
proteins are cleaved into peptides by the proteasome and these peptide fragments are 
transported by a transporter for antigen presentation (TAP) into the endoplasmatic reticulum 
(ER) where the peptide is bound to the HLA class I molecule. Via the Golgi apparatus the HLA-
peptide complex is transported to the cell surface (figure 1A). Presentation of extracellular 
antigens onto MHC class I happens through the cross presentation pathway, summarized 
in figure 1C. Loading of antigens onto HLA class II molecules involves a different pathway: 
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extracellular molecules such as antibody or complement-coated complexes or (particles 
from) dead cells are engulfed by the APC and processed to peptides en route through the 
endosomal/lysosomal pathway. The Invariant chain protein is necessary for transport of 
the HLA class II molecule into the ER and MHC class II compartments (MIIC). In the MIIC 
the Invariant chain is cleaved and a small remnant called Class II-associated invariant chain 
peptide (CLIP) remains in the binding groove of the HLA molecule. Subsequently CLIP is 
exchanged for an immunogenic peptide and presented by the HLA class II molecule onto 
Figure 1. HLA class I and II antigen presentation. In (A) HLA class I antigen loading is presented. 
Intracellular peptides are cleaved by the proteasome and then transported via the transporter of 
antigen presentation (TAP) into the endoplasmic reticulum (ER) and subsequently antigens are 
presented onto HLA class I. Presentation of extracellular antigens onto HLA class II (B) involves a 
different pathway. Exogenous antigens are processed through the endosomal/lysosomal pathway. In 
the Major Histocompatibility Complex class II compartments (MIIC) compartment the Invariant chain 
(li) –derived Class II-associated Invariant chain peptide (CLIP) peptide is exchanged for an antigen 
under influence of HLA-DM and presented on the surface. In (C) cross-presentation of exogenoous 
antigens onto HLA-class I is depicted
General introduction
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surface the antigen presenting cell (summarized in figure 1B). However, CLIP can remain 
in the binding groove and thus prevents presentation of antigenic peptides. This results 
in escape of recognition by CD4+ T helper cells; this immune escape mechanism and the 
role of CLIP on leukemic cells is discussed in PART II of this thesis and offers a target for 
immunotherapeutic strategies [8].
PART III: Cell based immunotherapy
Immunotherapy aims at generating an immune response directed against residual tumor 
cells which have escaped standard chemotherapy. Immunotherapy can be passive, e.g. 
antibody-based immunotherapy, or active, e.g. aimed at the in vivo induction of LAA-specific 
cytotoxic T cells and memory T and B cells. Activation of leukemia associated antigen (LAA)-
specific T cells is achieved by whole tumor cell-based anti-leukemia vaccination. In the 
1970s, the first cell-based vaccines were administered for the treatment of AML: patients 
received chemotherapy combined with a vaccine consisting of irradiated AML cells co-
administered with Bacillus Calmette-Guierin (BCG). In relation to the control group, addition 
of immunotherapy prolonged overall survival (545 vs. 303 days) [9]. However, compared to 
APC leukemic cells are poor inducers of immune responses due to lack of costimulation and 
inadequate antigen presentation. In an attempt to enhance the immunogenicity of leukemic 
cells, these can be cultured into leukemic cell-derived DC. Another option is to culture 
monocytes into DC and load these with for instance LAA-derived peptides or lysates from 
leukemic cells. For the development of new immunotherapeutic strategies it is essential to 
optimize the AML vaccine preparation of choice. In PART III of this thesis we discuss the role 
of DC preparation, antigen loading and subsequently compare the function of various DC in 
order to identify the most efficacious DC preparation methodology for immunotherapeutic 
purposes. 
Conclusion
In summary, in this thesis we exploit the additional value of immunologic methods for 
diagnosing AML and ALL with overlapping features i.e. MPAL. In addition, we investigate the 
biology of immune-escape mechanisms involved in antigen presentation by AML cells and 
exploit the role of immune modulation via DC for the immunotherapy of AML. These three 
pillars might be of importance in the understanding and subsequent further development 
of new emerging immunotherapeutic strategies for AML.
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Abstract
Acute leukemias (AL) can be categorized as myeloid AL (AML), B lymphoblastic or T 
lymphoblastic leukemia (B- or T-ALL) based on predominance for the myeloid, B- or 
T- lymphoid lineage respectively. In about 4% of AL it is not clear whether an AL should 
be diagnosed as AML, B- or T-ALL. Those leukemias with both lymphoid and myeloid 
characteristics were classified as bilineal or bi-phenotypical AL according to the WHO 
criteria from 2001. In 2008 the WHO published new criteria for diagnosing a leukemia with a 
mixed phenotype. These changes contain some major changes in the classification of MPAL; 
the impact of the WHO2008 guidelines is reviewed here. Furthermore, we discuss some 
advances in recent diagnostic tools. 
Introduction
Acute leukemias (AL) are classified according to commitment to the lymphoid or myeloid 
lineage. For differentiation between these two lineages immunophenotyping plays an 
important role. Using a flow cytometer cell specific features such as proteins present on 
the cell membrane or in the cytoplasm can be visualized. These proteins can be identified 
by monoclonal antibodies; the latter are grouped  as so-called clusters of differentiation (or 
clusters of designation, CD) which is an internationally used nomenclature for antibodies. 
For instance, CD34 is an antibody that recognizes a cell surface glycoprotein which functions 
as a cell to cell adhesion factor and is found on progenitor cells. Some antibodies (more 
frequently called markers) are often used for identification of various stages of differentiation 
and are summarized in figure 1 for the lymphoid lineage and in figure 2 for the myeloid 
lineage. After labelling of cells in vitro with different fluorescent labelled antibodies, the 
phenotype of cells can be analyzed using a flow cytometer. This technique allows analysis of 
various different antigens on an individual cell. 
In about 4% of AL it is unclear whether an AL should be classified as an acute myeloid 
leukemia (AML) or a precursor lymphoblastic leukemia (throughout this thesis abbreviated 
as ALL). The latter being devided in precursor B- and T-neoplasms. In the WHO criteria 
from 2001 AL with both lymphoid and myeloid characteristics are classified as bilinear 
or biphenotypical AL. Acute bilinear leukemia (aBLL) consist of AL with two (or more) 
separate blast populations with different cell lineage commitment. Biphenotypical AL 
(BAL) is classified when a single blast population is present with expression of antigens 
of different cell lineages. The prognosis of BAL or aBLL is worse compared with AML or 
ALL. This difference in prognosis can partly be explained by presence of the Philadelphia 
chromosome or complex chromosomal aberrancies [1]. Furthermore, extramedullary 
disease is more often present in aBLL or BAL compared to AML or ALL. As a consequence of 
the worse prognosis more intensive treatment might be necessary in case of BAL or aBLL. 
Furthermore, it is unclear whether BAL benefit from an AML or ALL-based (intensified) 
treatment protocol; this partly explains their unfavorable prognosis. [1-10] To unravel these 
questions randomised studies are warranted. Moreover, it is necessary that these studies 
are based on a uniform international classification system. Until 1995 no guidelines for 
classification of BAL or aBLL were available. With the development of the EGIL (European 
group for the immunological classification of AL) criteria clear guidelines were provided 
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Figure 1. Hypothetic scheme of differentiation of the lymphoid lineage in central lymphoid organs, 
including the thymus and peripheral lymphoid organs.  “++” strong expression, “c” cytoplasmic, “s” 
surface, eff: effector, mem: memory
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Figure 2. Hypothetic scheme of differentiation of the myeloid lineage in bone marrow, peripheral 
blood and tissues. “++” strong expression, “c” cytoplasmic, “s” surface, cMPO: cytoplasmic 
myeloperoxidase
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for immunophenotypical classification of aBLL or BAL which were in 2001 adopted in the 
WHO2001 guidelines for the classification of haematopoietic malignancies [11;12]. In 2008 
the adjusted WHO guidelines for diagnosis of haematopoietic and lymphoid malignancies 
were published [13]. The changes which these guidelines entail for diagnosis of AL with 
myeloid and lymphoid characteristics are reviewed here.  
Biphenotypical acute leukemia according to EGIL 1995 
and WHO 2001
Based on presence of immunological markers the EGIL group proposed criteria for 
differentiation between different cell lineages of AL [11]. Beside blast-like features such as 
presence of CD34 and diminished expression of CD45 (CD45dim), at least two early B cell 
lineage markers have to be present for classification of a B-ALL, for instance cytoplamsic IgM 
(cIgM), cytoplasmic CD22 (cCD22) or cytoplasmic CD79a (cCD79).  A T-ALL is defined based 
on presence of cytoplasmic or surface CD3 (cCD3 or sCD3) expression. An AML is classified 
based on expression of at least two of the following markers: cytoplasmic myeloperoxidase 
(cMPO), CD13, CD33, CD65 or CD117; from these cMPO has the highest cell lineage specificity. 
For determining a marker as positive at least 20% of blasts are required to express a marker. 
For cCD79a, sCD3, cCD3, cMPO and cTdT a lower cut-off of 10% is used, when confirmed by 
light microscopy. However arbitrary, in clinical practice this cut-off of 10% is used without 
confirmation by light microscopy [8]. 
Table 1. Scoring system based on the criteria of the EGIL working party for the definition of 
biphenotypical acute leukemia (BAL)*  
Points# B cell lineage T cell lineage Myeloid lineage
2 Cytoplasmic CD79a T cell receptor α/β Cytoplasmic MPO 
Cytoplasmic IgM T cell receptor γ/d 
Cytoplasmic CD22 CD3 (cytoplasmic or 
surface expression)
1 CD19 CD2 CD13
CD10 CD5 CD33
CD20 CD8 CD65
CD10 CD117
0,5 Cytoplasmic TdT Cytoplasmic TdT CD14
CD24 CD7 CD15
CD1a CD64
* A BAL is defined when more than 2 points for two cell lineages are present
# Every marker is scored according to the corresponding points when >20% 
positivity is found on the blast population; for cytoplasmic MPO, cytoplasmic CD79a, cytoplasmic TdT 
and cytoplasmic and surface CD3 a cut-off of 10% can be used when confirmed by light microscopy. 
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For diagnosis of aBLL, the WHO2001 proposed that at least two or more different populations 
should be present with expression of differentiation markers as defined for an AML or 
ALL. When one leukemic blast population expresses markers from different cell lineages 
differentiation between a BAL or AML or ALL with aberrant marker expression is necessary. 
The EGIL working party proposed a scoring system based on cell lineage specificity of 
various markers expressed on one blast population (table 1) [11;14]. An AL is considered a 
BAL when more than 2 points are scored for two different cell lineages.
Until 2000, CD117 was scored as 0.5 points, in that year it was changed to 1 point because 
of demonstrated higher specificity for the myeloid lineage[15;16]. The EGIL and WHO2001 
criteria offered a clear and simple basis for the diagnosis of BAL and aBLL and thus offered a 
uniform basis for research of treatment and prognosis. 
Limitations of the EGIL 1995 and WHO 2001 guidelines
Within the EGIL scoring system many different combinations of markers are possible and 
hence give rise to a heterogeneous group of BAL. Furthermore, some combinations of 
markers are less specific for BAL: a pro-B-ALL with MLL translocations often aberrantly 
express CD15, CD65, CD13, CD33. Furthermore, cCD79a expression is often observed in 
case of T-ALL. Another point of criticism is that the EGIL criteria have not implemented 
expression levels of various markers: for instance brighter expression of CD19 is considered 
more specific for the B cell lineage [8;17;18].  Moreover, various laboratories use different 
combinations of markers and often exclude some markers as proposed by EGIL, resulting 
in discrepancies in classification. Consequently, the WHO2008 guidelines provided revised 
criteria based on a shortened panel of markers and included new subgroups of acute 
leukemias based on cytogenetic changes. These WHO2008 guidelines provide the most 
recent criteria for classification of AL of unknown origin [19].
Biphenotypic acute leukemia according to the 
WHO2008: mixed phenotype acute leukemias
In the WHO2008 guidelines, no clear immunological criteria are provided for classification 
of a T-ALL, B-ALL or AML. Presence of myeloid markers combined with absence of lymphoid 
markers is sufficient for the diagnosis of an AML. Likewise, when lymphoid markers are 
present on blasts and myeloid markers are absent an ALL can be diagnosed. An AL 
unclassifiable can be considered when no cell lineage-specific markers are detected on blast 
cells (often CD34, CD38 and HLA-DR positive). The WHO2008 does not discriminate between 
bilinear leukemia and biphenotypic AL; both are classified as mixed phenotype AL (MPAL). 
When two different populations of leukemic cells are present with both clear different 
myeloid or lymphoid lineages (aBLL according to EGIL) this is sufficient for diagnosing a 
MPAL. When one population of blasts is present with combined expression of B-lymphoid, 
T-lymphoid or myeloid markers the WHO2008 has clear requirements for classification of 
MPAL (summarized in table 2). For the myeloid component of a MPAL expression of cMPO 
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is necessary; in contrast to the EGIL criteria, a combination of CD13, CD33 and CD117 is not 
sufficient to indicate myeloid restriction. Furthermore, when cMPO is absent but there is 
clear monocytoid differentiation (based on expression of two or more markers: being non 
specific esterase (NSE), CD11c, CD14, lysozyme or CD36) the myeloid component may be 
scored positive. For the T cell lineage expression of cytoplasmic or surface CD3 is sufficient 
when taking into account that the expression is as high as or higher than the non-malignant 
T cells of the patient. Whereas for the T cell and myeloid lineage, expression of solely 
CD3 and cMPO, respectively, is sufficient, for the B cell lineage expression of at least two 
markers is necessary. One of these markers should be CD19, combined with CD10 cCD22 
and/or cCD79a. Only one exception is made: when cCD22, cCD79a and CD10 are present in 
combination with the myeloid/T cell markers, a MPAL may be considered [19]. 
Limitation of the WHO 2008 classification of acute 
leukemias of unknown origin. 
Interestingly, the WHO2008 criteria did not include cut-off criteria for the various markers. 
Since intracellular markers such as cMPO and cCD3 are quite cell lineage-specific it can be 
hypothesized to maintain the 10% cut-off for these markers [8;11].  To diagnose a MPAL 
or AL unclassifiable, immunohistochemic and immunophenotypic analysis is necessary. Of 
note, NSE and lysozyme are essential to demonstrate commitment to the myeloid lineage 
but are not commonly used in flow cytometric analysis. Moreover, some phenotypes are 
not easily assigned to MPAL, AML or ALL.
 
Table 2. WHO 2008: requirements for diagnosing a mixed phenotype acute leukemia
B cell linage * T cell lineage * Myeloid lineage *
Strong expression$ of CD19 
combined with strong 
expression$ of:
Cytoplasmic CD22, CD10 or
Cytoplasmic CD79a
Strong expression$ of CD3 
(cytoplasmic or surface 
expression)
 Expression of MPO
or or
weak expression# of CD19 with 
strong$ expression of at least two 
of the following markers:
cytoplasmic CD22, CD10 όr 
cytoplasmic CD79a
Presence of monocytic 
differentiation as defined 
by presence of at least two 
monocytoid markers: CD11c, 
CD14, CD36, CD64, lysozyme 
or non specific esterase (NSE)
* A MPAL is defined when the blasts meet the criteria of two or more lineages as described in the 
table. 
$ Strong expression is defined when expression of the marker is as high or higher than the non-
malignant T or B cells in the patient’s samples
# Weak expression is defined when expression of the marker is lower than the non-malignant B cells 
in the patient’s samples. 
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 Furthermore, an AL that does not meet all criteria for an undifferentiated AL but shows 
markers from different maturation lineages, are not easily classified by the WHO2008 
criteria (these are by definition negative for cMPO, cCD3, cCD22, cCD79a and CD19). For 
instance, it is unclear how AL with expression of CD19 (diminished), cCD79a, CD33, CD13, 
CD11c, CD117 and absence of cMPO and CD34 should be classified (table 4). According to 
the EGIL criteria it is plausible to classify these AL as BAL.  
Exceptions to immunological classification of MPAL by 
WHO 2008
By the WHO2008 all AL that can be classified as AML or ALL based on molecular, cytogenetic 
or clinical features are excluded from the diagnosis MPAL. For instance an AL with t(8;21); 
t(15;17) or inv(16) are classified as AML by definition and are thus excluded from MPAL 
[20]. Furthermore, AL with FGFR1 mutations, CML blast crises, AL with MDS prephase and 
therapy-related AL cannot be classified as MPAL. 
Subclassification of MPAL
Next to immunophenotypic guidelines for AL with mixed phenotype, the WHO2008 provides 
further classification based on cytogenetics. Some translocations known to be commonly 
present constitute different subgroups of MPAL, for instance: MPAL with t (9;22)(q34;q11.2) 
(without CML pre-phase) and MPAL positive for the MLL gene. Besides these, many other 
genetic aberrancies have been described in combination with a MPAL phenotype as yet. 
However, these genetic aberrancies are not commonly present and cannot provide further 
classification of subclasses. The classification of MPAL according to the WHO2008 is 
summarized in table 3. 
Table 3: Classification of MPAL
MPAL B cell/Myeloid (B/My), Not Otherwise Specified (NOS)
MPAL T cell/Myeloid (T/My), NOS
MPAL with t(9;22)(q34;q11.2), excluded are blast crises with presence of pre-phase of CML
MPAL with (11q23)MLL
MPAL NOS, rare subtypes:
> MPAL with T and B cell characteristics (MPAL T/B)
> MPAL with characteristics of three lineages (T/B/My)
> MPAL with megakaryocytic characteristics (B/ or T/megakaryocytic leukemia)
> MPAL with erytroblastoid characteristics (B/ or T/erytroleukemia)
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Consequences of implemantation of the WHO2008
There are interesting differences between the BAL/aBLL according to WHO2001 and 
classification of a MPAL according to the WHO2008. A T/My or a B/MY BAL negative for 
(cytoplasmic) CD3, CD19 or cMPO cannot be classified as MPAL. Expression of cMPO or 
(cytoplasmic) CD3 is now sufficient for the myeloid or T cell lymphoid component of a MPAL. 
An AL with expression of cMPO and CD19 can be classified as a B/My MPAL depending on 
the expression of cCD22 cCD79a and CD10. In table 4 some illustrating examples are shown 
of differences in classification of a BAL/aBLL or a MPAL in clinical practice [21].
Furthermore, the cut-off for marker positivity (20% according to the WHO2001) is left 
open for interpretation in the WHO2008. Recently, we demonstrated that a cut-off of 10% 
for cMPO could be used independently from results of sudan black B (SBB) staining in 
deteminating the myeloid or lymphoid predominance according to the WHO2008 guidelines 
[22]. These ambiguities in the WHO2008 might impede further research for the treatment 
and prognosis of MPAL. 
Recently, a large retrospective study was published reviewing survival and different 
treatment schemes in 100 cases classified as MPAL. In these 100 MPAL the poor prognosis 
was confirmed however largely influenced by the Philadelphia positive subgroup of patients. 
Interestingly, treatment according to ALL protocols resulted in a favourable outcome, 
however these results were not correlated with different subgroups of MPAL as proposed by 
WHO2008 [23]. In conclusion, it would be highly favourable and a great challenge due to low 
frequency of AL with combined myeloid and lymphoid features, to prospectively validate 
the clinical impact of the WHO2008 compared with the WHO2001.
Table 4. Some examples of showing the differences in classification by the WHO 2001 and WHO2008
WHO2001 WHO 2008
AL positive for : cMPO, CD13, CD33, cCD79a, CD10 BAL AML
AL positive for: cMPO, CD33, CD13 and CD19strong, CD10 AML MPAL
AL positive for: cMPO, CD13, CD19(weak), CD10, cTdT BAL AML
AL positive for: CD19(weak), cCD79a, CD33, CD13, CD117 BAL Not classifiable
AL positive for: cCD3(strong), cMPO, cTdT T-ALL MPAL
Alternative classification strategies for acute leukemias 
of unknown origin
Classification of acute leukemias is based on different diagnostic tools: cytomorphology, 
flow cytometry, immunohistochemistry, cytogenetic analysis and molecular analysis. Yan 
et al. recently analyzed 117 MPAL cases for clinical, immunophenotypic, cytogenetic, and 
molecular genetic features and concluded that MPAL constitutes as a heterogenous group 
[24]. Thusfar, immunophenotypic analysis is the hallmark for identification of MPAL cases. 
However, the immunophenotype of acute leukemias is merely a limited reflection of the 
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genotypic state. Consequently, gene array or miRNA analysis might add to differentiating 
between AML, ALL or MPAL. Gene expression profiling on thirteen pediatric MPAL cases 
revealed that 5 cases clustered with AML; the rest constituted a separate entity, however, 
very close to B-ALL [25]. This suggest that some of the pediatric leukemias of ambiguous 
lineage assembly a separate entity. However, one could argue that these cases constitute a 
subtype within B-ALL since this separate group clustered very close to the B-ALL. In contrast 
to gene expression profiling, MiRNA expression profiling has shown to be more successful 
in the classification of tumors [26]. Furthermore, miRNA expression profiles can accurately 
discriminate AL of the lymphoid lineage from AL of the myeloid lineage [26-28].  Therefore, 
we recently evaluated the role of miRNA expression profiling for differentiation between 
MPAL, B-ALL, T-ALL and AML. Interestingly, the MPAL/BAL cases (n=15) did not segregate as 
a separate entity but showed microRNA expression profiles similar to that of either AML, 
B-ALL or T-ALL. This indicates the presence of a lineage specific genotype despite their mixed 
lineage immunophenotype. 
Conclusion
Based on cytogenetic aberrancies risk profiles have been developed which determine 
whether or not a patient needs an intensified treatment scheme. Ultimately, a personalized 
treatment should be based on the features of the leukemic cells as assessed by for instance 
gene arrays and may differ per patient. These developments in diagnostic procedures might 
be applied onto leukemias of unknown origin: gene or miRNA arrays might offer a more 
accurate classification method and differentiate more precisely between ALL, AML or truly 
MPAL than currently applied diagnositic tools such as immunophenotypic analysis. These 
techniques might add to the classification of MPAL in the future and thereby aid treatment 
decision making.
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Uncommon lineage switch warrants 
immunophenotyping even in relapsing 
leukemia
Introduction
Despite intensive treatment, 60% of adult patients with T-cell acute lymphoblastic leukemia 
(T-ALL), experience a relapse of the disease [1]. In the majority of cases this is due to the 
outgrowth of the initial T-ALL clone from minimal residual disease [2]. However, the induction 
of secondary acute myeloid leukemia (AML) by previous chemotherapeutic treatment, such 
as etoposide, has been described in about 5–7% of the cases at relapse, generally more than 
2 years after the initial diagnosis. In most of the cases specific chromosomal abnormalities 
are present, which were not present at diagnosis [3-4]. Alternatively, relapses with complete 
lineage switches can occur. This has been proposed to be the result of the outgrowth of an 
undifferentiated leukemic stem cell, the result of the preferential outgrowth of a minor AML 
subclone present at diagnosis or the result of therapy [5-10]. In general, the morphology 
of the leukemic cells at relapse suggests a switch from ALL to AML. The patient described 
here showed a complete immunophenotypic switch, which was not considered because 
of similar morphology and chromosomal abnormalities at relapse and at diagnosis. In 
view of the increasing use of monoclonal antibodies in the treatment of acute leukemia, 
immunophenotypic investigation of leukemic cells at diagnosis and relapse will be of 
importance in clinical practice [11-12].
Case
A 20-year-old man was admitted to the hospital with recurring and antibiotic-resistant 
paronychia. He experienced a 25-kg weight loss in the preceding 3 months and complained of 
night sweats and fever. His medical history was unremarkable. Physical examination revealed 
paronychia of two toes and enlarged tonsils. There were no signs of lymphadenopathy, 
hepatosplenomegaly nor gingival hyperplasia. Laboratory investigations revealed an elevated 
lactate dehydrogenase (690 U/l; normal values 0–250 U/l) and a decreased hemoglobin 
level (6.8 mmol/l; normal values 8.5–10.5 mmol/l). The total leukocyte count and platelet 
count was normal. In the differential count, 70% blasts were found. By light microscopy, 
the blast cells were stained negative for Sudan black with many hand mirror cells (figure 
1A). Flow cytometric analysis showed blasts (CD34+) of lymphoid origin (cytoplasmic CD3+ 
(cCD3), CD5+, CD2+, cTdT+, CD7+, CD3−, CD1a−, CD10−, cMPO−, CD33−, CD117−, CD19−), with 
aberrant expression of CD56 and weak expression of CD13 (figure 2A). Based on morphology 
and immunophenotyping the diagnosis of a precursor T-cell acute lymphoblastic leukemia 
(T-ALL) was made according to WHO 2001 criteria. Cytogenetic analysis of bone marrow 
cells revealed a complex karyotype 52, XY, +?X, +8, +10, +11, +13, +19 [11]; 46, XY [9]. FISH 
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analysis performed with the LSI MLL-probe (Vysis) confirmed the presence of trisomy 11 by 
detecting 3 copies of the MLL-gene in 75% of 200 cells analysed. No molecular aberrancies 
could be detected by PCR. A lumbar puncture showed no localization of T-ALL.
The patient was treated according to a current Dutch ALL protocol (HOVON 70; figure 3). 
As no HLA-identical sibling was available he proceeded to maintenance therapy following 
induction and consolidation therapy, resulting in a complete remission. After nine months 
of maintenance therapy, 21 months after initial presentation, a relapse occurred. A bone 
marrow aspiration showed 91% Sudan black negative blasts with morphological features 
similar to diagnosis (figure 1B). Cytogenetic analysis showed an identical abnormal 
karyotype as compared at diagnosis. Molecular investigations (PCR) revealed no t(8;21) 
and FISH analysis showed trisomy 11 by MLL-gene analysis in 88% of the cells. Remarkably, 
the immunophenotype of the cells was completely switched from a lymphoid to a myeloid 
Figure 1. Morphology of leukemic cells at diagnosis and relapse. (A) Bone marrow and peripheral 
blood May-Gruenwald Giemsa (MGG) staining at diagnosis of T-ALL. (B) Bone marrow MGG and Sudan 
black staining of AML at relapse.
A
B
Chapter 3
34
phenotype (CD117+, CD33+, CD13+, CD56+, cMPO−, cTdT−, CD7−, cCD3−, CD2−, CD5−, CD19+, 
figure 2B). AML was diagnosed following the WHO criteria. With the intention to perform 
an allogeneic stem cell transplantation with a matched unrelated donor, reinduction 
chemotherapy was initiated with high dose cytarabine (1000 mg/m2 tid for 4 days) and 
etoposide (120 mg/m2 oid for 4 days). Since no remission was reached, the patient 
subsequently underwent an autologous stem cell transplantation after treatment with high 
dose melphalan (200 mg/m2) [13]. Unfortunately, no remission was reached and he died 9 
months after diagnosis of relapse due to the complications of longstanding pancytopenia.
Discussion
True lineage switches from T-ALL to AML in adolescents and adults are rare [5-7, 9, 14-16]. In 
a few of these cases, like in our case, both lymphoid and myeloid blast appeared to originate 
from one clone, as shown by an identical karyotype of the malignant cells [5-9].
Figure 2. Immunophenotype of leukemic cells at diagnosis and relapse. (A) Immunophenotypic 
analysis of the T-ALL cells in bone marrow at diagnosis. A small myeloid subclone is encircled. (B) 
Immunophenotype of the myeloid cell population in peripheral blood at relapse. 
B
A
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Different hypotheses have been proposed for the occurrence of a lineage switch of clonally 
related cells in acute leukemia. It has been suggested that chemotherapy can induce 
changes in the differentiation program of the leukemic stem cell followed by switch of 
marker expression, while retaining its cytogenetic aberrancies [15, 17]. Interestingly, the 
group of Kurtzberg et al. described the occurrence of a lineage shift already 7 days after 
chemotherapy treatment with adenosine deaminase inhibitor 2´-deoxycoformycin. Because 
of the immature lymphoid phenotype (CD7+, CD4− and CD8−) and the rapid lineage switch, 
they hypothesized that the patient had a leukemia of a pluripotent stem cell that was 
capable of multilineage differentiation [8]. This outgrowth of an undifferentiated stem cell 
clone, could be confirmed in eight patients, from whom in vitro cultures of leukemic blasts 
gave rise to morphologically and immunophenotypically distinguishable progenitors of 
the myeloid, erythroid, megakaryocytoid, eosinophil, monocytoid, and lymphoid lineages 
independent of exposure to exogenous growth factors [18]. This is supported by the finding 
that in T cell leukemias with a CD7+, CD4−, CD8− and CD1− phenotype a stem cell phenotype 
can be determined defined as absence of both cCD3 and cMPO expression [19]. Additionally, 
in some of these patients a mixed lineage cell type could be determined, expressing both c
CD3 and cMPO. Accordingly, more recently it has been described that early thymic 
progenitor cells possess both T-cell as well as myeloid differentiation potential [20-22]. After 
discovery of this early immature phenotype (CD7+, CD4−, CD8− and CD1−) in ALL, these cases 
Figure 3. ALL treatment according to the Dutch standard protocol HOVON 70.
Week 1 Pre-phase Prednisone 60mg/m2 
Week 2-5 Induction Prednisone 40mg/m2; Vincristine 1.5mg/m2 (max 2.0); 
Daunorubicin 40mg/m2; Cyclophosphamide 1000mg/m2; 
Asparginase 6000IU/m2; Methotrexate intrathecal; 
Week 5-9 Consolidation A Thioguanine 60mg/m2; Cyclophosphamide 1000mg/m2; 
Cytarabine tid 30mg/m2; Methotraxate intrathecal 
Week 10-13 Consolidation B Prednisone 40mg/m2; 6-Mercaptopurine 50mg/m2;      
Vincristine 1.5mg/m2 (max 2.0); Methotrexate 5000mg/m2 
Week 14-17 Intensification IA Dexamethasone 10mg/m2; Vincristine 1.5mg/m2 (max2.0); 
Adriamycine 25mg/m2; Asparginase 6000IU/m2; 
Methotrexate intrathecale 
Week 18-21 Intensification IB Thioguanine 60mg/m2; Etoposide 150mg/m2; 
Cytarabine tid 30 mg/m2; Methotrexate intrathecale 
Week 22-25 Interphase A Predinsone 40mg/m2; Vincristine 1.5mg/m2 (max 2.0); 
6-Mercapthopurine 50mg/m2; Methotrexate 5000mg/m2
Week 26-29 Interphase B Prednisone 1dd 40mg/m2; 6-mercatopurine 50mg/m2; 
Vincristine 1.5mg/m2 (max 2.0); Methotrexate 5000mg/m2
Week 30-33 Intensification IIA Prednisone 40mg/m2; Vincristine 1.5mg/m2 (max2.0); 
Daunorubicin 30mg/m2; Asparginase 6000IU/m2; 
Methotrexate intrathecal 
Week 34-37 Intensification IIB Thioguanin 60mg/m2; Cyclophosphamide 1000mg/m2; 
Cytarabine tid 30mg/m2; Methotrexate intrathecal 
Week 38-104 Maintenance 
therapy 
6-mercaptopurine 75mg/m2 (daily);  
Methotrexate 25mg/m2 (weekly) 
Week 38-104 Re-induction Prednixone 40mg/m2 (monthly);  
Vincristine 1.5mg/m2 (max2.0) (monthly)
Chapter 3
36
were classified as immature T-ALL or T-stem cell leukemia [23]. Our patient also showed an 
immature T lymphoid phenotype: CD7+, CD4−, CD8− and CD1a− at initial diagnosis. At relapse 
this changed into an immature myeloid phenotype: CD34+, CD117+, CD13+, CD33+, CD19+, 
cMPO−, and CD7−. Therefore, also in our case it can be hypothesised that under pressure of 
anti-lymphoid-leukemia directed therapy, an undifferentiated stem cell clone grew out as a 
myeloid relapse. On the other hand, in retrospect, we found a small population of CD34high 
cells of 1.2% in the CD45dim population at initial presentation (with possible co-expression of 
CD117, CD33 and CD19). 
This population differed from the normal pre-B cells, which were brighter CD19 positive, 
lower in their CD34 expression and low in forward/side scatter compared to the CD34high 
population. Consequently, it can also be considered that a malignant population of myeloid 
blasts was already present at initial presentation (figure. 2A). Unfortunately, due to lack of 
material we were not able to classify this small population as myeloid malignant at diagnosis 
and therefore as bi-linear. In bi-lineage leukemias the therapy would have been directed 
towards the major population. Since the detected population in our patient covered only 
1% of the total amount of blasts, the therapy would have been similar. However, in case 
of bi-linear leukemia, regular immunophenotyping to determine the immunophenotype of 
residual disease might indicate the need for therapy switches. A recent case of AML which 
relapsed as a T-ALL was described in which evidence was gained for a small T-cell clone at 
initial presentation with similar cytogenetic aberrancies.
In conclusion, we showed that a complete switch of immunophenotype can occur, while 
both morphology and cytogenetic features remain identical to the disease at diagnosis. In 
view of the increasing use of monoclonal antibodies this will be of importance in clinical 
practice. In this case anti-CD33 could have been an option in complementing standard 
high doses chemotherapy in conditioning treatment before unrelated matched stem cell 
transplantation. This case emphasizes the clinical importance of flow cytometric analysis at 
any relapse in patients with acute leukemias.
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Challenging diagnosis in a patient with clear 
lymphoid immunohistochemical features 
and myeloid morphology: mixed phenotype 
acute leukemia with erythrophagocytosis
Introduction
Acute leukemia (AL) is classified according to commitment towards either the myeloid or 
lymphoid cell lineage. In about 4% of acute leukemias it is unclear whether the blasts are 
of myeloid or lymphoid origin. These AL with both myeloid and lymphoid characteristics 
represent a worse prognostic subgroup and it is still a matter of debate whether patients 
may benefit from an acute lymphoid leukemia (ALL) or acute myeloid leukemia (AML) 
treatment. In the WHO2008 criteria for defining mixed phenotype acute leukemia (MPAL), 
important changes have been made in defining cell line specific and characterizing markers 
in AL as compared to European Group for the Immunological Characterization of Leukemias 
(EGIL) criteria incorporated in the WHO2001. In the WHO2001 criteria a weighted points 
system is used for defining a Biphenotypic Acute Leukemia (BAL) to be Myeloid, B- or T-cell. 
In this scoring system at least one additional lineage defining marker for both lineages was 
necessary to diagnose a BAL. In the WHO2008 an AL expressing both myeloperoxidase 
(MPO) and CD19, can be considered as a MPAL (B/Myeloid) depending on expression of 
either cCD79a, CD10 or cCD22. Furthermore, the WHO2008 excludes AL with well-defined 
cytogenetic or clinical presentations from MPAL. For example, AL with t(8;21); t(15;17) or 
inv(16) are classified as AML, independent of their immunophenotypic marker expression 
[1-3]. Here we describe a case in which cytochemistry showed Sudan Black B (SBB) negative, 
vacuole rich, leukemic blasts with a monocytoid appearance and erythrophagocytosis. 
Remarkably, flow cytometric analysis and immunohistochemistry showed clear expression 
of B cell markers and weak cytoplasmic (c)MPO. This unique case demonstrates the 
challenges in diagnosing an AL with ambiguous morphologic, immunohistochemical and 
flow cytometric characteristics.
Case
A 65-year-old woman was admitted to the hospital with general discomfort and a fever 
of 2-week duration. She experienced a weight loss of 9 kg in the preceding month and 
complained of night sweats. Her medical history revealed diabetes mellitus type II, atrial 
fibrillation, a psychosis and a former drug addiction. Physical examination did not show 
relevant findings. Laboratory investigations revealed an elevated lactate dehydrogenase 
(948 U/l; normal values 0–250 U/l), leucopenia (2.0 × 109/l; normal values 4.0–10 × 109/l), 
thrombocytopenia (18 × 109/l; normal values 150-400 × 109/l) and a decreased hemoglobin 
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Figure 1. Morphology of leukemic cells at diagnosis (1000×). Bone marrow May-Grünwald Giemsa 
(MGG) staining of bone marrow smears at diagnosis: example of clear vacuole-rich blast cells (A), 
Sudan Black staining (B), arrow indicates erythrophagocytosis by blasts cells (C).
level (4.8 mmol/l or 7.7 g/dl; normal values 7.5–10.0 mmol/l or 12.1–16.1 g/dl).
Morphological peripheral blood (PB) examination revealed anisocytosis, polychromasia, 
dyserythropoiesis, dysgranulopoiesis and the presence of monocytoid leukemic blasts 
(60%) with pronounced vacuolization (figure 1A). The leukemic blasts stained negative for 
SBB (figure 1B). The bone marrow (BM) smear showed 64% blasts and a normal erythroid- 
and megakaryocytic lineage. Remarkably, erythrophagocytosis was observed in 4% of the 
leukemic blasts (figure 1C).
By flow cytometry two blast populations could be distinguished based on sideward scatter 
(SSC), CD45 and CD34 expression (figure 2). The largest population (97% of the total amount 
of blasts) was CD45 dim/neg, had a higher CD34 expression and an intermediate SSC. This 
population was positive for CD19, CD20, CD22, cCD79a and cTdT. Furthermore, these cells 
stained weakly for MPO and showed an over expression of CD90. The monocytic markers 
CD14 and CD36 were negative (data not shown). The smallest population (3% of the total 
amount of blasts) was CD45 positive, had a slightly lower CD34 expression and a low SSC. 
These blasts showed positivity for the following markers: CD13, CD117, CD33 and negativity 
for cMPO, CD19, CD10, CD20, CD22, cCD79a and cTdT. This population most likely resembled 
the normal myeloid blast compartment. 
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Figure 2. Immunophenotype of leukemic cells. Immunophenotype of leukemic cells analyzed with 
Infinicyt software (Cytognos, Salamanca, Spain). Plot A and B represent gating strategy for the two 
different blast populations. Plots C–I represent marker expression on the two populations.
Immunohistochemical analysis of the trephine biopsy revealed a hypercellular marrow with 
approximately 50% blast cells. The blasts were variable in size and showed irregular nuclear 
morphology with fine chromatin, small nucleoli and occasionally multi-lobulation. The cells 
stained positive for CD34, cTdT, CD20 and cCD79a, and also showed a weak staining for 
cMPO. A normal female karyotype (46,XX) in 20/20 cells was present while no molecular 
aberrancies could be detected (PCR or FISH for t(15;17), t(8;21), inv(16), t(9;22), t(10;17), 
MLL abnormalities, and FLT3-ITD were all negative).
To summarize, this patient presented with an AL with monocytoid morphology, 
erythrophagocytosis and a clear B-lymphocytic marker expression combined with positivity 
for cMPO in both flow cytometry and immunohistochemistry. Based on the combined marker 
expression of cCD79a, CD19, CD20 and cMPO, this patient was diagnosed as a MPAL (B/
Myeloid) according to the WHO2008 criteria. She was treated with AML like chemotherapy 
combined with intrathecal methotrexate prophylaxis resulting in complete remission (CR). 
Unfortunately she relapsed after 11 months of follow up. Because she refused further 
therapy only maximal supportive care was provided.
The role of flow cytomery in diagnosing acute leukemias
41
Discussion
Overall, this case has a paradoxical appearance: morphology revealed a clear monocytoid 
picture with prominent vacuolization and erythrophagocytosis, both mostly seen in myeloid 
leukemia. In contrast, immunohistochemistry and immunophenotypical analysis showed 
clear expression of B cell lineage defining and specific markers combined with cMPO. Unlike 
other myeloid markers such as CD13 and CD33, cMPO expression is very rarely found in AL 
with a clear B-ALL phenotype. Although immunophenotypical and immunohistochemical 
cMPO expression was found to be of low intensity, it was clearly positive and considered 
specific. Strikingly, cytological examination did not stain positive for SBB in this case. 
Following the WHO2001 criteria, this AL would have been classified as an ALL. However, 
based on additional expression of solely cMPO, this case was classified as MPAL according 
to the WHO2008 guidelines.
The most paradoxal and unique feature in this case is the erythrophagocytosis. This rare 
finding is reported in less than 1% of AL cases and is most commonly associated with AML, 
especially those from a monoblastic or monocytic origin [4]. Erythrophagocytosis has also been 
associated with other subtypes such as acute undifferentiated AL, AML without maturation, 
AML with maturation and acute megakaryoblastic leukemia. Erythrophagocytosis as seen 
in AL is often associated with cytogenetic abnormalities on chromosome 8(p11) involving 
the C-MOZ gene [5]. Most frequently, the t(8;16)(p11;p13) translocation is found that gives 
rise to the CMOZ/CBP chimeric transcript. Recently, AML with t(8;16)(p11;p13) has been 
described as a distinct entity with unique features like erythrophagocytosis, positive cMPO 
with strong positive non-specific esterase staining and poor prognosis [6]. Furthermore, 
other translocations have been described such as t(16;21)(p11;q22), t(10;17)(p13;p12), 
inv(8)(p11q13), as well as 20q- deletion [5-9]. However, in the present case none of these 
cytogenetic aberrancies could be detected. In biphenotypic leukemia erythrophagocytosis 
is only described twice, both associated with a cytogenetic aberrancy; t(9;22) and inv(8)
(p11q13) [5] and [8]. Considering the WHO2001 guidelines no cases of lymphoid AL with 
erythrophagocytosis have previously been described; the case presented here shows clear 
lymphoid marker expression and erythrophagocytosis. Moreover, based on the WHO2008 
criteria, this is the first MPAL to show erythrophagocytosis without cytogenetic aberrancies.
Although the introduction of the WHO2008 classification makes the diagnosis of a MPAL 
more clear and less frequent compared to the older EGIL criteria, diagnosing a MPAL 
remains difficult but important. Prospective trails are still needed to clearly understand 
its clinical impact. This case highlights the challenges in diagnosing an AL with ambiguous 
morphologic, immunohistochemical and flow cytometric characteristics.
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Introduction
Acute leukemias (AL) are classified according to their commitment to either the myeloid 
or lymphoid lineage. Immunophenotyping for various intra- and extracellular cell lineage 
specific markers is an important feature in differentiating between acute myeloid leukemia 
(AML) and acute lymphoid leukemia (ALL). In about 4% of AL cases it is not clear whether 
blasts are derived from myeloid or lymphoid progenitors and are classified as AL of 
ambigious lineage (ALAL). AL with biphenotypic characteristics represent a subgroup with 
a worse prognosis which can be partly explained by a higher incidence of the Philadelphia 
chromosome or other complex cytogenetic aberrancies; these patients present more 
often with extramedullar localization of disease which urges for more intensive treatment 
protocols including central nervous system prophylaxis. The question whether these 
patients benefit from an (intensified) ALL or AML protocol is still unresolved due to lack of 
solid randomized treatment protocols [1-5].
In 1995 the European group for immunological characterizing of AL (EGIL) presented 
guidelines for classification of AL with biphenotypic marker expression. These criteria 
were incorporated in the WHO2001 guidelines for classifying AL of ambigious lineages. 
For many years the EGIL guidelines offered a platform for harmonizing diagnostic criteria 
important for prognosis and clinical outcome measurements [6;7]. In 2008, new WHO 
criteria were proposed for classification of acute leukemias of ambigious lineages [8]. For 
acute leukemias with a mixed phenotype (MPAL), these new criteria implicated significant 
modification with the EGIL scoring system with potential implications for treatment and 
clinical research [8]. For instance, in the WHO2008 both bilineal and biphenotypic AL are 
classified as a MPAL, whereas these were distinct entities in the EGIL. Furthermore, single 
expression of cytoplasmatic myeloperoxidase (cMPO) or CD3 (surface or intracellular) is now 
regarded as sufficient to determine whether blasts belong to the myeloid or T cell lineage, 
respectively. AL that express both cMPO and CD19 are now diagnosed as MPAL depending 
on expression of cCD79a, CD10 or cCD22. In contrast to the EGIL, the WHO2008 excludes AL 
with certain cytogenetic aberrancies or clinical presentations from MPAL: AL with t(8;21), 
t(15;17) or inv(16) are classified as AML with recurrent cytogenetic abnormalities despite 
their immunophenotypic marker expression. Furthermore, AL with FGFR1 mutations, CML-
blast crises (CML-BC), AL with MDS pre-phase and therapy-related AL are separate entities 
according to WHO2008 criteria. 
These new criteria are likely to change diagnosis and hence therapeutic considerations 
in various patients. To investigate this issue, we retrospectively analyzed a cohort of 517 
patients admitted to our hospital with acute leukemia from 2000 to 2008 and compared 
diagnosis by applying both EGIL and WHO2008 criteria.
Material and Methods
Immunophenotyping of bone marrow samples was performed as part of regular clinical 
diagnostic procedures. Shortly, after bulk red cell lysis and antibody incubation at room 
temperature, expression levels of B cell, T cell and myeloid lineage specific and defining 
markers on blasts were determined by four-color flow cytometry on a FACS Calibur flow 
cytometer (Becton Dickinson, San Jose, CA). Cells were characterized for the following 
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markers:  CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, 
CD19, CD20,  CD22, CD25, CD33, CD34, CD36, CD42b, CD45, CD56, CD61 CD65, CD71, 
CD90, CD117, CD133 and HLA-DR. For analysis of cytoplasmic markers cells were fixed with 
paraformaldehyde and subsequently permeabilized with Facs Lyse (Becton Dickenson , 
San Jose, CA) followed by staining  for CD3, IgM, CD79a, TdT and MPO. All antibodies were 
obtained from: Becton Dickenson, Zebra biosciences (Enschede, The Netherlands), Dako 
(Glostrup, Denmark) or Sanquin (Amsterdam, The Netherlands). Results were analyzed 
using CellQuest Pro software (Becton Dickinson). Blasts were determined by low side scatter 
(SSC), diminished or low CD45 expression and CD34 expression. In case of CD34 negative AL, 
blasts were gated using other immature markers such as CD117, CD133, CD10 and cIgM. In 
our analysis we used a cut off of 20% marker positivity, as specified n the EGIL criteria[6]. 
In the WHO2008, cell line specific markers CD19 and CD3 should be highly expressed on 
blasts (expression equal or higher than the normal T- or B-cells within the patient’s sample) 
to assign a certain lineage positive in case of a MPAL. We considered blasts strongly positive 
(“s”)  for a certain marker if at least 20% of the population was positive as compared with 
the appropriate isotype control combined with a mean fluorescence intensity as high as, or 
higher than normal B or T cells within the same sample. Weak expression (“w”) is defined 
when the expression level does not reach expression of corresponding normal cells. In cases 
where normal B or T cells were absent, we compared expression level with historical normal 
controls. Molecular diagnostics procedures were performed as part of regular clinical 
diagnostic procedures. Quick frozen cell pellets were used for determination of presence 
of translocations t(9;22), t(8;21), t(15;17), MLL, FLIT3-ITD by PCR following institutional 
guidelines (www.modhem.nl). 
Results and discussion
Out of 517 AML patients 26 (5.0%) could be classified as either BAL (EGIL), MPAL (WHO2008) 
or both with a B cell /myeloid (B/My) combined phenotype (summarized in table 1A). Of 
those, 7 patients (UPN 1-4 and 6-8) showed an expression profile which allowed classification 
for both MPAL and BAL. Since AML with t(8;21) frequently show coexpression of CD19 and 
cCD79a next to the myeloid markers CD13, CD33 and MPO, UPN 6-8 are classified as AML 
with t(8;21) considering WHO2001 and as AML with recurrent cytogenetic abnormality 
according the WHO2008 criteria. 
Based on medical history UPN 11 and 12 were classified as AML with myelodysplasia-related 
changes and UPN 9 and 10 as a CML-BC, excluding these patients as possible MPAL. Despite 
presence of t(9;22), UPN 1 and 5 were not classified as CML-BC because of absence of a CML 
pre-phase; these ALAL substitute a subgroup of MPAL. There are only two patients, UPN 5 
and 27, who are considered a MPAL in WHO2008 guidelines based on expression of solely 
cMPO; these were classified as a B- and T-ALL, respectively, following EGIL criteria. In our 
cohort we did not find any cases with monocytoid differentiation (based on expression of 
CD14, CD11c, CD45 bright, HLA-DR and side and forward light scatter properties) combined 
with expression of lymphoid markers; especially not on those patients previously diagnosed 
as BAL. Although we did not include CD36 and CD64 in our analysis, detection of CD14 and 
CD11c is considered as adequate in assigning the monocytoid lineage. 
One argument to change the criteria in the WHO2008 classification was to distinguish the 
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Table 1A.  Comparison of EGIL and WHO2008 in classification of acute leukemias with combined 
expression of B-cell and myeloid lineage markers
UPN Age 
(years)
EGIL WHO
08
cMPO CD
13
CD
33
CD
117
CD
15
CD
65
CD
19
cIgM cCD79a
1 49 BAL MPAL 65 67w 35w 1 27w 1 99s 35 95s
2 9 BAL MPAL 38 21w 2 0 0 1 99s 0 80s
3 40 BAL MPAL 80 94 91 3 1 0 85s 0 80s
4 57 BAL MPAL 98 35 37 2 35 29 61s 1 52s
5 65 ALL MPAL 69 18w 3 1 1 0 98s 0 90s
6 46 AML* AML 98 80 95 82 20 2 63h 0 25h, s
7 16 AML* AML 98 45w 26w 98 11 1 95s 0 22h, s
8 15 AML* AML 96 74 97 98 14 9 97s 1 50w
9 52 BAL CML BC 1 99 26 67 0 5 10 0 30w
10 28 BAL CML BC 58 98 67 72 4 13 78w 0 56h, s
11 68 BAL AL* 29 98 99 98 3 10 7 0 43w
12 59 BAL AL* 96 91 99 92 19 23 3 85h 0
13 23 BAL AL** 1 94 98 82 1 1 0 12 52w
14 23 BAL AL** 7 97 99 71 13 39 73s 0 25w
15 52 BAL AML 73 98 97 91 22w 6 25w ND 52w
16 54 BAL AML 85 92 99 94 82 6 40h 4 53w
17 72 BAL AML 99 99 99 90 18 6 46w ND 50w
18 41 BAL AML 94 91 93 85 19 0 28w 0 22w
19 58 BAL AML 51 99 12 80 2 ND 45h 1 18
20 18 BAL AML 84 97 87 90 16 15 10 0 35w
21 69 BAL AML 37 99 21 94 41 21 4 0 30h, s
22 56 BAL AML 50 99 57 89 15 59 29w 1 31w
23 1 BAL AML 34 90 99 98 0 0 88w 2 59w
24 63 BAL AML 67 99 98 96 7 1 1 0 45w
25 36 BAL ALL 6 65w 82w 3 58w 2 96s 73 80s
26 15 BAL ALL 0 42w 60w 38w 9 1 97 0 80
Abbreviations: AML, acute myeloid leukemia; AL, acute leukemia; ALL, acute lymphoblastic leukemia; 
BAL, biphenotypic acute leukemia; cMPO, cytoplasmic myeloperoxidase; cTdT, cytoplasmic terminal 
deoxynucleotidyl transferase; CML-BC, chronic myleoid leukemia blast crisis; MPAL, mixed phenotype 
acute leukemia; NSE, Non-specific esterase; pos, positive; neg, negative; ND, not determined; 
xUPN, unique patient number. Results are shown for those samples, which are scored positive for 
a biphenotypic acute leukemia corresponding to the EGIL criteria and/or for a mixed phenotype 
acute leukemia (MPAL) corresponding to the WHO2008 criteria. Discrimination is made between 
weak, heterogeneous or strong expression. Strong expression (‘s’) is defined as higher or as high as 
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the expression on nonmalignant cells in the same sample or, known from healthy donors. Weak 
expression (‘w’) is defined when the expression level does not reach expression of corresponding 
normal cells. Heterogeneous and strong expression (‘h, s’) is defined when, next to a heterogenous 
expression, the cells with highest expression are as high or higher as the expression of non-malignant 
cells. Monoblastic appearance is defined by expression of at least CD14 or CD11c. AML*, UPN 6, 7 and 
8 are classified as AML with t(8;21) considering EGIL criteria; AL*, UPN 11, 12 & 28 are excluded from 
MPAL based on the classification as an MDS-related acute leukemia; AL**, for UPN 13, 14 and 29 it is 
not clear whether these should be classified as AML, ALL or MPAL in the WHO2008.
UPN CD
20
CD
22
CD
10
cTdT CD11c and/
or CD14
t(9;22) t(8;21) t(15;17) MLL FLIT-ITD
1 84 99 98 96 Neg pos neg neg neg ND
2 3 36 95s 78 Neg neg ND ND neg ND
3 1 48 85s 85 Neg neg neg neg neg Normal
4 63 55 79 86 Neg neg ND ND neg ND
5 74 98 99s 99 Neg pos ND ND neg ND
6 1 0 ND 1 Neg ND pos neg neg ND
7 1 6 1 37 Neg neg pos neg neg Normal
8 1 1 1 31 Neg neg pos neg neg Normal
9 0 0 0 87 Neg pos ND ND ND ND
10 1 2 1 91 Neg pos neg neg neg Normal
11 3 2 3 25 Neg neg neg neg neg Normal
12 2 0 0 21 Neg neg neg neg neg Heterozygous
13 1 55 2 46 Neg neg neg neg neg ND
14 0 5 0 1 Neg neg neg neg neg Normal
15 34 5 42 2 Neg neg neg neg neg ND
16 1 13 ND 1 Neg neg neg neg neg ND
17 0 0 ND 85 Neg ND ND ND ND ND
18 0 1 3 37 Neg neg neg neg neg Heterozygous
19 2 4 50h 82 Neg neg neg neg neg Normal
20 3 5 4 54 Neg neg neg neg neg Normal
21 1 21 1 53 Neg neg neg neg pos Normal
22 1 3 5 44 Neg neg neg neg neg Normal
23 0 1 0 72 Neg neg neg neg neg Normal
24 1 81 24w 0 Neg neg neg neg neg Normal
25 94 95 93 71 Neg ND ND ND ND ND
26 47 97 99 99 Neg ND ND ND ND ND
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UPN Age EGIL WHO 
08 T/
My
CD3 cCD3 CD4 CD8 CD2 CD5 CD7 CD
10
cTdT cMPO
27 23 ALL MPAL 2 48s 3 65 89 98 98 3 75 57
28 2 BAL MPAL 2 38 41 72 5 95 98 98 70 pos
29 67 BAL AL** 0 0 80 0 31w 61 93 23 1 1
30 10 BAL ALL 1 37s 13 4 92 81 97 68 97 9
31 59 BAL AML 2 0 40 2 56 7 46 31 21w 69
32 75 BAL AML 0 5 26 3 7 34 w 25w 33w 74 16
33 72 BAL AML 1 0 58 1 24w 23w 77w 16 2 25
Table 1B. Comparison of EGIL and WHO2008 in classification of acute leukemias with combined 
expression of T-cell and myeloid lineage markers.
Table 1C.  Comparison of EGIL and WHO2008 in classification of acute leukemias with combined 
expression of B-cell , myeloid and T-cell lineage markers
UPN CD 
15
CD 
65
CD 
34
CD 
19
cIgM cCD
79a
CD 
20
CD 
22
t(9;22) CD11c 
and/or 
CD14
t(8;21) t(15;7) MLL FLIT3-
ITD
34 13 19 2 8 0 41w 7 4 Neg Neg Neg Neg Neg Normal
35 35 3 87 1 0 24w 0 5 Neg Neg ND ND Neg ND
Abbreviations: AML, acute myeloid leukemia; AL, acute leukemia; ALL, acute lymphatic leukemia; 
BAL, biphenotypic acute leukemia; cMPO, cytoplasmic myeloperoxidase; cTdT, cytoplasmic terminal 
deoxynucleotidyl transferase; CML-BC, chronic myleoid leukemia blast crisis; MPAL, mixed phenotype 
acute leukemia; NSE, Non-specific esterase; pos, positive; neg, negative; ND, not determined; 
xUPN, unique patient number. Results are shown for those samples, which are scored positive for 
a biphenotypic acute leukemia corresponding to the EGIL criteria and/or for a mixed phenotype 
acute leukemia (MPAL) corresponding to the WHO2008 criteria. Discrimination is made between 
weak, heterogeneous or strong expression. Strong expression (‘s’) is defined as higher or as high as 
The role of flow cytometry in diagnosing acute leukemias
49
the expression on nonmalignant cells in the same sample or, known from healthy donors. Weak 
expression (‘w’) is defined when the expression level does not reach expression of corresponding 
normal cells. Heterogeneous and strong expression (‘h, s’) is defined when, next to a heterogenous 
expression, the cells with highest expression are as high or higher as the expression of non-malignant 
cells. Monoblastic appearance is defined by expression of at least CD14 or CD11c. AML*, UPN 6, 7 and 
8 are classified as AML with t(8;21) considering EGIL criteria; AL*, UPN 11, 12 & 28 are excluded from 
MPAL based on the classification as an MDS-related acute leukemia; AL**, for UPN 13, 14 and 29 it is 
not clear whether these should be classified as AML, ALL or MPAL in the WHO2008.
UPN CD
13
CD
33
CD
117
CD
15
CD
65
CD11c 
and/or 
CD14
CD
34
t(9;22) t(8;21) t(15;17) MLL FLIT-
ITD
27 5 0 0 0 0 Neg 39 Neg ND ND Neg ND
28 76 2 Neg 1 neg neg neg neg Normal
29 99 76 92 3 4 Neg 94 Neg Neg Neg Neg Normal
30 47 90 62 2 1 Neg 89 Neg ND ND Neg Normal
31 92 88 83 9 0 Neg 88 Neg Neg Neg Neg Normal
32 95 91 93 2 4 Neg 93 ND ND ND ND ND
33 99 97 94 23 77 Neg 93 Neg Neg Neg Neg Normal
UPN Age EGIL WHO 
2008 
CD 
3
cCD
3
CD 
4
CD 
8
CD 
2
CD 
5
CD 
7
CD 
10
c 
TdT
c 
MPO
CD 
13
CD 
33
CD 
117
34 75 BAL 
B/T/
My
MPAL 
T/my
4 39s 98 94 98 98 98 70 93 70 31 3 9
35 16 BAL 
B/T/
My
T-ALL 0 56s 0 0 99 0 99 0 91 1 99 11 92
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lineage markers expressed on leukemic blasts that truly reflect the biphenotypic nature of 
cells from the markers which are commonly seen on subtypes of AL. For instance pro-B-ALL 
and pre-pre-B-ALL often show expression of myeloid markers; UPN 25 and 26 showed, in 
absence of cMPO, high expression of CD19 and cCD79a combined with low expression of 
CD33, CD13 and CD15. Considering the EGIL guidelines these patients were classified as 
BAL, whereas in WHO2008 these patients have to be classified as B-ALL (table 1A).
In the EGIL and WHO2001 acute bilineal leukemias were classified as a distinct entity, 
whereas in the WHO2008 these are joined with biphenotypic AL as MPAL. In case of  MPAL 
of bilineal origin (WHO2008) or bilineal AL (EGIL) there should be two or more different 
populations in which at least one of these meets the immuphenotypic criteria for AML (with 
the exception that the population does not need to comprise at least 20%). In our cohort, 
five AL (1%) with a bilineal phenotype were found. Since criteria for bilineal origin are the 
same for EGIL and WHO2008, data are not shown.
Seven patients (1.4%) could be classified as BAL, MPAL or both with T cell / myeloid (T/
My) lineage (table 1B). Remarkably, only UPN 28 is considered a BAL and MPAL based on 
immunologic marker expression; nevertheless this patient was excluded from classification 
because of a known history of MDS. 
UPN 34 and 35 showed positivity for three lineages and can be considered as a B/T/My 
AL following the EGIL criteria (table 1C). In the EGIL classification system, discrimination 
between T and B cell lineage is difficult to define since CD10 and cTdT are cell lineage 
defining markers for both lineages. When CD10 and cTdT are only scored once for either 
T or B lineage according to EGIL criteria instead of double scored for both lineages, no B/T 
mixed phenotype AL could be found in our cohort.
Sometimes, current criteria fail to classify AL as a T-ALL, B-ALL or AML, i.e. in cases were CD3, 
CD19 and cMPO are negative and a BAL might be considered based on other cell lineage 
defining markers. For example, UPN 29 is negative for cMPO, cCD3 and CD3, but expresses 
CD5, CD7, CD2, CD13, CD33 and CD117; WHO2008 guidelines do not elucidate whether this 
case should be considered T-ALL or AML. Similarly, UPN 13 and 14 are indecisive for B-ALL or 
AML. In these cases, former EGIL criteria might give further directions.
Overall, we can conclude that the WHO2008 classification has a clear diagnostic impact 
for AL that express different cell lineage-specific and defining markers. Considering EGIL 
criteria 30/517 AL (5.8%) were classified as BAL, whereas in WHO2008 only 7 cases (1.3%) 
would have been classified as MPAL. BAL and MPAL cases did not fully coincide with each 
other, only 5/517 cases (0.9%) would have been classified as BAL as well as MPAL by EGIL 
and WHO2008 criteria, respectively. Based on our data almost all AL with combined myeloid 
and B or T characteristics are re-classified as ALL or AML in the new WHO2008 classification 
which in the future will have impact on therapeutic decision making. Therefore, the clinical 
significance of the WHO2008 criteria needs to be shown in prospective clinical studies.
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Abstract
Background
According to WHO2008 guidelines an important role is designated for cytoplasmic 
myeloperoxidase (cMPO) as measured by flow cytometry for classifying acute leukemia 
of myeloid or ambiguous origin (AML or MPAL). However, no threshold with respect to 
expression level and percentage positive cells is provided. Since the expression of solely 
cMPO can change the diagnosis from acute lymphoid leukemia into MPAL in the current 
WHO2008, a consensus is needed for the cut-off for cMPO. 
Methods
In this study, we investigated whether or not a cut-off of 10% positivity for cMPO equally 
defines an acute leukemia as AML or MPAL as compared to a cut-off for cMPO of 20% and 
compared this with results obtained for Sudan Black B (SBB) staining by cytomorphology. 
Results
Cell lineage-defining markers and SBB staining were analyzed retrospectively in a cohort 
of 198 patients who presented with acute leukemia. Eight patients were positive for SBB 
(>3%), but were considered negative for cMPO (<10%); six patients were negative for 
SBB (≤3%) and positive for cMPO (≥10%) staining. In six patients, we found 10-20% cMPO 
positive leukemic cells. Five of these cases were SBB positive; the sixth patient showed a 
clear myeloid phenotype without positivity of any lymphoid marker. Using a 10% cut-off 
instead of 20% would have changed diagnosis from ALL into MPAL in two patients; both 
cases were SBB positive by morphology.
Conclusion
We conclude that a 10% cut-off is a secure lower limit for cMPO expression and can be 
used independently from SBB expression. 
Introduction
Acute leukemias (AL) are classified by flow cytometry according to their commitment to 
either the myeloid or lymphoid lineage [1]. In about 4% of AL, blast cells express both 
myeloid and lymphoid markers directing the diagnosis towards a mixed phenotype AL (MPAL) 
rather than acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL) [2].  Based on 
WHO2008, a MPAL has to fulfill criteria based on expression of immunological markers that 
assign a blast cell to at least two lineages [1]. In case no directive conclusions can be drawn 
from molecular diagnostics, cytogenetics and morphology, flow cytometry has a decisive 
role when leukemic cells have both lymphoid and myeloid features. Expression of solely 
CD3 and flow cytometrically detected cytoplasmic myeloperoxidase  (cMPO) is sufficient to 
assign a blast cell to the T cell and the myeloid lineage, respectively; for the B cell lineage 
one particular B cell marker in addition to expression of CD19 is required [3]. Cell lineage 
specific markers CD19 and CD3 should be highly expressed on blasts; however, for cMPO no 
thresholds with respect to expression level or percentage positive cells are provided. Since 
the expression of cMPO as an isolated marker can change the diagnosis from ALL into MPAL 
in the current WHO2008, a consensus is needed for the cut-off for cMPO.
The former WHO2001 criteria clearly described a cut-off for positivity of a marker of 20% 
of the whole blast population as compared to the appropriate isotype control. The 20% 
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threshold was formerly defined based on one-color flow cytometry; this higher cut-off was 
necessary to exclude false positivity due to e.g. contamination of non-leukemic cells. With 
the development of multicolor flow cytometry and because of the high degree of specificity 
of cMPO, cTdT and cCD79a, a lower cut-off of 10% was implemented when positivity was 
confirmed by light microscopy (EGIL criteria); in clinical practice, this is usually assessed 
by Sudan Black B (SBB) staining on blood and bone marrow smears. In cytomorphology, 
SBB representing cMPO expression is considered the hallmark of the myeloid lineage; the 
presence of 3% or more SBB positive leukemic progenitor cells is diagnostic for myeloid 
leukemias [4]. 
In this study, we investigated whether or not a cut-off of ≥10% positivity for cMPO by flow 
cytometry equally defines an AL as AML or MPAL as compared to a cut-off for cMPO of 
≥20%; these results were compared with results obtained with SBB staining. 
Material and methods
Patient samples and standard diagnostic procedures
Cell lineage-defining markers and SBB staining were analyzed retrospectively in a cohort of 
198 patients who presented with AL in our hospital between 2001 and 2009; part of these 
patients were discussed in reference 2. Informed consent was obtained from all patients 
in accordance with the Declaration of Helsinki and institutional guidelines. Only those 
patients were selected in which cytochemistry and immunophenotyping were performed 
on the same samples drawn at equal time points. Diagnostic procedures were performed 
according to standard operating procedures for classifying AL as described previously [2]. 
For bone marrow aspirates, first needle aspiration was used for morphology; second and 
third needle aspirations were used for immunophenotypic, molecular and cytogenetic 
analysis. SBB and May-Grünwald-Giemsa (MGG) staining were performed on blood and 
bone marrow smears by standard morphologic and cytochemical procedures. All patient 
samples were screened for t(9:22), t(8:21), inv(16), t(15;17) and FLT-3ITD by routine 
molecular and cytogenetic diagnostics (6). 
Flow cytometric analysis
Blasts cells were analyzed for expression levels of B cell, T cell and myeloid defining- and 
specific-markers with FITC or PE-conjugated antibodies with ubiquitous CD45-PerCP and 
CD34-APC by performing a four-color flow cytometric analysis on a FACS Calibur flow 
cytometer (BD Biosciences, San Jose, CA), as described earlier [2].  Regarding cMPO 
expression we compared the impact of previously described cut-offs levels of 10 and 20%. 
Results were analyzed using CellQuestPro software (BD Biosciences). Percentage of marker 
positivity of blast cells and mean fluorescence index (MFI) were calculated as compared to 
appropriate isotype controls. 
Statistical analysis
By construction of receiver operating characteristic (ROC) curves using the SPSS 15.0 
software the specificity and sensitivity of various cut-offs for cMPO were compared with 
SBB results. 
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Table 1. Comparison of Sudan Black B and flow cytometric myeloperoxidase staining.  
SBB 1-3 SBB 4-100
MPO 0-9 63 8*
MPO 10-19 1† 5†
MPO 20-100 5# 116
Note: Total number of cases is shown subdivided in Sudan Black B (SBB) and cytoplasmic 
myeloperoxidase (cMPO) positive and negative groups. For SBB a cut-off of 3% of blasts is used. SBB 
positive and negative groups are organized into three groups, those expressing cMPO below 10%, 
those with 10-19% and those with 20% or more cMPO positive blasts as compared to the appropriate 
isotype control.
† Detailed information concerning these cases are shown in table 2A
* Detailed information concerning these cases are shown in table 2B
#  Detailed information concerning these cases are shown in table 2C 
Results 
In 121 out of 198 (61%) of AL in our cohort cMPO expression was found to be higher 
than 20% (table 1). These cases were classified as AML (n=115) or MPAL (n=6), the latter 
depending on co-expression of lymphoid markers. The vast majority of patients (116/121, 
(96%) showed no discrepancies in SBB and cMPO staining (table 1). By applying a cut-off 
of ≥10%, six more cases are recognized as cMPO positive (UPN 1-6, 3% of cases, table 2A). 
Two of these patients should be reclassified as MPAL instead of B-ALL or T-ALL according 
to their immunophenotypic profile (UPN1 and 2; simultaneous expression of lymphoid 
markers and cMPO≥10%). Notably, both patients scored positive for SBB and were thereby 
classified as AML by morphology. Cytomorphology classified UPN 3-6 as myelomonocytic or 
monoblastic and monocytic leukemias (former FAB M4 and M5, respectively). Of note, UPN4 
was classified as AML with inv(16) which is classified as an AML with genetic abnormalities 
according to the WHO2008. These leukemias often show a low to intermediate SBB and 
cMPO expression; thus, changing cMPO threshold did not affect the diagnosis. 
Regarding discordant results, eight patients (UPN7-14, table 2B) were positive for SBB 
(>3%), but negative for cMPO (<10%). In only a minority of patients (n=6) we found 
negative SBB (≤3%) and positive cMPO (≥10%) (UPN3 and UPN15-19, 3% of the cohort). 
These discrepancies did not affect the overall classification. Two examples of SBB and cMPO 
discordance are shown in supplementary figure 1.
Receiver operating curve was used to compare cMPO results with SBB positivity or negativity 
(either >3% or below); When choosing a 20% cut-off a sensitivity of 87% with a specificity 
of 92% was reached. However, when choosing a cut-off of 10% a slightly more favourable 
ratio is found: a sensitivity of 95% and specificity of 87% (data not shown); the area under 
the curve was 0.959 ( p<0.001). 
Discussion
Within the current WHO2008 classification of hematopoietic neoplasms, cMPO is considered 
the hallmark protein for defining the myeloid lineage. In this regard, we compared the effect 
of a cut-off of 10 and 20% for cMPO in diagnosing AL and compared the results with SBB 
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Table 2A. Marker expression of acute leukemias with 10-20% cMPO 
UPN 1 2 3 4 5 6
B cell markers
cCD79a 1 70 5 1 20 0
CD19 0 98 1 0 1 1
CD20 1 16 0 2 2 1
CD22 7 24 3 9 5 1
CD10 1 80 7 ND 0 ND
cIgM 0 0 0 15 2 0
T cell markers
CD2 92 3 5 23 2 1
CD3 0 0 0 0 1 1
cCD3 54 0 0 0 0 0
CD4 2 9 88 50 75 90
CD5 0 0 4 0 2 1
CD7 95 52 3 6 3 2
CD8 0 0 0 ND 10 ND
cTdT 79 65 49 1 17 0
Myeloid markers
CD117 96 13 91 68 94 6
CD13 99 97 99 98 89 90
CD14 0 0 4 25 1 39
CD15 17 2 9 54 25 52
CD33 2 91 80 99 99 99
CD65 14 2 4 5 19 7
cMPO 12 15 19 19s 18 10s
MFI cMPO 9.5 4 8.9 9.3 3.1 5.1
Cytohistochemical
MPO
ND pos neg ND ND ND
Histomorphological 
SBB
27 24 2 100 28 29
WHO2008 10% 
cMPO
MPAL T/
myeloid 
NOS
MPAL with 
t(9;22) 
(b2a2)
Acute 
monoblastic 
and monocytic 
leukemia
AML with 
inv(16)
Acute 
monoblastic 
and monocytic 
leukemia
Acute 
monoblastic 
and 
monocytic 
leukemia
WHO2008 20% 
cMPO
T-ALL B-ALL Acute 
monoblastic 
and monocytic 
leukemia
AML with 
inv(16)
Acute 
monoblastic 
and monocytic 
leukemia
Acute 
monoblastic 
and 
monocytic 
leukemia
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Table 2B. Marker expression of acute leukemias with positive SBB and negative cMPO
UPN 7 8 9 10 11 12 13 14
B cell markers
CD79a 20 0 5 0 8 2 2
CD19 5 1 8 0 3 0 3 12
CD20 6 5 1 14 4 17 1 1
CD22 43 6 1 0 7 31 1 1
CD10 6 ND 0 ND ND ND 1 ND
cIgM 30 5 0 4 33 ND 1 0
T cell markers
CD2 0 4 4 16 3 4 1 0
CD3 0 2 0 1 2 1 1 0
cCD3 0 0 0 1 9 0 0 0
CD4 90 87 60 97 42 52 20 57
CD5 7 4 0 1 1 0 3 0
CD7 7 12 79 4 7 35 4 89
CD8 0 ND 0 ND ND ND 1 ND
cTdT 30 1 24 0 9 4 27 0
Myeloid markers
CD117 40 12 93 1 94 95 96 96
CD13 90 37 99 92 93 95 98 98
CD14 3 21 3 46 2 0 2 0
CD15 8 93 20 98 34 45 1 2
CD33 95 98 83 99 91 99 91 99
CD65 40 47 10 50 3 11 1 3
cMPO 9s 9 7 6 5 1 4s 3s
Cytohisto-
chemical MPO
ND neg neg neg* ND neg* partly ND
Histomorpho-
logical SBB
19 22 31 50 26 80 7 4
WHO2008 10% 
cMPO
AL with 
(9;22) 
(b2a2)
Acute 
Myelo-
monocytic 
Leukemia
Acute 
mono-
blastic and 
monocytic 
leukemia
Acute 
mono-
blastic and 
monocytic 
leukemia
AML with 
minimal 
differen-
tiation
AML 
with 
differen-
tiation
Acute 
erythroid 
leukemia
Acute 
mono-
blastic 
and 
monocytic 
leukemia
WHO2008 20% 
cMPO
AL* Acute 
Myelo-
monocytic 
Leukemia
Acute 
mono-
blastic and 
monocytic 
leukemia
Acute 
mono-
blastic and 
monocytic 
leukemia
AML with 
minimal 
differen-
tiation
AML 
with 
differen-
tiation
Acute 
erythroid 
leukemia
Acute 
mono-
blastic 
and 
monocytic 
leukemia
MPO cut off of 10% in acute leukemia
59
Table 2C. Marker expression of acute leukemia with negative SBB and positive cMPO
UPN 15 16 17 18 19
B cell markers
CD79a 41 2 95 59 0
CD19 8 1 99 88 0
CD20 7 1 84 0 3
CD22 4 1 99 1 0
CD10 70 3 98 0 ND
cIgM 8 0 35 2 ND
T cell markers
CD2 98 89 2 2 0
CD3 4 2 15 0 4
cCD3 39 48 2 0
CD4 98 3 6 1 15
CD5 98 98 1 0 0
CD7 98 98 2 2 2
CD8 94 65 ND 0 ND
cTdT 93 75 96 72 13
Myeloid markers
CD117 9 0 1 98 99
CD13 31 5 67 90 99
CD14 2 0 0 1 0
CD15 13 0 27 0 0
CD33 3 0 35 99 2
CD65 19 0 1 0 0
cMPO 70s 57s 85 34 65
MFI cMPO 12.6 4.7 17.4 3 15.7
Histomorpho-
logical SBB
0 0 0 1 1
WHO2008 10% 
cMPO
MPAL T/myeloid, 
NOS
MPAL T/myeloid, 
NOS
MPAL with 
t(9;22)e1a2
MPAL B/myeloid, 
NOS
AML with 
MDS-related 
changes
WHO2008 20% 
cMPO
MPAL T/myeloid, 
NOS
MPAL T/myeloid, 
NOS
MPAL with 
t(9;22)e1a2
MPAL B/myeloid, 
NOS
AML with 
MDS-related 
changes
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percentages. By applying a cut-off of 10% for cMPO two patients would have been reclassified 
from ALL to MPAL based on expression of solely cMPO. Interestingly, both patients scored 
positive for SBB and were thereby classified as AML by morphology.   It might be more 
appropriate to use comparable cut-offs for cMPO and SBB. This cut-off should be high enough 
to ensure that the subpopulation is of malignant origin, since normal myeloid progenitor 
cells (CD34+ and cMPO+) might reside in the same CD45dim blast compartment. In CD34- AML 
it has been shown that up to 1.0% non-malignant CD34+ progenitors can be found [5]. For 
other AL the percentage of normal myeloid progenitor cells has to be revealed by further 
studies and should direct to the SBB and cMPO cut-off of choice. Overall, our data support 
to a cut-off of 10% for cMPO by flow cytometric analysis, independently of results found for 
SBB staining. Furthermore, by applying a cut-off of 10% a sensitivity of 95%  and specificity 
of 87% is reached, compared with 87 and 92% when using a  20% cut-off. Rarely in cases 
of ALL, SBB can stain intracellular lipoid inclusions not containing cMPO [6]. In our cohort, 
eight patients were positive for SBB and negative for cMPO (<10%). Of note, these AL were 
considered to be of myeloid origin according to morphology and their immunophenotypic 
profile. Thus, discussion on cMPO positivity would not have had diagnostic consequences 
in these cases. In 3% of patients discrepancies caused by negative SBB (3≤%) and positive 
cMPO (≥10%) were seen. However, cMPO was expressed at a very low intensity. It is known 
that in case of AML without and AML with  minimal differentiation SBB can be below 3% by 
light microscopy while cMPO may be positive by flow cytometry [1;7]. Yet, four out of five 
of these particular cases were classified as MPAL based on their immunophenotypic profile, 
one patient (UPN19) was classified as AML with MDS-related changes. In summary, a cut-off 
of 10% for cMPO expression would have changed diagnostic classification in only a minority 
of cases (1%); both were SBB positive by morphology. Therefore, we conclude that a 10% 
cut-off is a secure lower limit for cMPO expression and can be used independently from SBB 
expression. Clinical consequences have to be prospectively investigated.
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Supplementary figure 1. Examples of Sudan Black B and flow cytometric myeloperoxidase discordance. 
FACS density plots are shown. In plot A, CD45 diminished blast cells from UPN4 were selected and 
subsequently shown in plot B. Plot B represents the cytoplasmic control and plot C the cytoplasmic 
MPO staining (cMPO). In plot C, percentages represent the right lower quadrant for cMPO negative 
cells and right upper quadrant for cMPO positive cells. In plot D cMPO+ cells are backgated in the 
CD45/sideward scatter plot. For UPN16, the same gating strategy was applied and results are shown 
in plot E, F, G and H. In Plot I and J, results of Sudan Black B staining by cytomorphology are depicted 
UPN4 and UPN16; total number of SBB positive cells per 100 counted leukemic cells is displayed. 
Complete immunophenotypic profile of these two patients is shown in table 2a and 2c, respectively.
In UPN16, cytomorphology would consider SBB as negative, in contrast, flow cytometry would state 
cMPO positivity; otherwise, in UPN4, SBB staining is clearly positive while cMPO at a flow cytometry 
cut-off of 20% would be considered negative. Of note, a cut-off of ≥10% would convert cMPO to 
positive.
Supplemental material
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6MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid 
leukemia
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Abstract 
Purpose: Classification of acute leukemia (AL) is based on commitment of leukemic cells 
to either the myeloid or the lymphoid lineage. However, a small percentage of AL cases 
lack immunophenotypical lineage commitment. These leukemias of ambiguous lineage 
represent a heterogeneous category of AL that cannot be classified as either myeloid AL 
(AML) or lymphoid AL (ALL). he lack of clear classification of acute leukemias of ambiguous 
lineage as either AML or ALL is a hurdle in treatment choice for these patients. 
Experimental design: Here, we compared the microRNA (miRNA) expression profiles of 17 
cases with acute leukemia of ambiguous lineage and 16 cases of AML, B-cell acute lymphoid 
leukemia (B-ALL), and T-cell acute lymphoid leukemia (T-ALL).
Results: We show that leukemias of ambiguous lineage do not segregate as a separate entity 
but exhibit microRNA expression profiles similar to either AML, B-ALL or T-ALL. We show 
that by using only five of the most lineage discriminative microRNAs we are able to define 
AL of ambiguous lineage as either AML or ALL. 
Conclusion: Our results indicate the presence of a myeloid or lymphoid lineage-specific 
genotype, as reflected by miRNA expression, in these acute leukemias despite their 
ambiguous immunophenotype. MiRNA-based classification of acute leukemia of ambiguous 
lineage might be of additional value in therapeutic decision making. 
Introduction
Acute leukemias (AL) are classified as myeloid or lymphoid by using immunological markers 
that determine their lineage commitment. Four percent of AL cases cannot be classified as 
acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL) due to co-expression of 
both lymphoid and myeloid lineage markers [1-6]. The prognosis of leukemias of ambiguous 
lineage is worse compared to AML or ALL and no specific treatment programs exist for these 
leukemias. To date, it is unsettled whether patients benefit from AML, ALL or combination 
therapy which might cause their mistreatment and poor prognosis [7-12]. The therapeutic 
strategies used for treatment of AML or ALL are considerably different, indicating the 
importance of classification of AL cases at diagnosis as either myeloid or lymphoid. 
The diagnostic criteria for leukemias of ambiguous lineage were previously defined by the 
WHO 2001 classification and are based on the presence of immunological markers detected 
by flow cytometrie cytometry [1].  According to the WHO2001 scoring system many 
different combinations of immunophenotypic markers can define an AL as one with an 
ambiguous lineage and consequently this results in a heterogeneous group of biphenotypic 
acute leukemias (BAL). In 2008 these diagnostic criteria were refined: AML cases with 
recurrent chromosomal abnormalities and blast crises chronic myeloid leukemia (CML) 
cases were excluded from mixed phenotype AL (MPAL) [2]. The major immunophenotypic 
markers used by the WHO2008 to determine the lineage for these AL cases are cytoplasmic 
myeloperoxidase (cMPO), CD19, and cytoplasmic CD3 (cCD3). However, the current 
WHO2008 classification is difficult to interpret due to the implementation of expression 
intensities of B- and T-cell makers and the absence of clear cut-offs.
The discrimination between ALL and AML has been shown to be possible by morphologic, 
immunohistochemical, and immunological methods; however, also by gene expression 
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profiling [13,14] and microRNA (miRNA) expression profiling [15,16]. MiRNAs are small 
single stranded RNA molecules which regulate gene expression by promoting degradation 
of mRNAs or repressing their translation [17]. Cancer, including leukemia, is characterized 
by globally aberrant miRNA expression patterns which are highly informative for tumor 
classification. Remarkably, in poorly differentiated tumors, miRNA expression profiles can 
successfully classify these tumors in contrast to mRNA expression profiles [18]. In AML, 
genome-wide, large-scale miRNA expression profiles showed that miRNAs are associated 
with specific AML subtypes and may serve as biomarkers for classification and diagnosis 
of AML subtypes [19-23].  Several of those miRNA expression profiling studies showed the 
association of miRNA expression profiles with the outcome of AML patients [22-25]. Like 
in AML, miRNA expression signatures have been shown to be associated with prognosis of 
ALL patients [15]. Moreover, miRNA expression patterns showed to reflect the lineage state 
of acute leukemia [15,16,18]. Interestingly, from the 27 miRNAs differentially expressed 
between ALL and AML two were sufficient to accurately (97-99%) identify the myeloid or 
lymphoid identity of these AL [16]. In another study, 16 miRNAs (mir-23a, mir-27a/b, mir-
128a, mir-128b, mir-221, mir-222, mir-223, let-7b, mir-17, mir-20a, mir-29a/c, mir-29b, mir-
146a, mir-150, mir-155, and mir-196b) were found to be differentially expressed between 
AML and ALL [15]. 
Because miRNA expression profiles can classify AL cases as either AML or ALL [15,16,18] 
we decided to investigate the miRNA expression profile of AL cases that do not have a clear 
lineage commitment based on immunophenotypical marker expression. We compared 
the miRNA expression profiles of leukemia cases of ambiguous lineage with those of ALL 
and AML cases and showed that the cases with an ambiguous lineage do not segregate 
as a separate entity but have miRNA expression profiles similar to either AML, B-ALL or 
T-ALL. Thus, AL without clear immunophenotypic lineage commitment can be classified as 
either AML or ALL based on their miRNA expression profile. This classification might help 
the diagnosis of AL of ambiguous lineage as either AML or ALL and therefore in treatment 
decision making.
Material and Methods
Patient samples and cell lines
Sixteen patients with a leukemia of ambiguous lineage and 12 patients with AML, B-ALL 
or T-ALL were selected by database review of all patients with acute leukemia treated at 
the VU University Medical Center, Amsterdam, The Netherlands from 2000 until 2012. 
The 12 AML, B-ALL and T-ALL samples were selected based on a clear immunophenotypic 
myeloid or lymphoid lineage commitment. Immunophenotypical analysis was performed 
on bone marrow (BM) samples or peripheral blood (PB) samples in case no BM samples 
were available. The use of AML patient material for this study and the informed consent 
procedure has been approved by the medical ethical committee (MEC) of our institute. 
Bone marrow or peripheral blood samples from 16 patients diagnosed with a leukemia of 
ambiguous lineage and 17 patients with AML (n=7), B-ALL (n=6) or T-ALL (n=4) were used 
for miRNA expression analysis. Cell lines HL60 (CCL-240) and CCRF-CEM (CCL-119) were 
obtained from ATCC (American Type Culture Collection, Manassas, VA, USA).
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Immunophenotypic analysis
Analysis was carried out as part of regular diagnostic investigations. In short, red blood 
cells were lysed using Pharm Lyse lysing solution (BD Biosciences, San Jose, CA), washed 
with phosphate buffered saline (PBS) and incubated with antibodies defining or specific 
for the B cell, T cell and myeloid lineage. Samples were analyzed with four-color flow 
cytometry on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA). The following 
Fluorescein isothiocyanate (FITC), Phycoerythrin (PE), Peridinin chlorophyll protein (PerCP) 
or Allophycocyanin (APC) antibodies were used:  CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, 
CD11b, CD11c, CD13, CD14, CD15, CD19, CD20, CD22, CD25, CD33, CD34, CD36, CD42b, 
CD45, CD56, CD61, CD64, CD65, CD71, CD90, CD117, CD133 and anti-HLA-DR. Cytoplasmic 
markers CD3, CD22, IgM, cCD79a, cTdT and cMPO were evaluated after fixation with 
paraformaldehyde and subsequently permeabilization with Facs Lyse (Becton Dickenson, San 
Jose, CA). Antibodies were purchased from: BD Biosciences, Zebra biosciences (Enschede, 
The Netherlands), Dako (Glostrup, Denmark) or Sanquin (Amsterdam, The Netherlands). 
Data analysis was performed using CellQuest Pro software (BD Biosciences). Blasts were 
defined by low side scatter (SSC), diminished or low CD45 expression and CD34 expression. 
In case of CD34 negative AL, blasts were selected using other immature markers such as 
CD117, CD133, CD10 and cIgM. For defining the B-lymphoid lineage of a MPAL according 
to the WHO2008 criteria, CD19 should be highly expressed on blasts. We considered blasts 
strongly positive for CD19 if at least 20% of the population was positive as compared with 
the appropriate isotype control combined with a mean fluorescence intensity as high as, or 
higher than normal B cells within the same sample. When normal B cells were absent, we 
compared expression levels with historical normal controls [1-3,5].
Molecular diagnostics and cytogenetic analysis
Mononuclear cells were isolated using Ficoll-Paque Plus (Amersham Biosciences, Uppsala, 
Sweden) and subsequently snap frozen. DNA and/or total RNA was isolated from the cell 
pellets and used for determination of presence of translocations; t(9;22), t(8;21), t(15;17), 
MLL and FLT3-ITD by PCR following institutional standard operating procedures (www.
modhem.nl). Chromosomal analysis was performed on pretreatment bone marrow at 
diagnosis. Specimens were processed using short term unstimulated cultures. Chromosome 
banding was performed by the use of standard techniques, and karyotypes were described 
according to the International System for Human Cytogenetic Nomenclature.
Cell purification
BM or PB cells derived from AL patients and stored in liquid nitrogen were thawed, washed 
and labeled with fluorochrome-conjugated antibodies. In general, blasts were stained with 
CD45, CD34 and various patient specific markers, mostly CD3, CD7, CD19, CD10, CD13 and 
CD33. The blast population from all AL cases  were sorted by flow cytometry using FACS 
ARIA Cell Sorter (BD Biosciences, Franklin Lakes, NJ, USA)
RNA isolation and miRNA expression analysis
Total RNA was isolated with the NucleoSpin miRNA kit (Macherey-Nagel, Düren, Germany) 
according to manufacturer’s protocol. RNA was concentrated using a vacuum concentrator 
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(SPD111V, Thermo Savant) and the concentration was measured with a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific; Wilmington, DE). Human miRNA microarrays 
(Agilent Technologies; Palo Alto, CA), containing 60.000 probes representing 1205 human 
and 144 human viral miRNAs were used for miRNA expression profiling according to the 
manufacturers protocol. In short, 100ng of total RNA from each sample was dephosphorylated 
with Calf Intestinal Alkaline Phosphatase (CIP) and then ligated with a Cyanine3-pCp molecule 
using Agilent miRNA Complete Labeling and Hyb Kit (Agilent Technologies; Palo Alto, CA). 
Labeled RNA was hybridized to Human miRNA microarray for 20 hours at 55°C.  Microarray 
slides were scanned using a High-Resolution C Scanner (Agilent Technologies) and images 
were analyzed with Feature Extraction TM software, version 10.5.1.1 (Agilent). Microarray 
data are available on Array Express (accession no. E-MTAB-1459). The expression of several 
miRNAs was confirmed by Quantitative Real-Time Polymerase Chain reaction (Q-RT-PCR). 
Quantitative Real-Time Polymerase Chain Reaction
Selection of the most differentiating miRNAs in our cohort was performed using Significance 
Analysis of Microarrays (SAM) on the myeloid and lymphoid cluster as was formed by 
unsupervised clustering of all samples (controls combined with AL of ambiguous lineage). 
The five miRNAs with the highest observed relative difference were selected. This signature 
included; miR-23a, miR-27a, miR-221, miR-223 and miR-199b-5p (supplemental table 4). 
Specific primers (Applied Biosystems) for these five lineage discriminating miRNAs were 
used for Q-RT-PCR validation. RNU48 and miR-378, a miRNA which is highly expressed, 
has minimal variation in expression between samples and is not discriminative between 
AML and ALL, were used as control. PCR was performed on a 7300 Real-Time PCR System 
(Applied Biosystems). All experiments were performed in duplicate and Ct-values were 
averaged. Expression was calculated using 2^-ΔCT method, log2-transformed and analyzed 
with BRB-ArrayTools.
Data analysis
Green median signal values from the microarray data were normalized using the quantile 
method [26], and log2-transformed. As the arrays included probes mapping a set of 1347 
miRNAs spotted multiple times, we averaged the probes representing the same miRNA. 
The comparisons of the individual miRNAs between samples of the different lineage groups 
were performed using a linear regression model. This model  takes advantage of the large 
number of miRNAs simultaneously studied to improve upon the individual estimates by 
means of empirical Bayes [27]. P-value lists for each comparison were corrected by multiple 
testing using the step-up false discovery rate (FDR) procedure of Benjamini-Hochberg [28]. 
Each miRNA was considered as differentially expressed between groups if its corresponding 
FDR was up to 0.05, unless otherwise stated.
Hierarchical clustering was used to produce false-color heatmaps illustrating the data 
patterns. The clustering used average linkage and one-minus-correlation as distance 
measure.
Analyses were performed using the statistical package R (version 2.14.0) [29], the package 
limma [30] for empirical Bayes linear regression, and BRB-ArrayTools (version 4.2.0) for 
producing the heatmaps.
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Figure 1: MiRNA expression signatures discriminate between AML, B-ALL and T-ALL. (A) The top 
10 percent of most variable miRNAs were selected (n=134) for unsupervised clustering analysis of 
the AL samples. AML samples cluster separately from ALL samples. Within the ALL cluster, B-ALL 
and T-ALL samples can be discriminated. (B) Unsupervised clustering of the AL samples using the 32 
miRNA literature based signature. AML and ALL can be discriminated using previously reported lineage 
specific miRNA expression. In both A and B the columns represent patients; rows represent miRNAs; 
blue, AML samples; red, T-ALL samples; green, B-ALL samples; 
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MicroRNAs are differentially expressed between ALL and AML
To confirm the already observed differential expression of miRNAs in AML, B-ALL and 
T-ALL we analyzed the miRNA expression profiles of several AML, T-ALL and B-ALL cases. 
Blasts were purified by flow cytometry, RNA was isolated and hybridized with miRNA-
arrays (Agilent). The microarray data was normalized and the miRNAs with the highest 
mean absolute deviation (highest variation in expression between samples) were selected 
for further analysis. The subsequent unsupervised clustering analysis of these AL control 
samples generated two separate clusters. One cluster that contained all AML samples while 
the other contained all the ALL samples. This lymphoid cluster could be further separated 
in a T-ALL and B-ALL cluster (figure 1A). Next, we performed a Linear Model for Microarray 
Analysis (LIMMA) on these AML and ALL samples to see whether we could identify a similar 
miRNA profile as previously described that discriminates between the myeloid and lymphoid 
lineage [15,16]. The ten most significant miRNAs that are able to discriminate between AML 
and ALL are shown in table 1. One of these miRNAs (mir-150) showed enhanced expression 
in ALL as compared to AML, whereas the other nine miRNAs are higher expressed in AML 
as compared to ALL (miR-223, miR-199b-5p, miR-199a-3p, miR-27a, miR-27b, miR-23a, 
miR-340, miR-340* and miR-221). Seven of these 10 lineage discriminating miRNAs were 
described by others to discriminate between ALL and AML [15,16]. 
Since previous reports have described lineage discriminating miRNA signatures we used 
these discriminative miRNAs on our AML and ALL samples. In the study by Mi et al. [16] 
twenty-seven miRNAs were found to be significantly differentially expressed between 
the two subtypes of AL. In the study by Wang et al. [15], 16 miRNAs were differentially 
Table 1. miRNAs are differentially expressed between AML and ALL
Gene AMLvsALL t AMLvsALL p AMLvsALL FDR Max expression in 
dataset (selected 
>6)
hsa-miR-199b-5p -8,602706 0,000006 0,003259 7,61
hsa-miR-27b -8,449291 0,000007 0,003259 6,94
hsa-miR-150 8,393688 0,000007 0,003259 10,94
hsa-miR-199a-3p -7,008514 0,000035 0,011802 7,40
hsa-miR-223 -6,165671 0,000102 0,024114 13,21
hsa-miR-27a -6,126263 0,000107 0,024114 10,06
hsa-miR-340* -5,858288 0,000154 0,028143 6,68
hsa-miR-340 -5,731613 0,000183 0,028143 6,68
hsa-miR-23a -5,481022 0,000260 0,033675 10,26
hsa-miR-221 -5,293199 0,000340 0,038177 8,26
NOTE: Ten miRNAs were found to be differentially expressed betweenAMLand ALL (B-ALL and T-ALL) 
by LIMMA. “Max. expression in dataset” refers to the highest expression found in all samples for 
that particular miRNA. MiRNAs were considered expressed when median signal values after log2 
transformation and normalization were higher than 6.0. “AML versus ALL t” represents moderated 
t statistic values, “AML versus ALL P” represents P values. “AML versus ALL FDR” represents false 
discovery rate.
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expressed between AML and ALL. To generate a robust literature based miRNA signature 
we integrated the miRNA lists from these two studies which resulted in a miRNA signature 
containing 32 miRNAs (supplemental table 1). Using these 32 miRNAs in an unsupervised 
clustering analysis of our miRNA expression results we were able to define our control AL 
samples as either AML or ALL in the correct way (figure 1B). Moreover, using the expression 
of these 32 miRNAs, even the segregation of the lymphoid cluster in a B-ALL and T-ALL group 
was seen. Thus, our miRNA expression profiles can discriminate between AML and ALL in an 
unsupervised clustering approach by using either the most variable 10% expressed miRNAs 
or the 32 miRNA signature that was published before. These results confirm the potential 
of miRNA expression profiling in classification of AL as either belonging to the myeloid or 
lymphoid lineage.
Leukemias of ambiguous lineage are not a distinctive entity. 
Because the immunophenotype of cells is a limited reflection of the genotype and, as shown 
before, miRNA expression profiling can identify AL cases as either AML or ALL we analyzed 
the miRNA expression profiles of 9 AL cases of ambiguous lineage and compared these 
profiles with the AML, B-ALL and T-ALL samples. Using LIMMA we analyzed the expression 
of all the miRNAs in the four morphological and immunophenotypical defined groups of AL 
cases (AML, B-ALL, T-ALL and AL of ambiguous lineage) (supplemental table 4A-C). First, this 
showed that there is no significant difference in overall expression pattern observed in AL 
cases of ambiguous lineage as compared to AML samples (lowest false discovery rate, FDR 
>0.26), indicating that AL of ambiguous lineage was not significantly different from AML. 
However, when comparing the overall miRNA expression of the AL of ambiguous lineage 
with B-ALL cases, the miR-320 family (miR-320a/b/c/d/e) was found to be differentially 
expressed. Furthermore, the ambiguous lineage samples showed differential expression of 
miR-29c and miR-513a-5p when compared to T-ALL. This differential expression of miR-29c, 
miR-513a-5p and the miR-320 family is also observed between B-ALL and T-ALL samples 
(supplemental table 4D), likely indicating that the differential expression of these miRNAs is 
a direct result of intrinsic differential expression between B-ALL and T-ALL. Thus, we did not 
observe a distinctive pattern of overall miRNA expression between AL of ambiguous lineage 
and AML or ALL cases, suggesting that AL cases of ambiguous lineage are not a separate 
entity.  
Leukemias of ambiguous lineage can be assigned to the lymphoid or myeloid lineage by 
miRNA expression profiling.
To study whether miRNA expression analysis is able to identify the myeloid or lymphoid 
origin of the leukemias of ambiguous lineage, we performed unsupervised clustering of the 
miRNA expression of the AL cases with ambiguous lineage as well as the AML and ALL cases 
(11 AL cases and 9 AL cases with ambiguous lineage). This resulted in the identification of 
three AL groups, a myeloid group containing all AML samples and a lymphoid group that 
could be further divided in B-ALL and T-ALL (figure 2A). The miRNA expression signatures of 
the leukemias with ambiguous lineage showed great resemblance with the B-ALL, the T-ALL 
or the AML miRNA signature, resulting in grouping of these leukemias with either one of 
the AL groups (figure 2A). Using the 32 miRNA literature based signature in an unsupervised 
way on all our samples (figure 2B) showed as well grouping of leukemias with ambiguous 
lineage with either AML, T-ALL or B-ALL.
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Figure 2. Leukemias of ambiguous lineage show similar expression profiles as either AML, B-ALL or 
T-ALL cases. (A) Unsupervised hierarchical clustering was performed using all AL samples. Leukemias of 
ambiguous lineage show similar expression profiles as AML, B-ALL or T-ALL. (B) Unsupervised clustering 
using the 32 miRNA literature based signature. Columns represent patients; rows represent miRNAs; blue, 
AML samples; red, T-ALL samples; green, B-ALL samples; purple, AL of ambiguous lineage.
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All together, our results show that leukemias without a clear immunophenotypic lineage 
commitment do not display a distinct miRNA expression profile but one that can classify 
these leukemias as either of the myeloid or the lymphoid lineage. 
Acute leukemia of ambiguous lineage can be classified as ALL or AML by Q-RT-PCR 
expression analysis of a small selection of miRNAs.
AL patients are either treated with an ALL or an AML treatment protocol and the assignment 
of AL cases of ambiguous lineage as either one of those AL subtypes is therefore of most 
relevance. To investigate the feasibility of classification of AL cases of ambiguous lineage as 
either AML or ALL by the expression of only a limited set of miRNAs, we selected the top five 
significantly differentially expressed miRNAs that could distinguish between AML and ALL 
(supplemental table 3). These five miRNAs, miR-23a, miR-27a, miR-223, miR-221 and miR-
199b, are as well present in the top list of differentially expressed miRNAs between AML and 
ALL in two published studies (15,16). We analyzed the expression of these miRNAs by Q-RT-
PCR in 19 AL cases that were used for the array hybridization (9 AL of ambiguous lineage, 5 
ALL and 5 AML cases) as well as an additional 8 AL samples of ambiguous lineage, three ALL 
cases (two T-ALL, one B-ALL), two AML cases, the AML cell line HL60 and the T-ALL cell line 
CCRF-CEM. The expression profile of miR-23a, miR-27a, miR-221, miR-223 and miR-199b 
could discriminate two groups of AL cases, a myeloid and lymphoid group (figure 3). The 
nine AL of ambiguous lineage cases (unique patient number; UPN3, 5, 6, 7, 8, 12, 13, 18, 19) 
grouped in a similar fashion with either the AML or ALL cases by this Q-RT-PCR analysis as by 
array analysis. Moreover, the additional 8 AL of ambiguous lineage cases analyzed by Q-RT-
PCR grouped either with the AML group or with the ALL group. Thus, the sole expression of 
five specific miRNAs using Q-RT-PCR can assign AL cases of ambiguous lineage as either from 
the lymphoid or myeloid lineage.
Correlation of immunophenotypic marker expression and miRNA classification.
The diagnosis of AL as either AML or ALL according to their miRNA expression profile might 
correlate with specific expression of one or more immunophenotypic markers already used 
to classify these leukemias. MiRNA profiling diagnosed 8 out of 17 leukemias of ambiguous 
lineage as AML and 9 cases as ALL. Overall the diagnosis according to the WHO2008 
showed a more similar assignment to AML or ALL with the miRNA expression profiles 
than the WHO2001 criteria. This was most clear in samples that showed a myeloid miRNA 
expression profile from which 7 out of 8 samples were diagnosed as AML by the WHO2008 
criteria. In cases were miRNA profiling indicated a lymphoid origin the WHO2001 criteria 
were more likely to diagnose a lymphoid AL than the WHO2008 criteria. Three patients 
(UPN 13, 18, and 22) showed expression of several lymphoid markers (either B lymphoid 
or T lymphoid) in combination with cMPO as single myeloid maker (supplemental table 2). 
However, with miRNA expression profiling these cases showed a clear ALL profile (figure 3). 
This might indicate that the importance of expression of cMPO as a single myeloid marker 
in the classification as leukemia of ambiguous lineage is overestimated. Importantly, even 
in the absence of informative immunophenotypic markers, miRNA expression profiling can 
assign a lineage to these AL cases with undefined immunophenotypic lineage. For two of 
the AL of ambiguous lineage patients (UPN 12 and UPN 27) the diagnosis was unclear due to 
absence of cCD3, cMPO and absence or low expression of CD19; miRNA profiling clustered 
these samples clearly within the AML group (UPN 12) and ALL group (UPN 27). Another two 
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Figure 3. Unsupervised clustering of AL samples based on Q-RT-PCR expression analysis of miR-
223, miR-199b, miR-221, miR-27a and miR-23a. MiRNA expression analysis using Q-RT-PCR and 
unsupervised clustering resulted in two separate groups, an AML and ALL group. UPN, Unique patient 
number; WHO2001, diagnosis when using WHO2001 criteria; WHO2008, diagnosis when using 
WHO2008 criteria; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoid leukemia; T-ALL, T-cell 
acute lymphoid leukemia; B/My, BAL/MPAL expressing B-lymphoid and myeloid markers; T/My, BAL/
MPAL expressing T-lymphoid and myeloid markers; B/T/My, trilineage BAL/MPAL; UAL, unclassifiable 
acute leukemia; CL, cell line
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leukemias of ambiguous lineage expressed markers of all three lineages (UPN 5 and UPN 25) 
but miRNA analysis assigned these both to the lymphoid lineage. Both these cases and UPN 
22 were the only cases expressing cCD3 and all showed an underlying lymphoid lineage of 
origin possibly indicating the specificity of cCD3 in lymphoid lineage commitment.  
Discussion
AL of ambiguous lineage differs from ALL in atypical myeloid or combined B and T lymphoid 
antigen expression and from AML in atypical lymphoid antigen expression. However, the 
immunophenotype of AL, as detected by flow cytometry, is merely a limited reflection of 
the genotypic state. Therefore, we hypothesized that miRNA based classification might 
help to distinguish between a predominant myeloid or lymphoid origin of AL of ambiguous 
lineage. Our results indicate that AL of ambiguous lineage is not a separate entity but can be 
traced back to one of the hematopoietic lineages, lymphoid or myeloid. 
Reported data of gene expression profiling on thirteen pediatric MPAL cases showed that 
eight of the thirteen cases have a signature different from AML and B- or T-ALL. Whereas, 
the remaining five cases grouped with the myeloid leukemias [31]. In contrast to our 
data, these data suggest that at least a part of the leukemias of ambiguous lineage can be 
assigned as a separate identity by gene expression profiling. However, the separate group 
clustered very close to the B-ALL group, suggesting it could as well be a subtype within 
B-ALL. Since miRNA expression profiling has shown to be more successful in classification of 
tumors than gene expression profiling [31] we hypothesized that miRNA expression profiling 
might be superior in classification of leukemias without clear immunophenotypic lineage 
commitment. Indeed, our results show a classification of AL cases with ambiguous lineage 
as either AML, T-ALL or B-ALL. The difference in classification of leukemias of ambiguous 
lineage by gene expression profiling [18] and miRNA expression profiling is possibly due to 
the fact that miRNAs target a large panel of genes influencing a diverse network of signaling 
pathways. As a consequence, miRNA expression profiling might be superior over gene 
expression profiling in classification of cancers belonging to the same subtype since subtype 
classification is based on common impaired signaling pathways. Moreover, using miRNA 
expression profiling to define subclasses of leukemia might be more promising than mRNA 
profiling since miRNAs are more stable and can be used in smaller numbers than genes.
We identified five miRNAs that could be used to assign AL cases of ambiguous lineage to 
either AML or ALL. All of these five miRNAs have previously been reported to be associated 
with AML, such as miR-199b and miR-221 [16]. Furthermore, miR-223 has been show to 
function as a gene that plays a critical role in myeloid functions and differentiation [18,32]. 
MiR-23a and miR-27a are, together with miR-24-2, located in the same cluster which is 
regulated by PU-1. Each of these miRNAs are more abundantly expressed in myeloid as 
compared to lymphoid cells and both miR-23a and miR-27a are implicated in regulating the 
development of cells into the myeloid or lymphoid lineage [33]. In contrast to Wang et al 
[15], we could not use miR-222 to discriminate between ALL and AML, due to high expression 
of miR-222 in several of the B-ALL samples. All of the five selected miRNAs have enhanced 
expression in AML as compared to ALL which is due to their enhanced discriminative 
character as compared with miRNAs higher expressed in ALL. This is probably due to the 
fact that most miRNAs have increased expression in either B- or T-ALL and not in lymphoid 
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AL in general. The most significantly discriminative miRNA with enhanced expression in ALL 
was miR-150. Since at diagnosis, the discrimination between myeloid or lymphoid is most 
relevant, no miRNAs associated with only B-ALL or T-ALL were selected.
MiRNA profiling diagnosed 8 out of 17 leukemias of ambiguous lineage as AML and 9 cases 
as ALL. Since it might be that the karyotype and molecular aberrancies have an effect 
on miRNA expression and thereby potentially influence our clustering, we analyzed the 
distribution of the cytogenetic and molecular aberrations over the myeloid and lymphoid 
assigned AL of ambiguous leukemia groups. The most frequent cytogenetic abnormality 
was translocation t(9;22) which was positive in five leukemias of ambiguous lineage (UPN6, 
8, 13, 27 and 33). Three of these cases had a miRNA profile that was similar to the ALL cases 
while the other two clustered with the AML cases. This indicates that despite an identical 
karyotype the microRNA expression profile is able to distinguish myeloid and lymphoid 
leukemia, suggesting that lineage specificity influences the microRNA expression profile 
more than the presence of cytogenetic and/or molecular aberrancies. Furthermore this 
suggests that translocation of BCR and ABL is not decisive in whether an AL is assigned 
to the myeloid or lymphoid lineage but that lineage commitment of AL with the BCR-ABL 
translocation is likely determined by the cell of origin receiving the mutation.  
When we retrospectively classified the AL cases with ambiguous lineage containing 
an AML miRNA expression profile according to the WHO2001, all were diagnosed as 
AL with ambiguous lineage; while according to the WHO2008 seven out of eight cases 
were classified as AML. The other AL case with ambiguous lineage with an AML miRNA 
expression profile could not be classified using the WHO2008 criteria due to absence of 
CD19, cCD3 and cMPO. In the group AL with ambiguous lineage that had an ALL miRNA 
expression profiling, four out of nine cases were diagnosed as ALL by the WHO2001 criteria 
whereas only one out of nine cases was diagnosed as ALL by the WHO2008 criteria. Thus, 
classification by the criteria of the WHO2008 is less accurate in assigning ALL to the group 
of leukemias with a lymphoid miRNA expression profile than WHO2001, whereas it’s more 
accurate in assigning an AL case with a AML miRNA expression profile as an AML .The 
immunophenotypic classification of AL cases to the myeloid lineage is done when cMPO 
is expressed as a single myeloid marker. This leads to assignment of AL cases containing an 
ALL miRNA expression profile, but with cMPO expression as a single myeloid marker, to the 
group of leukemias of ambiguous lineage. This might partly explain the better response to 
ALL treatment protocols of AL cases with ambiguous lineage [12]. 
Acute leukemias with ambiguous lineage are associated with a poor prognosis as compared 
to AML and ALL cases [7-11]. The poor prognosis of these leukemias might be due, at least 
partly, to their mistreatment. However, leukemias with ambiguous lineage have been 
shown to be associated with several poor prognostic factors such as CD34+ phenotype, an 
unfavorable karyotype and PgP over-expression [7,9]. Our group was to small to perform 
survival analysis. However, generally overall survival was poor (median 20 months, range 
5-110 months) for AL of ambiguous lineage.
The 5-year overall survival rate of patients with AML is considerably lower than of ALL 
patients and indeed, ALL patients have a better response to standard chemotherapy than 
AML patients in almost every age group [34]. This indicates that accurate diagnosis of all 
AL cases as either AML or ALL is crucial for selection of the appropriate therapy. To base 
treatment decisions on miRNA expression profiles it is crucial that the results of a microRNA 
expression test can be obtained within the timeframe of the start of appropriate treatment. 
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Our experience is that the turnaround time from isolation of the leukemic blasts to obtaining 
miRNA expression results can easily be done within 1.5 day making it rapid and within the 
time where a treatment decision has to be made. Whether treatment decisions based on 
miRNA expression profiles improve outcome of patients with AL of ambiguous lineage is 
difficult to determine since these leukemias are very rare and effect of treatment can only 
be measured in large randomized trials.
Our finding that expression analysis of five miRNAs could accurately classify AL cases with 
ambiguous lineage as AML or ALL might add to the already used methods to classify these AL 
cases of ambiguous lineage. In conclusion, our results indicate that leukemias of ambiguous 
lineage are not an unique entity but can be classified as either AML or ALL using miRNA 
expression profiling. 
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Supplemental material
Supplemental table 1. Literature based signature. Result of integrating the lineage discriminating 
miRNAs previous reported by Mi et al. [15] and Wang et al. [14]. Both reports described miRNAs that 
could discriminate between AML and ALL, 27 and 16 respectively. Ten miRNAs that were found by 
Mi et al. were also investigated by Wang et al. However, differential expression between AML and 
ALL could not be confirmed for two of them. The integration of all reported lineage discriminating 
miRNAs (excluding the two unconfirmed miRNAs) generated a literature based signature containing 
32 miRNAs.
Supplemental table 1
1 hsa-let-7a 17 hsa-miR-21
2 hsa-let-7b 18 hsa-miR-210
3 hsa-let-7c 19 hsa-miR-22
4 hsa-let-7e 20 hsa-miR-221
5 hsa-miR-125a-3p 21 hsa-miR-222
6 hsa-miR-128 22 hsa-miR-223
7 hsa-miR-130a 23 hsa-miR-23a
8 hsa-miR-130b 24 hsa-miR-24
9 hsa-miR-146a 25 hsa-miR-27a
10 hsa-miR-150 26 hsa-miR-27b
11 hsa-miR-151-5p 27 hsa-miR-29a
12 hsa-miR-155 28 hsa-miR-29b
13 hsa-miR-17 29 hsa-miR-29c
14 hsa-miR-196b 30 hsa-miR-335
15 hsa-miR-199b-5p 31 hsa-miR-424
16 hsa-miR-20a 32 hsa-miR-451
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Supplemental Table 2 (next page). Patient characteristics The results of immunophentyping 
by flow cytometry of 17 AL of ambiguous lineage patients. Markers are indicated when 
expressed with a fluorescence intensity of > 10% of the appropriate antibody control. 
Discrimination is made between weak or strong for CD19, cCD22, and CD10. Strong 
expression (“s”) is defined as higher or as high as the expression on non-malignant cells in 
the same sample or, known from healthy donors. Weak expression (“w”) is defined when 
the expression level does not reach expression of corresponding normal cells. Monoblastic 
appearance is defined by expression of CD14 and CD11c.  UPN, Unique Patient Number; 
WHO2001, diagnosis when using WHO2001 criteria; WHO2008, diagnosis when using 
WHO2008 criteria; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoid leukemia; 
T-ALL, T-cell acute lymphoid leukemia; B/My, BAL/MPAL expressing B-lymphoid and 
myeloid markers; T/My, BAL/MPAL expressing T-lymphoid and myeloid markers; B/T/My, 
trilineage BAL/MPAL; UAL, unclassifiable acute leukemia; CD, cluster of differentiation; 
cTdT, terminal deoxynucleotidyl transferase; cMPO, cytoplasmic myeloperoxidase; cCD3, 
cytoplasmic CD3; cIgM, cytoplasmic immunoglobulin M; t(9;22), t(8;21), t(15;17), MLL, 
FLT3-ITD, Inv(16) are cytogenetic aberrancies analyzed by molecular diagnostics; Neg, 
negative for molecular aberrancy; Pos, positive for molecular aberrancy; ND, not done; 
n.a., not available; #, no CML prephase was present; Karyotype, analysis conducted by 
cytogenetic analysis; Complex*, 45,XX,+1,der(1;15)(p10;q10),-3,del(5)(q13q33),del(9)
(q2?2),add16(p13),-17,-1,+21,add(22)(p11),+mar; Complex**, 46,XX,t(9;22)(q34:q11,2) 
[4] 47,XX,t(9;22)(q34;q11,2),der(22),t(9;22) [1] 46,XX [15].
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Supplemental table 2. 
UPN B-cel markers T-cel markers Myeloid markers Monoblastic 
appearance
Age WHO 
2001
B/My
3 CD79aw,
 cCD22w, CD10w 
CD4, CD5,  
CD10w
CD13, CD33, 
CD117, cMPO
neg 28 B/My
6 CD19w, CD79aw, 
cTdT
CD4, CD7, 
cTdT
CD13, CD33, C
D117, cMPO
neg 52 B/My
8 CD19w, CD79aw, 
CD10s, cTdT
CD7, CD10s , 
cTdT
CD13, CD33, 
cMPO
neg 72 B/My
13 CD19s, CD79as,
 CD10s, CD20, 
cTdT
CD4, CD10s, 
cTdT
cMPO neg 65 B-ALL
18 CD19s, CD10s,
 cTdT
CD10s, cTdT cMPO neg 13 B-ALL
19 CD19s, CD79as, 
CD10s, cTdT
CD10s, cTdT CD13, cMPO neg 9 B/My
21 CD19s, CD79as, 
CD10s, cTdT
CD4, CD10s, 
cTdT
CD13, cMPO neg 14 B/My
23 CD19w, CD79aw, 
cTdT
cTdT CD13, CD33, 
CD117, cMPO
neg 1 B/My
24 CD10, CD20, 
cIgM
CD7, CD10 CD13, CD33, CD117, 
CD15, cMPO
neg 52 B/My
27 CD19w, CD10, 
cTdT
CD10, cTdT CD13, CD33 neg 62 B-ALL
28 CD19w, CD97aw, 
cCD22w, cTdT
CD4, cTdT CD13, CD33, CD15, 
CD117, CD133, 
cMPO
neg 75 B/My
33 CD19s, CD79as, 
CD10s, cTdT
CD4, CD10s, 
cTdT 
CD13, CD15, CD33, 
cMPO
neg 41 B/My
T/My
7 none CD2, CD4, CD5, 
CD7
CD13, CD33, CD15, 
CD65, CD117,
 cMPO
neg 72 T/My
12 CD10 CD2, CD4, CD5, 
CD7, CD10
CD13, CD33,
 CD117
neg 67 T/My
22 cTdT CD2, CD5, CD7, 
CD8, cytCD3, cTdT
cMPO neg 24 T-ALL
B/T/My
5 CD79aw, CD10w, 
cTdT
cytCD3, CD2, CD4, 
CD5, CD7, CD8, 
CD10w, cTdT
CD13, cMPO neg 75 B/T/My
25 CD79aw, cTdT CD2, CD7, cytCD3, 
cTdT
CD13, CD15, 
CD117, CD65
neg 16 B/T/My
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Supplemental table 2, continued
UPN WHO 
2008
Karyotype t(9;22) t(8;21) t(15;17) inv(16) MLL FLT3-
ITD
B/My
3 AML Complex* neg. neg. neg. neg. neg. norm.
6 AML 46,XY,t(9;22)
(q34;q11.2) 
Pos. 
e14a2# 
ND ND ND ND ND
8 AML n.a. Pos. 
e13a2# 
neg. neg. neg. neg. norm.
13 B/My Complex** Pos. 
e1a2# 
ND ND ND neg. ND
18 B/My 46,XX neg. neg. neg. neg. neg. norm.
19 B/My n.a. neg. ND ND ND neg. ND
21 B/My 46,XY,t(9;9) 
(p?13;q?12) 
neg. neg. neg. neg. neg. norm.
23 AML n.a. neg. neg. neg. neg. neg. norm.
24 AML n.a. neg. neg. neg. neg. neg. ND
27 UAL 46,XX,t(9;22)
(q34;q11.2)
Pos. 
e1a2# 
neg. neg. neg. neg. norm.
28 AML n.a. n.a. n.a. n.a. n.a. n.a. n.a.
33 B/My 46,XX,t(9;22) 
(q34;q11.2) 
Pos. 
e14a2# 
neg. neg. neg. neg. norm.
T/My
7 AML 46,XY,t(3;3)
 (q21;q26) 
neg. neg. neg. neg. neg. norm.
12 UAL 46,XX,t(2;3)
 (p23;q26),-
7,+mar 
neg. neg. neg. neg. neg. norm.
22 T/My 46,XY neg. ND ND neg. neg. ND
B/T/My
5 T/My n.a. neg. neg. neg. neg. neg. norm.
25 T-ALL n.a. neg. ND ND ND neg. ND
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Supplemental Table 3. Significance analysis of microarray (SAM) identifies 36 significantly discriminative 
miRNAs between the myeloid and lymphoid clusters obtained from unsupervised clustering analysis 
of all samples (figure 1A). 
The five microRNAs (miR-23a, miR-27a, miR-221, miR-223 and miR-199b) with the highest relative 
difference (d(i)) distinguishing AML from ALL were selected. Geometric mean intensity in AML and ALL 
as well as the fold change is indicated.
Supplemental Table 3
#
 
d(i) Geom mean of 
intensities in 
lymphoid leukemia
Geom mean of 
intensities in 
myeloid leukemia
Fold-change Symbol
1 -6.331 132.3 985.5 0.13 hsa-miR-27a
2 -5.997 38.8 111.9 0.35 hsa-miR-199b-5p
3 -5.617 152.2 941.8 0.16 hsa-miR-23a
4 -5.493 38.4 109.4 0.35 hsa-miR-199a-3p
5 -5.077 603.9 6323.6 0.10 hsa-miR-223
6 -5.043 78.0 238.2 0.33 hsa-miR-221
7 -4.137 148.7 530.5 0.28 hsa-miR-24
8 4.119 671.5 90.2 7.45 hsa-miR-150
9 -3.541 764.5 1980.0 0.39 hsa-miR-21
10 3.524 893.6 484.3 1.85 hsa-miR-25
11 3.417 288.3 118.8 2.43 hsa-miR-130b
12 -3.184 48.4 83.8 0.58 hsa-miR-340
13 3.109 1238.5 678.9 1.82 hsa-miR-106b
14 -2.840 47.0 68.3 0.69 hsa-miR-221*
15 2.746 73.8 44.6 1.66 hsa-miR-7
16 2.661 77.2 50.2 1.54 hsa-miR-625
17 2.563 845.4 526.6 1.61 hsa-miR-142-5p
18 2.560 340.6 172.7 1.97 hsa-miR-342-3p
19 2.505 117.4 86.4 1.36 hsa-miR-590-5p
20 2.495 180.0 81.1 2.22 hsa-miR-128
21 -2.410 34.1 41.6 0.82 hsa-miR-181c*
22 -2.408 40.9 51.4 0.80 hsa-miR-340*
23 -2.399 167.5 587.8 0.28 hsa-miR-130a
24 -2.368 80.3 186.9 0.43 hsa-miR-146b-5p
25 2.364 60.7 48.8 1.24 hsa-miR-454
26 2.324 1039.4 598.9 1.74 hsa-miR-29c
27 2.267 207.4 138.0 1.50 hsa-miR-320b
28 2.192 139.4 99.1 1.41 hsa-miR-140-3p
29 2.156 238.5 164.3 1.45 hsa-miR-320e
30 2.123 47.7 37.2 1.28 hsa-miR-210
31 2.089 76.9 57.9 1.33 hsa-miR-28-5p
32 2.072 54.0 44.0 1.23 hsa-miR-342-5p
33 2.064 100.8 74.0 1.36 hsa-miR-320a
34 2.041 326.0 220.4 1.48 hsa-miR-320d
35 2.022 199.9 147.6 1.35 hsa-miR-331-3p
36 1.975 85.5 66.9 1.28 hsa-miR-185
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Supplemental Table 4. MicroRNAs are differential expressed between leukemia of ambiguous 
lineage, AML, B-ALL and T-ALL samples analyzed by LIMMA.
Tables show the top 25 microRNAs with the lowest FDR. (A) Top differentially expressed microRNAs 
between leukemia of ambiguous lineage and AML. (B) Top differentially expressed microRNAs between 
leukemia of ambiguous lineage and T-ALL. (C) Top differentially expressed microRNAs between leukemia 
of ambiguous lineage and B-ALL. (D) MicroRNAs that are differentially expressed between leukemia of 
ambiguous lineage and B-ALL or T-ALL are differentially expressed between B-ALL and T-ALL. Columns 
show t-statistic, p- and False Discovery Rate-values for the differential expressed microRNAs. ‘ALAL vs. 
AML’ represents differential expression between leukemias of ambiguous lineage and AML. ‘ALAL vs. 
AML-T vs. AML’ represents differential expression between leukemias of ambiguous lineage and T-ALL. 
‘ALAL vs. AML-B vs. AML’ represents differential expression between leukemias of ambiguous lineage 
and B-ALL. ‘T vs. AML-B vs. AML’ represents differential expression between T-ALL and B-ALL.
Supplemental Table 4A
GeneName t-statistic values 
ALAL vs AML
p-values 
ALAL vs AML
False Discovery Rate 
ALAL vs AML
hsa-miR-3607-3p -4.267507 0.000511 0.268911
hsa-miR-150 4.194532 0.000599 0.268911
hsa-miR-181c* -4.613656 0.000243 0.268911
hsa-miR-199b-5p -3.593330 0.002216 0.722077
hsa-miR-181c -3.506007 0.002680 0.722077
hsa-miR-151-5p 3.274696 0.004429 0.739704
hsa-miR-18a 3.175115 0.005491 0.739704
hsa-let-7f -3.210894 0.005083 0.739704
hsa-miR-625 3.193295 0.005280 0.739704
hsa-miR-25* 3.184695 0.005379 0.739704
hsa-miR-611 2.989165 0.008186 0.761603
hsa-miR-20b 2.298159 0.034400 0.761603
hsa-miR-361-3p 2.153308 0.045817 0.761603
hsa-miR-27a* 2.778497 0.012802 0.761603
hsa-miR-302e -2.248856 0.037951 0.761603
hsa-miR-151-3p 2.335972 0.031888 0.761603
hsa-miR-363 2.481153 0.023752 0.761603
hsa-miR-19a 2.120831 0.048814 0.761603
hsa-miR-502-5p 2.533943 0.021312 0.761603
hsa-miR-92a-1* 2.524618 0.021725 0.761603
hsa-miR-892b -2.425146 0.026627 0.761603
hsa-miR-302d* 2.603964 0.018441 0.761603
hsa-miR-18b 2.735778 0.014006 0.761603
hsa-miR-1288 -2.560946 0.020158 0.761603
hsa-let-7i -2.019358 0.059368 0.761603
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Supplemental table 4B
GeneName t-statistic values 
ALAL vs AML-T vs AML
p-values    
ALAL vs AML-T vs AML 
False Discovery Rate 
ALAL vs AML-T vs AML
hsa-miR-513a-5p -5.157308 0.000077 0.051812
hsa-miR-29c -5.487066 0.000039 0.051812
hsa-miR-3923 -4.236257 0.000547 0.128627
hsa-miR-494 -4.228926 0.000556 0.128627
hsa-miR-3926 -4.214981 0.000573 0.128627
hsa-miR-1972 -4.521670 0.000296 0.128627
hsa-miR-663 -4.009495 0.000895 0.172247
kshv-miR-K12-5* -3.795835 0.001425 0.240014
hsa-miR-29c* -3.725784 0.001661 0.243450
hsa-miR-148a -3.686934 0.001807 0.243450
hsa-miR-3683 3.577376 0.002295 0.257571
hsa-miR-628-5p 3.612214 0.002127 0.257571
hsa-miR-3196 -3.465031 0.002930 0.291099
hsa-miR-15b* -3.450304 0.003026 0.291099
hsa-miR-4259 -3.394256 0.003417 0.306876
hsa-miR-146a 3.250343 0.004668 0.392993
hsa-miR-664* -3.162368 0.005645 0.447244
hsa-miR-1288 -3.053049 0.007140 0.470665
hsa-miR-222 2.913216 0.009625 0.470665
hsa-miR-15a* -2.922557 0.009436 0.470665
hsa-miR-345 -2.919248 0.009503 0.470665
hsa-miR-4262 3.057043 0.007079 0.470665
hsa-miR-941 3.008110 0.007861 0.470665
hsa-miR-4261 -2.959106 0.008729 0.470665
hsa-miR-7-1* -3.036012 0.007406 0.470665
MicroRNA based classification of acute leukemias
89
Supplemental tabel 4C
GeneName t-statistic values 
ALAL vs AML-B vs AML
p-values 
ALAL vs AML-B vs AML
False Discovery Rate 
ALAL vs AML-B vs AML
hsa-miR-320a -7.146909 0.000002 0.002099
hsa-miR-320c -5.946545 0.000015 0.010368
hsa-miR-320b -4.965371 0.000115 0.051651
hsa-miR-320e -4.670534 0.000215 0.057914
hsa-miR-320d -4.736786 0.000187 0.057914
hsa-miR-151-5p -3.912646 0.001105 0.156747
hsa-miR-611 -3.605835 0.002157 0.156747
hsa-let-7g -3.951326 0.001016 0.156747
hsv2-miR-H7-3p -3.703422 0.001744 0.156747
hsa-miR-204 -3.837317 0.001302 0.156747
hsa-miR-3653 -3.887423 0.001168 0.156747
hsa-miR-3118 -3.594424 0.002211 0.156747
hsa-miR-30a -3.769827 0.001509 0.156747
hsa-miR-1237 -3.600961 0.002180 0.156747
hsa-miR-30b -3.712394 0.001710 0.156747
hsv1-miR-H6-3p -3.596502 0.002201 0.156747
hsa-let-7f-1* -3.617080 0.002105 0.156747
hsa-miR-1225-3p -3.656371 0.001932 0.156747
hsa-let-7b* -3.811055 0.001379 0.156747
hsa-miR-4313 -3.568319 0.002340 0.157621
hsa-miR-4305 -3.464389 0.002934 0.165389
ebv-miR-BART13 -3.368950 0.003610 0.165389
hsa-miR-29a -3.444805 0.003062 0.165389
hsa-miR-324-3p -3.287697 0.004306 0.165389
hsa-miR-4295 -3.417819 0.003247 0.165389
Supplemental table 4D
GeneName t-statistic values  
T vs AML-B vs AML
p-values  
T vs AML-B vs AML
False Discovery Rate  
T vs AML-B vs AML
hsa-miR-513a-5p 5.173351 0.000556 0.044081
hsa-miR-320c -5.080220 0.000632 0.047263
hsa-miR-29c 4.685986 0.001096 0.060674
hsa-miR-320e -3.454607 0.007057 0.163881
hsa-miR-320d -3.239787 0.009959 0.200161
hsa-miR-320a -3.186858 0.010849 0.202963
hsa-miR-320b -2.986355 0.015036 0.227560
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Abstract
During onset, treatment and progression of acute myeloid leukemia (AML), inadequate 
immune responses against certain myeloid leukemic blasts might be associated with the 
occurrence of minimal residual disease (MRD) and subsequent relapse. Several studies on 
this subject have demonstrated that, in general, solid tumor cells are able to avoid CD8+ 
cytotoxic T cell (CTL) recognition by down-regulating HLA class I-restricted presentation of 
tumor-associated antigens (TAAs). In tumor cells that can express HLA class II molecules, 
such as myeloid leukemic blasts, abnormalities in the processing pathways of endogenous 
antigens could also result in impaired HLA class II-restricted TAA presentation to CD4+ T 
helper (Th) cells. More insight into impaired TAA presentation by myeloid leukemic blasts 
could explain their escape from immune recognition and might be crucial for selecting 
appropriate strategies to improve whole-cell or dendritic cell (DC)-based tumor vaccine 
efficacy in the treatment of AML patients.     
Introduction
One of the major obstacles in acute myeloid leukemia (AML) treatment is the recurrence of 
the disease after achieving complete remission. This is caused by the outgrowth of myeloid 
leukemic blasts that survived remission induction and consolidation therapy [1, 2]. Besides 
the involvement of other intrinsic factors, it could be possible that a subset of myeloid 
leukemic blasts, already present in the acute phase of the disease, are not recognized by the 
patients’ own immune system. In an attempt to overcome immune escape by these leukemic 
blasts, current treatment protocols for AML patients include immunotherapeutic strategies 
such as allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusion (DLI). 
The application of these strategies not only contributes to immune reconstitution, but also 
aims to generate graft-versus-leukemia (GvL) effects via donor allogeneic NK and T cells.
The role of donor NK cells in the GvL effects was demonstrated in AML patients that 
received HLA haplotype-mismatched transplants. An increased donor-to-recipient NK cell 
alloreactivity was significantly associated with a lower relapse rate [3, 4]. For haploidentical 
allo-SCT, donor T cells are recognized as the main effector cells involved in GvL reactions by 
reacting to tumor-associated antigens (TAAs) expressed on antigen-presenting cells (APCs) 
[5]. It was described by several studies however, that the use of haploidentical allo-SCT 
followed by DLI could not prevent relapse occurrence in the majority of patients [6, 7]. In 
addition, donor T cells can induce severe graft-versus-host disease (GvHD), which makes it 
very challenging to develop approaches that improve their ability to specifically recognize 
myeloid leukemic blasts. These approaches include the in vitro generation of effector T 
cells that are specific for either leukemia-associated antigens (LAAs), such as WT-1, PRAME, 
RHAMM and PR-1, or hematopoiesis-restricted minor histocompatibility antigens (mHags) 
[8, 9]. 
When host and donor T cells are not able to generate long-lasting anti-leukemic immune 
responses in patients with AML, it may be assumed that impaired immune recognition of 
myeloid leukemic blasts does not result from T cell defects in the host. Instead, it is more 
likely that the leukemic blasts themselves are involved. Under the continuous pressure 
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of the host immune system, some residual leukemic blasts may escape from immune 
surveillance through adaptations in their phenotype, a process termed immune editing 
[10]. In general, tumor cells can evade eradication by T cells in different ways: 1) secreting 
or inducing the secretion of immunosuppressive molecules that render T cells inactive (IL-
10, TGFβ, indoleamine 2,3-dioxygenase (IDO)); 2) overexpressing molecules that inhibit the 
apoptotic mechanisms employed by T cells to kill the tumor cell (Bcl-2, PI-9); or 3) down-
modulating TAA processing and presentation pathways, which results in impaired antigen 
presentation and ineffective recognition by T cells. Regarding myeloid leukemic blasts, we 
recently reported that high expression of IDO, a metabolic enzyme that causes immune 
suppression via the induction of cell cycle arrest of T cells upon tryptophan degradation, is 
a significant predictor of poor clinical outcome in AML [11]. In addition, we demonstrated 
that blasts of AML patients may escape TNF-related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis by using TRAIL-R3 as a decoy receptor [12]. As myeloid leukemic 
blasts are capable of presenting HLA class I and II as well as co-stimulatory molecules [13], 
impairment in TAA presentation could be another mechanism used by these tumor cells 
to prevent immune recognition. Although not much is known about this type of escape 
in AML yet, accumulating evidence from work in solid tumor cells together with recent 
observations in myeloid leukemic blasts implicate that impaired TAA presentation may be 
an underestimated issue in myeloid neoplasia and will be discussed in the current review. 
To overcome impaired TAA presentation by tumor cells, whole-cell and dendritic cell 
(DC)-based tumor vaccinations have been introduced in the last few years as promising 
immunotherapeutic strategies [14-16]. These strategies are based on the potential of 
tumor vaccines to present a broad range of TAAs to recipient T cells, thereby inducing a 
long-lasting anti-tumor response. Since TAA presentation could be disturbed in tumor cells, 
it is important for the efficacy of these vaccines to understand which antigen processing 
and presentation pathways are involved. In this review, we provide an update on the role 
of antigen presentation in tumor immunology and describe how this knowledge may be 
used to develop immunomodulatory approaches that optimize aberrant TAA presentation 
by whole-cell and DC-based tumor vaccines in the context of AML.
Tumor-associated antigen presentation: rationale and underlying pathways
For tumor immune surveillance, it is essential that the adaptive immune system is able to 
specifically recognize and eradicate tumor cells [17]. To generate effective and long-lasting 
anti-tumor immunity, professional APCs, e.g. DCs and macrophages, as well as B cells and 
tumor cells themselves, must efficiently present TAAs to CD8+ cytotoxic T cells (CTLs), which 
allows the activation of effector CTLs that will have to lyse the tumor cells. In addition, 
CD4+ T helper 1 (Th1) cells need to be activated to help establish an efficient TAA-specific 
CTL response and generate anti-tumor immune memory [18]. Upon TAA recognition and 
additional IFN-γ and IL-12 signalling, naive CD4+ T cells differentiate into Th1 effector cells 
and optimize the anti-tumor effect of CTLs, either directly via co-stimulatory molecules or 
the production of cytokines like IL-2, or indirectly via APC activation [19]. Moreover, TAA-
specific CD4+ Th1 cells have been described to have potent anti-tumor effects independent 
of CTL action [20]. APCs use different processing pathways to present TAAs to CTLs and CD4+ 
T cells, involving HLA class I and II molecules, respectively. 
Chapter 7
94
Classical HLA class I-restricted presentation: endogenous antigens
With respect to the conventional pathway of HLA class I-restricted antigen processing and 
presentation (figure 1A), endogenously synthesized proteins are first degraded into short 
peptides in the cytoplasm by a multicatalytic proteinase complex called the proteasome 
[21]. Thereafter, the proteasome-generated peptides are translocated into the endoplasmic 
reticulum (ER) via the transporter associated with antigen processing (TAP) [22], another 
major component of the HLA class I antigen processing machinery that is localized in the ER 
membrane. In the ER lumen, these peptides can be further trimmed by ER aminopeptidases 
associated with antigen processing (ERAAPs) into the nonameric peptides necessary for 
optimal HLA class I loading [23]. The macromolecular peptide loading complex, which 
consists of TAP, tapasin, calreticulin and ERp57 [24], ensures that newly formed HLA class 
I heavy chain-β2-microglobulin (β2m) dimers are properly folded in the ER, allowing the 
allele-specific peptides to bind to the HLA class I peptide-binding groove. After peptide 
loading, the HLA class I/peptide complex is dissociated from the chaperones that promote 
ER retention and transported into the default secretory pathway, after which it eventually 
reaches the plasma membrane for presentation to CTLs. 
HLA class I-restricted cross-presentation: exogenous antigens
The endogenous pathway of TAA loading onto HLA class I molecules explains how antigens 
are presented on tumor cells for recognition by activated CTLs. It does not explain however, 
how TAAs gain access onto HLA class I molecules in professional APCs for activation of TAA-
specific CTLs in the lymph nodes. Particularly in myeloid DCs (mDCs), it has been shown 
that in a process termed cross-presentation, TAAs can be taken up as exogenous material 
(in the form of tumor cell fragments of dead tumor cells) and are subsequently presented 
onto HLA class I molecules. The major cell biological questions regarding cross-presentation 
are how exogenous TAAs in the endosomal/lysosomal pathway are trimmed to the right 
size for loading and in which cellular compartment these TAAs are loaded onto HLA class I 
molecules. To date, the pathways of cross-presentation can generally be described as being 
indirect or direct. The cross-presentation pathway reported by Huang and co-workers is 
indirect and uses the endogenous HLA class I antigen processing machinery to process 
exogenous antigens [25]. After entry into early endosomes, these antigens are exported into 
the cytoplasm, degraded by the proteasome and translocated via TAP into the ER lumen for 
loading onto HLA class I. Another indirect cross-presentation pathway described by Burgdorf 
and co-workers and Guermonprez and co-workers involves the same mechanism of antigen 
processing, but in these cases the proteasome-generated exogenous peptides are imported 
again into the early endosomes via endosomal-localized TAP and loaded onto HLA class I 
molecules in the endosomes [26, 27]. It remains controversial whether this peptide re-import 
is made possible by Toll-like receptor 4 (TLR4)- and MyD88-dependent recruitment of TAP to 
the early endosomes [26] or whether this involves the fusion of early endosomes with the 
ER [27]. In addition, recent data show that lipid bodies may also act as key organelles in the 
indirect pathway of cross-presentation [28]. The direct cross-presentation pathway reported 
by Shen and co-workers and Di Pucchio and co-workers does not rely on cytoplasmic transit 
of exogenous antigens nor does it involve the function of the proteasome and TAP [29, 30]. 
Instead, the ‘classical’ endosomal/lysosomal pathway serves as the processing site for these 
antigens, in which peptide generation is strongly dependent on cathepsin S [29]. Antigen 
loading occurs within the endosomal storage compartments that acquire newly formed HLA 
class I monomers via pathways that are currently only partially defined [30].
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Classical HLA class II-restricted presentation: exogenous antigens
The endosomal/lysosomal pathway plays a central role in HLA class II antigen presentation 
by processing exogenously-derived antigens for loading onto HLA class II molecules [31]. 
Prior to peptide loading, newly synthesized HLA class II α and β heavy chains dimerize and 
associate with the Invariant Chain (Ii or CD74) in the ER to form a nonameric complex. This 
complex is then specifically targeted via two dileucine-based endocytic-sorting motifs in the 
cytoplasmic tail of Ii to specialized antigen-loading compartments, known as MIICs (MHC 
class II containing compartments) [32]. Besides its role in endosomal/lysosomal targeting, 
Ii also contributes to the stabilization and proper folding of HLA class II heterodimers in the 
ER [33]. During transport to the MIICs, Ii is degraded by specific pH-sensitive endosomal 
proteases (cathepsins) until a small remnant remains left in the HLA class II peptide-binding 
groove [34]. In the MIICs, this class II-associated invariant chain peptide (CLIP) is exchanged 
for an exogenous peptide, a process that is catalyzed by an HLA-like chaperone molecule, 
HLA-DM (DM) [35]. Especially in B cells, DM associates to yet another HLA-like chaperone, 
HLA-DO (DO), which down-modulates the function of DM [36]. After peptide exchange, the 
HLA class II molecule is transported from the MIICs to the plasma membrane, where it is 
presented to CD4+ T cells.  
HLA class II-restricted ‘reverse cross-presentation’: endogenous antigens
In the last few years, it has become evident that APCs, including mDCs, B cells and certain 
tumor cells, also have the ability to process endogenous antigens for presentation onto 
HLA class II molecules, which may be called ‘reverse cross-presentation’. Until now, studies 
carried out to unravel the antigen processing pathways for this type of presentation have 
yielded conflicting data. On the one hand, processing of endogenous antigens for loading 
onto HLA class II molecules has been described to take place in the endosomal/lysosomal 
pathway [37]. The transport of endogenous antigens from the cytoplasm into this pathway 
can be accomplished through two distinct forms of the cellular housekeeping mechanism 
known as autophagy. During macroautophagy, large cytoplasmic particles, like endogenous 
antigens, are taken up into autophagosomes and delivered to the endosomal/lysosomal 
pathway for degradation after fusion with lysosomal compartments (figure 1B) [38, 39]. 
Additional studies demonstrated that endogenous antigen processing via this mechanism 
of autophagy is primarily dependent on lysosomal proteases rather than the proteasome 
and TAP [40, 41]. A second autophagic mechanism, termed chaperone-mediated autophagy 
(CMA), is more specific and involves the translocation of small cytoplasmic products, such as 
endogenous peptides, into the lysosomes via the chaperone protein hsc70 and its receptor 
LAMP-2A on the lysosomal membrane (figure 1C) [42]. For processing via CMA, premature 
degradation of endogenous antigens into peptides by the cytoplasmic proteasome is 
considered to be a critical step [43]. This indicates that on the other hand, the HLA class 
I antigen processing machinery plays an important role in ‘reverse cross-presentation’ of 
endogenous antigens. Indeed, studies by Lich and co-workers and Tewari and co-workers 
showed that both the proteasome and TAP were required for certain endogenous antigens 
to be processed and loaded onto HLA class II molecules [44, 45]. Since these molecules were 
capable of presenting endogenous peptides irrespectively of the endosomal/lysosomal 
pathway, it could be possible that proteasome- and TAP-dependent endogenous peptides 
are loaded onto newly synthesized HLA class II heterodimers in the ER (figure 1D). This type 
of loading however, might be disturbed by the function of Ii, as this chaperone protein is 
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able to associate with the HLA class II peptide-binding groove to prevent premature binding 
of endogenous peptides in the ER [46]. 
Defective tumor-associated antigen presentation as tumor escape mechanism
The ability of tumor cells to present their own antigens (TAAs) to the immune system makes it 
very challenging to develop new immunotherapeutic strategies that specifically target these 
TAAs. Inhibition of HLA class I- and II-restricted TAA presentation, however, is a common 
mechanism by which tumor cells not only evade immune surveillance, but also become less 
sensitive to tumor-specific immunotherapy. In order to understand and deal with this type 
Figure 1. Potential pathways used by APCs to process and present endogenous antigens. Both HLA 
class I and II molecules are able to present endogenous antigens at the plasma membrane via several 
processing pathways. For loading onto HLA class I molecules, endogenous antigens are processed via 
the proteasome and transported into the ER by TAP (panel A). HLA class II molecules can be loaded 
with endogenous antigens in three different ways: 1) via delivery into the lysosomal compartments 
by autophagosomes during a process called macroautophagy (panel B); 2) via translocation into the 
lysosomes by the chaperone protein hsc70 and its receptor LAMP-2A on the lysosomal membrane, 
a process termed  chaperone-mediated autophagy (CMA; panel C); or 3) via the same processing 
pathway used for loading onto HLA class I molecules, involving the proteasome and TAP (panel D).  
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of tumor escape, it is important to examine tumor cells for the presence of abnormalities in 
the pathways normally involved in the processing and presentation of endogenous antigens, 
as described earlier and demonstrated in figure 1. 
HLA class I escape mechanisms in neoplasia 
In various types of solid tumors, multiple HLA class I abnormalities have been reported that 
can affect any phase of the processing and presentation pathway, including HLA synthesis, 
assembly, peptide loading and plasma membrane expression. These abnormalities are 
the result of genetic or epigenetic alterations involved in the expression of HLA class I 
molecules and components of the HLA class I antigen processing machinery. According to 
the definition of HLA class I deficiencies by Garrido and co-workers, HLA haplotype loss, 
HLA locus loss, HLA allelic loss, total HLA loss, or a combination of each represent the major 
altered phenotypes of tumor cells [47]. It is also possible that tumor cells are unable to 
upregulate HLA class I expression in response to interferons or present aberrant HLA-E 
after down-regulation of classical HLA-A, -B and -C molecules, but these phenotypes occur 
less frequently. HLA haplotype, locus and allelic losses provoke a selective absence of HLA 
class I molecules on tumor cells and are the consequence of loss of heterozygosity (LOH) at 
chromosome 6p21, transcriptional dysregulation and genetic mutations, respectively [48]. 
The most dramatically altered phenotype, total HLA loss, can directly result from alterations 
in HLA class I gene transcription. These alterations include disturbed DNA binding of nuclear 
transcription factors and epigenetic silencing of the HLA class I heavy chain gene, both 
leading to aberrant HLA class I synthesis [49, 50]. Another direct cause of total HLA loss 
involves β2m gene mutations, which hampers HLA class I assembly [51]. Furthermore, 
mutations in the genes encoding for tapasin or subunits of the proteasome (LMP-2 or -7) 
and TAP (TAP-1 or -2) indirectly cause total HLA class I loss by interfering with HLA class 
I peptide loading, release from the ER chaperones and consequently plasma membrane 
expression [52]. The latter deficiencies may not only result in total HLA loss, but could also 
stimulate cross-presentation of non-relevant exogenous antigens instead of endogenous 
TAAs. 
HLA class II escape mechanisms in neoplasia
In contrast to HLA class I-restricted antigen presentation, the occurrence of abnormalities in 
the HLA class II antigen processing and presentation pathway and their functional relevance 
have not been studied extensively in tumor cells. The main reason is that most solid tumors 
do not express HLA class II molecules. Several molecular mechanisms can be responsible 
for deficient expression of HLA class II molecules on tumor cells. Consistent with HLA class 
I, repression of gene transcription contributes to a loss of HLA class II synthesis, either 
directly via point mutations and deletions in the HLA class II genes [53], or indirectly via 
hypermethylation of the activator of immune response-1 (AIR-1) locus encoding for the 
‘master’ regulator of HLA class II gene transcription, class II transactivator (CIITA) [54]. Since 
CIITA additionally activates genes involved in classical HLA class II transport and peptide 
loading, including Ii and DM, respectively, silencing of this transcription factor also results 
in an inability of tumor cells to process HLA class II molecules in the endosomal/lysosomal 
pathway and present autophagy-dependent TAAs. Some tumor types, however, such as 
melanoma, lung carcinoma as well as B-cell and myeloid leukemias, do possess the capacity 
to express HLA class II molecules and activate tumor-specific CD4+ T cells. Still, also in these 
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tumor cells, total and partial HLA class II loss are common altered phenotypes, which have 
been demonstrated to be clinically and functionally relevant [55]. For melanoma and B cells, 
HLA class II-restricted escape may also be the result of selectively impaired TAA processing 
without affecting HLA class II expression per se. Melanoma cells deficient for gamma 
interferon-inducible lysosomal thiol-reductase (GILT) contain low DM levels and cathepsin 
activity [56], suggesting that not only MIIC-restricted loading, but also degradation of 
endogenous TAAs within the lysosomes is impaired during macroautophagy. In a study with 
lymphoma B cells, it was shown that under immunosuppressive conditions glutathione 
depletion resulted in a down-regulation of lysosomal proteolysis, which caused impaired 
antigen processing [57].      
HLA class I escape mechanisms in myeloid neoplasia
To explain the failure of the host immune system and currently used immunotherapeutic 
strategies to induce anti-leukemic immunity in AML, several studies have been performed 
on the role of these altered HLA class I phenotypes in the immune evasive capacity 
of myeloid leukemic blasts before and after treatment. It was previously described that 
reduced HLA class I expression on leukemic blasts is correlated with a high white blood cell 
(WBC) count in patients with newly diagnosed AML [58]. In other studies however, very 
low frequencies of total HLA class I loss in AML were detected on leukemic blasts from 
both diagnosis and relapse blood and bone marrow samples [59, 60], which indicates that 
the onset and progression of AML is not correlated with total HLA class I loss on leukemic 
blasts. Although no HLA haplotype loss was observed in leukemic blasts of untreated AML 
patients [61], recent data show that this phenotype may be important for the occurrence 
of relapse in patients who received DLI following haploidentical allo-SCT [62]. In 5 of 17 
patients with a relapse after DLI treatment, leukemic blasts were recognized that had lost 
the patient-specific HLA haplotype due to acquired LOH at chromosome 6p21. As a result, 
donor allogeneic T cells could not eradicate these mutant variants, in contrast to the original 
leukemic blasts, implicating that the HLA haplotype loss rendered these blasts insensitive 
to GvL effects in AML patients. HLA locus loss in leukemic blasts was shown to lead to 
down-regulation of locus HLA-A and -B, but not -C in some patients with untreated AML 
[63]. Demanet and co-workers additionally found a loss of HLA-A and -B alleles in 7 of 14 
patients examined, of which the majority belonged to the Bw6 group [64]. As the expression 
of most alleles from the Bw4 group was preserved, it was suggested that these selective 
HLA allelic losses serve as a compound HLA class I phenotype by which myeloid leukemic 
blasts circumvent both CTL and NK cell-mediated cytotoxicity during immune surveillance. 
Indeed, HLA allelic losses were demonstrated to be functionally relevant, but have only 
been reported for small numbers of AML patients [59].
HLA class II escape mechanisms in myeloid neoplasia
Since HLA class I abnormalities may not be of major importance in myeloid neoplasia, it is 
hypothesized that defects in the HLA class II LAA processing and presentation pathway of 
myeloid leukemic blasts may prevent CD4+ T cell recognition and hamper the potency of an 
anti-leukemic immune response. In the majority of newly diagnosed AML patients, HLA class 
II molecules are expressed on leukemic blasts, with no changes in expression at relapse [65]. 
There are some cases of AML in which leukemic blasts do lack HLA class II, including acute 
promyelocytic leukemia (APL). Despite this fact, patients with APL have a good prognosis, 
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which is due to the role of other molecular mechanisms, such as the generation of the PML/
RARα fusion proteins as the result of t(15;17) gene rearrangement, making these patients 
well treatable. Nevertheless, no differences in disease-free survival (DFS) were observed 
between HLA-DR-negative non-APL and HLA-DR-positive AML patients [65], indicating that 
the expression of HLA class II proteins on myeloid leukemic blasts may not play a role in the 
occurrence of relapse. We previously found indications, however, that impaired HLA class 
II-restricted LAA presentation is involved in AML progression, since high CLIP expression 
on myeloid leukemic blasts from patients significantly correlated to a shortened DFS [66]. 
Recently, we confirmed these findings in an expanded cohort of patients and additionally 
revealed that a high CLIP amount on these blasts abolishes the induction of autologous and 
allogeneic CD4+ T cells [67]. 
The immune escape by CLIP+ leukemic blasts likely reflects a diminished loading of LAAs 
onto HLA class II molecules, indicating the necessity to elucidate the molecular mechanism 
involved in this process. One possibility could be that the exchange of CLIP for autophagy-
dependent LAAs in the lysosomal MIICs is hampered due to a lowered DM/DO ratio. This 
is supported by our previous observation that the DM/DO ratio inversely related to the 
amount of CLIP per HLA-DR molecule in leukemic blasts of patients with AML [66]. Another 
possible explanation for aberrant LAA loading is that the association of Ii to the HLA class 
II peptide-binding groove interferes with loading of proteasome- and TAP-dependent LAAs 
in the ER [46]. Armstrong and co-workers confirmed this function of Ii in tumor cells by 
showing that the presentation of an ER-retained endogenous antigen was prevented in 
the presence of Ii alone or both Ii and DM [68]. Less is known about proteasomal and TAP 
deficiencies in myeloid leukemic blasts, which may result in insufficient LAA processing and 
loading onto HLA class II molecules in the ER when Ii expression is down-modulated. In this 
regard, we recently observed in TAPhigh myeloid leukemic blasts that HLA-DR expression at 
the plasma membrane occurred independently of Ii, but did depend on the function of the 
proteasome and TAP. HLA-DR expression by TAPlow myeloid leukemic blasts however, was 
completely dependent on Ii and did not involve the proteasome and TAP [69]. These findings 
suggest that HLA class II-restricted presentation of LAAs could also be affected by a deficient 
HLA class I antigen processing machinery in myeloid leukemic blasts silenced for Ii.  
Strategies to optimize tumor-associated antigen presentation on whole-cell vaccines
To enhance the efficacy of T cell-based strategies in cancer immunotherapy, the use of TAA-
presenting APCs as tumor vaccines is considered to be an attractive approach [70]. One of 
the ways to develop these vaccines could be loading of monocyte-derived DCs (moDCs) with 
TAAs. Regardless of which antigen source is the most suitable for loading, the possibility 
remains that immunogenic, potentially unidentified, TAAs are missing or not processed for 
presentation in the same manner as in tumor target cells. This might be avoided by using 
tumor cells as whole-cell vaccines, which are capable of presenting a broad range of TAAs at 
the plasma membrane. This type of vaccines may have great potential, as the presentation 
of endogenous TAAs to both CTLs and CD4+ T cells is likely to induce an efficient anti-tumor 
immune response in vivo. Although almost no HLA class I defects are detected, molecular 
mechanisms could still exist in myeloid leukemic blasts that interfere with the onset of HLA 
class II-restricted LAA presentation, as mentioned previously. For the design of optimal LAA-
presenting whole-cell vaccines, it is necessary to apply modulatory strategies that stimulate 
HLA class II-restricted LAA presentation on these blasts. The development of such strategies 
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depends on which aspect of this type of presentation is defective, as summarized in figure 
2A. First of all, leukemic blasts that lack co-stimulatory molecules may be differentiated 
into leukemic DC-like cells, resulting in increased expression of these molecules, as shown 
by Westers and co-workers [71]. In a recent study, another method to up-regulate co-
stimulatory molecules was proposed, which involved the simultaneous delivery of B7.1, 
B7.2 and 4-1BB genes to blasts using lentiviral transduction [72]. Via addition of IFN-γ, HLA 
class II expression can be transiently restored in most blasts, as the CIITA-encoding AIR-
1 locus consists of an IFN-γ-inducible promoter [73]. Some leukemic blasts, however, are 
Figure 2. The application of whole-cell vaccines in the treatment of AML. (A) Schematic overview of 
which defects in HLA class II-restricted presentation of leukemia-associated antigens can be encountered 
in myeloid leukemic blasts and how these defects may be overcome by specific modulatory strategies 
that enhance tumor immunogenicity. To increase the expression of co-stimulatory molecules, 
leukemic blasts could be differentiated into AML DCs or treated with lentiviral vectors encoding for 
B7.1, B7.2 and/or 4-1BB. HLA class II expression might be enhanced by IFN-γ stimulation or delivery 
of the CIITA gene. Serum starvation in combination with HDAC inhibitors might be used to boost LAA 
processing and loading in the MIICs. On the other hand, the use of HDAC inhibitors together with Ii 
siRNAs is probably the most appropriate strategy to induce LAA processing and loading in the ER. 
(B) The potential clinical impact of AML whole-cell vaccines with optimal LAA presentation. In non-
vaccinated patients, LAA presentation via HLA class II molecules on myeloid leukemic blasts is probably 
insufficient to activate CD4+ T cells, leading to transient anti-leukemic CD8+ CTL responses and AML 
recurrence. In vaccinated patients, AML whole-cell vaccines may present a broad range of LAAs via 
both HLA class I and II molecules, resulting in long-lasting anti-leukemic immunity and full eradication 
of leukemic blasts.
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resistant to this treatment due to lack of CIITA, similarly to the majority of solid tumor cells 
that are negative for HLA class II. In this respect, it has been described by the group of 
Suzanne Ostrand-Rosenberg that CIITA gene transfection in tumor cells not only increases 
HLA class II expression, but also boosts processing via co-expression of DM and Ii [68]. 
This modality could therefore also be useful for DM-deficient leukemic blasts, since CIITA-
induced DM expression might enhance loading of autophagy-dependent LAAs onto HLA 
class II molecules in the endosomal/lysosomal pathway. 
Suppression of protein kinase C (PKC) was demonstrated to affect DO expression in activated 
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B cells [74], potentially leading to an increased exchange of CLIP for antigenic peptides. Thus, 
the use of PKC inhibitors might serve as an alternative strategy to improve MIIC-restricted 
LAA loading in myeloid leukemic blasts. These strategies can only be effective however, in 
situations where LAAs are processed and transported via autophagic mechanisms into the 
lysosomal compartments (figure 1B-C). The specific induction of autophagy using different 
periods of serum starvation was shown to result in the presentation of endogenous instead 
of exogenous antigens [38]. This approach may be extended to myeloid leukemic blasts 
to ensure that LAA processing occurs in the endosomal/lysosomal pathway. A second LAA 
processing and loading mechanism does not depend on autophagy and DM, but probably 
involves the proteasome and TAP (figure 1D). Consistent with the studies by Ostrand-
Rosenberg’s group using solid tumor cells [75, 76], we found that Ii silencing by specific 
siRNAs is also a potent strategy to enhance the immunogenicity of myeloid leukemic blasts 
[67]. In blasts that are able to express HLA class II molecules in the absence of Ii, it is likely 
that LAA loading takes place in the ER instead of the MIICs, since newly formed heterodimers 
require peptide binding to remain stable [33]. In this situation, suboptimal proteasome 
or TAP expression may prevent the sufficient supply of LAAs into the ER for loading onto 
HLA class II molecules. To recover the function of these components, such blasts could be 
treated with histone deacetylase inhibitors (HDACi), like trichostatin A, which have recently 
been reported to be a powerful tool to increase the expression of proteasomal and TAP 
subunits in tumor cells [77, 78]. 
Concluding remarks and future perspective
In patients with AML, the onset and progression of the disease may be explained by the 
potential of myeloid leukemic blasts to evade immune recognition before and after induction 
treatment. Although allo-SCT and DLI are potent T-cell based strategies, impairments in 
LAA presentation on these blasts might prevent the induction of an efficient anti-leukemic 
immune response in vivo. The limited studies performed demonstrated that HLA class 
I abnormalities are rarely found, in contrast to the situation in most solid tumors. Since 
AML is one of the few tumor types in which HLA class II molecules can be presented on 
tumor cells, defects in HLA class II-restricted LAA presentation might be involved in the 
capacity of myeloid leukemic blasts to escape from CD4+ T cell recognition. Analyzing these 
defects at time of diagnosis and upon relapse of the disease could give insights in the 
progression of the disease and the potential failure of currently used immunotherapeutic 
strategies. Furthermore, knowledge about these defects is crucial for the design of an 
optimal AML whole-cell vaccine as immunotherapeutic strategy. This type of vaccine has 
the advantage that a full range of LAAs can be presented at the plasma membrane. When 
modulatory strategies can be applied that target specific defects in HLA class II-restricted 
LAA presentation, AML whole-cell vaccines might be developed that present LAAs on both 
HLA class I and II molecules, potentially leading to long-lasting anti-leukemic immunity in 
AML patients, as schematically represented in figure 2B. These defects could involve the 
expression of HLA class II and co-stimulatory molecules, but also LAA processing and loading, 
which all interfere with efficient HLA class II-restricted presentation of immunogenic LAAs. 
Immunophenotyping of blasts from patients for the expression of co-stimulatory molecules, 
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HLA-DR and CLIP may give indications about aberrancies in these processes. With both Ii 
and CLIP as possible modulatory targets for designing optimal AML whole-cell vaccines, it 
must be kept in mind that the pathways used for LAA processing and loading need to be 
characterized. We recently found in myeloid leukemic blasts that besides the endosomal/
lysosomal pathway, also the cytoplasm (the proteasome) and the ER (TAP) may serve as 
sites for HLA class II-restricted LAA processing and loading, respectively. By transiently 
silencing Ii in CLIP+ leukemic blasts using siRNA duplexes, insight can be gained which LAA 
processing pathway is active. When HLA class II expression at the plasma membrane is 
affected by Ii silencing, autophagy-dependent LAA or exogenous antigen processing is likely 
to be dominant in these blasts, as both rely on the endosomal/lysosomal pathway and the 
effective delivery of newly synthesized HLA-DR molecules into this pathway by means of Ii. 
If Ii silencing does not affect HLA-DR plasma membrane expression, the proteasome and 
TAP are probably involved in supplying LAAs into the ER, which are subsequently loaded 
onto newly synthesized HLA-DR molecules. In conclusion, a better understanding of the 
LAA processing pathways is needed to develop modulatory strategies that improve LAA 
presentation on AML whole-cell vaccines. As AML is a heterogeneous disease, future goals 
towards the design of optimal autologous whole-cell vaccines may include the development 
of an efficient monitoring system by which HLA class I and II-resticted LAA processing and 
presentation pathways can be characterized to choose the best-suited tailor-made strategy 
to improve LAA presentation in each individual patient.
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8High class II-associated invariant chain peptide (CLIP) expression on aberrant myeloid progenitor cells is associated with increased 
relapse risk in acute myeloid 
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Abstract
The presence of minimal residual disease (MRD) determined by flow cytometry is highly 
predictive for relapse of acute myeloid leukemia (AML). Impaired immunogenicity of low 
frequency MRD cells might play an important role in relapse of leukemia. Class II-associated 
invariant chain peptide (CLIP) plays a role in the immune escape of leukemic cells. Here, 
we evaluated CLIP and HLA-DR expression on leukemia-associated phenotype (LAP)-positive 
cells during follow-up and before relapse by flow cytometry. We found that CLIP expression 
on residual LAP+ cells  significantly correlated  with a shortened relapsefree survival, even 
in those cases with a percentage of LAP+ cells below 0.14 which is generally considered as 
MRDlow. Consequently, analysis of CLIP expression on LAP+ cells during follow-up could be of 
additional value in the evaluation of MRD to predict relapse of AML.
Introduction
In acute myeloid leukemia (AML) the arrest in differentiation due to acquired mutations in 
hematopoietic (stem) cells results in excessive proliferation and accumulation of immature 
myeloid cells. Although high-dose chemotherapy effectively reduces the tumor burden 
in most AML cases, some leukemic cells survive treatment and cause a relapse. Presence 
of aberrant immunophenotypic markers on malignant cells, the so-called leukemia-
associated phenotype (LAP), provides a powerful tool to monitor minimal residual disease 
(MRD) [1]. By flow cytometric identification of LAP+ cells, information is gained about MRD 
frequency in the bone marrow (BM), which serves as a highly reliable predictor of relapse 
free survival (RFS) and overall survival (OS) after chemotherapy. One possible mechanism 
for outgrowth of residual leukemic cells is their escape from immune surveillance due to 
a non-immunogenic phenotype [2]. During immune surveillance, presence of HLA class II 
on antigen-presenting cells (APC) is critical for optimal anti-tumor immunity by inducing 
a T helper cell response [3,4]. To enable loading and presentation of antigenic peptides, 
HLA class II molecules should release class II-associated invariant chain peptide (CLIP) from 
their antigen-binding groove [5,6]. Besides professional APC, also tumor cells can serve as 
potent APC by expressing costimulatory and HLA molecules [7,8]. Previously, we showed 
that CLIP expression on primary HLA-DR+ leukemic cells interferes with effector T helper 
cell activation, indicating that it may serve as an immune escape mechanism in AML [9]. 
Additionally, high CLIP expression (>35%) on leukemic cells at diagnosis is associated with 
a shortened disease-free survival [7,10]. Here, we investigate the clinical impact of CLIP 
expression on LAP+ cells during follow-up in AML.
Materials and methods
Patient samples
For our study, we selected blood and BM samples from 50/412 AML patients who were 
admitted to our hospital between 2001 and 2010.  From the total of 412 patients, ~60% 
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were eligible for both induction and consolidation therapy and reached complete remission. 
Since we were interested in the role of CLIP on leukemic cells in the context of HLA class 
II, we excluded acute promyelocytic leukemia (APL) cases, which are HLA-DRlow or HLA-DR-
negative. Also AML without a leukemia-associated phenotype (LAP) had to be excluded 
because follow-up analysis using flow cytometry is not possible. In approximately one third 
of the remaining patients, CLIP could be analyzed and evaluated during follow-up, resulting 
in the final inclusion of 50 AML cases. Informed consent was obtained from all patients 
in accordance with the Declaration of Helsinki. Patients received chemotherapy according 
to the Dutch-Belgian cooperative trial group for Hematology Oncology (HOVON)-protocols 
(www.hovon.nl). 
Immunophenotypical analysis
The presence of a LAP was determined as previously described [1]. In short, a panel of 
different monoclonal antibodies (moAb) was used to define a LAP on leukemic cells at 
diagnosis (summarized in Supplementary table 1.). BM was obtained after each treatment 
cycle or stem cell transplantation (SCT) and thereafter on a regular base. The last available 
follow-up sample before relapse was used for MRD and CLIP analysis. During follow-up, at 
least 1x106 BM-derived WBC were labeled after red blood cell lysis with the moAb that 
defined the LAP, together with a primitive marker (i.e. CD34 and/or CD117), CD45 and anti-
CLIP (cerCLIP.1; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-HLA-DR moAb [1, 
7]. First, the total WBC compartment was characterized by CD45 expression and FSC. Next, 
aberrancies were analyzed at diagnosis on primitive marker-positive cells with a low to 
intermediate SSC. In general, a single LAP marker was sufficient to analyze CLIP and HLA-DR 
expression on LAP+ cells; all samples were measured using a FACS Calibur flow cytometer 
(four-color based; Becton Dickenson). If an extra LAP-defining marker was necessary 
for CLIP and HLA-DR analysis on LAP+ cells, data files from different immunofluorescent 
stainings were merged based on the presence of common markers using Infinicyt software 
(Cytognos, Salamanca, Spain). In this case at least two markers (e.g. CD45 and CD34) and 
FCS/SSC were used as common markers. For detection of LAP+ cells a cut-off of 0.01% was 
used (i.e. 1x102 positive cells out of a total of 1x106 leukocytes); presence of 0.14% or more 
LAP+ cells (defined as LAP+ cells but corrected for percentage LAP+ cells at diagnosis)[1] was 
considered as MRDhigh, while presence of 0.01-0.14% LAP+ cells was regarded as MRDlow. The 
frequencies of CLIP-expressing cells within the LAP+ population were determined as indicated 
in Supplementary figure 1. A 35% cut-off was used to discriminate between patients with 
CLIPhigh and CLIPlow expression, as previously described [7]. Relative CLIP expression was 
determined by calculating the ratio between CLIP and HLA-DR expression based on both the 
percentage and mean fluorescence intensity [9]. 
Statistical analysis
Relapse free survival (RFS) was defined as the interval between the date of complete 
remission (CR) and relapse (respectively <5% and ≥5% leukemic cells in BM, as determined 
by cytomorphology). For survival data analysis, Kaplan Meier curves were compared by 
means of log-rank test; Cox univariate linear regression analysis was performed to evaluate 
the predictive value of LAP and CLIP percentages, p<0.05 was considered significant. 
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Figure 1.  Schematic overview of the analyzed AML patient group with respect to leukemia associated 
phenotype (LAP), minimal residual disease (MRD), class II associated invariant chain peptide (CLIP) 
expression and occurrence of relapse. 
Results and discussion
Previously, we reported that high MRD frequency is associated with poor prognosis and 
early relapse in AML [1]. This could be confirmed in our current cohort of 50 AML patients. 
Presence of MRDhigh  (>0.14% LAP+ cells) was largely discriminative for a shortened RFS; 
all but one of the 13 MRDhigh patients experienced a relapse compared to 14/37 patients 
considered MRDlow or MRD-negative (<0.14% LAP+ cells; p<0.001; data not shown) [1]. The 
median frequency of LAP+ cells in the 26  patients who showed a relapse was 0.05% (range 
0.00-4.53%) as compared to 0.03% (range 0.00-0.09%) in the 24 patients who remained in 
continuous remission (p=0.03, n=50, data not shown). There was no difference in distribution 
of the LAP in the MRDlow and MRDhigh group.
Subsequently, we assessed the role of CLIP expression on LAP+ cells regarding relapse 
occurrence during follow-up. In 5 patients, LAP+ cells as defined at diagnosis were not 
detected during follow-up. Consequently, we were able to evaluate CLIP on LAP+ cells in 
45 patients; 24 experienced a relapse, while 21 remained in continuous CR (summarized 
in figure 1). Both the percentage of LAP+ cells and the percentage of CLIP+ cells within the 
LAP+ population significantly predicted the occurrence of a relapse (p=0.025 and p=0.038, 
respectively; Cox univariate analysis, data not shown). Notably, high CLIP expression on 
LAP+ cells was negatively associated with RFS (p=0.001 [log rank]; figure 2A). No significant 
differences were found in leukocyte counts, percentages of blasts in the bone marrow, 
cytogenetic risk scores at diagnosis and inclusion of an allogeneic stem cell transplantation 
in the treatment regimens between CLIPhigh and CLIPlow patients. Recently, we showed that 
the presence of  CLIP on leukemic cells from HLA-DR+ AML patients inhibits activation 
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of autologous leukemia-reactive CD4+ T cells [9], indicating that HLA-DR-mediated CLIP 
presentation might be an immune escape mechanism of leukemic cells. Moreover, in 
concordance with CLIP as a sole marker, the CLIP/DR ratio on leukemic cells at diagnosis 
was shown to be of importance in predicting RFS in AML [7]. For all cases in the present 
study, more than 90% of LAP+ cells were HLA-DR positive at diagnosis, however, the mean 
fluorescence did vary (MFI range 35-470). In 16 patients we analyzed both CLIP and HLA-DR 
expression on LAP+ cells during follow-up. A shortened RFS was found for patients with a 
high CLIP/DR ratio (CLIP/DR ratio cut off: 0.05; p=0.03 [log rank], data not shown). 
In the group regarded as MRDlow (0.01%-0.14% LAP+ cells), a minority of patients experienced 
a relapse (12 out of 32, figure 1). Interestingly, the presence of CLIP on LAP+ cells predicted a 
significantly shortened RFS in these MRDlow cases (p=0.003 [log rank]; figure 2B). Previously, 
it has been reported that flow cytometric detection of MRD is important for predicting a 
relapse in AML [1]. However, for a few patients, the presence of MRD is not predictive for 
a relapse although a relapse is experienced. In these cases, analysis of CLIP on LAP+ cells 
during follow-up may help to better define MRD and to identify patients who will likely 
develop a relapse. Consequently, current treatment modalities may be utilized earlier in 
these high risk cases. In addition, CLIP-positive cases might benefit from developments in 
immunomodulatory treatment that can enhance the immunogenicity of MRD cells. For 
instance, modulation of CLIP or other components of the HLA class II antigen presentation 
pathway could offer new possibilities for immunotherapy of AML patients. 
  Remarkably, no correlation was found between CLIP expression on LAP+ cells during follow-
up and CLIP expression in AML at diagnosis; from 11 patients with CLIPhighLAP+ cells during 
follow-up, 7 patients showed low CLIP expression (<35%) at diagnosis, while 4 patients had 
high CLIP expression (>35%; data not shown). In cases with CLIPlow expression at diagnosis, but 
CLIPhigh expression at relapse, it remains to be investigated whether the small group of CLIPhigh 
leukemic cells preferentially survived chemotherapy and escaped immune surveillance 
or residual leukemic cells acquired CLIP expression during follow-up. In either case, the 
high CLIP expression could reflect a state of leukemic cells in which endogenous antigen 
Figure 2.  The association of class II-associated invariant chain peptide (CLIP) on leukemia-associated 
phenotype (LAP)-positive cells with relapse-free survival (RFS). CLIP expression on LAP+ cells was 
analyzed using a previously defined cut-off of 35%.7 Its impact on RFS was evaluated in all patients 
with LAP+ cells, i.e. minimal residual disease-high (MRDhigh) and MRDlow (A) and in patients with 0.01-
0.14% LAP+ cells and thus considered MRDlow (B). 
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presentation is hampered due to a deficiency in antigen processing machinery. For example, 
the function of the transporter associated with antigen processing (TAP) could be impaired, 
which is a common immune escape mechanism of solid tumors [11,12] and might also be 
involved in CLIP+ leukemic cells [13]. As a result, TAP-mediated translocation of potentially 
leukemia-associated endogenous antigens into the ER or endosomal compartments may 
be downregulated, resulting in less antigen loading of HLA molecules. This may not only 
impair HLA class I-, but also HLA class II-mediated presentation of endogenous antigens, as 
previously reported for solid tumor cells [14,15] Moreover, there are indications that CLIP 
is also involved in HLA class I antigen presentation, since it can bind to various HLA class I 
allotypes (e.g. HLA-A2) [16]. The role of CLIP presented by HLA class I molecules in tumor 
immune escape has to be further elucidated. 
In conclusion, the data presented here demonstrate the clinical impact of CLIP on LAP+ cells 
during follow-up in AML. Expression of CLIP on LAP+ cells resulted in poor survival, not only 
in MRD-positive AML patients, but also in patients with low MRD (<0.14% LAP+ cells). This 
may point to CLIP expression as a mechanism for MRD cells to escape immune surveillance 
and consequently a promising target for future research aiming at prevention of relapse. 
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Supplementary Figure legends
Supplementary Figure 1: Gating strategy for flow cytometric analysis of CLIP expression on LAP+ cells 
First CD45dim cells (i.e. blasts) were gated (A) and selected for expression of CD34 as primitive 
marker in this example (B); when CD34 expression was absent, CD117 was used as primitive marker. 
Subsequently, cells were backgated from plot A and B to ensure that precursors cells formed a distinct 
population in CD45 expression, SSC (see panel C) and in FSC (not shown). In dotplot D, CLIP expression 
is depicted against expression of the aberrant marker as defined at diagnosis. In this example, 88% of 
LAP+ cells (aberrant CD7 expression) were CLIP-positive. 
Supplementary Table 1. Patient characteristics
UPN LAP marker  WHO classification 
1 CD7+ acute erythroid leukemia
2 CD7+ acute erythroid leukemia
3 CD7+ acute erythroid leukemia
4 TdT+ acute monoblastic and monocytic leukemia
5 CD56+ acute monoblastic and monocytic leukemia
6 CD34- acute monoblastic and monocytic leukemia
7 CD7+ acute monoblastic and monocytic leukemia
8 CD7+ acute monoblastic and monocytic leukemia
9 CD7+ acute myeloid leukemia without differentiation
10 CD7+ acute myeloid leukemia without differentiation 
11 CD7+ acute myeloid leukemia with minimal differentiation
12 CD56+ acute myeloid leukemia with minimal differentiation
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UPN LAP marker  WHO classification 
13 CD19+ acute myeloid leukemia with minimal differentiation
14 CD11c+ acute myeloid leukemia with minimal differentiation
15 CD11b+ acute myeloid leukemia not otherwise specified
16 CD11b+ acute myeloid leukemia not otherwise specified
17 CD19+ acute myeloid leukemia with maturation
18 CD56+ acute myeloid leukemia with maturation
19 CD7+ acute myeloid leukemia with maturation
20 CD7+ acute myeloid leukemia with maturation
21 CD7+ acute myeloid leukemia with maturation
22 CD15+ acute myeloid leukemia with maturation 
23 CD7+ acute myeloid leukemia with maturation 
24 CD117+++ acute myeloid leukemia with maturation 
25 CD7+ acute myeloid leukemia with t(8;21)
26 CD56+ acute myeloid leukemia with t(8;21)
27 CD11c+ acute myelomonocytic leukemia
28 CD56+ acute myelomonocytic leukemia
29 CD7+ acute myelomonocytic leukemia
30 CD7+ acute myelomonocytic leukemia
31 CD7+ acute myelomonocytic leukemia
32 CD34- acute myelomonocytic leukemia
33 CD7+ acute myelomonocytic leukemia
34 CD15+ acute myeloid leukemia with inv(16)
35 CD13- acute myeloid leukemia with inv(16)
36 CD15+ acute myeloid leukemia with inv(16)
37 TdT+ acute myeloid leukemia with inv(16)
38 CD2+ acute myeloid leukemia with inv(16)
39 CD15+ acute myeloid leukemia with inv(16)
40 CD15+ acute myeloid leukemia with inv(16)
41 CD7+ AML with multilineage dysplasia
42 CD13- AML with multilineage dysplasia
43 CD7+ AML with multilineage dysplasia
44 CD33- AML with multilineage dysplasia
45 CD13- AML with multilineage dysplasia
46 CD13- AML with multilineage dysplasia
47 CD7+ AML with multilineage dysplasia
48 CD13- AML with multilineage dysplasia
49 CD5+ AML with multilineage dysplasia
50 CD56+ AML with multilineage dysplasia
The various leukemia-associated phenotypes (LAP) used for determination of CLIP on LAP positive 
cells are shown. Phenotypes considered as aberrant were: presence of CD7, CD11c or CD56; over 
expression of CD13; absence of CD13 or CD33 combined with presence of another myeloid marker; 
absence of CD34 but presence of primitive marker CD117 or diminished expression of CD45. UPN: 
Unique Patient Number.
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Abstract
The capacity of tumor cells to escape from immune surveillance has become a substantial 
obstacle to successful cancer immunotherapy. Multiple tumor-related mechanisms underlie 
defects in HLA class I antigen presentation, but less is known about the role of impaired 
HLA class II antigen presentation. Our previous findings showed that presence of the class 
II-associated invariant chain peptide (CLIP) on HLA class II+ leukemic blasts is correlated to a 
poor survival in acute myeloid leukemia (AML). In this study, we thoroughly examined the 
functional significance of CLIP expression on leukemic blasts of AML patients. CD4+ T cells 
of patients were co-cultured with autologous CLIP- and CLIP+ primary leukemic blasts and 
analyzed for several functional parameters by flow cytometry. Increased HLA-DR and IFN-γ 
expression was observed for CD4+ T cells stimulated with CLIP- leukemic blasts, in contrast 
to CLIP+ leukemic blasts, indicating activation and polarization toward T helper 1 cells. Also, 
CLIP- leukemic blasts induced more outgrowth of effector memory CD4+ T cells with HLA-
DR-restricted TCR Vβ repertoires as well as leukemia-specific reactivity compared to CLIP+ 
leukemic blasts. These data provide a rationale for using immunotherapeutic strategies that 
can down-modulate CLIP on leukemic blasts to generate effective leukemia-specific T cell 
immunity in patients with AML.  
Introduction
Many approaches instrumental for developing additional immunotherapeutic strategies 
in the treatment of cancer patients are currently investigated. These include the ex vivo 
generation of autologous T cells that specifically recognize and eradicate tumor cells [1], 
and loading of professional antigen-presenting cells (APCs), such as dendritic cells (DCs), 
with apoptotic tumor cells to present tumor-associated antigens (TAAs) and activate tumor-
specific T cells in vivo [2]. It is of utmost importance to better understand how target tumor 
cells interact with the immune system of patients (‘immune editing’) and which tumor-
associated mechanisms are present that affect immune recognition (‘immune escape’; 
reviewed in ref. [3], potentially leading to the onset and progression of the disease).
Especially in solid tumors, but also in acute myeloid leukemia (AML), one of the main 
mechanisms of tumor cells to circumvent immune surveillance is T cell suppression. Certain 
tumor cells inhibit the effector function of T cells by interacting with negative costimulatory 
receptors or expression and secretion of immunosuppressive cytokines [4]. To escape from 
specific recognition by T cells, many solid tumors not only aberrantly express HLA class I 
molecules and components of antigen processing machinery (reviewed in ref. [5]), but also 
lack HLA class II expression. The absence of TAA presentation via HLA class II molecules 
prevents tumor cells from being recognized by CD4+ T cells, which impairs T helper 1 (Th1) 
cell activation that is crucial for effective anti-tumor immunity [6;7].
In patients with HLA class II-negative tumors, tumor-specific CD4+ T cells can only be 
activated by professional APCs that engulf, process and present exogenous TAAs derived 
from tumor cells. Studies to augment HLA class II expression and processing in such tumors 
demonstrated that tumor cells are also able to present endogenous TAAs by HLA class II 
molecules and mount a tumor-specific CD4+ T cell response [8;9]. Moreover, the ability of 
these tumor cells to activate CD4+ Th1 cells was strongly enhanced in the absence of the 
Invariant Chain (Ii; ref. [10], a chaperone protein important for HLA class II function [11]. 
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Therefore, it is of interest to examine the impact of HLA class II presentation machinery on 
the immune escape potential of tumor cells that do express HLA class II molecules, such as 
leukemic blasts.
According to the classical HLA class II antigen presentation pathway, newly formed HLA class 
II molecules associate with Ii and are transported to specialized lysosomal antigen-loading 
compartments (MIICs; ref. [12;13]). During transport, Ii is cleaved leaving a small remnant 
bound to the HLA class II peptide-binding groove, the class II-associated invariant chain 
peptide (CLIP; ref. [14;15]). This self-peptide is then exchanged for an antigenic peptide in 
the MIIC compartments by the peptide editor HLA-DM [16], and the formed HLA class II/
peptide complex is transferred to the plasma membrane for presentation. In the absence of 
HLA-DM, peptide exchange in the MIICs does not occur and CLIP is abundantly expressed at 
the plasma membrane [17;18]. 
Previously, we described that high CLIP expression on HLA class II+ leukemic blasts negatively 
correlated to the clinical outcome of patients with AML [19;20]. In addition, down-
modulation of CLIP on myeloid leukemia cell lines resulted in an increased ability to induce 
allogeneic CD4+ T cells [20], suggesting that CLIP on leukemic blasts influences CD4+ T cell 
recognition in AML patients. Here, we investigate the functional impact of CLIP on leukemic 
blasts directly derived from patients by performing co-cultures with autologous CD4+ T cells. 
We show differences in CD4+ T cell activation, Th1 skewing, effector memory differentiation, 
TCR Vβ repertoire and leukemia-specific reactivity, which points to a critical role for CLIP in 
T cell recognition of leukemic blasts in AML patients.
Materials and Methods
Patient selection
Diagnosis of AML was based on the French-American-British (FAB) criteria [21]. Cytogenetic 
risk groups were classified as previously reported [22]. AML patients received induction and 
consolidation treatment in accordance with HOVON (Dutch-Belgian Hematology-Oncology 
Cooperative Group) protocols (www.hovon.nl). For co-cultures with autologous CD4+ T cells, 
we needed to select patients who were in complete remission for at least 6 months and did 
not receive an allogeneic stem cell transplantation. Additionally, a large number of leukemic 
blasts from the same patients at diagnosis had to be able to stimulate CD4+ T cells, which 
were screened for high expression of CD40 and HLA-DR using flow cytometry. The clinical 
features and immunophenotypical characteristics of leukemic blasts of 8 selected patients 
are summarized in table 1. 
Patient samples
We collected bone marrow samples at the time of diagnosis and peripheral blood samples 
during remission of the same patients after obtaining informed consent and according to 
the declaration of Helsinki. Mononuclear cell fractions were freshly isolated by the use 
of density-gradient centrifugation (Ficoll-PaquePLUS, Amersham Biosciences, Freiburg, 
Germany), frozen at -80°C and stored in liquid nitrogen using RPMI 1640 medium (Gibco, 
Paisley, UK) supplemented with 20% heat-inactivated FBS (Greiner, Alphen a/d Rijn, The 
Netherlands) and 10% dimethylsulphoxide (Merck, Darmstadt, Germany). For their use in 
co-cultures, cells were rapidly thawed, washed twice in RPMI supplemented with 40% FBS 
and resuspended in the required medium for cell sorting, as described below.
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Antibodies
The mouse monoclonal antibodies (mAbs) used for flow cytometry included: PE-conjugated 
CD25 (Dako, Glostrup, Denmark), CD27 (Beckton Dickinson (BD), San Jose, CA), CD40 
(Beckman Coulter, San Diego, CA), anti-CLIP (clone cerCLIP.1; Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-IFN-γ and anti-IL-4 (both BD); FITC-conjugated CD28 (Dako), CD45RA 
(Sanquin, Amsterdam, The Netherlands), CD45RO (Dako), CD4, CD14, CD86, anti-HLA-DR 
(clone L243) and anti-IFN-γ; APC-conjugated CD3; PerCP-conjugated CD45; and 7-amino-
actinomycin D (7AAD; Via-Probe, all BD). Anti-HLA-DR blocking mAb L243 was prepared 
from supernatants of the HB-55 hybridoma (ATCC, Teddington, UK). 
Immunofluorescence staining
Before antibody labeling, 1 x 105 cells were incubated with 10% human gamma-globulin (60 
mg/ml; Sanquin) for 10 min. Mouse mAbs were added during 15 min at room temperature 
(RT). T cell receptor (TCR) Vβ repertoires were analyzed using the IOTest Beta Mark TCR Vβ 
Repertoire kit (Beckman Coulter), consisting of PE-, FITC- or both PE- and FITC-conjugated 
mAbs directed against 24 different TCR Vβ families. Before Vβ-specific staining, cells were 
stained with APC-conjugated CD3 and PerCP-conjugated CD4 mAbs and washed with PBS-
0.1% HSA-0.05% sodium azide. 
For cytokine expression, leukemic blast-activated CD4+ T cells were restimulated at day 12 
and 20 after activation with PMA (25 ng/ml) and ionomycin (1 μg/ml) for 6 h in culture 
medium [RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10% human AB serum 
(ICN Biochemicals, Aurora, OH, USA), 1% penicillin/streptomycin (Sigma-Aldrich, St Louis, 
MO) and 50 μM 2-ME (Gibco) at 37°C in a humidified atmosphere containing 5% CO2. To 
address CD4+ T cell specificity, we used different autologous cells (1:1 ratio) as stimulators 
instead of PMA/ionomycin. After 2 h of stimulation, cells were incubated with brefeldin 
A (10 μg/ml), fixed with PBS-1% paraformaldehyde, permeabilized with PBS-0.1% saponin 
(Sigma-Aldrich) and stained with anti-cytokine mAbs (30 min at RT). 
Stained cells were washed with PBS-0.1% HSA-0.05% sodium azide and evaluated by a 
FACSCalibur flow cytometer (BD). Flow cytometric analysis was performed with CellQuest 
software (BD). Myeloid blasts were defined as side scatter (SSC) low, CD45 intermediate 
[23]; the percentage of positive cells was determined as compared to PBS controls. Mean 
fluorescence index (MFI) was defined by the mean value of positive cells devided by that 
of the negative control. The following formula was applied to calculate relative expression: 
(% of positively stained cells / 100) * mean fluorescence intensity of positively stained cells. 
Cell sorting of primary leukemic blasts and CD4+ T cells
To select CLIP- and CLIP+ primary myeloid leukemic blasts, thawed mononuclear cells from 
patients with de novo AML were resuspended in PBS-0.1% HSA, pre-incubated with 10% 
human gamma-globulin for 10 min and then stained with sterile-filtered PerCP-conjugated 
CD45 (BD) and PE-conjugated anti-CLIP (Santa Cruz Biotechnology) mAbs for 15 min on 
ice. Selected HLA-DR+ patients revealed differential CLIP expression, in line with previous 
observations [19]. After washing with PBS, stained cells were analyzed and sorted for CLIP- 
and, if present, CLIP+ cells within the CD45dim/SSClow population by using a FACSAria flow 
cytometer (BD). The viability of the sorted cell fractions was confirmed by using trypan 
blue dye exclusion (>90%). Sorted cells were washed twice in PBS and used immediately for 
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culture experiments. The remaining cell fractions were frozen in several aliquots for later 
use.
For the isolation of CD4+ T cells, we thawed mononuclear cells obtained from peripheral 
blood samples of patients in remission, as described above, and selected CD14-CD4+ cells 
with anti-CD14 and anti-CD4 microbeads using magnetic cell separation (MACS; Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to manufacturer’s instructions. The purity 
of cells that were negatively selected for CD14 and positively selected for CD4 exceeded 
95%, as determined by flow cytometric analyses (data not shown). Depleted CD14+ cell 
fractions were frozen and stored in liquid nitrogen.
Autologous co-cultures
Flow cytometrically sorted leukemic blasts were irradiated (30 Gy) and added to 2.5-5 x 105 
remission CD4+ T cells of the same patient at a stimulator-to-responder ratio of 1:1 in culture 
medium supplemented with IL-7 (10 ng/ml; Miltenyi Biotec). CD4+ T cells were cultured with 
irradiated autologous blasts for 3 weeks at 37°C in a humidified atmosphere containing 5% 
CO
2
. To study HLA-DR restriction of the CD4+ T cell responses, we used CLIP--sorted leukemic 
blasts pre-treated with the anti-HLA-DR blocking antibody L243 [24] (9.2 μg/ml) at the start 
of culture. Following one week of stimulation, CD4+ T cells were re-stimulated with the same 
irradiated and sorted blasts (1:1 ratio) and cultured again in fresh medium. IL-2 (50 U/ml; 
Miltenyi Biotec) was added 2 days after each round of stimulation. Samples were taken 
from co-cultures at the same day to investigate functional parameters indicative for T cell 
function by using flow cytometry.
Table 1. Patient characteristics.
AML patient number 1 2 3 4 5 6 7 8
Gender (M/F) F M F M F F M M
Age at diagnosis (years) 37 55 56 61 72 70 40 61
WBC at diagnosis (109/l) 110 84 21 20 18 79 56 68
FAB classification M2 M5 M4 M4 M2 M5 M1 M4
Cytogenetic risk group* favor-
able
stan-
dard
ad-
verse
favo-
rable
stan-
dard
stan-
dard
stan-
dard
stan-
dard
Immunophenotype of blasts
CD45dim/SSClow (%) 89.0 85.7 78.5 18.5 50.1 26.5 51.4 46.8
     CD40 (%) 47.8 77.7 21.0 52.7 84.8 70.8 48.1 76.1
     CD86 (%) 1.6 11.9 5.4 34.3 35.3 96.5 21.7 83.3
     HLA-DR (%) 94.2 59.1 83.4 99.5 96.1 99.7 89.7 100
     CLIP (%) 1.0 17.6 53.4 13.3 42.7 49.0 76.1 50.9
Screening of selected AML patients that were in remission for at least 6 months and did not receive 
allogeneic stem cell transplantation. CD40, CD86, HLA-DR and CLIP expression is shown as the 
percentage of positive CD45dim/SSClow-gated primary leukemic blasts at diagnosis. Abbreviations: 
WBC, white blood cells; FAB, French-American-British; int, intermediate. * Groups were classified as 
previously described.[22]
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Functional analyses
Paired t tests were used to compare IFN-γ and IL-4 expression in CD4+ T cells between co-
cultures of patients. Only CD4+ T cells that received two or more rounds of stimulation with 
leukemic blasts were used for statistical analysis. For assessment of TCR Vβ repertoires, a 
given TCR Vβ family was interpreted as positive when Vβ expression was enhanced at least 
20% after stimulation with leukemic blasts, as compared to unstimulated CD4+ T cells, and 
greater than two times the standard deviation over the average for healthy controls. 
Results
Establishment of CLIP- and CLIP+ co-cultures from the same AML patients
We analyzed the functional impact of CLIP on primary leukemic blasts by performing co-
cultures of CD4+ T cells with autologous CLIP- and CLIP+ leukemic blasts from eight AML 
patients, who were selected as described in Materials and Methods and shown in table 1. 
In all cases, we could flow cytometrically sort CLIP- primary leukemic blasts for at least two 
rounds of stimulation of autologous CD4+ T cells. For patient 1, too few viable CD4+ T cells 
were left after co-culture with CLIP- leukemic blasts to do functional analyses. For patient 1 
and 2, it was technically impossible to acquire sufficient amounts of CLIP+ leukemic blasts to 
stimulate CD4+ T cells, as the majority of leukemic blasts were negative for CLIP (table 1). For 
A
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Figure 1. CD4+ T cell activation following stimulation with autologous CLIP- and CLIP+ primary 
leukemic blasts. (A) Flow cytometric analysis of HLA-DR and CD25 expression on unstimulated CD4+ T 
cells (‘-‘) and CD4+ T cells stimulated with three rounds of autologous CLIP-CD45dim or CLIP+CD45dim 
leukemic blasts. (B) MFI of CD25 expression on CD4+ T cells following two (day 12) and three (day 20) 
rounds of stimulation with untreated and L243-treated autologous CLIP- leukemic blasts. (C, D) Patients 
analyzed for HLA-DR and CD25 expression (%) on CD4+ T cells stimulated with equal rounds of CLIP-, 
L243-treated CLIP- or CLIP+ leukemic blasts. HLA-DR (%): ‘CLIP- vs CLIP+’, p=0.13; CD25 (%): ‘CLIP- vs 
CLIP+’, p=0.10; ‘CLIP-‘ vs ‘CLIP- +L243’, p=0.035 (paired t tests). As compared to CLIP- co-cultures, only 
patient 8 showed an increase in the percentage of positive cells.
C D
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patients 3-8, it was possible to study the influence of both CLIP- and CLIP+ leukemic blasts on 
CD4+ T cells after equal rounds of stimulation.
CLIP- leukemic blasts activate CD4+ T cells more efficiently than CLIP+ leukemic blasts 
from the same patient
To examine the capability of CLIP- and CLIP+ primary leukemic blasts to activate autologous 
CD4+ T cells, we assessed CD4+ T cells from different co-cultures for expression of HLA-DR 
and CD25, two common activation markers. 
As indicated for patient 3, HLA-DR and CD25 expression levels were strongly increased on 
CD4+ T cells after three rounds of stimulation with CLIP- leukemic blasts, as compared to 
unstimulated CD4+ T cells (day 20; figure 1A and figure 1B). For patient 4, CD4+ T cells from 
CLIP- co-cultures revealed a similar increase in expression, which was already observed 
after two rounds of stimulation with CLIP- leukemic blasts (day 12; figure 1B). In CLIP+ co-
cultures, the expression of HLA-DR and CD25 on CD4+ T cells were reduced compared to 
CLIP- co-cultures (figure 1A and figure 1C), demonstrating that CLIP on leukemic blasts 
affects CD4+ T cell activation. To investigate if CD4+ T cell activation by CLIP- leukemic blasts 
was HLA-DR restricted, we blocked HLA-DR expression on these blasts with the L243 mAb. 
Stimulation with L243-treated CLIP- leukemic blasts resulted in decreased CD25 expression 
on CD4+ T cells compared to CLIP- co-cultures without co-incubation with L243 (figure 1B 
A
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Figure 2. The role of CLIP on primary leukemic blasts in CD4+ T helper 1/T helper 2 skewing. 
Th1 and Th2 polarization of CD4+ T cells in CLIP- and CLIP+ co-cultures of the same AML patients. 
After PMA/ionomycin restimulation, CD3+CD4+ cells were analyzed at the same day of culture for 
intracellular IFN-γ and IL-4 expression by flow cytometry. The relative expression was defined as 
described in Materials and Methods. (A) IFN-γ and IL-4 expression in CD4+ T cells cultured alone or 
with autologous CLIP- or L243-treated leukemic blasts. (B) IFN-γ and IL-4 expression in CD4+ T cells 
cultured with autologous CLIP- or CLIP+ leukemic blasts.
and figure 1D). For patient 6 and 7, we found additional increases in HLA-DR-restricted CD4+ 
T cell proliferation during CLIP- co-cultures, in contrast to CLIP+ co-cultures and controls, as 
recently reported [20]. One patient (patient 8) showed excessive spontaneous proliferation 
of CD4+ T cells in culture (data not shown), which possibly explains the aberrant activation 
differences between CLIP- and CLIP+ co-cultures for this patient only (figure 1C).
To conclude, for 5 out of 6 AML patients, CD4+ T cells were generally more activated in 
cultures with CLIP- leukemic blasts than in cultures with CLIP+ leukemic blasts, indicating 
that the presence of CLIP on primary leukemic blasts negatively influences autologous CD4+ 
T cell priming.  
CLIP- primary leukemic blasts prime CD4+ T cells toward a T helper 1 phenotype in 
contrast to CLIP+ primary leukemic blasts
For effective anti-tumor T cell immunity, it is necessary that CD4+ T cells are activated and 
differentiate into Th1 cells, which augment tumor-specific CTL responses by triggering APCs 
B
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or secreting IFN-γ [25]. Therefore, we next investigated whether CLIP on primary leukemic 
blasts had an effect on Th1 and Th2 skewing of autologous CD4+ cells. 
CLIP- leukemic blasts induced significant IFN-γ production in CD4+ T cells as compared to 
unstimulated CD4+ T cells (p=0.0465; figure 2A). This induction was HLA-DR-dependent, 
since L243 treatment of these blasts prior to stimulation abrogated the effect. No significant 
increases in IL-4 were encountered. CD4+ T cells that received equal rounds of stimulation 
with CLIP+ leukemic blasts hardly produced IFN-γ, in accordance with unstimulated CD4+ T 
cells (figure 2B). IFN-γ expression between CD4+ T cells of CLIP-  and CLIP+ co-cultures was 
significantly different (p=0.0477), in contrast to IL-4 (figure 2B). Interestingly, in addition to 
a decrease in IFN-y+ T cell number, an increased amount of IL-4+ CD4+ T cells was found in 
CLIP+ compared to CLIP- co-cultures of patient 6 and 8 (Supplementary figure S1).
Overall, for 7 out of 8 AML patients, CLIP- leukemic blasts induced IFN-γ expression in 
Figure 3. Increases in effector memory phenotype of highly activated CD4+ T cells in  CLIP- compared 
to CLIP+ co-cultures. Percentages of naive (N; CD45RA+CD27+), central memory (CM; CD45RA-CD27+) 
and effector memory (EM; CD45RA-CD27-) CD4+ T cells in different co-cultures of AML patients, 
as determined by flow cytometry. Patients showing the largest increases in CD4+ T cell activation 
between CLIP- and CLIP+ were assessed. CD4+ T cells received equal rounds of stimulation.
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autologous CD4+ T cells, demonstrating polarization toward a Th1 phenotype. Moreover, for 
all AML patients tested, CLIP+ leukemic blasts were not able to significantly enhance IFN-γ 
levels, which indicates that absent CLIP expression on primary leukemic blasts boosts Th1 
differentiation.
Highly activated CD4+ T cells in CLIP- co-cultures have an increased effector memory 
phenotype as compared to CD4+ T cells in CLIP+ co-cultures 
As CD4+ T effector memory cells are critical for long-term immune protection against tumor 
growth [26], we studied if the presence of CLIP on primary leukemic blasts was associated 
with changes in CD4+ T cell memory phenotype. This was analyzed for patients whose CD4+ 
T cells revealed a large difference in activation following stimulation with CLIP- and CLIP+ 
leukemic blasts (n=4; figure 1C).
For patient 3 and 4, an increased amount of CD4+ T cells obtained an effector memory 
(CD27-CD45RA-) phenotype in CLIP- co-cultures, as compared to control cultures (25% and 
40% versus 9% and 14%, respectively; figure 3). This increase was HLA-DR restricted, as it 
was abolished by stimulation with L243-treated CLIP- leukemic blasts (data not shown), and 
accompanied by a decreased percentage of naive (CD27+/CD45RA+) and central memory 
(CD27+/CD45RA-) cells (figure 3). In CLIP+ co-cultures, we observed a reduced percentage 
of effector memory cells (12% and 3%, respectively), whereas the percentage of naive and 
A
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central memory cells was enhanced. For patient 6 and 7, despite the high effector memory 
and low naive and central memory cell numbers in control cultures, similar differences in 
memory phenotype were seen between CLIP- and CLIP+ co-cultures (figure 3). These data 
were confirmed by CD27 and CD45RO expression analyses (data not shown).
Thus, for all AML patients tested, the activation of autologous CD4+ T cells in CLIP- co-cultures 
caused enhanced differentiation of naive and/or central memory cells into effector memory 
cells, as compared to CLIP+ co-cultures. This implicates that the ability of primary leukemic 
blasts to generate effector CD4+ T cells involves the expression of CLIP. 
CLIP- primary leukemic blasts activate distinct subsets of HLA-DR-restricted CD4+ T cells in 
comparison with CLIP+ primary leukemic blasts 
To provide evidence that CLIP- leukemic blasts can present leukemia-associated antigens 
(LAAs) and thus activate distinct antigen-specific CD4+ T cell subsets, we studied the relation 
of CLIP on primary leukemic blasts and TCR Vβ repertoires of outgrowing CD4+ T cells. The 
well-expanding CD4+ T cell populations of patient 6, 7 and 8 were compared for the presence 
of 24 different TCR Vβ families after three rounds of stimulation with CLIP- or CLIP+ leukemic 
blasts using flow cytometry. 
We detected six TCR Vβ families for patient 6 and ten TCR Vβ families for patient 8 that 
were strongly expanded in cultures of CD4+ T cells stimulated with CLIP- leukemic blasts as 
compared to unstimulated CD4+ T cells and healthy controls. (figure 4A and figure 4B). Four 
and two of these families, respectively, were exclusively expanded by CLIP- and not by CLIP+ 
Figure 4. TCR Vβ CD4+ T cell expansion in long-term cultures with CLIP- and CLIP+ primary leukemic 
blasts. TCR Vβ analyses were performed for well-expanding CD4+ T cells in culture with autologous 
CLIP- and CLIP+ primary leukemic blasts (panel A and B). The positive TCR Vβ families of CLIP- co-
cultures that were present (rectangles) or absent (circles) in corresponding CLIP+ co-cultures are 
highlighted. To assess HLA-DR restriction, we analyzed the presence of positive families in co-cultures 
with L243-treated CLIP- leukemic blasts (panel C).
C
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leukemic blasts. CD4+ T cells from long-term CLIP- and CLIP+ co-cultures were restimulated with 
autologous CLIP- primary leukemic blasts and analyzed for intracellular IFN-γ expression by flow 
cytometry. Results were compared to restimulation with autologous non-malignant monocytes (A) or 
CLIP+ primary leukemic blasts (B). The relative expression was defined as described in Materials and 
Methods and, in panel A, normalized to that of CD4+ T cells restimulated with PMA/ionomycin in the 
same co-culture.  
A
B
leukemic blasts. The majority of CLIP--specific TCR Vβ families did not expand in L243 CLIP- 
co-cultures (figure 4C), demonstrating that activation was primarily restricted to HLA-DR. 
The activation of all TCR Vβ families equally present in CLIP- and CLIP+ co-cultures was not 
HLA-DR restricted. For patient 8, no differences in TCR Vβ expression were found between 
CD4+ T cells from CLIP- and CLIP+ co-cultures (data not shown), consistent with the earlier 
described strong spontaneous CD4+ T cell proliferation.
In conclusion, for 2 out of 3 AML patients, we reveal that CLIP- leukemic blasts activate 
specific subsets of HLA-DR-restricted CD4+ T cells that are not activated by CLIP+ leukemic 
blasts. These results show that CLIP on primary leukemic blasts interferes with expansion 
of antigen-specific CD4+ T cells, and thus may prevent activation of leukemia-reactive CD4+ 
T cells.  
CD4+ T cells stimulated with CLIP- primary leukemic blasts reveal leukemia-specific 
reactivity in contrast to those stimulated with CLIP+ primary leukemic blasts 
To further examine leukemia specificity, we evaluated if the well-expanding ‘CLIP--primed’ 
CD4+ T cells from patient 6 could detect antigens presented by other autologous APCs.
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CD4+ T cells from CLIP- and CLIP+ co-cultures were studied for IFN-γ expression after 
restimulation with autologous non-malignant monocytes or CLIP- primary leukemic blasts. 
An almost 2-fold reduction in IFN-γ expression was observed in ‘CLIP--primed’ CD4+ T cells 
restimulated with non-malignant monocytes compared to those restimulated with CLIP- 
leukemic blasts (figure 5A). This difference was not found for ‘CLIP+-primed’ CD4+ T cells, 
confirming that recognition of CLIP- leukemic blasts by these CD4+ T cells is determined by 
specific priming. As another control, similar experiments for the spontaneously outgrowing 
CD4+ T cells from patient 8 showed hardly any recognition of CLIP- leukemic blasts or non-
malignant monocytes (figure 5A). 
To evaluate whether the recognition of primary leukemic blasts by ‘CLIP--primed’ CD4+ 
T cells of patient 6 was dependent on CLIP expression, we compared the ability of these 
CD4+ T cells to recognize autologous CLIP- or CLIP+ leukemic blasts. Restimulation with CLIP- 
leukemic blasts clearly induced IFN-γ expression in ‘CLIP--primed’ CD4+ T cells, in contrast to 
restimulation with CLIP+ leukemic blasts (figure 5B). This shows that the expansion of ‘CLIP--
primed’ CD4+ T cells is antigen-specific and relies on a CLIP- background. 
Taken together, these data indicate that CD4+ T cell priming by CLIP- leukemic blasts can 
result in increased leukemia-specific reactivity, demonstrating the potential relevance of 
CLIP expression on primary leukemic blasts in the induction of an effective leukemia-specific 
CD4+ T cell response.
Discussion
Impaired T cell recognition of tumor cells is an essential issue to address in translational 
cancer research, since it could not only explain disease progression, but also provide new 
immunotherapeutic targets to induce effective anti-tumor immunity. In AML patients, this 
may be a pathologic event as T cells constantly encounter leukemic blasts in the peripheral 
blood without the ability to control or eradicate the disease. Recent studies have shown 
that the number of peripheral blood T cells is increased at diagnosis [27], but that, despite 
the excess of leukemic blasts as APCs, these cells are not fully activated [28]. This suggests 
that AML patients induce an immune response, but lack leukemia-specific T cells due to 
mechanisms used by leukemic blasts that prevent activation. In this study, we demonstrate 
that one of these mechanisms could be the expression of CLIP, a self-peptide known to be 
presented by HLA class II molecules instead of antigenic peptides to CD4+ T cells. 
By using cells from the same AML patients, co-culture experiments were performed in a 
setting that might be representative for the in vivo situation. In this way, we also minimized 
the influence of inter-patient variability, a feature commonly observed in AML. To acquire 
autologous CD4+ T cells, we had to select AML patients that were still in complete remission. 
This restricted the number of cases that could be assessed, as CLIP expression in patients 
with prolonged remission is generally low at diagnosis in contrast to early-relapsing patients 
[19]. For the patients whose CD4+ T cells could be primed with CLIP- and CLIP+ leukemic 
blasts, strong differences in T cell function were found, caused by either a direct or indirect 
effect of CLIP.   
For most patients, CLIP+ leukemic blasts were less able to activate CD4+ T cells during co-
cultures (figure 1C). This points to a direct role for CLIP in the induction of aberrant T cell 
activation pathways, which were recently found in AML T cells that lacked the ability to form 
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immunologic synapses after conjugation with leukemic blasts [27]. Interestingly, for patient 
6 and 7, CD25 expression on CD4+ T cells remained relatively high after stimulation with CLIP+ 
leukemic blasts, which might represent CD25high regulatory T cells (Tregs). In agreement with 
this, CLIP+-restricted CD4+ T cell priming was seen for both patients, as TCR Vβ families 3 
and 17 were markedly expanded in CLIP+, but not in CLIP- co-cultures, respectively (figure 
4). Self-peptides can indeed promote Treg expansion [29] and a role for CLIP in this context 
has been proposed [30]. Also Tregs are highly prevalent in patients with untreated AML [31], 
but further investigation is needed to confirm this association. Although expression levels of 
IL-4 were relatively low compared to IFN-γ, for some patients, CLIP+ leukemic blasts seemed 
to stimulate IL-4+ Th2 cells more efficiently than CLIP- leukemic blasts (Supplementary 
figure S1). This suggests that high expression of CLIP together with CD86 (patient 6 and 8; 
table 1) contributes to a tumor-protective Th2 immune response, in line with the findings 
of Rohn and co-workers for maturing DCs [32]. In AML, CLIP may therefore be involved in 
the correlation of CD86 with hyperleukocytosis and the capacity of CD86-positive leukemic 
blasts to boost Treg- or Th2-related cytokine production [33]. 
Another possibility is that CLIP on leukemic blasts indirectly affects CD4+ T cell function. In 
the absence of CLIP, we observed increases in T cell activation, Th1 skewing and effector 
memory differentiation (figures 1-3). HLA-DR-specific blocking on leukemic blasts abrogated 
these effects, which points to the involvement of a contact-dependent mechanism in which 
peptides other than CLIP are recognized and cause an effective CD4+ T cell response. Since 
not only the amount of naïve cells, but also of central memory cells was lowered in CLIP- co-
cultures (figure 3), CD4+ T cells from patients in remission probably have already encountered 
these immunogenic peptides at disease onset. Earlier studies reported that the precursor 
of CLIP, Ii, blocks loading of endogenous peptides onto HLA class II molecules in the ER 
[34-36], thereby preventing peptide loading until the MIICs are reached for exchange of 
CLIP with exogenous peptides. Thus, Ii has an important role in discriminating HLA class 
I and II-mediated presentation of endogenous and exogenous peptides, respectively [37]. 
Based on these findings, it is likely that in CLIP- leukemic blasts, HLA class II complexes are 
loaded with endogenous peptides for presentation to CD4+ T cells. A CLIP- myeloid leukemic 
cell line, KG-1, was already shown to present HLA-DR molecules occupied with endogenous 
rather than exogenous peptides [38]. Recently, we extended this by showing that contrary 
to CLIP+ leukemic blasts, CLIP- KG-1 blasts present such peptides via a proteasome- and TAP-
dependent pathway [39]. The current study indicates that this type of processing in CLIP- 
primary leukemic blasts may lead to activation of specific subsets of HLA-DR-restricted CD4+ 
T cells (figure 4) with leukemia-specific reactivity (figure 5). Collectively, these data support 
our hypothesis that the absence of CLIP on leukemic blasts is critical for endogenous LAA 
presentation and the induction of a leukemia-specific T cell response, resulting in prolonged 
disease-free survival of CLIP- AML patients [19;20]. 
Until now, little was known about the functional consequences of CLIP on HLA class II-
bearing tumor cells. Here, we reveal that the presence of CLIP on leukemic blasts of AML 
patients interferes with optimal activation of leukemia-reactive CD4+ T cells. This deserves 
more attention in the development of immunotherapy for patients with such tumors. 
Current immunotherapeutic strategies are based on the delivery of optimal DCs or T cells to 
boost the immune system of patients against tumor cells. In AML, we now demonstrate that 
CLIP can also be detrimental for the recognition of primary leukemic blasts, indicating that 
Absence of CLIP promotes activon of leukemia reactive CD4+ T cells
135
priming or delivery of leukemia-specific T cells by such strategies, respectively, might not 
be enough for the generation of anti-leukemic immunity in vivo. CLIP+ leukemic blasts also 
have to be recognized well by leukemia-specific T cells via presentation of endogenous LAAs 
instead of CLIP, which otherwise leads to tumor immune escape and outgrowth. Recent 
studies report that gene expression of the two main processors of endogenous antigens, the 
proteasome and TAP, can be increased in tumor cells using histone deacetylase inhibitors 
(HDACi; ref. [40]. Furthermore, preliminary experiments in our laboratory showed strongly 
reduced CLIP levels on leukemic blasts of AML patients after treatment with the clinically 
applicable HDACi suberoylanilide hydroxamic acid (SAHA). Therefore, we propose that CLIP 
down-modulation by pharmacological agents may serve as a promising strategy to enhance 
endogenous LAA presentation on primary leukemic blasts in vivo, leading to improved 
immunotherapy in AML.
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Summary
Therapeutic vaccination with dendritic cells (DC) is recognized as an important experimental 
therapy for the treatment of minimal residual disease (MRD) in acute myeloid leukemia (AML). 
Many sources of leukemia associated antigens (LAA) and different methods for antigen (Ag) 
loading of DC have been used in an attempt to optimize anti-tumor responses. For instance, 
monocyte-derived DC (moDC) have been loaded with apoptotic whole-cell suspensions, 
necrotic cell lysates, tumor-associated peptides, eluted peptides and cellular DNA or RNA. 
Furthermore, MoDC can be chemically or electrically fused with leukemic blasts and DC have 
been cultured out of leukemic blasts. However, it remains unclear and a challenge in cancer 
immunotherapy to identify which of these methods is the most optimal for Ag loading and 
activation of DC. This review discusses recent advances in DC research and the application of 
this knowledge towards new strategies for Ag loading of DC in the treatment of MRD in AML.
Introduction
Acute myeloid leukemia (AML) is characterized by proliferation of clonal neoplastic myeloid 
hematopoietic precursor cells and impaired hematopoiesis. About 30% of AML cases can be 
classified as AML with myelodysplasia related changes, often preceded by a myelodysplastic 
syndrome (MDS). Chemotherapeutic induction regimens achieve complete remission (CR) in 
70-80% of adult AML patients younger than 60 years; when older than 60, CR is achieved 
only in 50-60% of patients [1]. Despite intensive consolidation chemotherapy, relapses occur 
in approximately 50-60% of patients, probably caused by the presence of minimal residual 
disease (MRD). In the last decade, new treatment modalities have revealed the important 
role of the immune system in the prevention and control of leukemia, e.g. the graft versus 
leukemia (GvL) effect induced by allogeneic stem cell transplantation (SCT) and the reinduction 
of CR after donor lymphocyte infusion (DLI) after allogeneic SCT for patients with relapsed 
(chronic myeloid) leukemia. These effects are considered to be mediated by anti-tumor T 
cells. The induction, regulation and maintenance of such responses in AML are thought to be 
coordinated by dendritic cells (DC). 
In 1995, the first cancer patients were vaccinated with DC and since then DC vaccines have 
been administered to patients with a variety of solid tumors, most frequently melanoma 
followed by prostate cancer and renal cell carcinoma, as well as to multiple myeloma and 
leukemia patients [2;3]. So far, more than 180  trials have been conducted; an overview of 
the DC-based clinical studies for cancer can be found at  www.mmri.mater.org.au [4]. In 
the majority of trials immune responses against tumor associated antigens (TAA) could be 
detected. However, the same data emphasized the need for improving vaccination strategies, 
as in only a minority of patients clinical responses were achieved [5;6]. These poor clinical 
results could be partly explained by the use of immature DC and the late disease stage in 
which patients were treated. Overall, it was concluded that therapeutic cancer vaccines are 
feasible, easy to administer in an outpatient setting and do not cause many side effects. The 
number of randomized trials remains limited and evaluation of the efficacy of DC vaccination 
regimens is difficult [5;7]. To our knowledge, only one placebo controlled vaccination trial 
in prostate cancer patients has been performed with DC-like cells; encouragingly, results 
suggest a survival advantage for the vaccinated group [8]. Questions remain about which DC 
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precursor should be used for DC preparation, how immature DC should be activated and 
which source of TAA should be used.  Moreover, there is no consensus yet on the timing and 
route of vaccine administration and methods of immunomonitoring. To date, most research 
has focused on solid tumors. This review discusses recent advances in DC research and 
the application of this knowledge towards new strategies for Leukemia Associated Antigen 
(LAA) loading of DC in the treatment of AML.
Principles of immunotherapy
Immune surveillance
Both unlimited growth and a differentiation block are needed for a cell to evolve into a 
malignant clone able to cause all clinical symptoms of solid or leukemic tumors. A model 
has been proposed for solid tumors by which the immune system plays an important role 
in the elimination of tumor cells, called immune surveillance [9]. The immune surveillance 
model describes the role of the immune system in the evolution of solid malignancies 
in three different phases. Hypothetically, the same model can be applied to AML and is 
summarized in figure 1. The first phase encompasses a state in which the immune system 
recognizes and eliminates (pre-)leukemic cells and the immune response is not yet inhibited 
by immune suppressive effects of (pre-) leukemic cells and/or their microenvironment, i.e. 
the elimination phase. This phase is followed by an equilibrium phase in which there is still 
a low tumor burden and immune cells are able to remove part of the malignant cells and 
prevent full-blown leukemia (equilibrium phase). In this phase, the mutation of malignant 
cells into escape-variants is promoted. In AML, the MDS prophase might be considered as 
the equilibrium state in some cases. In about 30% of the MDS cases, leukemia will develop 
which might at least be in part due to escape of immune surveillance [10]. Additionally, the 
immune system might control MRD cells in patients in first CR; in 50% of patients who reach 
CR relapse of AML occurs, even years after the last cycle of chemotherapy. The equilibrium 
phase is followed by the escape phase: malignant variants are no longer recognized by 
the immune system. This  will result in uncontrolled expansion of leukemic blasts and 
development of manifest disease [9;11]. 
The role of DC in immune surveillance
DC are professional antigen (Ag)-presenting cells orchestrating the immune response. 
Immature DC sense Ag with their pattern recognition receptors (PRR). Antigenic peptides 
are thought to be chaperoned by peptide-binding heat shock proteins (HSP) such as 
glycoprotein 96 (gp96), HSP90, HSP70 and calreticulin. These chaperone-peptide complexes 
bind phagocytic PRR (pPRR) receptors, resulting in internalization and cross-priming [12]. As 
tumor cells constitute an exogenous source of Ag for the DC, TAA need to be processed and 
presented by MHC class I via a process called cross-presentation [13]. As well as binding of 
pPRR, instructive PRR (iPRR) are involved in providing DC with signals that regulate their 
capacity to elicit T cell responses, for instance Toll Like Receptors (TLR) [14;15]. Activation 
of TLR results in enhanced Ag presentation, production of inflammatory cytokines, 
upregulation of co-stimulatory molecules and overall activation of adaptive immune 
responses [16;17]. When the T cell receptor (TCR) of a naive T cell recognizes the TAA-
derived epitopes presented by the DC, the T cells will become activated and a TAA-specific T 
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cell clone will expand. In AML, relatively few LAA have been identified, such as: WT1 (Wilms’ 
tumor-gene product), PRAME (preferentially expressed Ag of melanoma), RHAMM (receptor 
for hyaluronic acid mediated motility), PR1 (a proteinase 3 derived peptide), hTERT (human 
telomerase reverse transcription Ag) and Survivin [11;18]. 
Immune escape 
Various immunosuppressive effects, directly or indirectly induced by leukemic blasts, are 
known. Leukemic blasts can escape T cell-mediated cytoxicity directly by upregulating 
T cell inhibitory molecules, such as Programmed Death receptor ligand 1 (PD-L1) [19]. 
Furthermore, presentation of LAA by MHC class II, and thereby T helper (Th) cell activation, 
is reduced when the class II-associated invariant chain peptide (CLIP) is not replaced by an 
(immunogenic) peptide [20;21]. Without T cell help cytoxic T lymphocyte (CTL) responses 
cannot be maintained and tolerance will be induced. In addition, in  AML indoleamine-2,3-
dioxygenase expression is associated with poor clinical outcome, possibly by skewing the 
immune response towards a tolerogenic state [22;23]. Furthermore, increased frequency of 
and suppression by regulatory T cells (Treg) in patients with acute myelogenous leukemia 
Figure 1. The three phases recognized in immune surveillance applied to AML. (1) The first phase, 
the elimination state, shows an immune system capable of eliminating (pre-)malignant AML blasts by 
NK and T cells activated by dendritic cells (DC). (2) This phase is followed by the equilibrium phase, 
wherein the immune cells remove part of the AML blasts, but some of the blasts cells escape with help 
of, for instance, T regulatory cells (Treg) or myeloid-derived suppressor cells (MDSC). (3) When these 
malignant cells are not recognized anymore by the immune system, this will result in an uncontrolled 
expansion of AML blasts and impaired numbers and function of granulocytes and other white blood 
cells (WBC). Adapted from Dunn and co-workers [8].
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is observed in AML [24]. Factors such as vascular endothelial growth factor (VEGF), IL6, 
GM-CSF, IL-10 and TGFβ are associated with inhibition of DC function and maturation and 
induction of suppressive cells  [22;23].  
Immunotherapy
All the escape pathways discussed above are potential targets for immunotherapy. For 
instance, passive immunotherapy with adoptive transfer of specific T cells can restore rates 
of functional CTL [25]. Unfortunately, no memory response will be elicited and therefore 
after the lifespan of the CTL, the effect will disappear allowing dormant MRD cells to grow 
out. In contrast, active immunotherapy, for instance with DC vaccination, induces CTL and 
memory responses in vivo. In myeloid leukemia various sources of DC can be thought 
of: leukemia-derived-DC, AML-derived DC lines with DC differentiation capacity, CD34+ 
normal precursor cell-derived DC or monocyte-derived DC (MoDC). Most in vitro generated 
immature DC can be primed and matured with cytokines and/or with tumor Ag in different 
ways [26]. There are numerous ways to interfere with and to modulate the escape pathways 
of blasts, which all may be of help to enhance the efficacy of DC vaccine regimens [27]. A 
selection is discussed in this paper focussing on the current state of the art. 
Dendritic cells for immunotherapy; leukemic cell derived 
DC
Leukemic blasts, being malignantly transformed precursor cells, often have the ability to 
differentiate into DC-like cells. These AML-derived DC could provide a distinct opportunity 
to generate Ag presenting cells (APC) that harbor the full range of identified and unidentified 
LAA (figure 2D). AML-derived DC have the capacity to induce leukemia-specific T cell 
responses in vitro as well as in vivo, thus offering an immunotherapeutic modality for AML 
patients with MRD [28;29]. Unfortunately, leukemic DC might still harbor features of the 
leukemic blast, such as reduced expression of MHC molecules and molecules related to 
adhesion and induction of the co-stimulatory pathway as well as inhibitory features such as 
IDO expression [22]. Furthermore, vaccination with AML-DC is limited to 60-70% of cases 
where AML blasts can be cultured into leukemic DC [29;30]. Therefore, a more reliable 
and continuous source for differentiation into DC may be an AML-derived cell line, such 
as MUTZ-3 [figure 2D]. This cell line behaves as the immortalized equivalent of CD34+ DC 
malignant precursor cells. Upon stimulation with cytokine cocktails, MUTZ-3 progenitors 
acquire a phenotype consistent with either interstitial DC or Langerhans cells (LC), superior 
to other AML cell lines such as THP-1, KG1 and HL60  [31-33]. As MUTZ-3 has an HLA-A2+/
HLA-A3+ phenotype, it can be used as a vaccine in patients with matching alleles, i.e. 70% 
of the Caucasian population. However, similar to leukemic DC, MUTZ-3 DC might exhibit 
features which potentially influence the efficacy of MUTZ-3 DC vaccines [34]. Therefore, 
other sources of DC, for instance MoDC cultured at the time of complete remission, loaded 
with tumor-specific peptides or patients’ tumor material may serve as an alternative. A few 
papers have compared MoDC with AML-DC and indicate MoDC as a valid alternative for 
clinical application, especially for those patients where no leukemic DC can be obtained 
[35-39]. 
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Dendritic cells for immunotherapy; monocyte-derived 
DC
Source of MoDC 
Immature MoDC can be cultured with GM-CSF and IL-4 from monocytes of AML patients 
at the time of complete remission after induction therapy or from monocytes of matched 
healthy donors. Subsequently, maturation can be induced by various stimuli, such as 
cytokine cocktails (IL1β, TNF-α, IL6, and PGE
2
 being the most widely used clinically) or Toll 
Figure 2. Dendritic cell (DC) vaccine preparation for clinical purposes. A. Mature DC can be loaded 
with peptides eluted from leukemic blasts or with synthetic 8-mer peptides. B. Immature DC can be 
loaded with synthetic long peptides, leukemic blast-derived lysate or apoptotic cells. Apoptotic cells 
can be subdivided in blebs or apoptotic cell bodies (ACB). Upon phagocytosis of tumor derived cell 
material, antigens are cleaved by the proteasome (1), cross-presented onto MHC class I molecules 
(2) and presented to LAA specific naive Tcells (3). Subsequently maturation can be induced with 
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like receptor ligands TLR-L (such as LPS) [7]. During active disease and shortly after complete 
remission the yields of functional MoDC are low, probably due to suppressive effects of 
leukemic blasts and intensive chemotherapy. Approximately three weeks after the last cycle 
of chemotherapy negative effects wane, suggesting that MoDC can best be obtained at a 
later timepoint after first CR [40;41]. For patients with an HLA-matched sibling, vaccination 
with MoDC derived from the donor might be an option, thereby circumventing leukemia- 
and treatment-related problems in the culture of patient-derived MoDC. Although the use of 
matched allogeneic MoDC is limited to those patients who have an eligible donor; emerging 
donor-banks for matched unrelated donors might overcome this problem. Furthermore, the 
a cytokine cocktail. C. Mature DC can be eletroporated with tumor-derived DNA or RNA. This is 
transcribed intracellularly and processed via the proteasome onto MHC class I molecules. D. AML 
blasts or MUTZ-3 cells can be cultured with a cytokine cocktail into AML-DC or MUTZ-3-DC. These cells 
will present endogenous tumor-assaociated peptides by MHC class I molecules. E. Mature DC can be 
fused with an AML blast or AML cell line, such as the MUTZ-3. 
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use of non-matched allogeneic DC has been explored. An estimated 1-10% of the circulating 
T cell repertoire is directed against allo-Ag; alloDC are expected to trigger a broad T cell 
response thereby activating tumor-reactive T cells through cross-reactivity. On the other 
hand, high frequencies of allo-reactive T cells could overwhelm the proliferation of rare LAA-
specific precursors [42]. Overall, clinical trials using allogeneic non-matched MoDC loaded 
with autologous lysates or apoptotic cells in solid malignancies were feasible and in general 
well tolerated [42-45].
Whereas, leukemic DC harbor a full range of endogenous LAA, MoDC need to be pulsed 
with exogenous LAA. Various sources of LAA have been used in an attempt to optimize 
anti-tumor responses. These include known LAA-derived peptides, apoptotic whole-cell 
suspensions, necrotic cell lysates, eluted peptides, cellular DNA or RNA, as well as chemical 
or electrical fusion of whole tumor cells with DC, and will be discussed in the next paragraps 
(summarized in figure 2.) [3;46]. 
Peptides derived from LAA
As mentioned above, WT1, PRAME, RHAMM, PR1, hTERT and survivin may all be considered 
as relevant peptide sources for DC loading. Unfortunately, some of these LAA are also 
expressed in normal hematopoietic progenitor cells and their overexpression is common but 
not uniform in leukemia [47]. Other obstacles to the use of MHC-I binding peptides for DC 
loading are low affinity of peptide binding to MHC class I molecules, the short time peptides 
reside on the surface of DC and a lack of Th cell activation [48]. Moreover, targeting a single 
Ag may result in immunologic pressure against the parent protein resulting in selection of Ag-
loss leukemia variants [49]. Promotion of Ag-loss variants might be prevented by combining 
epitopes from different LAA. Unfortunately, HLA restriction of peptides limits the application 
to patients with certain HLA profiles. Many of these problems might be overcome by the use 
of longer peptides where the DC needs to process the long peptide into smaller parts before 
presentation onto MHC class I and II molecules [50]. Additionally, electroporation of RNA 
encoding for LAA epitopes might be preferable over the use of LAA peptides [51].  
Eluted peptides
Naturally processed and presented peptides can be eluted from the surface of AML 
blasts. These peptides comprise all known and unknown presented LAA and therefore are 
hypothetically advantegous over known LAA, where only a few, mostly HLA-A2 associated 
epitopes, can be used. Eluted peptides from patients’ blasts are unique for every patient and 
not hampered by HLA-restriction. In contrast to known LAA, eluted peptides can bind both 
HLA class I and II molecules and thereby activate both CD8+ and CD4+ T cells. Although further 
research is required concerning the low affinity of peptides binding to MHC molecules and 
the short time peptides reside on the surface of DC [48]. Elution of peptides from leukemic 
blasts can be done by using either citrate-phosphate (CP) or trifluoroacetic acid (TFA) buffer; 
for AML the TFA elution method to extract immunogenic AML-associated peptides was 
found to be favourable [52;53]. Application of this method might even be more efficacious 
when combined with depletion of regulatory T cells [54]. A direct comparison of eluted 
peptides and other LAA sources for loading strategies has not yet been made.
Apoptotic cells and blebs
Apoptosis, i.e. physiological programmed cell death, is associated with diverse cellular 
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changes to ensure that cells are cleared by the immune system. These changes include 
changes in the distribution of membrane lipids, membrane blebbing, condensation of 
both cytoplasm and chromatin, and fragmentation of the nucleus and cellular constituents 
into membrane-enclosed apoptotic bodies. Changes of molecules in the membrane make 
cells palatable for phagocytes. For example, translocation of soluble molecules such as 
phosphatidylserine and calreticulin to the plasma membrane or adsorption of soluble 
proteins from outside the cell such as C1q and thrombospondin are known to enhance 
uptake of apoptotic cells by DC and to lead to their activation [55-57]. One of the first 
studies showed that CD34+-derived DC loaded with irradiated blasts were able to prime 
CD8+ T cells into anti-leukemic CTL [58]. Furthermore, apoptotic cell loaded MoDC were able 
to generate anti-leukemic Th cells [59]. For loading of DC with apoptotic cells, induction of 
apoptosis should be as immunogenic as possible. For instance, upregulation of calreticulin 
by irradiation with UV light or by treatment with chemotherapeutic drugs, is associated 
with immunogenic apoptosis of colon carcinoma cells [55]. In myeloma, the proteosome 
inhibitor bortezomib induces upregulation of  HSP90 and thereby enhances DC-mediated 
induction of immunity [60]. Furthermore, activation of cells before apoptosis induction, for 
instance with PHA, might trigger DC responses [61]. The importance of identification of 
immunogenic forms of cell death is further emphasized by the observation that apoptotic 
cell bodies can inhibit NF-κB signalling and thereby induce tolerogenic DC [62]  This is in 
agreement with data showing that apoptotic cells cannot induce maturation of DC to the 
same level as lysates [63;64]. Cell death associated with upregulation of for instance TLR-L, 
might change a potentially tolerogenic source to an immunogenic source of Ag for DC 
loading [57;65]. Artificial introduction of TLR-L into leukemic blasts might be another way to 
make otherwise tolerogenic blasts more immunogenic prior to DC loading [66].
It is believed that in the process of dying, apoptotic cells shed immunogenic particles in the 
form of so-called blebs. After blebbing a remnant remains which is termed the apoptotic 
cell body (ACB). It was shown that these small blebs are taken up more efficiently by DC 
than (whole-cell) apoptotic bodies [67;68].  Blebs are vesicles with a size of 1-3μm, and can 
thereby be differentiated from other smaller extracellular microvesicles such as exosomes 
(size 40-100nm). This is of importance in tumor immunology as exosomes derived from 
tumor cells are thought to exert immunosuppressive effects [69]. Due to their size and 
weight, blebs can easily be separated from ACB and exosomes by centrifugation and thereby 
constitute a source of tumor Ag easily applicable for loading strategies of DC. Furthermore, 
in mouse studies blebs were shown to skew the immune response to a Th1 type [68]
Whole-cell lysate or necrotic material 
It has long been assumed that apoptotic cell death is poorly immunogenic or even 
tolerogenic, whereas necrotic cell death is considered immunogenic [64;70-72]. However, 
the association of necrosis with local immune suppression in solid tumors has been shown as 
well [73]. Freeze/thaw cycles, used to generate whole-cell lysates, represent a form of brisk 
tumor cell death, most closely related to necrosis. These lysates harbor both known and 
unknown LAA. This advantage is a limitation as well, as lysates contain many non-malignant 
peptides which might increase the risk of auto-immunity [74]. Moreover, cell lysates may also 
contain intracellular proteases with inhibitory activity and immunosuppressive cytokines, 
such as TGFβ which might impair the immune response [75;76]. In order to combine the 
positive effect of upregulation of apoptosis related molecules with the immunogenicity of 
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lysates, a combination of heating before induction of necrosis by freeze-thaw cycles has 
been found favourable in a colon cancer model [77]. On the other hand, in in vitro assays 
lysate-loaded DC have been effective in priming CD8+ cells, even more so than leukemic 
DC [35]. Furthermore, CTL primed in vitro with lysate-loaded DC demonstrated cytotoxic 
activity against leukemic targets [78;79]. Lysate-loaded DC vaccines administered to two 
AML patients were well tolerated without apparent side effects. In these two patients, an 
increase in autologous T cell stimulatory capacity of the DC and immunological responses by 
positive delayed-type hypersensitivity (DTH) skin reactivity could be shown [80].
Whole cell RNA/DNA
Whole cell RNA or cDNA encode for all cellular peptides and, hence, cover all known 
and unknown LAA and can be easily extracted or generated from whole-cell lysates and 
transfected into MoDC.[81-83]. Furthermore, amplification of RNA enables the use of small 
populations, such as the stem cell compartment, presumably containing the leukemia-
initiating cell. Mature DC can be efficiently transfected through square wave electroporation 
with RNA (figure 2D). Peptides encoded by the transfected RNA are produced intracellularly 
and, therefore, directly processed and loaded onto MHC class I molecules, bypassing the 
need for cross presentation. On the other hand, CD4+ T cells are of crucial importance to 
induce effective and long lasting immune responses [84]. This problem may be overcome by 
introducing both intracellular and extracellular Ag. Loading of MoDC with RNA and lysates 
from AML blasts was shown to be supplementary, leading to an enhancement of Ag loading 
onto both MHC class I and II molecules [85]. Other strategies with for instance LAMP-1 gene 
fusion for routing peptides to the lysosomes and class II presentation pathways have been 
explored for solid malignancies and might also be an option for AML [86].
Hybrids
Autologous AML blasts can be fused with mature MoDC, thereby generating hybrids that 
express LAA derived from the blast fusion partner as well as co-stimulatory and adhesion 
molecules from the MoDC (figure 2E).  Although specific features of AML blasts such as 
low expression of co-stimulatory or adhesion molecules might hamper the Ag presenting 
and immunologic capacity of the DC. Banat and co-workers showed that DC hybridisation 
with AML blasts containing the chromosomal aberration inversion 16 (inv(16)) generated 
memory T cells able to react to AML blasts upon re-stimulation. This was not found for 
other aberrations and implies that different forms of AML could affect the outcome of 
this approach [87]. When using non-matched allogeneic MoDC, a fusion cell is generated 
expressing MHC molecules from the patients’ leukemic blasts and co-stimulatory molecules 
from the donors’ MoDC. These hybrids are able to induce anti-leukemic CTL in vitro [38]. 
Therefore, allogeneic MoDC [38;88] or MUTZ-3-DC fusions with AML blasts from patients 
might be an attractive option.  AML is thought to originate from a malignant stem cell, which 
might be less sensitive for chemotherapeutics. These AML initiating cells with a CD34+CD38- 
phenotype might be the cause of relapse. Ideally, these malignant stem cells should be 
targeted in immunotherapeutic protocols. By selecting CD34+CD38-  AML stem cells for the 
preparation of DC fusion cells, induced CTL may potentially eradicate AML by directly or 
indirectly targeting the leukemia initiating cells [89]. However, this approach is restricted by 
low numbers of stem cells and persistent controversy about the definition of malignant and 
normal hematopoietic stem cells.
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Comparison of loading strategies
Weigel and co-workers compared AML-derived lysate-loaded MoDC with hybrids in mice 
but could not classify one as favourable over the other [90]. One in vitro study however, 
showed better CTL responses with DC-AML hybrids as compared to apoptotic cell-loaded 
DC or lysate-loaded DC [91]. In vitro anti-leukemic T cell responses could be found after 
co-culture of autologous remission lymphocytes with irradiated AML blast–loaded DC 
and fusion hybrids of AML blasts with DC. Interestingly, responses were observed against 
MoDC loaded with irradiated blasts in 2 out of 6 patients and against hybrids in 3 other 
patients out of the same 6 patients tested [88]. These results might imply that various AML 
patients need different vaccine preparations in order to achieve improved outcome and 
might explain the different results in small studies. Furthermore, different DC preparation 
protocols were used, complicating comparison. Translating results of DC loading of other 
tumors to AML is complicated due to different protocols in preparation of MoDC, the low 
number of patients tested, and varying results. [92;93]. Therefore, no definite conclusion 
can be drawn so far about which source of LAA and loading methods are preferred. 
Vaccine adjuvants 
The term adjuvant describes all compounds with intrinsic immunostimulatory and/or 
immunomodulatory properties. Adjuvants are used to manipulate or modulate different 
steps of the immune response. For instance, binding of pPRR enhances uptake of Ag and 
ligation of iPRR enhances processing and triggering of specific peptide presentation by MHC 
molecules combined with maturation of immunogenic DC. Different adjuvants may enhance 
the induction of different co-stimulatory signals in order to improve T cell responses or 
may inhibit negative co-stimulatory signals. The challenge is to define an optimal and 
safe combination of these different adjuvants which will result in an effective anti-tumor 
immune response when combined with MoDC vaccination [94]. 
Using adjuvants in vitro to improve DC loading protocols
Uptake of immunogeneic material by DC can be mediated by various receptors. The most 
well-known receptor family in this regard is the Fc receptor family. Coating of apoptotic or 
necrotic tumor cells with an Fc-domain containing antibody has been explored. Phagocytosis 
via Fc receptors is known to facilitate efficient cross-priming of exogenous Ag via MHC class 
I molecules. Tumor cells coated with an IgG antibody are internalized via Fcγ receptors 
on DC.  In a murine B-cell lymphoma model this resulted in improved tumor protection 
[95;96]. Other groups of receptors related to phagocytosis are the scavenger receptors and 
TLR [16]. Upregulation of for instance the TLR-L calreticulin can be induced by irradiation 
with UV light or treatment with antracyclins [55;56]. Furthermore, various ways of inducing 
apoptosis or necrosis, such as heat shock, are associated with enhanced heat-shock 
protein (HSP) expression. HSP-peptide complexes are more easily taken up via scavenger 
receptors and TLR and induce cross-priming and skew the immune response towards a Th1 
response  [97;98]. Various other TLR-L have been used for in vitro vaccine preparation and 
administered as adjuvant together with the vaccine. Of note, careful dosing of these TLR-
agonists in vivo is important, as high concentrations can be immunosuppressive [99;100]. 
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Roughly, TLR-L can be divided into two groups: those with extracellular receptors (TLR-1, -2, 
-4, -5, and -11), and those with intracellular receptors (TLR-3, -7, -8 and -9). Since binding 
of TLR-1, -2 and -6 mostly results in a Th2 response and TLR-7 and -9 are not expressed on 
human MoDC, most research focused on other TLR-L. The most well known TLR-L is the TLR-
4-agonist LPS, which is frequently used for maturation of DC in vitro. Since LPS itself is not 
clinically applicable, substrates from LPS have to be used, such as monophosphoryl lipid A 
(mLPA) [101]. In addition, components of the frequently applied adjuvant Bacillus Calmette 
Guérin (BCG) act as TLR-2/4 agonists stimulating cross-priming of Ag. Intracellular binding 
of TLR-3 and -8 (by their natural virus-derived ligands single- and double stranded RNA 
respectively) acts as a danger signal and results in enhanced cross-priming of exogenous 
Ag  [102]. R848 (a TLR-7/8 agonist) and imiquimod (a TLR-7 agonist) have been shown to 
increase IFNα production in plasmacytoid DC and even induce perforin and granzyme B 
expression in myeloid DC [103] . The latter indicates the induction of direct cytotoxic immune 
responses and tumor destruction by myeloid DC. Next to activation of DC, TLR-L can facilitate 
the effector arm of the immune response: TLR-9 ligand cytosine-phophate-guanosine (CpG) 
that contains motifs from bacterial DNA, is able to skew the host immune response towards 
a Th1 response [104]. Nevertheless, CpG should be used with caution in future clinical trials 
as CpG has been shown to also recruit Treg in mice [105]. Smits and co-workers showed that 
electroporation of the TLR3-L poly-IC into AML blasts resulted in upregulated expression 
of MHC and co-stimulatory molecules and enhanced production of interferons by the AML 
blast itself. Furthermore, upon phagocytosis of these electroporated blasts by MoDC and 
subsequent co-incubation with T cells, their production of pro-inflammatory cytokines and 
Th1-polarizing capacity was enhanced [66].
In vivo comparison of loading strategies in AML
In AML only a few clinical phase-I vaccination trials with AML-DC have been performed and 
even less clinical trials using MoDC loaded with whole-cell derived LAA. The available data 
are summarized below.
Clinical studies on leukemic DC-based vaccination
The first AML-DC vaccine phase 1 trial in 5 patients was published in 2006 and showed 
promising results. T cells specificly recognizing a PRAME-derived peptide could be detected 
upon vaccination [106]. Another phase I/II study with AML-DC was performed by Roddie 
and co-workers (2006) [29]. Five patients, four de novo and one relapse, achieved CR and 
were vaccinated with autologous leukemic blasts that underwent DC differentiation ex 
vivo. Increased anti-leukemic T cell responses in four patients were observed. MRD was 
monitored by RT-PCR for WT1 gene expression. Two patients relapsed shortly after start of 
vaccination; the remaining patients had relatively constant WT1 expression levels following 
vaccination. Two patients remained in remission for more than 12 months post-vaccination 
[29]. 
Clinical applicability of these vaccines is limited by many factors, i.e. insufficient numbers of 
leukemic blasts for culture of AML-DC, failure of leukemic blasts to undergo DC differentiation 
and failure of patients to achieve CR due to progressive disease or death before vaccination. 
Overall, it could be concluded that leukemia-derived DC-based vaccination is only feasible 
in a subgroup of patients [30;107]. 
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Clinical studies on MoDC-based vaccination 
Clinical experiences with immunotherapy mostly focus on vaccination with synthetic 
peptides. For instance, vaccination with a RHAMM peptide resulted in clinical and 
immunological responses in MDS, AML and Multiple Myeloma patients and comparable 
results were found with WT1 and PR1 peptide vaccines [108-111]. Beside vaccination 
with AML-DC, there is little clinical experience with other DC vaccination strategies in the 
treatment of AML. In 2007, the first AML patient (who relapsed after allogeneic stem cell 
transplantation) was vaccinated with WT1 and KLH peptide-loaded MoDC derived from a 
healthy donor. Vaccination induced immune responses to KLH, whereas immune responses 
to WT1 could not be detected and the leukemia gradually progressed [112]. Another Phase I 
study using MoDC electroporated with RNA encoding for the WT1 antigen showed that this 
approach is safe in a clinical setting [51]. 
Even less studies have been performed with DC loaded with whole-blast cell derived LAA. DC 
loaded with blast lysates were administered at a 2- to 3-week interval to two patients with 
relapse after autologous peripheral blood SCT (PBSCT) in four infusions. Mixed leukocyte 
reaction and DTH tests with leukemic lysates showed no response before vaccination but 
did so afterwards, though no hematological responses were observed [80]. More DC-based 
clinical vaccination trials in AML have been started and are expected to be published in 
the near future. These include, amongst others, loading of MoDC with whole-cell RNA and 
mRNA encoding for WT1 or hTERT, fusion of MoDC with leukemic cells, and can be found at 
http://www.clinicaltrials.gov or http://clinicaltrialsfeeds.org.
Timing of vaccination in relation to standard AML 
therapy
DC vaccination is thought to be more effective when the immune system is intact and not 
affected by cancer [7;113]. Although frequencies are low in healthy donors, LAA-specific T 
cells can easily be expanded upon stimulation with Ag loaded autologous MoDC. In CML, 
it has been demonstrated that significantly higher percentages of BCR-ABL specific CTL 
can be detected in patients by tetramer (Tm) screening, but these Tm-specific CTL could 
not be expanded [114]. Chemotherapy and stem cell transplantation (SCT) treatment are 
likely to influence the effect of immunotherapy by affecting composition and functionality 
of T cell compartments. In vitro priming studies with AML-DC at various time points during 
remission resulted in different immune responses.  During early remission anti-AML immune 
responses seem to be largely MHC-restricted, but to shift towards non-MHC restricted 
immune response later in CR [115]. Furthermore, leukemic blasts induce T cell suppression 
by production of suppressive cytokines and activation of suppressive cells such as MDSC and 
Treg. When considering these suppressive effects of both leukemic blasts and chemotherapy, 
DC vaccines should ideally be administered during CR. With sensitive detection methods, 
for instance by flow cytometry or with molecular tools, minimal residual disease (MRD) 
cells can be followed and a relapse can be detected in an early phase [116;117]. Therefore, 
the time frame in which a vaccine can be administered can be accurately determined by 
intensive follow up for MRD. After SCT it takes about 6 months before CD8+ cells are fully 
reconstituted; for CD4+ T cells this can take more than one year. As a consequence, the 
immune system is not fully capable of controlling MRD or responding to a DC vaccine. Donor 
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lymphocyte infusion (DLI) is used clinically for controlling MRD and preventing relapse of 
AML [117]. DLI might be of interest to combine with DC vaccination protocols. Furthermore, 
in vivo depletion of CD25+ Treg cells, has been shown to increase the efficacy of an eluted 
peptide-loaded DC vaccine in an AML mouse model [54]. In order to administer the vaccine 
early after treatment, other options such as reducing the immunosuppressive effects of 
chemotherapy should be explored. Various chemotherapeutic immunomodulatory drugs 
have been described, such as antracyclins, able to stimulate anti-cancer immune responses 
[55].  Other new immunomodulaory drugs are of interest, such as lenalidomide, histone 
deacetylase inhibitors (HDACi) and 5-Azacitidine. 5-Azacitidine is known to enable cell 
proliferation and differentiation, which may allow normal hematopoietic progenitor cells 
to grow and differentiate and HDAC inhibitors have been shown to induce MHC class I 
and II expression on tumor cell lines and enhance differentiation of AML blasts into DC. 
Furthermore, lenalidomide has been demonstrated to enhance in vitro expansion and 
Th1 skewing of cells [118-121]. The immunomodulatory effects of these drugs might thus 
increase the window in which a vaccine could be administered. 
The choice of vaccination site
Next to timing, the site of vaccination is a matter of debate. Intradermal, subcuteanous, 
intravenous and intranodal vaccination differentially affects the primary immune response 
and the distribution of memory cells and thereby the ability to control the outgrowth of 
tumors [122]. When a vaccine is administered intradermally or subcutaneously, this may 
improve T cell responses as compared to intravenous administration [123;124]. Intradermal 
or subcutaneous vaccination requires the DC to migrate to the lymph node. In this respect, 
addition of PGE
2
 in DC preparation protocols is necessary [125;126].  However, PGE
2 
diminishes IL-12 secretion and adversely affects CTL stimulatory ability of DC [127;128]. 
In addition, it was recently demonstrated that PGE
2
 matured DC can recruit Treg [129]. 
Addition of TLR-L might (partially) overcome these inhibitory effects. Therefore, vaccine 
preparation protocols might determine the preferred site of vaccination [130]. Intranodal 
administration may circumvent this problem but requires technical expertise and includes 
the risk of damaging the architecture of the lymph node [131]. Available evidence points to 
the dermis as a preferred site of vaccine administration [132]. 
Conclusion and future perspectives
DC vaccination in AML holds promise as a treatment modality. LAA-loaded MoDC-based 
vaccines can be produced on a large scale, are easy to administer in an outpatient setting 
and are generally well-tolerated. The use of leukemia-derived DC is feasible in approximately 
60% of AML patients. As an alternative, MoDC have been loaded with apoptotic whole-cell 
suspensions, necrotic cell lysates, tumor-associated peptides, eluted peptides and cellular 
DNA or RNA, but none of these loading strategies has yet been definitively proven favourable 
over another. In addition, MoDC have been chemically or electrically fused with leukemic 
blasts and DC have been cultured out of leukemic blasts. In vitro research on monocyte-
derived vaccines in AML is limited by the low number of patients tested, differences 
The role of immunotherapy in leukemia
153
in vaccine preparation protocols and the heterogeneity of AML. The identification of an 
optimal approach for inducing tumor cell death or obtaining peptides that would lead to 
effective endocytosis and activation of MoDC remains controversial. Ongoing research is 
needed in order to achieve consensus about which Ag loading strategy for MoDC combined 
with administration of optimal adjuvants is most suitable. In addition, major progress can be 
made through the development of a read out system in which the TAA loading efficiency of 
various MoDC preparations can be tested. 
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Abstract 
Active immunotherapy may prevent relapse of acute myeloid leukemia (AML) by inducing 
leukaemia-specific T cells. Here we investigated whether WT1 and PRAME specific T cells 
could be induced after priming of healthy donor and patient derived T cells with HLA-A2 
matched, peptide-loaded allogeneic dendritic cells. AML-reactive, tetramer (Tm) binding, 
and interferon producing, cytotoxic T Lymphocytes specific for PRAME could be cultured 
readily from healthy donors. PRAME specific priming efficiencies were significantly higher 
than for WT1. Priming of T cells from patient derived T cells was proved near-impossible: no 
LAA-specific T cells could be primed from patients shortly after reaching CR (n=4); in only 
1 out of 3 patients with sustained CR did we find low-frequency WT1 specific T cells. This 
finding points to differences in the functionality or repertoire of T cells between HD and AML 
patients in CR and may have repercussions for the implementation of active vaccination 
approaches for AML. 
Introduction
Therapeutic vaccination with dendritic cells (DC) is regarded as a viable option for the 
treatment of minimal residual disease in (MRD) acute myeloid leukemia (AML). DC 
vaccination aims to elicit a leukemia associated antigen (LAA)-specific immune response, 
directed against residual leukemic cells, thus preventing relapse [1]. In this respect, peptides 
carrying defined LAA-epitopes are an attractive source of antigen. Amongst others, Wilms 
tumor 1 (WT1) and preferentially expressed antigen of melanoma (PRAME) are both LAA 
that are over-expressed in various hematological malignancies and share the potential for 
the induction of specific T cell responses [2;3]. Expression rates in AML of each of these LAA 
are high, ranging from 60 to 90% [4]. Both PRAME and WT1 are involved in leukemogenesis. 
PRAME influences disease progression by interfering with retinoic acid (RA) receptor 
signalling and gene transcription [5], while WT1 inhibits differentiation through as yet 
unknown mechanisms [6;7]. Their involvement in leukemogenesis and their expression in 
malignant stem cells make PRAME and WT1 attractive antigens for the detection of MRD and 
valuable targets for therapy [8-12]. CTL epitope sequences of WT1 and PRAME have been 
characterized for both HLA-A2 and -A24 molecules [13-16]. Moreover, T cells recognizing 
PRAME- and WT1-derived endogeneous peptides that are presented by HLA-A2 molecules 
on the surface of tumor cells have been reported in various malignancies including myeloid 
leukemia [2;17;18]. 
Here, we investigated the relative priming efficiencies of cytotoxic T lymphocytes (CTL) in 
peripheral blood (PB) from healthy donors (HD) and leucapheresis (LF) material or Peripheral 
Blood samples from AML patients in first complete remission (CR). 
Material and methods
Patient material
Peripheral blood cells were drawn from 9 AML patients after obtaining the patients’ informed 
consent. Peripheral blood mononuclear cells from 3 patients in first complete remission for 
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1.5 year or longer (long-term CR1, LT-CR1; table 2) were isolated by density centrifugation 
using Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). Peripheral blood 
mononuclear cells, containing >80% leukemic cells, from 2 patients at diagnosis were 
isolated using Ficoll-Paque (Amersham Pharmacia Biotech) and stored upon use for cytoxicity 
assays. Cells were cryopreserved at a controlled rate in liquid nitrogen using RPMI 1640 
medium (Gibco, Paisley, UK) supplemented with 20% heat-inactivated FCS (Greiner, Alphen 
a/d Rijn, The Netherlands) and 10% dimethylsulphoxide (Merck, Darmstadt, Germany). 
Autologous leucapheresis products from 4 patients (Table 2, AML-CR1) were cryopreserved 
at a controlled rate according to institutional guidelines. Before application cryopreserved 
material was rapidly thawed and washed twice in RPMI-1640 supplemented with 40% FCS. 
The cells were then resuspended in culture medium as described below.
Cell lines
The CD34+ human acute myeloid leukemia cell line MUTZ-3 (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen [DSMZ], Braunschweig, Germany) was cultured in 
MEM-α medium containing ribonucleosides and deoxyribonucleosides (Life Technologies, 
Paisley, UK) supplemented with 20% Fetal calf serum (FCS, Perbio, Helsingborg, Sweden), 
100 I.E./ml sodium penicillin (Yamanouchi Pharma, Leiderdorp, The Netherlands), 100 μg/ml 
streptomycin sulfate (Radiumfarma- Fisiopharma, Naples, Italy), 2.0 mM L-glutamine (L-glut, 
Invitrogen, Breda, The Netherlands), 0.01 mM 2-mercaptoethanol (βME, Merck, Darmstadt, 
Germany) and 10% 5637-conditioned medium (CM) [13, 19]. The EBV-transformed B cell 
line JY ( HLA-A2+) was cultured in IMDM (BioWhittaker, Verviers, Belgium) supplemented 
with 10% fetal calf serum, 100 I.E./ml sodium penicillin, 100 lg/ml streptomycin sulphate, 
2.0 mM ,-glutamine and 0.01 mM 2-mercapoethanol (complete medium). The CML cell 
lines K562 (HLA-A2- and PRAME+), K562-A2+ (a kind gift from Dr Carl June, Philadelphia PA; 
PRAME+ and HLA-A2+), and ME1 (HLA-A2+ and PRAME-) (all from ATCC, Manassas, VA) were 
cultured in IMDM complete medium (consisting of IMDM; 10% FCS, 100 I.E/ml Penicillin, 
100μg/ml Streptomycin, 2.0mM L-glut and 0.01 mM βME); medium was replenished twice 
a week.
In vitro isolation of CD8+ T cells from buffy coats and generation of MUTZ-3-derived DC 
Buffy coats were obtained from healthy volunteers according to institutional guidelines 
in accordance with the Helsinki Declaration of 1975. Peripheral blood mononuclear cells 
(PBMC) were isolated by density centrifugation using Ficoll-Paque. Subsequently, CD8+ 
T cells were obtained by negative depletion using an untouched magnetic Microbead-based 
kit (Miltenyi Biotec GmbH Bergisch Gladbach, Germany). MUTZ-3 DC were generated as 
described [19]. Briefly, MUTZ-3 progenitors were cultured in 12 well tissue culture plates at 
a concentration of 1x105/ml in MEM-α medium without 5637-CM in the presence of 100 ng/
ml GM-CSF (Strathmann Biotec, Hamburg, Germany), 1,000 U/ml IL-4 (Strathmann Biotec) 
and 2.5 ng/ml TNF-α (Strathmann Biotec) for 7 days. Every 3 days new cytokines were added. 
At day 7, maturation of MUTZ-3 DC was induced by adding Monocyte Conditioned Medium 
(MCM) at 30% over a period of 3 days. For preparation of MCM, see next paragraph.
Monocyte conditioned medium
Buffy coats were obtained from healthy volunteers according to institutional guidelines. 
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation 
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using Ficoll-Paque. Subsequently, monocytes were obtained by plating PBMC onto 
immunoglobulin (30μg/ml; Sanquin, Amsterdam) coated plastic culture plates. Non 
adherent cells were washed away. Adherent cells were incubated for 24h in IMDM culture 
medium supplemented with Penicilin, L-glutamine and 8%FCS. Supernatants, containing 
cytokines produced by monocytes were harvested, aliquoted and stored at -20C until usage. 
All cultures were performed at 37˚C and 5% CO2 in a humidified incubator.
Tetramers and flow cytometry
PE- and/or APC-labeled HLA-A2 tetramers (Tm) presenting the WT1 (126-134) or 
PRAME(100-108) (Sanquin) were used for flowcytometric analysis. As control HIV1 Tm was 
used (a kind gift from Ton Schumacher (NKI), Amsterdam, The Netherlands). Tetramer staining 
was performed in PBS for 15 min at 370C. Stained cells were analyzed on a FACScalibur (BD 
Biosciences) using Cell QuestPro software. To exclude dead cells in flow cytometric tetramer 
analysis, 0.5 lg/ml propidium iodide (ICN Biomedicals, Zoetermeer, The Netherlands) was 
used. Tetramer-guided flow sorting was performed on a FACSAria (BD Biosciences).
CTL induction
MUTZ3-DC represent a standardized source of allogeneic DC that can be used to generate 
fully functional tumour-specific T cells [19;20] In vitro antigen-specific CTL were generated 
as described previously 30. Mature MUTZ-3 DC, prepared as described above, were loaded 
with 10 μg/ml peptide in the presence of 3 μg/ml β2-microglobulin (Sigma-Aldrich, St. Louise, 
MO, USA) for 2–4 h at room temperature and irradiated (50 Gy). Peptides used were PRAME 
100-108 (VLDGLDVLL), synthesized according to FMOC technology (IHB-LUMC, Leiden, the 
Netherlands) and WT1 126-134 (RMFPNAPYL) obtained from Sanquin. 1·105 peptide-loaded 
DC were cultured for 10 days with 1·106 CD8+ cells and 1·106 irradiated (50 Gy) CD14-/CD8- 
PBMC in Yssel’s medium 43 supplemented with 1% human AB serum (ICN Biochemicals), 
10 ng/ml IL-6 and 10 ng/ml IL-12 in a 24 well tissue-culture plate. At day 1, 10 ng/ml IL-10 
(R&D Systems) was added. From day 10, CTL cultures were stimulated every week for 5 
weeks with 1·105 fresh peptide-loaded antigen presenting cells (10ng/ml) in the presence of 
5 ng/ml IL-7 (Strathmann Biotec). For the first restimulation MUTZ-3 DC were used, for the 
second and further restimulations HLA-A2+ JY cells were used as antigen presenting cells. 
One day prior to each restimulation, a sample was taken and analyzed by flow cytometry 
using both PE- and APC labelled Tm presenting the relevant epitope. Two days after each 
restimulation, 10 U/ml IL-2 (Strathmann Biotec) was added. PRAME Tm+ CTL were isolated 
by Tm+ flow sorting and subsequently cloned by limiting dilution. For this purpose, CTL were 
weekly stimulated with irradiated feeder-mix consisting of allogeneic PBMC (1:10 ratio with 
CTL) and JY cells (1:100 ratio with CTL) in Yssel’s medium supplemented with 100 ng/ml 
phytohemagglutin (PHA; Murex Biotech, Dartford, UK) and 20 U/ml IL-2. Human telomerase 
reverse transcriptase (hTERT) was introduced in the PRAME-specific CTL clone. PRAME-
specific CTL, stimulated for 48 h with feeder-mix as described above, were transduced 
with retrovirus encoding LZRS-hTERT-IRES-DNGFR, in fibronectin-coated cell culture plates 
(Retronectin, Takara, Japan) in the presence of 100 U/ml IL-2. During transduction, the plates 
were centrifuged at 2,000·g for 90 min at 230C and subsequently incubated at 370C for 4.5h. 
Then, cells were washed and cultured overnight in Yssel’s medium containing 20 U/ml IL-
2. Next day, retroviral transduction was repeated. After 48h, transduction efficiency was 
determined by flow cytometric analysis of nerve growth factor receptor (NGFR) expression 
on the surface of the cell. 
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Intracellular IFN-γ detection 
To determine the capacity of the CTL clones to produce IFN-γ upon recognition of a specific 
target, intracellular IFN-γ staining was performed. Target cells used included HLA-A2+/
PRAME+, HLA-A2-/PRAME+ tumour cell lines and JY cells or T2 cells pulsed with either 
relevant or irrelevant peptide. CTL were cultured with target cells at an effector:target cell 
(E:T) ratio of 2:1 in 96-well round-bottom plate and 0.5 μl of GolgiPlug (BD Biosciences) 
was added to each well. After 6 h, cells were harvested, washed, stained with PE-labeled 
tetramer and APC-labeled anti-CD8 mAb. After fixation with 4% paraformaldehyde (Merck) 
and permeabilization with BD Perm/wash solution (BD Biosciences), cells were labeled with 
FITC conjugated anti-IFN-γ Ab (BD Biosciences) and were analyzed on a flow cytometer.
FACS based cytotoxicity assay 
Cytotoxic activity of the PRAME CTL clone was assessed by a flow cytometry based 
cytotoxicity assay as described previously [21]. In short, effector T cells were labelled with 
CFSE (1μM for 10 min, Molecular Probes, Eugene, OR) and subsequently co-cultured with 
104 target cells (cell lines and patient samples) in ratios of 20:1, 10:1, and 5:1 in sterile 
round bottom polystyrene tubes (BD Biosciences). All E:T ratios were tested in duplicate. Cell 
suspension volume was adjusted to 100μl with IMDM complete medium. Separate control 
cultures of effector and target cells alone were performed to check spontaneous apoptosis 
and secondary necrosis. Co-cultures were kept for 6h in a 370C humidified incubator. At the 
end of cytotoxic contact, target cells were stained at 37°C with anti-CD34-PE, followed by 
staining for SYTO62 and 7-AAD [21] MHC-restriction was tested by addition of MHC class 
I-blocking antibodies (W6.32, 2.5 mg/ml, a kind gift of Dr. SM van Ham, Department of 
Immunopathology, Sanquin Research, Amsterdam, The Netherlands) or the appropriate 
isotype control (mouse IgG2a, 2.5 mg/ml, Sanquin).
Statistical analysis
Statistical significance of differences between the various cytotoxicity experiments was 
determined by the paired sample student’s t-test (two-tailed). Fisher’s Exact test was 
used to examine significance between different priming efficacies. P-values of <0.05 were 
regarded as significant.
Results
WT-1 and PRAME tetramer specific T cells can be primed in HD, but not in AML patients
Primed Tm+ T cells were detectable in samples from HD for both tested LAA (figure 1). 
PRAME and WT1 Tm+ T cells were induced in 3 out of 4 and in 2 out of 5 HD, respectively 
(table 1). Multiple parallel priming cultures of CD8+ T cells were set up in separate wells with 
a fixed number of CD8+ T cells per well (1 x 106 cells). WT1 Tm+ CD8+ T cells were detected 
in 4 out of a total of 104 cultures (table I; 3/28 for donor 1; 1/20 for donor 2). The priming 
efficiency of PRAME CD8+ T cells in HD was significantly higher at 20 Tm+ cultures out of a 
total of 51 (tabe I; 8/12 for donor1; 6/15 for donor 2; 6/9 for donor 3). Of note, the same 
healthy donor derived T cells were used for PRAME and WT1 priming experiments, WT1 and 
PRAME specific T cells were both detected in donor 1 and 2. Highest frequencies of PRAME 
or WT1 Tm+ CD8+ T cells were detected after 1 to 5 rounds of (re-)stimulation (table I). Tm+ 
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CD8+ T cell frequencies ranged from 0.02 to 1.07% for the PRAME epitope and from 0.01 to 
0.09% for the WT1 epitope. 
In addition, we analysed the priming efficiencies of CD8+ T cells obtained from patients 
directly after reaching CR or patients in sustained CR (tabel 2). No PRAME and WT1 Tm+ T 
cells could be expanded from CD8+ T cells obtained from patients shortly after achieving CR 
(1-6 months duration, Fisher’s Exact test HD versus CR p<0.001 for PRAME) (table I) and in 
only one patient with a sustained CR WT1 specific T cells were detected at low frequencies 
in 2 out of 6 wells (UPN 1, table I).
Tetramer positive T cells produce IFNγ upon recognition of  peptide  
Induced Tm+ CD8+ T cells from HD produced IFNγ upon recognition of the PRAME or WT1 
peptides (figure 1). For PRAME, expanded T cells were tested for intracellular IFNγ expression 
upon stimulation with the corresponding peptide and Tm+ populations were able to produce 
IFNγ (in a range of 24-71% of Tm+ T cells, for a representative result, see figure 1C). CD8+ 
T cells from two HD were found to be Tm+ for WT1 after priming (table I); IFNγ production 
Figure 1.Detection of tetramer positive (Tm+) T cells and interferon (IFNγ) production of Tm+ T cells 
induced in healthy donor peripheral blood mononuclear cells. Plot A shows one representative 
example of PRAME (100-108) Tm+ T cells, plot B of WT1 (126-134) specific T cells. Plot C shows IFNγ 
production after incubation with T2 cells loaded with an irrelevant peptide or PRAME (100-108). The 
depicted cells were pre-gated on Tm positivity. 
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Table 1 Priming efficiencies of CD8+ cells from healty donors (HD), or leucapheresis products from 
AML patients during short-term (1-6 months) complete remission (AML-CR) or after long term CR 
(>1.5 years, AML-LT-CR) , all after stimulation with leukemia-associated antigen derived peptide 
loaded HLA-A2-matched MUTZ -3-DC.
Tm+ rates after 
co-culture (per 
no. of tested 
HD/patients)
Total no. 
of Tm+ co-
cultures#
Median % 
Tm+ cells 
per positive 
culture (range)
Number of 
restimulations 
at maximum of 
Tm +
PRAME(100-108) HD 3/4 21/50 0.10% 
(0.02-1.07)
1-5
WT1(126-134) HD 2/5 4/104 0.07% 
(0.03-0.09)
1-4
PRAME(100-108) AML-CR1 0/4 0/44* 0.00% -
WT1(126-134) AML-CR1 0/3 0/38 0.00% -
PRAME(100-108) AML-LT-CR1 0/3 0/14 0.00% -
WT1(126-134) AML-LT-CR1 1/3 2/14 0.05% 4
*AML-CR1 vs HD, p<0.001 by Chi-Square test. AML-LT-CR1: AML in long term (>1.5years), first 
complete remission. AML-CR1: AML in first complete remission. 
# Multiple cultures of 1 million CD8+ T cells per donor were started. The number of TM positive wells 
per total number of wells are shown. A well was counted positive when 0.01% or more Tm+ cells were 
found.
upon re-stimulation with WT1 peptide was tested in one HD, showing 27.7% IFNγ positive 
cells within the Tm+ cell fraction (data not shown). 
PRAME specific T cells lyse AML cell lines and leukemic cells from patients in a dose 
dependent manner
Tm+ T cells recognizing the PRAME epitope were sorted from HD1, followed by limiting 
dilution cultures for the generation of a PRAME-specific CTL clone. A thus derived T cell 
clone was immortalized by retroviral hTERT transduction [22], after which its functionality 
was tested. In peptide titration experiments with intracellular IFNγ read-out, the clone was 
shown to be of intermediate functional avidity with half-maximal IFNγ production at 10 to 
1 ng/ml PRAME peptide concentration. PRAME(100-108) peptide loaded JY cells were killed 
efficiently by the PRAME-specific T cell clone, whereas unloaded JY cells remained viable 
(figure 2A). Furthermore, HLA-A2 transduction of K562 cells (known to be PRAME+ [23]), 
provoked specific IFNγ production (data not shown) and rendered the cells susceptible 
to specific kill by the PRAME-specific CTL clone as determined by a flow cytometry based 
cytotoxicity assay (figure 2A), demonstrating recognition of the endogenously expressed 
and processed PRAME epitope. HLA class I restriction of the observed K562 eradication was 
confirmed by the inclusion of a neutralizing monoclonal antibody (figure 2B). 
To confirm the ability of the CTL clone to eliminate AML blasts, it was co-cultured with titrated 
amounts of HLA-A2+ AML target cells and shown to kill both MUTZ-3 cells (the PRAME+ AML 
precursors rather than differentiated DC, see figure 2C) and HLA-A2 matched allogeneic 
primary AML blasts (one representative example shown out of two tested patients, figure 
2D), both in a dose dependent manner. 
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Discussion
T cells recognizing WT1 and proteinase 3 have previously been detected in AML at diagnosis 
by their reactivity in a very sensitive Elispot assay and by IFNγ production after specific 
stimulation [18]. However, detection of T cells through Tm analysis offers a means of 
isolation and more extensive functional characterization of specific CTL clones. Since T cells 
from HD have not encountered leukemic cells, outgrowth of PRAME and WT1-specific CD8+ 
T cells should be the result of priming of naive T cells. PRAME-specific Tm+ T cells could 
be readily detected after priming in HD, whereas the frequency of WT1-specific T cells 
were low. Others have studied priming with WT1 (126-134)-loaded DC and found that 10 
out of 10 HD low-frequency Tm+ T cells could be primed, with up to 10% Tm+ T cells after 
extensive in vitro expansion [24]. This difference in efficiency compared to our data could be 
a result of differences in the employed protocols [25], most notably the use of 2-day “fast” 
Figure 2. Cytotoxic activity of the PRAME CTL clone (derived from a healthy donor and specific for 
epitope 100-108) towards leukemic cell lines and patient samples. (A) In a flow cytometry-based 
assay cytotoxic activity against cell lines K562 (CML, PRAME+, HLA-A2 negative or transduced with 
HLA-A2), ME1 (AML, PRAME-, HLA-A2 positive ), unloaded JY and PRAME(100-108) peptide loaded 
JY was tested in a 10:1 effector to target ratio, relative percentages of viable cells are depicted after 
incubation without or with T cells. In figure 2B percentage viable K562-A2+ cells is shown after 
incubation with PRAME specific T cells in presence of HLA class I-blocking antibody or isotype control. 
In figure (C) and (D) relative percentage of precursor MUTZ-3 cells and viable leukemic AML cells 
(one representative example of two HLA-A2 matched patients tested) respectively, is depicted after 
incubation with PRAME specific T cells in different effector-to-target ratios
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DC and PBMC in the expansion rounds. However, employing the same protocol as in the 
current study, we previously observed higher priming efficiencies of other tumor-associated 
antigens such as hTERT, EBP-1 and CEA[19]. Moreover, Quintarelli and co-workers found 
similar priming efficiencies from HD blood for the PRAME(100-108) epitope as we did [26]. 
The same group recently reported on the ability of high-avidity PRAME-specific CTL to 
eliminate CML lines and primary colony forming precursors; we now confirm these findings 
for AML [27]. Together, these data validate our methodology and the low CTL precursor 
frequencies we found for WT1. 
Immunotherapeutic treatment strategies necessitate an adequately responding immune 
system. In AML it is not yet clear at what time point the immune system has sufficiently 
recovered from the disease and chemotherapy treatment. Therefore, we analysed the 
priming efficiencies from patients directly after reaching CR or patients in sustained CR. 
Remarkably, no PRAME and WT1 Tm+ T cells could be expanded from CD8+ T cells from 
patients in short CR. This failure to prime LAA-specific T cells can be explained by an 
immunosuppressed state or by a disturbed T cell repertoire with very low T cell numbers 
directly after chemotherapeutic treatment; it can take up to six months before the numbers 
of T cells are fully restored from the interfering effects of the abundance of AML blasts and 
chemotherapeutics[28;29]. Furthermore, G-CSF, given before performing leucapheresis in 
these patients can induce T cell tolerance and is likely to hamper priming efficiencies [30]. 
Similar observations have been made for CML patients [26]. These negative effects could be 
far less in patients that have sustained CR. Indeed, we were able to induce the outgrowth 
of WT1-specific CD8+ T cells , but not of PRAME specific T cells, from patients in long CR, 
after stimulation with WT1 epitope loaded MUTZ-3 DC, in one out of three patients (table 
1). Remarkably, no PRAME-specific T cells could be primed in any of the patients, suggesting 
that either no PRAME naive T cell were present or PRAME CTLs were anergic and not able 
to expand. Although not conclusive, since we could not expand sufficient T cell numbers for 
functional testing, these findings strongly suggest that even after longer CR AML-reactive 
T cells remain relatively dysfunctional (or their repertoire exhausted) and may never fully 
recover sufficiently to respond to WT1 and PRAME. It remains to be investigated whether 
this applies to a wider range of AML-derived antigens and epitopes. Of note, in case of 
allogeneic stem cell transplantation (SCT), the immunosuppressive effects of chemotherapy 
and AML will not have affected the donor-derived haematopoietic cell lineages and under 
Table 2. Patient characteristics of AML patients in long-term complete remission (LT-CR) and in 
patients in short-term complete remission, leukapheresis 
AML subtype  duration CR at start priming
AML-LT-CR1 UPN 1 MDS-RAEB 1.5 years
AML-LT-CR1 UPN 2 M1 12 years
AML-LT-CR1 UPN 3 M4 14 years
AML-CR1 UPN 1 AML, not further classified 6 months
AML-CR1 UPN 2 AML-M2 1 month
AML-CR1 UPN 3 Therapy related AML 1 month
AML-CR1UPN 4 AML-M5B 2 months
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these circumstances T cells are thus likely to respond as HD derived unprimed T cells. 
Moreover, allo-reactive T cells specifically recognizing PRAME positive tumour cells might 
prove particularly powerful antitumour effector cells [31].
In conclusion, we show that expanding LAA-specific T cells remains a challenge in patients 
recovering from their disease and treatment and indicates that active immunotherapy may 
be more effective in a prophase of AML, for instance MDS. This may then be combined with 
treatment with demethylating agents such as 5-azacytidine which might augment PRAME 
expression and subsequent PRAME-specific recognition and lysis by CTL clones [32;33]. In 
addition, the ability of PRAME Tm+ T cells derived from healthy donors to recognize and 
kill target cells efficiently indicates that PRAME is a promising candidate for adoptive T cell 
transfer, e.g. employing TCR gene transfer, and deserves further research for implementation 
in induction and consolidation regimens in the treatment of AML.  
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Abstract 
Vaccination with Acute Myeloid Leukemia (AML)-derived Dendritic Cells (DC) is a promising 
immunotherapeutic approach to prevent relapse of AML. However, in clinical practice AML-
derived DC culture is unfeasible in 40% of cases. Here, we demonstrate that AML cells can 
be expanded in vitro prior to differentiation with cocktails of cytokines with known myeloid 
growth-promoting effects. We show that 9 out of 13 initially CD14- samples gain de novo 
CD14 (>10%) expression (69%  increment, p=0.01) after in vitro expansion. These expanded 
CD14+ leukemic cells displayed a high probability (6 out of 6 initially CD14- samples tested) 
to differentiate into DC upon culture with GM-CSF, TNFα and IL-4. In conclusion, induction 
of CD14 on initially CD14- AML cells potentially increases the number of patients eligible for 
DC-based immunotherapy. 
Introduction
After high-dose chemotherapy, 50-85% of patients with acute myeloid leukemia (AML) 
achieve complete remission. Despite intensive treatment, including allogeneic stem cell 
transplantation, about 50% of patients relapse due to persistence of leukemic cells [1]. 
Further intensification of treatment regimens is not possible due to increased (extra)
medullary toxicity. Therefore, other treatment modalities focusing on controlling minimal 
residual disease (MRD) are under investigation. In this respect, active immunotherapy 
with antigen presenting cells (APC), such as dendritic cells (DC), is regarded as an attractive 
alternative [2]. Leukemic cells have been proven to be able to differentiate into DC-like 
APC [3, 4]. Importantly, AML-derived DC harbor known and unknown individual leukemia-
associated antigens (LAA) and possibly immunogenic mutations and have a T cell activating 
phenotype [5, 6]. AML-derived DC-based vaccination regimens have been proven feasible in 
clinical settings and might provide a  therapeutic option [7, 8]. In clinical practice, however, 
leukemic cells can be differentiated into DC in only 60% of patients; this can be predicted 
by expression of CD14, TNFαRI and FLT3-ITD as we described previously [3, 4, 9, 10]. Others 
have tried different leukemic cell-differentiation strategies, thereby increasing the number 
of patients eligible for DC-based immunotherapy [11, 12]. Nevertheless, AML-DC vaccine 
preparation is hampered by an inability to culture sufficient numbers of AML-derived DC or 
lack of enough precursor cells for differentiation [5]. This might be overcome by expansion 
of leukemic cells prior to differentiation into DC. In the present study we expanded leukemic 
cells with various cytokine cocktails in order to achieve sufficient numbers of DC precursor 
cells and tested their ability to differentiate into DC. Expansion of CD14- AML cells resulted 
in a gain of CD14, a major positive predictor for DC differentiation. In contrast, in a priori 
CD14+ AML CD14 expression was down-regulated during expansion. These results indicate 
that expansion of CD14- AML cells and their subsequent gain of CD14 expression by the use 
of specific cytokine cocktails increases the number of patients eligible for AML-derived DC 
based vaccination. 
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Material & Methods 
Patient samples 
Peripheral blood or bone marrow mononuclear cells from 46 patients with AML were 
isolated by density centrifugation using Ficoll-Paque (Amersham Pharmacia Biotech, 
Uppsala, Sweden); see Supplementary table 1 for patient characteristics. Since acute 
promyelocyctic leukemias are a distinct subgroup with in general a good progonis,  t(9;22)-
positive promyelocyctic leukemia cases (n=5) were excluded from analysis. All samples 
were drawn after the patients’ informed consent at the time of collection. Cells were 
cultured immediately, or cryopreserved at a controlled rate in liquid nitrogen using RPMI 
1640 medium (Gibco, Paisley, UK) supplemented with 20% heat-inactivated fetal calf serum 
(FCS, Greiner, Alphen a/d Rijn, The Netherlands) and 10% dimethylsulphoxide (Merck, 
Darmstadt, Germany). Cryopreserved material was rapidly thawed and washed twice in 
RPMI1640 supplemented with 40% FCS, the cells were then resuspended in culture medium 
as described below. Of note, DC differentiation after expansion was feasible both from fresh 
and cryopreserved samples.
Culture conditions of leukemic cells 
Leukemic cells were suspended in culture medium consisting of MEM-α medium (Lonza; 
Basel, Switzerland), supplemented with 15% FCS (Hyclone, Logan, UT), β-Mercaptho-
ethanol (Merck, Darmstadt, Germany), 100U/ml Penicillin (Astellas Pharma, Leiden, The 
Netherlands), 100 μg/ml Streptomycin (Fisiopharma, Palamonte, Italia), further referred to 
as complete culture medium. Cell numbers and viability were determined by Trypan blue 
dye exclusion (0.2 g/ml, Merck). Cells were plated in flat bottom 24-wells plates (Greiner) 
at 0.5x106 cells/ml per well at a maximum of 1x106 cells per condition. Different cytokine 
cocktails were tested as shown in  table 1; these cocktails consisted of various combinations 
of GM-CSF (10ng/ml; Berlex, Montville, NJ), G–CSF (10ng/ml; R&D Systems, Minneapolis, 
MN), IL-3 (10 ng/ml; R&D systems), FLT3-ligand (25ng/ml; Peprotech, Rocky Hill, CT) SCF 
(10ng/ml; Peprotech) and 5637-conditioned medium (see below). These cytokines have 
known growth promoting activity for myeloid DC precursors [13].  Cells were passaged 
every 3-4 days, only when cells had expanded at least 2-fold; maximum number of achieved 
passages was defined as the penultimate passage number at which cells did not expand at 
least 2-fold within 3-4 days. Culture viability and cell numbers were evaluated using trypan 
blue exclusion. To induce DC differentiation, expanded cells were plated at 0.2x106 cells/
ml in complete culture medium supplemented with GM-CSF (100ng/ml; Berlex), TNFα (2.5 
ng/ml; Strathmann, Hamburg, Germany) and IL4 (1000U/ml; R&D Systems). At day 3 and 
6 medium was replenished and fresh cytokines were added. Of note, this culture method, 
including the use of FCS, is comparable with methods used for preparation of clinically 
applied DC-based vaccines (www.DCPrime.nl)
5637-conditioned culture medium 
The bladder carcinoma cell line 5637 (obtained from DSMZ, Germany) is a constitutive 
producer of a number of myeloid growth-promoting cytokines, with high GM-CSF 
concentrations and low in IL-3  [14]. Cells were plated in culture flasks at 0.3x106/ml in IMDM 
supplemented with Penicillin, L-glutamine and 10% FCS. Once 80% of the culture flask was 
covered with cells, medium was replenished. Cells were incubated for 24h; supernatants 
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containing cytokines produced by 5637 cells, were harvested and stored at -20˚C until usage. 
Immunophenotypic analysis
Before and after expansion of AML cells, four-color flow cytometric analysis (FACS-Calibur 
flow cytometer, Becton Dickinson (BD), San Jose, CA) was performed; surface marker 
expression was examined and included differentiation related and growth promoting 
receptors with the following antibodies: CD14FITC, CD14PerCP (BD), CD34APC (Pharmingen), 
CD34PE  (Sanquin, Amsterdam, The Netherlands ), CD11cPE (Immunotech, Prague, Czech 
Republic),  CD123PE (IL3R) (BD), CD124PE (IL4R, Immunotech), CD114PE (G-CSFR; BD), 
CD116FITC (GM-CSFR; BD), CD117PE (SCFR; BD), CD120aFITC (TNFαRI; R&D systems, 
Mineapolis, MN), CD120bPE (TNFαRII; R&D systems), CD135PE (FLT3PE, Immunotech) and 
CD19PE  (BD). Isotype controls used were IgG1FITC (BD), IgG1PE (BD), IgG1PerCP (DAKO, 
Glostrup, Denmark) and IgG1 APC (BD). Before and after differentiation, cells were analyzed 
using the following markers: CD14, CD34 as described above, CD1aPE (BD Pharmingen), 
DC-SIGN, CD40FITC, (Pharmingen) CD80PE (BD), CD83PE (BD), CD86PE (Pharmigen ) and 
HLA-DRPE, (BD). 
Results were calculated as percentage positive cells relative to the appropriate isotype 
control. Results were analyzed with CellQuestPro software (BD). In regular diagnostic 
procedures, myeloid origin of leukemic cells was confirmed following WHO2008 guidelines 
[15]. Percentages of marker positive cells were calculated on leukemic cells, defined as those 
cells with CD45dim expression combined with low sideward light scatter and immature 
markers such as CD34 and/or CD117. We considered DC differentiation successful when low 
expression (<10%) of CD14 and CD34 and increased expression (>10%) of all of the following 
markers was found in comparison with the corresponding progenitor cells: CD1a DC-SIGN, 
CD40, CD80, CD86 and HLA-DR. 
RT-qPCR for PRAME, RHAMM and WT1
To ensure persistence of cells in the expansion cultures from leukemic origins carrying 
relevant antigens for AML vaccination we screened by qPCR for mRNA expression of the LAA 
Preferentially Expressed Antigen in Melanoma (PRAME), Receptor for Hyaluronan-Mediated 
Table I. Composition of different cytokine cocktails used for expansion of AML cells
Culture Cocktail GM-CSF G-CSF IL-3 FLT3-Ligand SCF 5637CM
1 10ng/ml 10 mg/ml - - - -
2 - - 10ng/ml - - -
3 - - - 25ng/ml 25ng/ml -
4 - - - 25ng/ml 25ng/ml -
5 10ng/ml 10 mg/ml - 25ng/ml 25ng/ml -
6 10ng/ml 10 mg/ml - - - 10%
7 - - 10ng/ml - - 10%
8 - - - 25ng/ml 25ng/ml 10%
9 - - 10ng/ml 25ng/ml 25ng/ml 10%
10 10ng/ml 10 mg/ml - 25ng/ml 25ng/ml 10%
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Motility (RHAMM) and Wilms’ Tumor 1 (WT1). The human chronic myeloid leukemia (CML) 
cell line K562 (RHAMM+ and PRAME+) and the human AML cell line HL60 (WT1+), both 
obtained from ATCC (LGC Standards, Teddington, UK) were used as positive controls. AML 
samples and cell lines were pelleted and freeze-dried; RNA was isolated and subsequently 
cDNA was generated employing a standard RNA isolation kit and cDNA preparation kit 
(both Applied Biosciences, Carlsbad CA). cDNA was synthesized from 1µg total RNA using 
M-MLV Reverse Transcriptase and random hexamer primers in a 40µl reaction according 
to protocol. For expression of PRAME, RHAMM and WT1, standard TaqMan Gene 
Expression Assays were used (Hs01022301; Hs00234864; Hs0110349 respectively, Roche 
Applied Biosystems, Almere, the Netherlands) following product guidelines. Target gene 
expression was normalized against the expression of the housekeeping gene GUS to adjust 
for variations in RNA quality and efficiencies of cDNA synthesis (Biolegio, Nijmegen, The 
Netherlands) qPCR was run on the ABI/PRISM 7500 Sequence Detection System (Applied 
Biosystem, Carlsbad, CA); all qPCR experiments were performed in duplicate. Mean Ct 
value for each sample was used for relative quantification using the ∆∆Ct method [16]. 
mRNA expression of the antigen was classified as either not detectable (-; 2^-∆∆Ct = 0), 
very low but detectable mRNA expression in up to 33 cycles (+; 2^-∆∆Ct >0 and <0.5), 
expression comparable with housekeeping gene (++; 2^-∆∆Ct >0.5; <1.5), and higher than 
the housekeeping gene (+++; 2^-∆∆Ct >1.5). 
Statistical analysis
Relationships between variables were analyzed using Spearman’s correlation coefficient. 
Changes in marker expression during expansion were analyzed with a paired t-test, 
differences in maximum passage numbers were evaluated with Mann Whitney U-test. P 
values were regarded as significant at p<0.05. 
Results 
Low expression of TNFαRI and high expression of TNFαRII predicts ability of AML to 
expand in in vitro cultures
Mononuclear cell fractions from 41 patients with AML were cultured in various conditions 
and expanded through various passages (mean 15, range 1-66). No correlation could be 
found between growth capacity (in number of attained passages) and different types of 
AML according to WHO2008 criteria (for a complete overview, see Supplementary table 
I). In leukemic cells from 25 patients, 10 different cytokine cocktails (see table I) were 
tested simultaneously; in these cultures no significant differences in maximum passage 
numbers between the various cytokine combinations were observed (see figure 1a). 
No significant correlation was found between the expression levels of any of the tested 
cytokine receptors on pre-expansion AML cells and the observed expansion rate in the 
corresponding AML cultures. TNFαRI and TNFαRII have previously been associated with 
a limited and large proliferative capacity of leukemic cells, respectively [17]. Independent 
of the applied cytokine expansion cocktail, we observed a prolonged expansion capacity 
for a TNFαRI/TNFαRII ratio below 2 (based on percentage positivity on leukemic cells, on 
average 10 vs.18 passages, p=0.02, figure 1b).
Chapter 12
178
Leukemic cells acquire CD14 expression upon cytokine-induced expansion and 
differentiate into DC
Upon culture with various cytokine cocktails marker expression on leukemic cells changed. 
Expression levels of GM-CSFR, G-CSFR, and IL-3R decreased (data not shown).  Furthermore, 
we observed a significant decrease in CD34 expression on leukemic cells (p= 0.03, pre- vs 
post-expansion; n=12, data not shown). We did not observe any significant alterations in 
expression of either TNFαRI or -II upon culture (paired t- test: p= 0.8; n=6 and p= 0.9; n=6, 
respectively), moreover, no correlation was seen between post-culture TNFαRI/II ratio 
and DC differentiation ability (MWU: p=0.3; n=10). In contrast, expression levels of the 
known positive predictor for DC differentiation, CD14 [4,9], increased upon expansion of 
cells with originally low expression levels (≤5%) (figure 2). For one representative patient 
the cumulative number of CD14+ cells in culture is shown over the course of expansion in 
Table2. Tumor type, phenotypic and culture characteristics, and LAA expression in expanded AML 
cells
Leukemic cells able to differentiate into immature leukemic-DCs after expansion
UPN* Nr of passages 
at time of  DC 
diff†
culture 
probability at 
diagnosis‡
WHO2008 
classification
PRAME WT1 RHAMM
11 15 16% AML without 
maturation 
ND ND ND
15 9 76% AML with maturation Neg Neg pos
23 14 0.6% Acute 
myelomonocytic 
leukemia
ND ND ND
28 10 No FLT3-ITD 
known 
Acute monoblastic  
leukemia
Neg Pos Pos
25 8 16% Acute monoblastic 
leukemia
Neg Neg Pos
38 8 0.6% AML with inv(16) ND ND ND
Leukemic cells not able to differentiate into immature leukemic-DCs after  expansion
UPN Nr of passages 
at time of DC 
diff  
culture 
probability at 
diagnosis
WHO2008 
classification
PRAME WT1 RHAMM
14 20 16% AML with maturation Pos Pos Pos
17 15 76% AML with maturation ND ND ND
18 15 99% AML without 
maturation
ND ND ND
27 8 84% Acute monoblastic 
leukemia
Neg Neg Pos
34 8 76% AML with 11q23 
(MLL) abnormalities
ND ND ND
UPN, Unique Patient Number; † DC diff, dendritic cell differentiation; ‡culture probability at diagnosis 
is based on expression of CD14, FLT3-ITD and TNFR-alpha and calculated as described previously in 
REF8. FLT3-ITD, fms-like tyrosine kinase receptor-3 internal tandem duplication; ND, Not Done
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Figure 1. Markers predictive for AML expansion capacity.(A) Maximum number of passages attained 
during AML expansion, also in relation to (B) pre-expansion AML TNFαRI/TNFαRII expression ratio 
(above and below 2; ratio was calculated by dividing percentage of leukemic cells positive for these 
markers). 
supplemental figure 2A. CD14 expression increased significantly upon expansion in 11 out 
of 17 cases tested; mean expression after culture 68% (range 0-89%); p<0.01, see figure 
2B. In contrast, CD14 expression was down-regulated in 2/3 cultures with high baseline 
expression levels (>40%, see figure 2B). Acquired CD14 expression was associated with the 
ability of expanded AML cells to differentiate into DC in response to GM-CSF, TNFα and IL4; 
6 out of the 7 tested samples were able to differentiate into DC (figure 2B; DC differentiation 
defined as down-regulated, low expression of CD14 (<10%) and CD34 (<10%) and increased 
expression of CD1a (>10%), DC-SIGN, CD40, CD80, CD86 and HLA-DR). In contrast, both cases 
with down-regulated CD14 expression were unable to differentiate into DC after expansion. 
Presence of RNA encoding for LAA in leukemic cells after expansion 
To assess leukemic origin of the expanded cells we screened for the presence of transcripts 
of the LAA PRAME, RHAMM and WT1 [17]. In all five samples screened for LAA, expression 
of at least one LAA could be found (RHAMM was detected in all samples tested); three of 
these were able to differentiate into leukemia-derived DC (table I). 
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Figure 3. Expansion capacity and post-expansion differentiation ability. (A) One representative 
example of total and CD14+ cell numbers during expansion of a CD14-converting AML sample 
with a cytokine cocktail consisting of GM-CSF, G-CSF, FLT3-Ligand and SCF.  (B) Changes in CD14 
marker expression on leukemic cells after expansion culture. Open symbols (∆, n=6) indicate that 
post-expansion DC differentiation could be achieved, i.e. low expression of CD14 (<10%) and CD34 
(<10%) and increased expression of CD1a (>10%), DC-SIGN, CD40, CD80, CD86 and HLA-DR; open 
triangles denote successful DC differentiation whereas closed inverted triangles (n=5) indicate that 
AML-derived DC could not be generated; “▪”: post-expansion DC-differentiation capacity was not 
tested. (C) Schematic overview of numbers of patients in relation to CD14 expression and tested DC 
differentiation capacity over the course of expansion.
A B
C
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Discussion
In clinical practice, AML-derived DC based immunotherapy is hampered by low numbers 
of DC precursors and the inability of a considerable proportion of AML to differentiate into 
DC. To overcome these limitations we evaluated the expansion of leukemic cells prior to 
induction of differentiation into DC. We show that leukemic cells can indeed be efficiently 
expanded in vitro. No major differences in expansion efficiency were found between the 
tested cytokine expansion cocktails; consistently good results were obtained with a cytokine 
mix consisting of GM-CSF, G-CSF, FLT3-L and SCF (Cocktail 5, see table 1).
Although antigen-pulsed monocyte-derived DC or allogeneic DC vaccines have also been 
explored (by others and by us [19]), the use of whole-cell autologous leukemic cell products, 
such as AML-derived DC, for immunotherapy is of particular interest because they harbour 
both known and as yet unidentified LAA as well as individual immunogenic mutations. 
Previous studies have shown the potency of leukemic cell-derived DC in terms of generating 
an anti-leukemia T cell  response [20]. Such personalized AML-derived DC vaccines require 
conservation of LAA expression. In all of the five post-expansion AML samples tested we 
confirmed the presence of mRNA encoding LAA derived peptide sequences (i.e. PRAME, 
RHAMM and WT1). Especially the presence of PRAME transcripts demonstrated the presence 
of bona fide AML cells since these transcripts are not found in normal mononuclear cells or 
non-malignant CD34+ cells isolated from bone marrow. For RHAMM however, activated T 
cells have also been reported to express this protein, thereby potentially inducing T cell 
fractricide [21].
During expansion we observed a decrease in expression of GM-CSFR, G-CSFR, and IL-3R. 
This decrease may either be due to receptor occupancy, internalization of the receptors 
or differentiation of the AML blasts. The latter appears most likely in view of the observed 
simultaneous up-regulation of CD14. It was previously shown that cytokines such as SCF 
and FLT3-L can induce differentiation from normal CD34+ precursor cells into CD14+ DC 
precursors [22]. Furthermore, CD14 up-regulation in leukemic cell lines has been induced by 
incubation with human bone marrow stromal cell lines or with iron chelators and vitamin D 
analogues [23, 24]. This development of AML cells into a monocytoid precursor is in keeping 
with their subsequent propensity to differentiate into leukemic DC [25]. Indeed, CD14 is a 
recognized predictive marker for DC differentiation capacity of precursors in AML samples 
[4,9]. In keeping with this, we found that de novo gain of CD14 expression after cytokine-
mediated expansion was associated with cytokine-induced  DC-differentiation ability (see 
figure 1B), while loss of CD14 expression was associated with a subsequent inability to 
differentiate into DC. Based on our previous and current findings, the percentage of CD14- 
AML samples with cytokine-based DC differentiation ability can now be raised from 26% [4] 
to approximately 70% (69% in figure 2C) through prior cytokine-mediated expansion and 
CD14 induction. 
In summary, for CD14- AML samples, expansion prior to DC differentiation overcomes two of 
the major limitations for DC vaccination, i.e. low numbers of DC precursors and the inability 
of leukemic cells to develop into DC. Specifically, we suggest that expansion of CD14- AML 
cells with a cocktail of GM-SCF, G-CSF, FLT3-L and SCF facilitates their acquisition of CD14 
surface expression and DC-differentiation ability in the presence of commonly used cytokine 
cocktails containing GM-CSF, TNFα and IL4. Importantly, a priori CD14+ leukemic cells did not 
profit from expansion, but these CD14+ cells already have a good chance of DC differentiation 
with a standard combined expansion and differentiation cytokine cocktail [4]. 
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Conclusion
In conclusion, we demonstrate that AML cells can be expanded in vitro prior to differentiation 
with cocktails of cytokines with known myeloid growth-promoting effects (i.e. GM-CSF, 
G-CSF, SCF and FLT3-L). CD14 negative leukemic cells can gain CD14 expression upon 
expansion which is a positive predictor for differentiation. In this study we confirm that 
CD14+ expanded leukemic cells are able to differentiate into DC. This approach will result 
in an increase the number of patients eligible for AML-DC vaccination in whom previously 
AML-DC vaccination was hampered due to low cell numbers at diagnosis.  
Future perspectives
By expansion of CD14- leukemic cells prior to DC preparation, the number of patients eligible 
for DC-based immunotherapy based on cytokine-induced DC differentiation capacity will 
be increased (based on our previous and current findings an estimated increase from 60% 
to about 80% of all AML cases) and thereby the overall feasibility of this experimental 
approach to the treatment of residual AML. Future trials are needed to confirm the general 
applicability of AML-DC vaccination in clinical practice. 
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UPN WHO-classification Cytogenetics % blasts CD 14 CD 34 CD  11c
1 AML not further classified not analysed 41% - - 81
2 AML not further classified not analysed 9% - -
3 AML not further classified not analysed 89% 60 0 63
4 AML not further classified no metaphases 74% 0 25 3
5 AML not further classified not analysed 74% 1 1 -
6 AML not further classified no metaphases 95% 4 84 -
7 AML not further classified not analysed 95% 0 0 -
8 AML minimally differentiated 46,XY 83% 0 98 2
9 AML without maturation not analysed 71% 5 3 5
10 AML without maturation not analysed 97% - - 8
11 AML without maturation not analysed 95% 5 0 58
12 AML with maturation not analysed 64% - - 5
13 AML with maturation no metaphases 86% 0 15 36
14 AML with maturation 46,XY 35% 1 2 68
15 AML with maturation 46,XY,+t(17;17)(p1?3;q2?3)[5] 73% 5 90 46
16 AML with maturation 46,XY 40% - 0 3
17 AML with maturation 46,XY 21% 1 1 33
18 AML without maturation 46,XX 70% 42 1 66
19 Acute myelomonocytic 
leukemia
not analysed 65% 2 95 2
20 Acute myelomonocytic 
leukemia
not analysed 40% - - 9
21 Acute myelomonocytic 
leukemia
not analysed 69% 2 0 15
22 Acute myelomonocytic 
leukemia
46,XX 46% - - 41
23 Acute myelomonocytic 
leukemia
not analysed 80% 0 0 4
24 Acute myelomonocytic 
leukemia
45,X 33% 52 1 75
25 Acute monoblastic and 
monocytic leukemia
47,XY,+8[10] 89% 0 11 5
26 Acute monoblastic and 
monocytic leukemia
46,XY 84% 0 27 66
Supplemental material
Supplementary table 1 legend: Patient characteristics. Abbreviations: UPN, Unique patient number; 
SCF-R, stem cell factor receptor; GCSF-R granulocyte colony stimulating factor receptor; GMCSF-R, 
granulocyte, macrophage colony stimulating factor receptor; TNF-R, ratio of tumor necrosis factor 
receptor; FLT3-ITD, fms-like tyrosine kinase receptor-3 internal tandem duplication: “0” not detectable, 
“1” detectable “-“ not done; Diff y/n, DC differentiation yes or no; “-“, not done.
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UPN SCF-R GCSF-R GM 
CSF-R
TNFa 
RI/RII
FLT3-
ITD
Diff 
y/n
T(9;22) T(8;21) T(15;7) MLL 
rearrangement
1 49 15 44 0,64 - - - - - -
2 47 62 54 0,63 - - - - - -
3 23 15 20 0,66 - - neg neg neg neg
4 36 19 11 8,91 Y - neg neg neg neg
5 - - - - Y - neg neg neg neg
6 - - - - Y - neg neg neg neg
7 - - - - Y - neg neg neg neg
8 91 5 3 0,46 - - neg neg neg neg
9 9 26 82 9,74 Y - neg neg neg neg
10 84 40 20 0,86 - - - - - -
11 11 54 35 0,28 Y Y neg neg neg neg
12 85 65 5 0,56 - - - - - -
13 24 46 8 2,28 - - - - - -
14 52 39 26 0,37 N N neg neg neg neg
15 80 60 15 0,15 N Y neg neg neg neg
16 61 9 4 0,51 Y - neg neg neg neg
17 28 3 75 0,77 N N neg neg neg neg
18 11 39 86 0,42 N N neg neg neg neg
19 98 27 16 2,24 N - neg neg neg neg
20 97 53 34 0,42 - - - - - -
21 58 44 22 0,96 Y - neg neg neg neg
22 14 5 16 10,14 - - - - - -
23 2 5 67 0,16 Y Y neg neg neg neg
24 22 63 89 0,45 N - neg neg neg neg
25 89 61 8 2,24 Y Y neg neg neg neg
26 94 43 10 0,80 Y - neg neg neg neg
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UPN WHO-classification Cytogenetics % blasts CD 14 CD 34 CD  11c
27 Acute monoblastic and 
monocytic leukemia
46,XX,der(8)t(8;16)(p11;p13) 
dup(8)(q11q24),der(16)
t(8;16)
94% 1 1 76
28 Acute monoblastic and 
monocytic leukemia
not analysed 91% 9 56 57
29 Acute monoblastic and 
monocytic leukemia
not analysed 93% 0 0 3
30 Acute monoblastic and 
monocytic leukemia
not analysed 30% 7 0 69
31 Acute monoblastic and 
monocytic leukemia
46,XY 84% 0 27 49
32 Acute monoblastic and 
monocytic leukemia
46,XX 23% 0 1 32
33 Acute erythroid leukemia not analysed 16% 4 82 22
34 AML with 11q23 (MLL) 
abnormalities
11q23 mutation present 65% 66 13 51
35 AML with t(8;21)(q22;q22); 
RUNX1-RUNX1T1
nuc ish (ETOx2, AML1x3)
[44/200]
24% 2 91 31
36 AML with t(8;21)(q22;q22); 
RUNX1-RUNX1T1
not analysed 15% 2 80 2
37 AML with inv (16)(p13.1q22); 
CBFB-MYH11
46,XX,inv(16)(p13q22)[11] 95% 41 55 56
38 AML with inv (16)(p13.1q22); 
CBFB-MYH11
46,XX,inv(9)(p22q13)c 52% 3 84 83
39 Acute leukemia of ambigious 
lineage: MPAL
Cytogenetic changes on 
chromosome 3
23% 9 88 6
40 Acute leukemia of ambigious 
lineage: MPAL
46,XX,t(2;3)(p23;q26),-
7,+mar[10].ish del(7)(q11.2)
(D7Z1+,D7S486-)
53% 3 94 37
41 Acute leukemia of ambigious 
lineage: MPAL
45,XY,-7 23% 1 99 11
Supplementary table 1, continued
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UPN SCF-R GCSF-R GM 
CSF-R
TNFa 
RI/RII
FLT3-
ITD
Diff 
y/n
T(9;22) T(8;21) T(15;7) MLL 
rearrangement
27 5 57 7 0.48 N N neg neg neg neg
28 33 32 69 12,39 - Y - - - -
29 91 46 90 0,27 - - - - - -
30 33 32 15 8,42 - - - - - -
31 98 31 21 6,28 Y - neg neg neg neg
32 24 4 18 2,13 Y - neg neg neg neg
33 78 18 34 1,83 N - neg neg neg neg
34 1 1 6 0,05 - N neg neg neg POS
35 1 94 27 0,32 N - neg POS neg neg
36 49 3 8 4,32 N - neg POS neg neg
37 96 56 64 0,21 N - neg neg neg neg
38 5 72 85 86,36 Y Y neg neg neg neg
39 27 6 6 4,17 - - neg neg neg neg
40 69 26 14 1,08 N - neg neg neg neg
41 94 20 72 7,16 N - neg neg neg neg
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Abstract
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors such as 
Imatinib mesylate, dasatinib and nilotinib results in high rates of cytogenetic and molecular 
responses. However, in many patients minimal residual disease (MRD) is detected by 
molecular techniques. Since CML cells are particularly good targets for immune surveillance 
mechanisms, we explored active specific immunotherapy using leukemia lysate-loaded 
dendritic cells (DCs) in vitro. Our data show the potency of DC-based vaccination strategies 
for the induction of allogeneic anti-leukemia T cell-mediated responses to eradicate MRD.
Background
Treatment of chronic myeloid leukemia (CML) with Imatinib mesylate or other tyrosine 
kinase inhibitors (TKI), such as dasatinib and nilotinib, results in high rates of cytogenetic 
and molecular responses. Nevertheless, in many patients minimal residual disease (MRD) 
is detected by highly sensitive molecular techniques [1-4]. BCR-ABL, the target of the TKI, is 
not only a critical oncogene, but a CML-specific antigen as well. Amino-acid sequences of the 
fusion protein BCR-ABL can be processed and presented by HLA-molecules on the surface 
of leukemic cells [5-8]. Thus, CML cells are particularly good targets for immunological 
surveillance mechanisms; this has been demonstrated by the curative potential of allogeneic 
stem cell transplantation (SCT) and the re-induction of complete remission upon donor 
lymphocyte infusion in patients with relapsed CML [9;10]. Dendritic cells (DCs) are better 
inducers of immune responses than leukemic cells [11;12]. Therefore, active specific DC-
based vaccination strategies may eradicate MRD when applied in combination with TKI or 
supplementary in patients resistant to TKI. In a small phase I study, we have demonstrated 
that vaccination with in vitro generated autologous CML-derived DCs in patients in late 
chronic phase CML induced an anti-leukemia immune response, evidenced by strong 
delayed type of hypersensitivity (DTH) [13]. A phase I/II vaccination trial, also based on 
autologous CML-derived DCs, in 10 patients that failed to achieve cytogenetic responses 
after treatment with α-interferon or Imatinib mesylate, showed similar results [14]. CML-
derived DCs enable presentation of both known (e.g. BCR-ABL and WT-1) and unknown 
tumor-associated antigens [15]. Since CML-derived DCs are hampered by functional defects 
resulting in inferior migratory capacity and antigen presentation which may negatively 
influence the outcome of DC-based immunotherapy normal, non-leukemic monocyte-
derived DCs (MoDCs) can serve as an alternative [16-18]. Similar to CML-derived DCs, 
MoDCs loaded with whole cell CML lysates will present the full range of known and unknown 
tumor-associated antigens. In AML, MoDCs loaded with leukemia cell-derived lysates have 
been exploited in vivo and results were encouraging [19]. In mice, the combination of CML 
lysate-loaded DCs and Imatinib mesylate resulted in activation of antigen-specific cells and 
superior anti-tumor activity against bcr-abl+ leukemic cells as compared to lysate-loaded DCs 
or Imatinib mesylate alone. [20]  This points toward a role for immunotherapeutic strategies 
complementary to standard treatment protocols. In this report we evaluated the potency of 
normal allogeneic MoDCs pulsed with whole cell CML lysates to stimulate T cell-mediated 
immune responses towards CML progenitor cells.
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Materials and Methods 
Generation of dendritic cells and leukemia-lysate preparation
Mononuclear cells were isolated by Ficoll-density centrifugation (Amersham Pharmacia 
Biotech, Uppsala, Sweden) from bone marrow samples of three CML patients in chronic 
phase and buffy coats of two HLA-A2+ donors. All samples were drawn after informed 
consent; the study was approved by the local Medical Ethics Committee.  MoDCs and 
lysates were prepared as described previously [21]. In short: CML lysates were prepared by 
four repetitive cycles of freeze-thawing. CML CD34+ progenitor cells were isolated by CD34 
Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s 
instruction using an AutoMACS device (Miltenyi Biotec). Donor monocytes and CD8+ T 
cells were isolated by CD14 and CD8 Microbeads (both Miltenyi Biotec), respectively. 
Immature MoDCs were cultured from CD14+ cells in 5 days. Half of the amount of MoDCs 
was incubated with CML lysate for 2h. in a DC to CML ratio of 1:1; the other half was left 
untouched. This ratio was determined based on the literature on other DC loading strategies 
(e.g. AML) [19;22]. Thereafter, unloaded and lysate-loaded DCs (LL-MoDCs) were matured 
for 48h. with a standard mixture of inflammatory cytokines TNF-α (10ng/ml), IL-1β (10ng/
ml, specific activity 107U/mg protein, Strathmann Biotec, Hamburg, Germany), IL-6 (10ng/
ml, R&D Systems, Abingdon, UK) and prostaglandin E2 (1μg/ml, Sigma, St. Louis, MO) and 
characterized by flow cytometry as described previously [17]. 
 
Analysis of T cell subpopulations during co-culture of T cells and dendritic cells
During 4-6 weeks, donor CD8+ T cells were weekly stimulated with irradiated MoDCs or LL-
MoDCs at a 5:1 ratio in the presence of irradiated CD4+ lymphocytes as feeder cells. RhIL-7 
(5 ng/ml, specific activity 5*107U/ml, Strathmann Biotech GmbH, Hannover, Germany) was 
supplied from culture start, whereas rhIL-2 (10 U/ml, specific activity 107U/mg, Strathmann 
Biotech) was added from the second day after (re)stimulation. For every CML patient co-
cultures were initiated using one donor; one donor was used in two separate experiments. 
A flow-chart of the study design is shown in figure 1. 
Proliferative activity, cytokine production and proportion of naïve, memory and effector 
CD8+ subpopulations were assessed weekly. T cell subpopulations were characterized by 
flow cytometry based on expression patterns of CD27 (Immunotech, Marseille, France) and 
CD45RA (Sanquin, Amsterdam, The Netherlands). Cell free supernatants of the co-cultures 
(24h. after re-stimulation) were used for evaluation of IFN-γ and IL-4 production by ELISA 
according to the manufacturer’s instructions (Sanquin). Detection limit of both assays was 
1 pg/ml. The percentage of cytokine-producing T cells was assessed as described previously 
[23].  After stimulation by PMA (25 ng/ml, Sigma) and ionomycin (1 μg/ml, Sigma) for 6 h. at 
370C. Brefeldin A (10 μg/ml, Sigma) was added for the last 4 h. of incubation; subsequently 
the percentage IFN-γ and IL-4 positive T cells were determined. Skewing of CD8+ T cells was 
analyzed by flow cytometry using a panel of monoclonal antibodies representing the most 
frequently expressed Vβ chains in the normal Vβ repertoire (BeckmanCoulter, Immunotech). 
Increase above mean plus 2 times the standard deviation according to the manufacturer’s 
reference chart was regarded as outgrowth of a population expressing a certain TCR-Vβ 
subtype.
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Analysis of cytolytic potential of T cells
At the end of co-culture CD8+ T cells were used as effector cells in a cytotoxicity assay as 
previously described [24]. CML CD34+ progenitor cells derived from the same patient as the 
CML lysate were used as target cells. In short, CML CD34+ progenitor cells and stimulated 
allogeneic CD8+ T cells were co-cultured for 6h., stained by a progenitor marker (CD34-APC) 
and a specific T cell marker (CD3-PE), respectively, followed by a SYTO-16/7-AAD viability 
staining. To investigate whether the cytotoxic activity was MHC-restricted the cytotoxicity 
assay was performed in the presence and absence of MHC class I-blocking antibodies or the 
appropriate isotype control. [23]
Figure 1. Schematic representation of the study design. The grey panel depicts preparation of lysate 
and selection of CD34+ cells from CML samples. CD34+ cells were used for testing of cytotoxicity. 
The white panel depicts the preparation of allogeneic MoDCs after CD14+ cell selection; these were 
cultured into immature MoDCs, and loaded with CML lysate (border of grey and white panel) or left 
untouched; subsequently maturation was induced with IL1-β, TNFα, PGE2 and IL6. CD8+ cells from the 
same donor were isolated and used for co-culture with lysate-loaded or unloaded MoDCs.
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Figure 2. Immunophenotype of CML lysate-pulsed MoDCs and unloaded MoDCs. Panel A. shows 
percentage positivity for the displayed antigens of MoDCs before maturation (white bars) and after 
maturation in the absence or presence of CML lysate (grey and black bars respectively); panel B depicts 
mean fluorescence intensities. HLA-ABC results are not available (na) in immature DCs.
Results
Preserved phenotypic characteristics of lysate-loaded MoDC
To investigate whether loading of CML lysate affects DCs, immunophenotype of DCs was 
analyzed by flow cytometry. Maturation of immature MoDCs in the presence of CML lysate 
induced similar expression levels of costimulatory molecules CD40, CD80 and CD86 as 
compared to maturation without lysate (figure 2). Maturation marker CD83 was expressed 
in 85% of the DCs; the mean fluorescence intensity was approximately two-fold higher 
after lysate-loading. Expression of CCR7, a receptor important for lymph node homing of 
DCs, decreased from 79 towards 54%. Interestingly, maturation in the presence of CML 
lysate increased intensity of HLA-DR expression two-fold and HLA-ABC expression 1.3 fold 
indicating improved antigen presentation by lysate-loaded DCs and possibly enhanced T cell 
stimulation.
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Lysate-loaded MoDCs induce differentiation and increased IFN-γ production in allogeneic 
CD8+ T cells. 
Before co-culture, the majority of the T cells had a naïve or central memory phenotype 
(CD45RA+CD27+ and CD45RA-CD27+, mean 25% and 55%, respectively (n=2)).  Upon 
stimulation with LL-MoDCs as well as with unloaded MoDCs a preferential outgrowth of 
effector-memory cells was observed (three separate co-culture experiments: from 10-15% 
CD45RA-CD27- at start of co-cultures up to 60-95% after 4-6 weeks). LL-MoDC stimulation 
resulted in highest percentages of effector T cells (CD45RA+CD27-:   mean 4.6% versus 1.5% 
in unloaded MoDC co-cultures, figure 3A). Of note, CD8+ T cells co-cultured with LL-MoDCs 
showed a less pronounced proliferation as compared to those co-cultured with unloaded 
Figure 3. Distribution of T cell subpopulations and proliferation of CD8+ T cells after co-culture with 
CML lysate-pulsed MoDCs and unloaded MoDCs. Panel A. depicts distribution of effector memory 
T cells (grey, triangles) and effector T cells (black, circles) after unloaded (dashed lines and open 
symbols) and CML lysate-loaded DC stimulation (solid lines and closed symbols). Panel B. depicts a 
representative example of proliferation of CD8+ T cells after co-culture with unloaded MoDCs (dashed 
line) and LL-MoDCs (solid line).
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Figure 4. TCR Vβ analysis before and after co-culture with CML lysate-pulsed MoDCs and unloaded 
MoDCs.  Results obtained in three separate experiments are depicted; for every CML patient co-
cultures were initiated using one donor; one donor was used in two separate patients. White bars 
represent TCR Vβ repertoire before co-culture, grey bars represent results after co-culture with 
unloaded MoDCs, black bars after co-culture with LL-MoDCs and striped bars represent normal 
distribution. Increase above mean plus 2 times the standard deviation according to the manufacturer’s 
reference chart was regarded as outgrowth of a population expressing a certain TCR-Vβ subtype. 
Skewing towards a certain Vβ type observed after both LL-MoDC and unloaded MoDC stimulation 
was considered non-specific. Circles indicate outgrowth only observed after co-culture with LL-
MoDCs, this might indicate potentially leukemia-specific skewing. Inserted percentages in the upper 
right corner of every panel indicate the percentage of the T cell population characterized with the 
antibody panel after co-culture with LL-MoDCs.
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MoDCs (figure 3B). Effector-memory and effector T cells are able to produce IFN-γ. At 
the end of co culture with LL-MoDCs, the number of IFN-γ-producing T cells as measured 
by flow cytometry was median 25%, i.e. 2.8 fold higher as compared to stimulation with 
unloaded MoDCs (median 8.9%). The same holds true for IFN-γ as detected in cell free 
culture supernatants:  median 1306 and 268 pg/ml upon LL-MoDC and unloaded MoDC 
stimulation, respectively. IL-4 production was low for both LL-MoDC and unloaded MoDC 
stimulation (below 7pg/ml). 
Skewing of allogeneic T cells upon lysate-loaded MoDC stimulation
When CML-specific T cells expand after stimulation, a skewing of the T cell repertoire is 
expected. Therefore, a TCR-Vβ analysis was performed comparing the TCR-Vβ repertoire 
of T cells before culture and after co-culture with either unloaded MoDCs or LL-MoDCs 
(figure 4). T cells expressing certain TCR-Vβ subtypes preferentially expanded after LL-MoDC 
stimulation; these populations represented median 16% of the CD8+ T cell population. This 
might indicate leukemia-specific skewing.
Lysate-loaded MoDCs induce MHC-restricted T cell-mediated cytotoxicity against CML 
progenitor cells.
To assess whether these allogeneic T-cells were functional, cytotoxic activity of stimulated T 
cells towards CML CD34+ progenitor cells was analyzed by flow-cytometry. Indeed incubation 
with LL-MoDC-stimulated T cells resulted in a higher percentage of apoptotic and secondary 
necrotic CD34+ CML progenitor cells as compared to unloaded MoDC-stimulated T cells 
(84% versus 36%, 36% versus 29% and 42% versus 29% at E:T=10:1 for LL-MoDC-stimulated 
and unloaded MoDC-stimulated T cells, respectively, figure 5A). In two out of three cases, 
induction of apoptosis/necrosis in CML progenitors by LL-MoDC-stimulated T cells was 
abrogated in the presence of MHC class I antibody, indicating MHC class I-restriction (figure 
5B).
Discussion 
Specific T cell responses against CML progenitor cells might effectively eliminate MRD after 
treatment with TKI. LL-MoDC-based vaccines in CML may offer an advantage over single 
antigen-derived peptide vaccination (i.e. BCR-ABL and WT1) as they have the ability to 
present a broad spectrum of potential leukemia-associated antigens resulting in a broader 
T cell response. Moreover, the use of leukemia lysate as an antigen source for vaccine 
preparation circumvents the cumbersome need for viable, fresh leukemia cells for leukemic 
DC-based vaccines [25]. In this study we showed that MoDCs can be loaded with CML lysates 
and that these LL-MoDCs have the potency to induce, at least in vitro, anti-leukemic T cell 
responses as demonstrated by TCR-Vβ skewing and cytolytic activity. A limitation of the use 
of lysates may be that they contain many non-malignancy associated peptides which might 
increase the risk of auto-immunity [26]. Nevertheless, in clinical trials with CML-derived 
DCs, AML-derived DCs and MoDCs loaded with AML lysates no or only minor auto-reactivity 
was reported [13;19;22;27]. Moreover, cell lysates may impair DC function because they 
contain intracellular proteases with potential inhibitory activity, and immunosuppressive 
cytokines, such as TGF-β, which might impair immune responses [28-30].  In fact, our data 
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Figure 5. MHC-restricted cytotoxicity towards CD34+ CML progenitor cells induced by lysate-loaded 
MoDC-stimulated CD8+ T cells. A representative example of the analysis of cytotoxic activity of DC-
stimulated T cells is shown in panel A; cytotoxic activity is depicted at several effector to target ratios 
(E:T). The solid line represents apoptosis/secondary necrosis of target cells after 6 hours of co-culture 
with CD8+ T cells stimulated by LL-MoDCs; the dashed line represents apoptosis/secondary necrosis 
of target cells after 6 hours of co-culture with CD8+ T cells stimulated by unloaded MoDCs. In panel B, 
analysis of MHC class I restriction of cytotoxic activity is depicted. White bar represents spontaneous 
apoptosis of CD34+ CML progenitor cells, black bar represents apoptosis of CD34+ CML progenitor cells 
after co-culture with LL-MoDC-stimulated CD8+ T cells, light grey bar after co-culture with LL-MoDC-
stimulated CD8+ T cells in the presence of a MHC class I blocking antibody (W6.32) and the dark grey 
bar after co-culture with LL-MoDC-stimulated CD8+ T cells in the presence of isotype control antibody. 
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showed less proliferation of T cells in co-cultures with LL-MoDCs; an alternative explanation 
of this phenomenon might be antigen-induced cell death due to overstimulation by CML 
lysate-derived antigens. Indeed, LL-MoDCs showed increased expression of MHC class I 
and II molecules, indicating potentially increased presentation of LAA-derived peptides and 
hence improved immunogenicity. In contrast, LL-MoDCs showed decreased expression of 
CCR7, potentially indicating decreased migratory capacity. Whether this decrease has any 
clinical impact in vivo is not clear, since in general, only low numbers of DCs reach the lymph 
node after vaccination [31]. 
In CML, the leukemic population is rather heterogeneous with regard to maturation and 
differentiation of the myeloid cells, which may influence the susceptibility to different 
cytotoxic modalities [32]. This was confirmed in this study by partial killing of CML-derived 
CD34+ progenitor cells in vitro. Escape of CML progenitor cells from immunotherapeutic 
intervention causes persistence of MRD. MRD cells in CML are thought to be quiescent 
progenitor cells mainly residing in the bone marrow; these cells are more resistant to TKI 
than their cycling counterparts [33-36]. One way to target this specific subpopulation is 
to load DCs with lysates of leukemic stem cells. However, some reports argue that RNA- 
and protein-pulsed DCs are more effective in inducing CML-specific T cell responses in vitro 
than lysate-loaded DCs [37;38]. An advantage of RNA is that it can be amplified from small 
populations such as stem cells, moreover, as with whole cell lysates, it covers both known 
and unknown antigens. Leukemic stem cells in CML, defined as CD34+CD38- or CD34-lin-, can 
be distinguished by flow cytometry from normal stem cells by scatter profile and aberrant 
antigen expression [39;40]. These characteristics can be used to sort leukemic stem cells for 
application in DC-based vaccine preparation. 
Conclusion 
Here we provide proof of principle that MoDCs loaded with CML lysates were able to induce 
T cell proliferation and IFN-γ production by CD8+ T cells. Importantly, these allogeneic T cells 
were able to recognize and lyse CML cells in vitro. Hence, our data show the potency of DC-
based vaccination strategies in the induction of anti-leukemia responses and offer a basis for 
further optimalization of MoDC-based vaccination strategies. 
Future perspectives
CML patients that have residual disease after conventional treatments with TKIs are at high 
risk for relapse and might benefit from additional therapeutic strategies. In these cases, DC-
based immunotherapy might provide an additional therapeutic option.  The data shown in 
this manuscript provide a starting point for further research in this respect. Our results are 
a first step down the road towards DC vaccination after allogeneic SCT. Moreover, the data 
prelude application of DCs specifically directing T cell responses towards the eradication of 
leukemic stem cells thereby reducing the risk of relapse.
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Abstract
Therapeutic vaccination with dendritic cells (DC) is an emerging investigational therapy for 
eradication of minimal residual disease in acute myeloid leukemia (AML). Various strategies 
are being explored in manufacturing DC vaccines ex vivo, e.g. monocyte-derived DC (MoDC) 
loaded with leukemia-associated antigens (LAA). However, the optimal source of LAA and 
the choice of DC-activating stimuli are still not well defined. Here, loading with leukemic cell 
preparations (harboring both unknown and known LAA) was explored in combination with 
a DC maturation-inducing cytokine cocktail (CC; IL-1β, IL-6, TNF-α and PGE
2
) and Toll-like 
receptor ligands (TLR-L) to optimize uptake. Since heat shock induced apoptotic blasts were 
more efficiently taken up than lysates we focused on uptake of apoptotic leukemic cells. 
Uptake of apoptotic blast was further enhanced by the TLR-7/8-L R848 (20-30%); in contrast, 
CC-induced maturation inhibited uptake. CC, and to a lesser extent R848, enhanced the 
ability of MoDC to migrate and stimulate T cells. Furthermore, class II-associated invariant 
chain peptide (CLIP) expression was down-modulated after R848- or CC-induced maturation, 
indicating enhanced processing and presentation of antigenic peptides. To improve both 
uptake and maturation, leukemic cells and MoDC were co-incubated with R848 for 24h 
followed by addition of CC. However, this approach interfered with CC-mediated MoDC 
maturation as indicated by diminished migratory and T cell stimulatory capacity and the 
absence of IL-12 production. Taken together, our data demonstrate that even though R848 
improved uptake of apoptotic leukemic cells, the sequential use of R848 and CC is counter-
indicated due to its adverse effects on MoDC maturation.
Introduction
Acute myeloid leukemia (AML) is characterized by proliferation of clonal neoplastic myeloid 
hematopoietic precursor cells and impaired normal hematopoiesis. Although 70-80% 
of patients (<60 years) achieve complete remission after intensive chemotherapy, AML 
frequently relapses due to the persistence of minimal residual disease (MRD) [1].  Escape of 
leukemic cells from immune surveillance has been associated with poor clinical outcome. 
For instance, a high occupancy of HLA-DR molecules with the class II-associated invariant 
chain peptide (CLIP) instead of an antigenic peptide is correlated with a shortened disease 
free and overall survival [2;3]. In contrast, immune control of leukemia, as shown for 
instance by the graft-versus-leukemia effect induced by allogeneic stem cell transplantation 
(SCT) or the reinduction of complete remission after donor lymphocyte infusion following 
allogeneic SCT, demonstrates the potential of exploiting the immune system in aid of anti-
AML therapy [1]. 
The induction, regulation and maintenance of primary immune responses, including specific 
anti-tumor T cell responses is coordinated by dendritic cells (DC). Vaccination with DC 
has been recognized as a promising investigational therapy due to the uniquely powerful 
antigen (Ag) presenting capacity of DC and its potential to circumvent immunosuppressive 
features of leukemia [4]. The first steps down the road to DC vaccination in AML have 
been taken and results from small clinical trials have been reported [5]. The general lack 
of clinical responses evoked important questions concerning the optimal methodologies 
for DC vaccine preparation as well as the design of clinical vaccination protocols. Many 
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strategies are explored in the preparation of DC vaccines ex vivo; among these, autologous 
monocyte-derived DC (MoDC) loaded with leukemia-associated Ag (LAA) are promising [6]. 
Various sources of LAA and different methods of loading LAA onto DC have been explored 
in an attempt to optimize anti-tumor responses [7]. For AML, several relevant LAA have 
been identified including PRAME, RHAMM, WT1 and PR1. Unfortunately, overexpression 
of these LAA is common but not uniform in leukemia [8]. Moreover, HLA restriction of LAA-
derived peptides limits application of such vaccines to patients with certain HLA profiles. 
These restrictions inherent to the use of defined LAA or LAA-derived peptides may be 
overcome by using whole AML cells as a source of LAA, for instance by generation of AML 
lysates or apoptotic leukemic cells. Among other whole AML cell derived antigen loading 
strategies that have been explored, is electroporation of DC with AML derived RNA [9]. 
Also vaccination with modified AML cells, such as AML derived DC or fusions between AML 
cells and DC has been investigated; further modification of DC with 4-1BB-L or CD40 might 
enhance efficacy of such vaccines [10-13]. It has long been assumed that apoptotic cell 
death is poorly immunogenic or even tolerogenic, whereas necrotic cell death is considered 
to be immunogenic. However, stress-induced heat shock protein (HSP)-peptide complexes 
(commonly induced during apoptosis) are more efficiently taken up via scavenger receptors 
and Toll-like receptors (TLR) on the DC surface and induce efficient cross-priming and 
skewing of the immune response towards a Th1-type profile [14;15], whereas necrosis 
has been associated with local immune suppression in solid tumors [16]. Furthermore, 
apoptosis induction after irradiation with UV light or by treatment with chemotherapeutic 
drugs results in upregulation of calreticulin, a scavenger receptor class-A ligand associated 
with immunogenic apoptosis as demonstrated for colon carcinoma cells [17;18]. For AML 
it is not yet clear whether cell lysates or apoptotic cells are preferable for Ag loading onto 
MoDC [9;19-25]. Next to enhancing immunogenicity of tumor Ag sources by, for instance, 
heat shock, addition of DC-maturing stimuli such as TLR-ligands (TLR-L) are explored; for 
example, electroporation of  TLR3-L poly(I:C) into AML cells results in enhanced uptake of 
leukemic cells by DC and improves their subsequent maturation and cytokine production 
[26]. Furthermore, intracellular binding of TLR8 by its ligand R848 has been reported to 
result in enhanced cross-priming of exogenous Ag by MoDC [27]. Various whole AML cell 
preparations loaded onto MoDC in combination with DC maturation-inducing cocktails have 
been explored [9;21]; however the quantitative effects of TLR-L and cytokines on uptake of 
leukemic cells is still unclear.
In this study we compared uptake of allogeneic apoptotic leukemic cells with lysates derived 
from leukemic cells. We investigated the uptake of heat shock-induced apoptotic leukemic 
cells by MoDC and DC maturation by combining a standard cytokine cocktail (CC) with the 
clinically applicable TLR7/8-L R848.
Material and Methods
Patient samples 
Peripheral blood or bone marrow mononuclear cells from AML patients were isolated by 
density centrifugation using Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). 
All samples were drawn after obtaining the patients’ informed consent at time of collection. 
Cells were cultured immediately or cryopreserved at a controlled rate in liquid nitrogen 
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using RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 20% heat-inactivated 
FCS (Greiner, Alphen a/d Rijn, The Netherlands)  and 10% dimethylsulphoxide (Merck, 
Darmstadt, Germany). Before application of stored AML cells, cryopreserved material was 
rapidly thawed and washed twice in RPMI-1640 supplemented with 40% FCS. The cells were 
then resuspended in culture medium as described below.
Culture of monocyte-derived dendritic cells (MoDC)
Buffy coats were obtained from healthy volunteers according to institutional guidelines. 
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation using 
Ficoll-Paque. Subsequently, monocytes were obtained by magnetic bead isolation, using 
CD14-labeled Microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). MoDC 
were cultured from CD14+ monocytes in CellGro serum-free medium (CG) (CellGenix, 
Freiburg, Germany) supplemented with 100IU/ml penicillin and 100μg/ml streptomycin, 
GM-CSF (800IU/ml, specific activity 1x105 IU/mg protein; Pepro Tech, Rocky Hill NJ) and 
IL-4 (500 IU/ml, specific activity 1x107 U/mg protein, Pepro Tech). After five days immature 
MoDC were harvested. Purity and phenotype of immature DC were evaluated by flow 
cytometry for expression of CD14, CD40, CD34, CD80, CD86, HLA-DR, CD54 and CD83. For 
maturation induction the following TLR-L were used: R848 (3 μg/ml; Alexis Biochemicals, 
Axxora, Grünberg, Germany), LPS (100ng/ml; Sigma-Aldrich, Saint Louis, MO), Polyinosinic-
polycyticylic acid potassium salt (Poly(I:C) 25μg/ml; Sigma-Aldrich), Flagellin (5μg/ml; 
Invivogen, San Diego CA) and Peptidoglycan (PGN; 5μg/ml; Sigma-Aldrich). Maturation with 
CC was induced using the following combination of cytokines and reagents: recombinant 
TNF-α (200IU/ml; Strathmann Biotec, Hannover, Germany), IL-1β (10 ng/ml; Strathmann 
Biotec), PGE
2
 (1 μg/ml; Sigma-Aldrich) and IL-6 (10 ng/ml; R&D Systems, Abingdon, UK). 
Loading of MoDC with allogeneic leukemic cell lysates and apoptotic leukemic cells 
Leukemic cells were labeled with 5- (and 6-) carboxyfluorescein diacetate, succinimidyl 
ester (CFSE; Molecular Probes, Eugene, Oregon). Cells were suspended in buffered saline 
(PBS) at 10x106/ml and labeled for 10 min with 1 M CFSE at 37°C, washed three times with 
RPMI-1640, 10% FCS and incubated overnight in RPMI-1640, supplemented with 100IU/
ml penicillin and 100μg/ml streptomycin and 10% FCS. Leukemic cells were harvested 
and taken up in PBS and apoptosis was induced by heat shock (two hours at 420C) or by 
incubation for two hours at 370C with ARA-C (10μg/ml; Mayne Pharma, Warwickshire, UK). 
The percentage of necrotic, apoptotic and viable cells was determined before and after 
apoptosis induction by incubation with Syto-62 (5 nM; Molecular Probes, Eugene OR), 
PSC833 (2μM; Novartis, Basel, Switzerland) and 7-amino-actinomycin D (7-AAD; ViaProbe, 
Pharmingen, San Diego CA) for 45 min at 370C and by flow cytometric analysis as described 
previously [28]. Syto-62 is a fluorescent nucleic acid stain that exhibits bright fluorescence 
upon binding to nucleic acids and is retained in viable cells. Together with the dead-cell dye 
7-aminoactinomycine-D (7-AAD) discrimination between viable (Syto+/7AAD-), and early 
(Syto-/7AAD-) and late (Syto-/7AAD+) stages of apoptosis can be made. MoDC were labeled 
with CellVue Plum, (Polysciences, Washington, CO), or with PKH26 (Sigma, MO, USA) 
according to manufacturers’ guidelines. After labeling, DC were washed three times and put 
in CG medium. MoDC were cultured in a 1:1 or 1:3 ratio with pretreated leukemic cells in 
CG medium combined with 100IU/ml penicillin and 100μg/ml streptomycin and 800IU/ml 
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GM-CSF and 500IU/ml IL-4 at 370C, 5% CO
2
. Using different time schedules, cultures were 
supplemented with the indicated maturation stimuli.  
Flow cytometric analysis of MoDC
Four-color flow cytometry was performed on a FACSCalibur flow cytometer (Becton Dickinson, 
San Jose CA). Results were analyzed using CellQuest software (Becton Dickinson). Immature 
DC and DC after maturation were stained by appropriate dilutions or mouse isotype-
matched control moAb of fluorescein isothiocyanate (FITC)-labeled CD14 (Becton Dickinson, 
San Jose CA), CD1a (Sanquin), CD54 (DAKO, Glostrup, Denmark). Phyco-erythrin (PE)-labeled 
monoclonal antibodies (moAb) were used against CD40 (Coulter Immunotech, Marseilles, 
France), CD80, CD86, CCR-7 (CD197, Becton Dickinson, San Jose CA), CLIP (cerCLIP.1; Santa 
Cruz Biotechnology, Santa Cruz CA), CD83 (Coulter Immunotech) and peridinin chlorophyll 
protein (PerCP)-labeled anti-HLA-DR and CD34 (Becton Dickinson). Isotype controls used 
were FITC-labeled IgG1 (DAKO) and IgG2b (Sanquin), PE-labeled IgG1 (Becton Dickinson) and 
IgG2b (DAKO) and PerCP-labeled IgG1 and IgG2a (Becton Dickinson). For HLA-DO and HLA-
DM the following mouse moAb were used: HLA-DM (Becton Dickinson) and IgG1 isotype 
control (Becton Dickinson); FITC-labeled HLA-DO (Becton Dickinson) and IgG2b (Becton 
Dickinson). Cells were stained for DO and DM after fixation with paraformaldehyde followed 
by permeabilization with  PBS-0.1% Saponine (Sigma-Aldrich). Results are presented as 
either the percentage of positive cells compared to the appropriate isotype control or the 
mean fluorescence index (MFI). MFI represents the mean fluorescence obtained through 
binding of the moAb of interest divided by the mean fluorescence of the appropriate isotype 
control. Relative CLIP expression was determined by calculating the ratio between CLIP and 
HLA-DR expression based on both the percentage and MFI of positive cells, as described 
previously [2].
 
DC migration assay
The migratory capacity of DC was evaluated in a transwell system (5 μm poresize, Corning 
Costar, Corning, NY, USA) under serum-free conditions. Cells were allowed to migrate 16h 
towards medium with or without chemoattractant CCL19 (MIP3β, 300ng/ml; R&D Systems, 
Abingdon, UK). The percentage of migrated cells was quantified by flow cytometry using 
a fixed amount of fluorescent beads as a reference (FlowCount Fluorospheres, Coulter, 
Miami, FL, USA). 
CD40 ligation and cytokine release
DC were harvested, washed and seeded in a 96-well round-bottomed plate at 40 x 103 cells 
in 200 μl of medium containing 10% FCS per well. CD40L expressing cells (i.e. muCD154-
transfected J558 cells) were used as stimulator cells at 40 x 103 per well. After twenty-four 
hour, supernatants were harvested and analyzed for IL-12 by ELISA, as described previously 
[29].
Mixed Leukocyte Reaction
The ability of the various AML-loaded DC to stimulate T cells was tested in an allogeneic 
mixed leukocyte reaction (MLR). After isolation of peripheral blood mononuclear cells 
(PBMC) from a buffy-coat, CD8+ cells were obtained by magnetic cell sorting with anti-CD8- 
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Figure 1.  Uptake of leukemic cells by MoDC is a dose-dependent and active process.  Blast cells 
were labeled with CFSE and subsequently apoptosis was induced by heat shock at 42ºC or incubation 
with ARA-C for 2 hours; lysates were generated by three freeze-thawing cycles. Immature MoDC were 
labeled with CellVue Plum (emitting in the FL4 channel) or with PKH-26 (emitting in the FL2 channel) 
and co-incubated with leukemic cells. (A) Uptake of leukemic cells by MoDC is depicted after 24h of 
co-incubation. Results of 1:3 blast:DC ratio (filled bars) are presented as relative uptake compared to 
uptake at blast:DC ratio of 1:1 (open bars) (±SEM) (n=14). (B) CFSE-positive MoDC after co-incubation 
of CFSE labeled lysate (400x magnification). (C) Dot plots representing uptake of CFSE-labeled blasts 
after 2h incubation at 0ºC or (D) 37ºC; insets represent percentage of PKH26-labeled MoDC positive 
for CFSE.
labeled magnetic Microbeads (Miltenyi Biotec GmbH Bergisch Gladbach, Germany) and 
used as responder cells. DC were irradiated at 30Gy and then added to round-bottomed 96-
well tissue-culture plates (Costar, Corning NY) at various stimulator to responder ratios. All 
ratios were tested in triplicate; cells were cultured in RPMI containing 10% FCS. After 5 days 
Thymidine was added (0.4 µCi per well; Amersham Pharmacia Biotech, Buckinghamshire, 
U.K.) for 16h, after which the cells were harvested onto fiberglass filters and 3H-Thymidine 
incorporation was determined using a flatbed scintillation counter (Wallac, Turku, Finland).
Statistical analysis
Statistical significance of differences between the various loading and maturation procedures 
was determined by the paired sample student’s t-test (two-tailed). P-values of <0.05 were 
regarded as significant.
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Results 
Uptake of apoptotic leukemic cells or lysates by MoDC is a dose-dependent and active 
process
To investigate the use of whole leukemic cells as a source of LAA for loading onto DC, we co-
incubated monocyte-derived DC from healthy donors (HD) with either apoptotic leukemic 
cells or lysates, each labeled with different fluorochromes. “Apoptotic samples contained 
less than 25% (range 25-0%) viable cells; the ratio early apoptotic/viable cells was 5 times 
higher after 2h incubation at 420C compared with the control situation (2h at 370C, data not 
Figure 2.  Differential effects of R848 and a cytokine cocktail on uptake of apoptotic AML cells or 
AML lysates. Apoptosis of AML cells was induced by heat shock at 420C or incubation in ARA-C for 
2h. Leukemic cells and MoDC were incubated for 2h, R848 was added for another two hours for the 
R848 and R848 & cytokine cocktail (CC) conditions. Four hours after the start of co-culture CC was 
added for the CC and R848 & CC condition (as depicted in the schematic illustration). Uptake was 
measured by flow cytometry and indicated as the percentage of CFSE-positive MoDC, 48h after the 
start of co-culture. Relative uptake of blast products by MoDC is depicted, i.e. relative increase as 
compared to no addition of cytokines or R848. Mean percentage of CFSE-positive DC in the control 
group is listed in the lower left corner of each graph; horizontal lines represent means; * = p<0.05; 
n=6.
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shown). The percentages of apoptotic cells did not differ between the methods (incubation 
with Cytarabine (ARA-C) or heat shock (HS) at 420C) used to induce apoptosis. Uptake of 
apoptotic cells or apoptotic cell fragments and lysates by MoDC was dose-dependent (figure 
1A). Moreover, uptake of HS-induced apoptotic AML cells was more efficient than AML 
lysates (p=0.03; paired t-test, n=6; tested in MoDC from three different HD). Fluorescence 
microscopic observations revealed actual uptake of AML preparations and not mere binding 
to DC cell surface (figure 1B). Co-incubation of CFSE-labeled leukemic cells with MoDC for 
2h at 370C resulted in high levels of CFSE+ MoDC (35%), whereas co-incubation for 2h at 0ºC 
resulted in only low percentages of CFSE+ MoDC (5%), indicating that the observed uptake 
is an active endocytic process (figure 1c and figure 1d). The efficiency of uptake differed per 
patient; no correlation was observed regarding AML subtype or percentage of apoptotic 
cells. Since HS-induced apoptotic leukemic cells were more efficiently taken up than lysates 
further analysis was focused on uptake of HS-induced apoptotic leukemic cells.
Uptake of heath shock induced-apoptotic AML cells by MoDC is enhanced by R848 and 
diminished by a DC maturation-inducing cytokine cocktail
As TLR-mediated activation of DC has previously been associated with enhanced endocytosis 
[30], we tested the influence of the clinically applicable TLR-L Poly(I:C) and R848 and, as well 
as PGN,  flagellin and LPS on AML cell uptake by MoDC. Administration of a maturation-
inducing cytokine cocktail (CC) two hours after co-incubation of MoDC with lysed or 
apoptotic leukemic cells resulted in a significantly lower uptake by MoDC (figure 2). Of 
all the TLR-L tested (data of Poly(I:C), R848, LPS, PGN and flagellin not shown), only R848 
Figure 3.  Differential effects of R848 and a cytokine cocktail on uptake of apoptotic AML. Uptake of 
blast preparations by MoDC is depicted. Apoptosis of AML cells was induced by heat shock for 2h at 
420C. After 24h of co-incubation of apoptotic blasts and MoDC, either in presence or absence of R848, 
a cytokine cocktail (CC) was added. Uptake was measured by flow cytometry and indicated as the 
percentage of CFSE-positive MoDC, 72h after the start of co-culture. Relative increase to no addition 
of cytokines or R848 is depicted. Mean percentage of CFSE-positive MoDC from the control group is 
listed in the lower left corner of the graph; horizontal lines represent means; * = p<0.05; **= p<0.005, 
n=5.
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Figure 4  Immunophenotype of MoDC after co-incubation with apoptotic blast cells. Marker 
expression levels of (A) CD83, (B) CCR7, (C) CD86, (D) CD40 and (E) relative CLIP are shown after 
uptake of heat shock induced apoptotic blast cells by MoDC, either in presence or absence of R848 
or CC; the time intervals used are depicted in the schematic illustration in panel F. For CD83 and 
CCR7, the percentage of positive cells are shown (panel A and B, respectively). For CD86 and CD40, 
mean fluorescence indices (MFI, as calculated in relation to the isotype control) are shown (panel 
C and D, respectively) (n=10). Fold change compared with immature MoDC (immat) in relative CLIP 
expression is depicted in panel E by calculating the ratio of CLIP and HLA-DR expression as indicated 
in the material and methods section (n=13). Horizontal lines represent mean, *  p<0.05; **  p<0.005,
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was able to enhance uptake of HS-induced apoptotic leukemic cells significantly. Of note, 
addition of R848 enhanced uptake of apoptotic but not of lysed AML cells by MoDC (figure 
2). Remarkably, combined administration of R848 and CC abolished this positive effect. We 
hypothesized that prolonged incubation with R848 combined with delayed administration 
of CC might result in higher uptake. Therefore, we pre-incubated HS-induced apoptotic 
leukemic cells and MoDC with R848 for 24h, after which CC was added for 48h (figure 3). In 
this time frame, we found more efficient uptake of HS-induced apoptotic leukemic cells by 
R848-treated MoDC as compared to control and CC-treated MoDC. However, this enhanced 
uptake was counteracted by sequential incubation with CC.
Maturation induction of AML-loaded MoDC 
Next, we investigated if incubation of MoDC from HD with AML cells with or without R848 
and/or CC affected their maturation state. Uptake of HS-induced apoptotic cells by immature 
MoDC resulted in significant decrease of CD86 and CD40 expression (figure 4). Addition of 
CC 24h after loading resulted in MoDC maturation as shown by de novo expression of CD83 
and chemokine receptor CCR7 (figure 4). Only partial maturation was induced after addition 
of R848 alone, as demonstrated by low-level CD83 expression and the absence of CCR7. 
Of note, pre-incubation with R848 blocked full maturation by CC as shown by significantly 
lower levels of CD83, CCR7, CD40 and CD86 (figure 4). 
MHC class II antigen presentation requires the exchange of CLIP for an antigenic peptide 
in the peptide-binding groove, a process that is catalyzed by HLA-DM. HLA-DO, another 
nonclassical MHC class II molecule, is able to down-regulate the catalytic function of HLA-
DM [2].  The intensity of HLA-DR varied between different maturation stimuli (data not 
shown). Relative to HLA-DR, moderate CLIP down-regulation was observed upon loading of 
immature DC with HS-induced apoptotic AML cells, but a more profound decrease in CLIP 
expression was seen upon maturation induction by R848 and/or CC (figure 4E). These data 
indicate efficient HLA-DR mediated presentation of endocytosed antigens after maturation. 
Both HLA-DM and -DO levels were in accordance with the observed relative CLIP levels (data 
not shown). 
Function of heat shock-induced apoptotic AML-loaded versus unloaded MoDC 
To further investigate effects of the applied loading strategies on HD-derived MoDC, we 
examined their migratory and T cell stimulating capacity. Upon CC-induced maturation, the 
lymph node homing receptor CCR7 was upregulated (figure 4B). In line with this, maturation 
with CC resulted in a high migration rate towards the CCR7 ligand CCL19; combined 
maturation with R848 resulted in lower migration efficiencies (figure 5A).
In response to overnight CD40 ligation, HS-induced apoptotic AML-loaded MoDC stimulated 
with R848 or CC released reduced levels of the Th1-skewing and CTL-activating cytokine IL-
12p70  in comparison to non-stimulated unloaded MoDC (mean relative decrease (±SD) 0.65 
(±0.27) and 0.52 (±0.16), respectively; median IL12 production unloaded non-stimulated 
MoDC: 520 (286-5199) pg/ml) (figure 5B). Of note, IL-12p70 release was almost completely 
abolished by the combined sequential use of R848 and CC (mean relative decrease 0.97 
(±0.06)). However, incubation with R848 and CC increased the ability of MoDC to prime naive 
T cells in an allogeneic MLR in accordance with observations for phenotypic maturation: 
addition of CC after 24h pre-incubation with R848 enhanced T cell stimulating capacity but 
not to the same level as seen for CC alone (figure 5C). 
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Figure 5  Function of unloaded and heat shock induced apoptotic blast loaded MoDC after incubation 
with or without R848 and/or cytokine cocktail. (A) Migration of DC towards CCL19 was tested in a 
0.5μm-pore transwell system; percentages of MoDC that migrated towards CCL19 (grey bars) and 
medium (white bars) are depicted; * = p<0.05.(B) IL-12p70 production was measured after overnight 
CD40 ligation; relative IL-12p70 release compared with immature unloaded MoDC is depicted, mean 
IL-12p70 release in the control group is listed in the lower left corner of the graph; * = p<0.05; ** 
= p<0.005. (C) The ability of DC to induce proliferation in a mixed leukocyte reaction is shown after 
5 days of co-incubation of MoDC and allogeneic CD8+ T cells in various MoDC: T cell ratios. [3H]
thymidine was added and incorporation was measured after 16h. Each ratio was tested in triplicate 
and means±SD are shown. One representative experiment out of six is shown.
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Discussion  
This study was undertaken to investigate various MoDC vaccine preparation strategies in 
order to create an optimized MoDC vaccine for treatment of MRD in AML. The ability of 
HD-derived MoDC to take up whole cell derived material in combination with TLR-L was 
investigated in order to enhance uptake of LAA. Furthermore, we explored the capability of 
MoDC to mature under influence of various TLR-L and a standard cytokine cocktail (CC) as 
positive control. 
Immature DC are capable of taking up Ag, e.g. from infected cells or tumor cells, in the 
form of apoptotic bodies or necrotic cell particles [31;32]. Next to the Ag source, agents 
such as TLR-L or cytokines can affect the outcome AML of this uptake [33]. Upon encounter 
with for instance microbial agents or other inflammatory stimuli, DC mature from cells 
specialized in Ag uptake into cells specialized in T cell stimulation. Inflammatory cytokines 
are considered as strong maturation inducers but, as we demonstrated, CC inhibits further 
Ag uptake by DC. In contrast, TLR-L are known to enhance uptake of antigenic material and 
subsequently induce maturation [30]. In accordance with this we found enhanced uptake 
after co-incubation with TLR- L R848, whereas addition of CC after 24h of co-incubation with 
R848 halted further uptake.
The method by which leukemic cell death was induced, influenced the amount of cellular 
material taken up by MoDC: less uptake was achieved in DC after co-incubation with lysate 
as compared to apoptotic cells. In the process of dying, apoptotic cells are known to shed 
immunogenic particles, i.e. so-called blebs. Murine studies have demonstrated that these 
blebs are taken up more efficiently by DC than the remaining, larger, apoptotic bodies 
[34]. This may offer an explanation for our observation that apoptotic AML cells are more 
efficiently taken up by MoDC than AML lysates. Additional knowledge about the ability of 
DC to prime LAA-specific T cells is clearly warranted to further differentiate between both 
whole leukemic cell derived antigen sources.
One of the key players in the MHC class II presentation pathway is CLIP and its regulators 
HLA-DM and HLA-DO. TLR-L regulate processing of the Invariant chain (Ii) and influence the 
exchange of CLIP with antigenic peptides. TLR signaling is necessary to direct internalized 
antigens via the classical pathway for presentation by MHC II, whereas tolerogenic DC can 
upregulate CLIP expression and hamper T cell signaling [35-37]. Consistent with this, CLIP 
expression was decreased when DC and apoptotic AML cells were co-incubated in the 
presence of R848 and/or CC, indicative of a putative increase in LAA presentation by the 
loaded MoDC. 
Maturation of DC is necessary to enable migration to lymph nodes and activation of T 
cells. Consistent with literature, CC induced upregulation of CD86, expression of CD83, 
CCR7 and hence enhanced migratory capacity, the latter most likely due to the presence 
of Prostaglandin-E2 (PGE
2
) in the cocktail. R848 is able to induce phenotypic maturation, 
but far less prominently than CC [38;39]. In this setting our results indicate that R848 is 
rather an enhancer of antigen uptake than a straightforward maturation inducer, whereas 
CC only promotes maturation. We hypothesized that both high uptake and maturation 
might be achieved by combining prolonged R848 incubation (24h) followed by addition 
of CC. However, maturation was only slightly increased compared to R848 alone. These 
data indicate that TLR-L antagonize the maturation efficacy of CC. Recent studies showed 
inhibitory effects of TLR-L LPS and Poly(I:C) on DC by activation of so-called suppressors 
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of cytokine signaling (SOCS). It has been described that SOCS1, 2 and 3 are required for 
appropriate TLR signaling in maturing human DC via both the MyD88-dependent and 
-independent signaling pathway [40-43]. By first enhancing uptake with TLR-L the DC 
might become resistant to cytokines due to activation of SOCS1/2, resulting in disturbed 
maturation. Moreover, TLR-mediated induction of maturation-inhibitory cytokines (e.g. 
IL-10) might be responsible for this maturation inhibitory effect [44;45]. We did attempt 
inhibition of putatively involved down-stream signaling elements (a.o. p38 MAPK, PI3K, 
STAT3) to abolish this R848-mediated block in CC-induced DC maturation, but to no avail. 
PGE
2
, part of the cytokine cocktail, is known to impair production of IL-12p70 [46;47]. As 
a consequence of reduced IL-12p70 levels, immunosuppressive cells such as T regulatory 
cells might be recruited [48;49]. Various combinations of cytokines and other DC-maturing 
factors such as TLR-L direct MoDC maturation towards a migratory and/or Th1-activating 
cytokine release profile [38;50]. Recently, it was shown that simultaneous addition of 
PGE
2
 and TLR 3/7/8 ligands resulted in higher levels of co-stimulatory molecules on DC 
as well as IL-12p70 production and migration capacity [38;51]. We hypothesized that by 
pre-incubating MoDC with R848, followed by maturation with CC (containing PGE
2
), both 
effective IL-12 p70 production, migratory capacity as well as improved AML cell uptake 
might be established. Addition of CC after prolonged incubation with R848 enhanced the 
migratory capacity but not to the same levels as CC alone. Furthermore, IL-12p70 production 
was abolished as compared to CC stimulation alone. This might be explained by the longer 
incubation time and thereby exhaustion of MoDC before measuring the overnight IL-12p70 
production. However, in a mixed leukocyte reaction we demonstrated that the CD8+ T cell 
stimulatory capacity of R848 and/or CC matured MoDC was significantly higher than that 
of controls, indicating that irrespective of IL-12p70 production, R848 and/or CC matured 
DC are able to stimulate CD8+ T cells. Since IL-12p70 is an important cytokine in Th1 and 
CTL activation, careful analysis of the ability to prime functional leukemia-specific T cells is 
needed to design optimal MoDC vaccine preparation strategies. 
In conclusion, our results demonstrate that uptake of leukemic cells by MoDC and their 
maturation state is differentially affected by TLR-L R848 and CC. As compared to CC alone, 
the sequential use of R848 and CC interfered with effective MoDC maturation as indicated 
by diminished migration and T cell stimulatory capacity and abolished IL-12p70 production. 
These findings do not justify incorporation of TLR7/8-L in DC-maturing cocktails for clinical 
development of whole-cell AML-loaded MoDC vaccines.
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Abstract
Since few leukemia-associated antigens (LAA) are characterized for acute myeloid leukemia 
(AML), apoptotic tumor cells constitute an attractive LAA source for DC-based vaccines. 
However, loading DC with apoptotic tumor cells may interfere with DC function. Previously, 
it was shown in mice that apoptotic blebs induce DC maturation, whereas apoptotic cell 
remnants (ACR) do not. Here, we analyzed human monocyte-derived DC (MoDC) functionality 
in vitro, after ingesting either allogeneic AML-derived ACR or blebs. We show that MoDC 
ingest blebs to a higher extent, and are superior in migrating towards CCL19, as compared 
to ACR-loaded MoDC. Although MoDC cytokine production was unaffected, co-culturing 
bleb-loaded MoDC with T-cells led to an increased T cell proliferation and IFNγ production. 
Moreover, antigen-specific CD8+ T-cells frequencies increased to 0.63% by priming with 
bleb-loaded MoDC, compared to 0.16% when primed with ACR-loaded MoDC. Importantly, 
CD8+ T cells primed by bleb-loaded MoDC recognized their specific epitope at one to two 
orders of magnitude lower concentrations compared to ACR-loaded MoDC. In conclusion, 
superior ingestion efficiency and migration, combined with favorable T cell cytokine release 
and CD8+ T cell priming ability and avidity, point to blebs as the preferred component of 
apoptotic leukemic cells for LAA loading of DC for the immunotherapy of AML.
Introduction
As key regulators of immune responses, dendritic cells (DC) have the ability to ingest and 
process exogenous proteins and to present derived peptides thereof at the cell surface in 
complex with HLA class II molecules, or via cross-presentation in the context of HLA class I 
molecules. DC can potentiate antigen-specific T cell responses and are therefore of major 
interest as mediators of anti-tumor immunity in vaccination strategies [1,2]. In order to 
induce tumor-specific immune responses, DC are required to present tumor-associated 
antigen(s) (TAA). Next to the generation of DC from chronic- and acute myeloid leukemia 
(CML and AML, respectively) cells [3, 4], multiple strategies for loading DC with TAA have 
been investigated, such as peptide pulsing [5, 6], TAA-specific mRNA electroporation [7–9] 
and loading of necrotic or apoptotic tumor cells via phagocytosis [4,5,10,11]. Currently, 
targeting  DC in vivo, using (antibody-based) conjugates targeting DC-specific receptors (e.g. 
DEC-205, DC-SIGN, CD40 and Clec-9a) gains more interest [12–15]. Although the field of 
DC vaccination is clearly moving forward, many challenges remain, e.g. increasing clinical 
responses by overcoming T cell/tumor cell regulatory mechanisms, broadening the array of 
TAA used for vaccination, and inducing (long-term) immune protection in cancer patients. 
In most studies, the focus has been on targeting solid tumors (mostly melanoma), but DC 
vaccination is a potential therapy for treating AML patients in a minimal residual disease 
setting as well, either as a mono- or combination therapy. Recently, a small-scale phase 
I clinical study demonstrated vaccination of elderly AML patients with autologous AML 
blast cell-loaded monocyte-derived DC (MoDC) to be safe, and to induce (transient) disease 
stabilization and specific CD8+ T cells [16]. The use of leukemic blasts as a source of leukemia-
associated antigen (LAA) for DC loading is particularly attractive, as they will contain both 
known and as yet unidentified LAA. Using tumor cells as a source of LAA could, moreover, 
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pave the way to generate a tumor- and patient-specific therapy in a minimal residual disease 
setting in AML and other tumor types. However, loading DC with apoptotic blasts could 
impair DC function, due to the immunosuppressive nature of apoptotic cells [17–22].
In recent years, more knowledge has been gained on the tightly regulated process of 
apoptosis, which is controlled by the balance between the pro- and anti-apoptotic 
members of the Bcl-2 family and is executed by initiator and effector caspases [23, 24]. 
Apoptotic cells undergo multiple macro- and microcellular rearrangements, e.g. cellular 
condensation, pyknosis, karyorrhexis, redistribution of specific organelles into peripheral 
membrane protrusions (blebbing) and the exposure of apoptosis-specific structures on the 
cell membrane e.g. phosphatidyl serine, calreticulin as well as alterations in the glycocalyx 
that act as “eat-me” signals for phagocytes [24–27]. 
The peripheral membrane protrusions (or blebs) are formed during the active blebbing 
phase, a process dependent on the activation of caspases, phosphorylation of the myosin 
light chain and death-associated protein kinase [26,28,29]. During the blebbing phase mainly 
the endoplasmic reticulum (ER), RNA and chromatin are enclosed in blebs, which become 
detached from the main apoptotic cell at later stages of apoptosis [26,30]. Although the 
exact functional relevance of blebbing during apoptosis remains elusive, it was shown that 
ingestion of blebs by mouse bone marrow-derived DC (BMDC) induced DC maturation, and 
subsequent T helper-17 cell activation when co-cultured with splenocytes in vitro, whereas 
the remaining apoptotic cell remnants (ACR) did not. Of note, there is some confusion in 
literature regarding the use of the term apoptotic bodies, which is at times used to describe 
both ACR and blebs [30,31]. Although multiple studies have analyzed the effect of loading 
apoptotic cells or apoptotic bodies (ACR) on DC, no studies have been conducted thusfar 
which analyzed the selective use of apoptotic blebs (microvesicles that require additional 
isolation steps) as a source of TAA. Since blebs have been shown to activate BMDC in mice 
[30] , and in view of a growing recognition of the need to utilize the unique mutanome of 
individual tumors for vaccination strategies,  DC loaded with AML blast-derived blebs may 
constitute an effective vaccine. Here, we compared MoDC phenotype and function in vitro, 
after ingestion of either ACR or blebs derived from a human AML cell line.
Material and methods
Cell lines
The human HLA-A2 negative AML cell line HL60 (ATCC, Wesel, Germany) was cultured in 
RPMI containing 10% FCS, 100 IU/ml penicillin and 100 μg/ml streptomycin (all Gibco, 
Paisley, UK) , further referred to as complete medium. 
Generation of MoDC
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy 
volunteers by centrifugation on a Ficoll-Paque density gradient medium, after informed 
consent. Subsequently, monocytes were isolated from PBMCs by positive selection using 
magnetic activated cell sorting with CD14 microbeads (Miltenyi biotec, Utrecht, The 
Netherlands). MoDC were generated by culturing monocytes for 5 days at 37°C in complete 
medium, in the presence of 800 U/ml GM-CSF (10 * 106 U/mg, Peprotech, The Netherlands) 
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and 500 U/ml IL-4 (5 * 106 U/mg, Peprotech, The Netherlands). After 5 days of culture, MoDC 
were either used directly or stored in liquid nitrogen until further use. 1 hour after loading 
MoDC with ACR or blebs, maturation was induced by a cytokine cocktail consisting of IL-1β 
(10 ng/ml, 1 * 109U/mg, Sanquin, Amsterdam, The Netherlands), IL-6 (10 ng/ml, 2 * 106 U/
mg, R&D systems, Abingdon, UK), TNFα (200 U/ml, 20 * 106 U/mg, Sanquin, Amsterdam, 
The Netherlands) and PGE
2
 (10 ng/ml, Sigma-Aldrich, Zwijndrecht, The Netherlands). 
Preparation of apoptotic cell fractions
Apoptosis of HL60 cells was induced by adding 3 μM mitoxantrone dihydrochloride 
(mitoxantrone; Sigma-Aldrich, Zwijndrecht, The Netherlands) per 2 * 106 HL60 cells per 
ml of complete medium, for 48 hr at 37°C, 5% CO2. We were unable to perform priming 
experiments with MoDC loaded with either ACR or blebs from mitoxantrone-induced 
apoptotic HL60 cells, since T cells did not expand, or underwent apoptosis during co-
culture (data not shown). This is likely to be the result of leaked mitoxantrone from the 
loaded MoDC. We therefore alternatively induced apoptosis of HL60 cells by heat shock, as 
described before [11]. In short, cells were washed with RPMI 1640 and resuspended at 5 * 
106 cells/ml in RPMI 1640, and subsequently incubated for 2 hours at 42°C. Next, the cells 
were irradiated at 5000 rad, washed, resuspended at 2 * 106 per ml in full medium, and 
incubated for 48 to 72 hours at 37°C, 5% CO
2
.
The percentage of apoptotic cells was determined by Syto16 labeling (Molecular Probes, 
Leiden, The Netherlands). In short, 50 * 103 cells were resuspended in 1 ml PBS, containing 
10% FCS (Greiner Bio-One, Alphen a/d Rijn, The Netherlands), 20 mM HEPES (Sigma-Aldrich), 
1 ml/ml glucose anhydrous (Baker B.V. Deventer, The Netherlands), 4 mM L-glutamine 
(Invitrogen), MEM amino acids (Sigma-Aldrich). Syto16 (42 nM) and the PgP pump inhibitor 
PSC833 (5 μM; a kind gift from Novartis, Basel, Switzerland) were added, and the cells 
were incubated for 30 minutes at 37 °C, 5% CO
2
 and washed with an excess of PBS. The 
subsequent caspase-dependent loss of syto16 labeling was analyzed on a BD FACSCanto™ II 
flow cytometer (BD Biosciences), to assess the level of apoptosis. In all cases, > 90% of the 
cells was apoptotic.
ACR and blebs were isolated by differential centrifugation. The centrifugal force for 
separating ACR and blebs was determined by assessing the size and appearance of 
the separated fractions by a Zeiss Axioskop 50 fluorescence microscope (Zeiss, The 
Netherlands), and a CM100 BioTwin electron microscope (Philips, The Netherlands). ACR 
were isolated by centrifugation at 600g at 4 ˚C for 10 minutes, after which the apoptotic 
blebs were isolated from the resulting supernatant by centrifugation at 4,000g at 4 ˚C for 
10 minutes. Apoptotic fractions were washed twice with excess PBS prior to determining 
the protein concentration. Apoptotic cell material was lysed by 5 cycles of snap-freezing 
in liquid nitrogen, followed by thawing in a water bath at 37 °C. Subsequently, cellular 
material was lysed by 5 cycles of sonication (5 second pulse, followed by 5 seconds rest) 
at 18 micron (Sanyo MSE Soniprep 150, Amsterdam, The Netherlands) in the presence of 
a protease inhibitor cocktail, following manufacturers’ protocol (Complete Mini Protease 
Inhibitor Cocktail Tablets, Roche Diagnostics, Almere, The Netherlands). Subsequently, the 
protein concentration was determined by analyzing the absorption at 280/260 nm from 
50 μl of lysed samples, using a ND-1000 Nanodrop spectrophotometer (Thermo Fisher 
Scientific, Breda, The Netherlands). ACR and blebs were either used directly or frozen in 
liquid nitrogen and thawed prior to usage.
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Uptake and internalization of ACR and blebs by- and immunophenotyping of MoDC
Prior to inducing apoptosis, HL60 cells were labeled with 1 µM carboxyfluorescein 
succinimidyl ester (CFSE; Invitrogen, Breda, The Netherlands) and Hoechst 33342 1 µg/ml 
(Molecular Probes, Eugene, OR, USA) for fluorescence microscopic imaging and MoDC were 
labeled with 1 µM CellVue Plum (eBioscience, Vienna, Austria). Analysis of the ingestion of 
apoptotic material by MoDC was analyzed by flow cytometry using a BD FACSCanto™ II flow 
cytometer and BD FACSDiva™ software. 
Internalization of the apoptotic fractions was visualized using confocal microscopy. Thawed 
ACR and blebs were labeled with 1 μM PKH26 red fluorescent cell linker kit (Sigma-Aldrich), 
following the manufacturer’s protocol. MoDC were labeled with 2 µM CFSE, and co-
cultured with PKH26-labelled ACR or blebs for 8 hours. Loaded MoDC were harvested and 
washed, and transferred to 4 wells Lab-Tek™ Permanox Chamber Slides (Thermo Scientific, 
The Netherlands). After overnight adherence, the supernatant was carefully removed and 
the loaded MoDC were fixed using 1% paraformaldehyde solution for 15 minutes at 4 °C, 
washed with PBS and dried. Vectashield (Vector Laboratories, United Kingdom) was added 
on the slides, which were covered by a coverslip and analyzed using a Leica TCS SP2 confocal 
microscope (Leica Microsystems, The Netherlands).
MoDC phenotype was determined by flow cytometric analysis 48 hours after loading 
the apoptotic material, using fluorochrome-conjugated antibodies CD1a, CD54 (Dako 
Cytomation), CD14, CD80,  CD86, CD209, (BD Biosciences) CD40, CD83 (Beckman Coulter) 
and the unlabeled CCR7 antibody (BD Biosciences)  followed by PE-conjugated goat anti-
mouse IgM (Beckman Coulter).
Transwell migration assay
Migratory capacity of MoDC after ingesting apoptotic material was analyzed using a 
transwell migration assay, using membranes with a 5 μM pore size (Corning). Specific 
versus non-specific migration of 1 * 105 MoDC (deposited in the upper compartment) was 
determined by performing the transwell migration assay in the presence or absence of 
250 ng/ml MIP-3β (added to the lower compartment, CCL19, R&D systems, Abingdon, 
UK). After 5 hours, the number of migrated viable MoDC was quantified using FlowCount™ 
beads (Dako, Enschede, The Netherlands) on a BD FACSCanto™ II flow cytometer. 
MoDC cytokine release 
4 * 104 (loaded) MoDC were cultured overnight with 4 * 104 CD40-ligand expressing J558 
cells (irradiated at 50 Gy) [32] in the presence of 1000 U/ml IFN-γ (Sanquin, Amsterdam, 
The Netherlands) in a 96-wells plate. Next, the plates were spun at 1000 x G and the 
supernatants were directly analyzed for the presence of cytokines using an inflammatory 
cytokine bead array (BD Biosciences, Breda, The Netherlands), following the manufacturer’s 
protocol.
Mixed lymphocyte reaction and cytokine release
Peripheral blood lymphocytes (PBL) from healthy donors were labeled with 1 μM CFSE and 
subsequently co-cultured with allogeneic (loaded) MoDC for 6 days, after which the cells 
were harvested and labeled with CD3, CD4, and CD8 (BD biosciences), and the CFSE dilution 
over the daughter CD3+CD4+ and CD3+CD8+ T cells was measured using flow cytometry (BD 
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FACSCanto™ II) and analyzed using BD FACSDiva™ software. Moreover, supernatants were 
harvested for cytokine analysis using a Th1/Th2/Th17 cytokine bead array (BD Biosciences, 
Breda, The Netherlands), following the manufacturers protocol.
CD8+ T cell priming and avidity analysis
Autologous in vitro T cell priming experiments were conducted as described previously [33]. 
CD14+ monocytes from healthy HLA-A2 positive donors were isolated and differentiated 
into MoDC, as described above. CD8+ cells were positively selected from CD14- PBMC using 
CD8 microbeads (Miltenyi biotec), frozen and stored in liquid nitrogen until further use. The 
remaining PBL were frozen and stored in liquid nitrogen. In order to analyze MART-1-specific 
CD8+ T cell outgrowth, we generated a MART-1 expressing HL60 cell line (as well as a K562 
cell line, referred to as K562-M, as a (HLA-A2) negative control for the analysis of cytotoxicity) 
by retroviral transduction of LZRS-MART-1-IRES-ΔNGFR, as reported previously [34]. After 5 
days of culture, MoDC were isolated and loaded with 40 μg MART-1 positive ACR or blebs 
per 0.2 * 106 MoDC, and one hour after loading MoDC with ACR or blebs, maturation 
was induced by a cytokine cocktail consisting of IL-1β (10 ng/ml, 1 * 109 U/mg, Sanquin, 
Amsterdam, The Netherlands), IL-6 (10 ng/ml, 2 * 106 U/mg, R&D systems, Abingdon, UK), 
TNFα (200 U/ml, 20 * 106 U/mg, Sanquin, Amsterdam, The Netherlands) and PGE
2
 (10 ng/
ml, Sigma-Aldrich, Zwijndrecht, The Netherlands). After overnight co-culture, loaded MoDC 
were isolated and seeded at 0.1 * 106 per 24-well (8 x 24-wells per condition) in IMDM 
(Gibco, Paisley, UK), containing 50 μM β2-Mercaptoethanol (Merck, The Netherlands), 100 
IU/ml penicillin (Gibco) and 100 μg/ml streptomycin (Gibco), 5% Yssels supplement [33], 
and 1% pooled human AB serum (MP biomedicals, Amsterdam, The Netherlands), further 
referred to as Yssels medium. Next, isolated CD8+ cells and CD14-/CD8- PBL were thawed and 
washed twice with complete medium. CD8+ cells were resuspended in Yssels medium and 
added to the (loaded) MoDC at 1 * 106 per 24-well. CD14+ monocytes from healthy HLA-A2 
positive donors were isolated and differentiated into MoDC, as described above. CD8+ cells 
were positively selected from CD14- PBMC using CD8 microbeads (Miltenyi biotec), frozen 
and stored in liquid nitrogen until further use. The remaining PBL were frozen and stored 
in liquid nitrogen. In order to analyze MART-1-specific CD8+ T cell outgrowth, we generated 
a MART-1 expressing HL60 cell line (as well as a K562 cell line, referred to as K562-M, as 
a (HLA-A2) negative control for the analysis of cytotoxicity) by retroviral transduction of 
LZRS-MART-1-IRES-ΔNGFR, as reported previously [34]. After 5 days of culture, MoDC were 
isolated and loaded with 40 μg MART-1 positive ACR or blebs per 0.2 * 106 MoDC, and one 
hour after loading MoDC with ACR or blebs, maturation was induced by a cytokine cocktail 
consisting of IL-1β (10 ng/ml, 1 * 109 U/mg, Sanquin, Amsterdam, The Netherlands), IL-6 
(10 ng/ml, 2 * 106 U/mg, R&D systems, Abingdon, UK), TNFα (200 U/ml, 20 * 106 U/mg, 
Sanquin, Amsterdam, The Netherlands) and PGE
2
 (10 ng/ml, Sigma-Aldrich, Zwijndrecht, 
The Netherlands). After overnight co-culture, loaded MoDC were isolated and seeded at 
0.1 * 106 per 24-well (8 x 24-wells per condition) in IMDM (Gibco, Paisley, UK), containing 
50 μM β2-Mercaptoethanol (Merck, The Netherlands), 100 IU/ml penicillin (Gibco) and 100 
μg/ml streptomycin (Gibco), 5% Yssels supplement, and 1% pooled human AB serum (MP 
biomedicals, Amsterdam, The Netherlands), further referred to as Yssels medium. Next, 
isolated CD8+ cells and CD14-/CD8- PBL were thawed and washed twice with complete 
medium. CD8+ cells were resuspended in Yssels medium and added to the (loaded) MoDC 
at 1 * 106 per 24-well.
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Cytotoxicity assay
Cytotoxicity was determined by co-culturing primed and sorted CD8+ T cells (labeled with 
50 nM CFSE (Invitrogen)), at effector to target ratios starting from 0:1 through 10:1, with 
200 nM CellVue (eBiosciences) labeled melanoma Mel AKR cells (HLA-A2 positive & MART-
1 positive; Netherlands Cancer Institute, Amsterdam, The Netherlands), JY cells (HLA-A2 
positive, MART-1 negative), or K562-M (HLA-A2 negative & MART-1 positive). After an 
overnight co-culture, target cells were shortly (< 5 minutes) incubated with 50 μl 0.05% 
Trypsin-EDTA solution (Invitrogen), suspended by careful tapping and washed with 150 μl 
complete medium. Next, the cells were resuspended in a 2% BD Via-Probe/PBS/0.1%human 
serum albumin solution, incubated for 10 minutes and the percentage of BD Via-Probe-
positive CellVue+/CFSE- target cells was measured using flow cytometry (LSRFortessa™, BD 
Biosciences).
Statistical analysis
Statistical analysis was performed in GraphPad Prism version 5 for Windows (GraphPad 
Software Inc.), using a paired two-tailed Student T-test. P-values ≤ 0.05 were regarded as 
significant.
Results
ACR and blebs isolated from HL60 AML cells represent distinct cellular components
After isolation of ACR and blebs from mitoxantrone treated apoptotic HL60 cells, we 
analyzed their morphological appearance and size, using transmission electron microscopic 
imaging (figure 1A-B). ACR appeared as a heterogeneous population of large cellular bodies 
of approximately 2 to 10 μm in size with a ruffled plasma membrane that appeared to 
be locally disintegrated (figure 1A, arrows). Electron dense areas resided within the ACR 
(figure 1A, asterisk), that were enclosed by a membrane and represent the latest stages of 
chromatin translocation to the periphery of the cell, which was confirmed by fluorescence 
microscopy after the labeling of proteins (CFSE) and DNA (Hoechst 33342) in apoptotic ACR 
(figure 1C).
Apoptotic blebs are described as 100 nM to 1000 nM microvesicles, containing both 
chromatin and endoplasmic reticulum (ER). Both cellular components are actively 
translocated from the apoptotic cell into peripheral vesicles during apoptosis, and become 
enclosed by a sheet of ER membrane and a sheet of plasma membrane [26;36]. The isolated 
fraction contained a heterogeneous population of blebs 200 nM to 600 nM in diameter 
(figure 1B). They were indeed enclosed by a characteristic double membrane, as described 
previously [26], and as shown in figure 1B, open arrows. Moreover, characteristic structures 
resembling ER and ribosomes were also observed (figure 1B, closed arrows). Using electron 
microscopic imaging, we could not detect blebs containing electron dense areas (chromatin). 
Fluorescent imaging showed few blebs to stain positive for Hoechst 33342 (figure 1D).
Blebs are ingested by a higher percentage of MoDC than ACR
We analyzed whether MoDC were able to internalize both mitoxantrone-induced ACR and 
blebs, by co-culturing CFSE-labeled MoDC with PKH26-labelled apoptotic material. Indeed, 
analysis using confocal microscopy demonstrated that both ACR (figure  2A, upper panel) 
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and blebs (figure  2A, lower panel) could be internalized by MoDC. Next, we quantified the 
ingestion of ACR or blebs using flow cytometry (figure  2B), by co-culturing MoDC overnight 
with either CFSE-labeled ACR or blebs. During co-culture, MoDC did not receive any additional 
maturation stimuli (further referred to as immature DC), or received a maturation inducing 
cocktail one hour after initiation of the co-culture, consisting of the cytokine cocktail IL-1β, 
IL-6, PGE-2, and TNF-α (further referred to as maturing DC). Blebs were ingested by 70% 
(mean, range 41% - 95%) of the immature MoDC whereas ACR were ingested by 46% (mean, 
range 26% - 86%) (figure  2C, immature). These percentages decreased to a mean of 63% 
(range 13% - 92%) and 35% (range 6% - 80%), respectively, after inducing MoDC maturation 
(figure  2C maturing). Similar results were obtained when loading MoDC with ACR or blebs 
derived from heat shock (HS)-induced apoptosis (data not shown). Moreover, the uptake 
of blebs was significantly increased, whereas there was no significant difference in the 
uptake of ACR, compared to unseparated apoptotic cells (figure  2D). Therefore, subsequent 
experiments were performed using the seperated fractions.
Figure 1: Analysis of isolated apoptotic fractions. (A-D) Transmission electron microscopic analysis 
of isolated ACR (A & B) and blebs (C & D). The isolated ACR fraction contained large cellular bodies of 
4 – 10 µm in diameter, of which the membrane appeared to be locally disintegrated (A & B, arrows). 
Electron dense areas reside within the ACR (A & B, asterisks), that are enclosed by a membrane and 
represent the latest stages of chromatin translocation to the periphery of the cell. The bleb fraction 
contains an heterogeneous population of vesicles which are 0.2 µm to 0.6 µm in diameter and have a 
double membrane (C & D open arrows). Structures resembling ER and ribosomes (C, closed arrows) 
could be detected in some blebs. 
(E-F) Fluorescence labelling with CFSE (green; protein) and Hoechst 33342 (blue; DNA) of ACR (E) and 
blebs (F) derived from apoptotic HL60 cells. 48 hours after inducing apoptosis using mitoxantrone, 
most ACR lost all (E; solid arrows) or most (E; open arrows) chromatin. The isolated bleb fraction 
contained mainly vesicles that did not stain positive for Hoechst 33342 (F; open arrows). Few blebs 
did enclose detectable amounts of chromatin (F; solid arrows).
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Figure 2: Uptake of apoptotic material by  MoDC. (A) CFSE-labeled MoDC (green) were loaded with 
either PKH26-labelled ACR or blebs (red) and analyzed using confocal microscopy. Both ACR (upper 
panel) and blebs (lower panel) are internalized by MoDC (yellow), as visualized by the enclosure of  both 
apoptotic  fractions by MoDC in X, Y and Z directions. Optical magnification 42x and 3.5x digital zoom. 
(B) Representative flow cytometric analysis of the uptake quantification of the apoptotic fractions 
by MoDC. (C) Uptake by immature  and maturing DC of blebs and ACR (n = 14). (D) The percentage 
ingestion of isolated ACR and blebs, as compared to the unseperated apoptotic cell preparation, by 
maturing MoDC (n  = 5).
Increased CCR7 expression and migration towards CCL19 by MoDC which have ingested 
blebs.
Next, we determined whether ingestion of mitoxantrone-induced ACR or blebs altered 
MoDC phenotype. After 48 hours of co-culture, we could not detect differences in the 
expression levels of the tested markers (CD1a, CD14, CD40, CD54, CD80, CD83, and CD86, 
data not shown), between ACR- or bleb-loaded MoDC, except for the lymph node homing 
receptor CCR7. CCR7 expression was upregulated on mature MoDC that had ingested blebs, 
compared to unloaded or ACR-loaded MoDC (figure 3A). In line with the latter, an increase 
in the migration of bleb-loaded mature MoDC towards the lymph node homing chemokine 
CCL19 (Mip-3β) was observed; mean 14% (range 2% - 35%) of the MoDC that had ingested 
blebs were able to migrate towards CCL19, as compared to only 5% (range 1% - 16%) of 
MoDC that had ingested ACR (figure 3B).
Unaffected production of pro-inflammatory cytokines by MoDC after ingesting either 
ACR or blebs 
To avoid interference of trace amounts of mitoxantrone with MoDC function (as described 
in the methods and materials section), we assessed whether ingestion of either HS-derived 
ACR or blebs induced an altered cytokine profile, as compared to unloaded MoDC. To this 
end, ACR- or bleb-loaded MoDC were activated by the CD40 ligand expressing cell line J558 
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Figure 4: Cytokine production by (loaded) MoDC after CD40 ligation. (A-C) Cytokine production by 
unloaded, ACR-, or bleb-loaded immature MoDC after CD40 ligation.  Supernatants were analyzed 
after an over-night incubation in the presence of 1000u/ml IFN-γ.
No differences could be detected in the production of the measured cytokines IL-10 (A), IL-6 (B) or 
IL-12p70 (C). The mean cytokine concentrations of unloaded MoDC are shown and set to one (n = 3).
Figure 3: CCR7 expression on (loaded) MoDC, and subsequent migration towards CCL19. (A) Whereas 
no difference in expression of the lymph node homing chemokine receptor CCR7 could be detected 
in immature MoDC (closed bars), loading of mature MoDC (open bars) with either ACR or blebs led to 
an increased expression of CCR7. This increase was most pronounced when MoDC were loaded with 
blebs (n=3). (B) In concordance with an increased expression of CCR7, migration of ACR or bleb loaded 
mature MoDC revealed that MoDC which had ingested blebs, were also able to migrate towards CCL19 
(Mip-3β) to a higher degree (14%; range 2% - 35%) in a transwell migration assay, compared to ACR 
(5%; range 1% - 16%) (p = 0.003)  (n = 8).
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in the presence of 1000 U/ml IFN-γ. After overnight incubation, the concentration of the 
Th-skewing cytokines IL-6 (Th17), IL-10 (Th2) and IL-12p70 (Th1) were determined in the 
culture supernatants. No clear differences in the production of either IL-6 (figure 4A), IL-
10 (figure 4B), or IL-12p70 (figure 4C) could be detected, when analyzing either unloaded, 
ACR-, or bleb-loaded MoDC. 
Increased IFNγ production by allogeneic T cells after priming with bleb-loaded MoDC 
Subsequently, we determined whether the loading of MoDC with either HS-derived ACR 
or blebs led to changes in T cell activation and/or proliferation, by priming with allogeneic 
T cells with differentially loaded MoDC. Loading of immature MoDC with ACR led to a 
reduction in CD4+ T cell proliferation as compared to unloaded- and bleb-loaded MoDC 
(figure 5A). In contrast, mature MoDC loaded with blebs induced a slight, but significant 
increase in CD4+ T cell proliferation as compared to unloaded- and ACR-loaded MoDC 
(figure 5A). No significant differences in CD8+ T cell proliferation could be detected between 
the conditions (figure 5B).
Next, we determined whether we could detect differences in TH skewing by analyzing 
the cytokines produced by allogeneic T cells that were stimulated by differentially loaded 
MoDC. No differences could be detected in the production of IL-2, IL-4, IL-6, IL-10, IL-17a, 
or TNFα (data not shown). However, priming of T cells with bleb-loaded MoDC led to an 
increased release of the Th1 effector cytokine IFNγ as compared to unloaded or ACR-loaded 
MoDC (figure 5C).
Figure 5: Allogeneic mixed lymphocyte reaction with (loaded) MoDC. (A) CFSE-labelled, CD14 
negative, peripheral blood lymphocytes were cultured with MoDC, or MoDC loaded with either 
heat shock-induced ACR or blebs for 6 days, after which the CFSE dilution was analysed using flow 
cytometry, as a measure for T cell proliferation. The proliferation of CD4+ T cells stimulated with ACR-
loaded immature MoDC was diminished compared to unloaded- (p=0.07) and bleb-loaded immature 
MoDC (p=0.04). Moreover, Bleb-loaded mature MoDC induced a significant increase in proliferation 
of CD4+ T cells, as compared to unloaded MoDC (p=0.05) (n=7). (B) No significant differences could be 
detected in CD8+ T cell proliferation, between the different loading strategies (n = 7). (C) Peripheral 
blood lymphocytes were stimulated with (loaded) MoDC for 6 days, after which the cytokine 
production was determined in the supernatant. Of the cytokines tested (IL-2, IL-4, IL-6, IL-10, TNFα, 
IFNγ and IL-17a), only IFNγ production was significantly altered. T cells stimulated with bleb-loaded 
MoDC produced approximately 2-fold higher levels of IFNγ, as compared to both unloaded and ACR-
loaded MoDC (n = 4).
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B. Priming efficiency MART-1
# Donors Wells 
positive
Mean 
%
Range % Range # 
Restim.
ACR 4 26/28 0.15 0.047%-
1.009%
1-5
BLEBS 4 28/28 0.63 0.041%-
11.662%
1-5
Figure 6: CD8+ T cell cross priming, cytotoxicity and avidity. (A) Priming of CD8+ T cells (gated on FCS/
SSC, 7AAD-, CD3+, and CD8+) with heat shock-induced ACR- or bleb-loaded  MoDC led to an expansion 
of MART-126-35L specific CD8+ T cells, as measured by tetramer staining. (B) A total of 4 priming 
experiments with CD8+ T cells and autologous MoDC from healthy donors were performed, with a 
mean expansion of 0.16 % (range 0.05 % – 1.01 %) MART-126-35L specific CD8+ T cells, when CD8+ T cells 
were primed with ACR-loaded MoDC. The mean expansion of MART-126-35L specific CD8+ T cell, when 
primed with bleb-loaded MoDC, was 0.63 % (range 0.04 % - 11.66 %). Positive wells were defined as 
>0.03% and >15 Tm+ events, or >20 Tm+ events in two subsequent measurements. (C) Co-culture of 
sorted and expanded MART-126-35L specific CD8+ T cells at increasing effector to target ratios with JY, or 
K562-M target cells, did not result in an increase in cytotoxicity, as measured by 7AAD positive target 
cells (C: top four panels; representative example of 2 cytotoxicity experiments). However, co-culture 
with Mel AKR target cells showed an increasing cytotoxicity with increasing number of effector cells, 
by MART-126-35L specific CD8+ T cells primed with both ACR- and bleb- loaded MoDC (C: lower two 
panels). (D) T cell avidity analysis showed, that MART-126-35L specific CD8+ T cells primed with bleb-
loaded MoDC (triangles) could detect 12-fold to 107-fold lower MART-126-35 peptide concentrations, as 
compared to those primed with ACR-loaded MoDC (circles; avidity assays from 2 independent priming 
experiments).
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Higher frequencies of antigen-specific CD8+ T cells with a higher avidity are primed by 
bleb-loaded MoDC
Finally, we assessed the priming of antigen-specific CD8+ T cells with MoDC loaded with 
HS-derived ACR or blebs. The apoptotic cell fractions were isolated from HLA-A2 negative 
HL60 AML cells, transduced with the MART-1 model tumor antigen, in order to prevent 
direct antigen-presentation of the apoptotic cell fractions to T cells. As such, outgrowth 
of antigen-specific T cells must be the result of cross-priming by loaded (HLA-A2-positive) 
MoDC. Priming CD8+ T cells with differentially (i.e. with ACR or blebs) loaded MoDC, led to 
an expansion of MART-126-35L-specific CD8+ T cells in both experimental conditions (figure 
6A). However, the maximum percentage of MART-126-35L positive CD8+ T cells differed 
dramatically, with 1.01 % (mean 0.16 %, range 0.05 % – 1.01  %) vs.11.66 % (mean 0.63 %, 
range 0.04 % - 11.66 %) of CD8+ T cells primed by ACR- or bleb-loaded MoDC respectively, as 
summarized in figure 6B. After sorting and polyclonal expansion, we analyzed the cytolytic 
capacity of the primed MART-1-specific CD8+ effector T cells, by co-culturing them with 
Mel AKR (HLA-A2+MART-1+ positive target), or with HLA-A2+MART- JY or HLA-A2-MART-1+ 
K562-M (negative control) target cells. MART-126-35L CD8+ T cells primed by either ACR- or 
bleb-loaded MoDC were capable of lysing Mel AKR at similar rates (figure 6C). Interestingly, 
analysis of functional T cell avidity by peptide titration followed by IFNγ release read-out, 
showed that MART-126-35L CD8+ T cells primed with bleb-loaded MoDC were able to recognize 
HLA class I:peptide complexes loaded with peptide concentrations two orders of magnitude 
lower as compared to CD8+ T cells primed by ACR-loaded MoDC (i.e. 12-fold and 107-fold, 
see figure 6D).
Discussion
Broadening the repertoire of LAA presented by MoDC is likely to increase the efficacy of 
DC vaccination. However, only a limited number of LAA have been characterized to date 
and even fewer can be used in a patient-specific setting. Moreover, patient-specific frame-
shift mutations are described to play a role in anti-tumor immunity [36], most of which 
are yet to be defined. The use of whole-tumor cell vaccines circumvents the need for LAA 
characterization and HLA matching, and furthermore broadens the array of presented LAA 
as well as facilitating personalized immunotherapy.
The finding that apoptotic blebs, in contrast to ACR, can induce maturation of BMDC in mice 
[30;37], led us to investigate the possibility of using blebs as source of LAA for DC loading in 
the context of a vaccination strategy. In the current study we show that blebs, as compared 
to ACR, derived from apoptotic AML cells, were ingested more efficiently by MoDC. It 
remains to be determined whether this increase was induced by 1) an enrichment of eat-
me signals (e.g. phosphitadyl serine & calreticulin) on the surface of blebs, 2) a different 
mechanism of ingestion (phagocytosis vs. receptor-mediated endocytosis or fusion), or 3) 
whether the increased uptake was solely based on spatial considerations as a result of the 
approximately tenfold size difference between ACR and blebs. 
One of the hurdles in effective DC vaccination, is the limited migration of (intradermally) 
injected DC from the site of injection towards the afferent lymph node [38]. The increased 
CCR7 expression we observed on MoDC that have taken up blebs and the subsequent CCL19 
directed migration are clearly favorable in this regard. Apart from CCR7 expression, neither 
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ingestion of ACR nor of blebs resulted in clear alterations in phenotype, nor in cytokine 
production of MoDC. Contradictory data have been published on the effects of apoptotic 
cells on DC maturation. Presentation of self-antigens by DC under non-inflammatory 
conditions has been shown to induce self-tolerance [17]. Moreover, ingestion of apoptotic 
cells by DC inhibits NFκB activation, and induces the production of regulatory cytokines (e.g. 
IL-10, TGFβ), whereas the production of pro-inflammatory cytokines (e.g. IL-12 and TNFα) 
are hampered following Toll-like receptor ligation [18-22]. The expression of co-stimulatory 
molecules and T cell stimulatory capacity by apoptotic cell-loaded DC are diminished 
compared to unloaded DC [39-41]. In contrast, apoptotic cell-loaded DC have also been 
shown to induce T cell responses [42;43]. The contradictory data on apoptotic cell loading 
strategies for DC vaccination purposes could be a result of either the method of apoptosis 
induction, and/or the method of isolation after induction. Moreover, discrepancies observed 
after administration of apoptotic cells in murine models could be a result of the ingestion by 
different phagocytes (DC vs. macrophages, and non-professional phagocytes). 
In contrast to dampening MoDC function and T cell activation, both ACR and bleb-loaded 
MoDC were able to stimulate T cells, although loading of MoDC with ACR, without the 
induction of DC maturation (using IL-1β, IL-6, PGE
2
, and TNFα), did significantly diminish 
CD4+ T cell proliferation compared to unloaded, or bleb-loaded MoDC. Importantly, co-
culture of peripheral blood lymphocytes with bleb-loaded (immature) MoDC led to Th1 
skewing, based on significantly higher levels of IFNγ production, compared to unloaded and 
ACR-loaded MoDC. Our data are in concurrence with the data obtained by Fransen et al 
[30], although we could not detect an increase in IL-17 production by PBL after stimulation 
with bleb-loaded MoDC (data not shown). This lack of IL-17 production in a MLR could be a 
result of 1) the species difference, 2) the origin of the DC used (MoDC vs. BMDC), or 3) the 
responder cells used in the MLR (PBL vs. splenocytes), and does not exclude the induction 
of IL-17 producing T cells in vivo. 
We observed a higher percentage of MART-126-35L specific CD8+ T cells when primed with 
bleb-loaded MoDC in the conducted priming experiments, which can be explained by 
multiple factors. For instance, the increase in uptake of blebs by MoDC could lead to an 
increased antigen-load per MoDC, by which these MoDC are able to present LAA in a greater 
number of HLA class I molecules, or for a prolonged period of time. Also, blebs could contain 
more readily processible sources of antigen, e.g. defective ribosomal products (DRIPs), 
rapidly degradable poly-peptides and translated proteins, due to the presence of the ER. 
These antigen sources have been described to be presented very efficiently in the context 
of HLA class I and are essential sources of presented antigen during viral infections [44;45]. 
Whether the presence of these peptides in blebs is elevated remains to be elucidated, but 
DRIPs within autophagosomes have been reported to be efficiently cross-presented [46]. 
Combined with the efficient uptake, this could render blebs a more effective source of LAA 
compared to ACR. In addition, membrane transfer or fusion can occur, by which HLA:peptide 
complexes (and other structures) are transferred onto MoDC, a process referred to as DC 
cross-dressing, or trogocytosis [47;48]. Whether cross-dressing occurs during the co-culture 
of blebs with MoDC remains to be determined. In this study we solely analyzed the effect of 
antigen uptake and the effects thereof on MoDC function, since we used HLA-A2 negative 
apoptotic material to prevent direct presentation of LAA by the apoptotic leukemic cell 
fractions, and thus it remains unclear whether, and to which degree, these mechanisms 
contribute to T cell priming. Our observation that bleb-loaded MoDC prime CD8+ T cells of 
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higher avidity compared to ACR-loaded MoDC, is likely to be an effect of the ingested blebs 
on the functionality of the MoDC, rather than differences in processing and presentation 
efficiency of the antigen. As we found no differences in e.g. release of IL-12p70 or other T 
cell stimulatory cytokines or expression levels of co-stimulatory molecules, the underlying 
mechanism in this regard as yet remains obscure. Nevertheless, this impressive difference in 
functional avidity clearly indicates a preferred use of blebs over ACR for immunotherapeutic 
purposes.   
In conclusion, we have shown that ingestion of human apoptotic blebs derived from the 
AML cell line HL60, can induce lymph node migration capacity in MoDC as well as the ability 
to prime IFNγ producing effector T cells and high-avidity tumor reactive CTL. Using bleb-
loaded MoDC for the induction of tumor-directed cytotoxic T cell responses, could therefore 
be a potent novel strategy for treating AML patients.
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Introduction
In 1811 William Cullen described a case of ‘splenitis acutus’ in which the serum of the blood 
had the appearance of milk; with our current knowledge Cullen is most likely the first to 
describe a case of chronic leukemia. In 1827 a more detailed case report on a 63 year old 
patient, Mr Vernis, was published by Alfred Velpeau. Mr Vernis’s illness started at the age of 
54 and was followed by a stable phase for three years. This phase was followed by a period of 
recurrent fevers and difficulty urinating. Eventually, the patient was admitted to hospital at 
the age of 63 with tumors in the abdomen and died the next morning. An autopsy revealed 
an enlarged liver and spleen and pus-filled blood. Then, Alfred Donné discriminated in his 
morphological atlas (published in 1845) between accumulation of pus in the blood as seen 
in infections or abscesses and of so called “mucous globules” (leucocytes) as he found in a 
case of a 44-year old woman with splenomegaly. John Bennett stated in 1845 that in case 
of leucocytosis this should be considered as a primary systemic blood disorder. In 1847 
Rudolf Virchow was the first pathologist to describe this clinical and pathological condition 
as leukemia based on the Greek words leukos (λευκός), and aima (αίμα), meaning white 
and blood respectively. With further development of microscopy of blood smears Virchow 
was able to differentiate between splenic and lymphatic leukemia in 1856; it was not until 
1869, when Neumann discovered that the origin of leukaemia should be connected to the 
bonemarrow. Further development of stained blood smears designated the beginning of a 
new era in which more details of leukemia were unravelled but yet many more complicated 
questions raised [1].
Figure 1. Anatomy lessons of Dr Velpeau. 1864, by Francois Nicolas Augustin Teyen-Perrin.
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Models for the development of leukemia  
Over the last decades, more and more is revealed about the development of cancer. 
Simplified models have been proposed, however, none of these are simple. For instance, 
massive exposure to radioactive substances will lead to breaks in double stranded DNA and 
thereby translation into proteins may stop which finally leads to death of hematopoietic 
stem cells: acute radiation syndrome. When one is exposed to lower amounts of radiation, 
this will lead to multiple DNA breaks which can be repaired by the cell itself. When this 
mechanism fails, the improperly repaired DNA might encode for proteins which promote 
unlimited growth of hematopoietic stem cells and in this case in months to years leukemia 
might develop. Especially mutations in DNA repair mechanisms or other tumor suppressor 
genes are well described. For instance, the P53 gene plays a decisive role in DNA repair and it 
can induce cell cycle arrest to provide time for DNA repair and when repair is not possible P53 
can induce apoptosis. Mutation in P53 genes and abolishment of its function can promote 
development of cancer [2]. However, no model can yet explain why one hematopoietic 
progenitor cell becomes malignant and another progenitor cell will not. Moreover, the 
development of models answering these questions is complicated by the heterogeneity 
of leukemic cells between patients and even within one patient. Nevertheless, different 
models are developed trying to explain the heterogeneity of a tumor: the stochastic model 
points out that tumors are inherently biologically homogenous and heterogeneity is caused 
by random intrinsic or extrinsic influences that alter the behavior of individual cells in the 
tumor. In contrast, the deterministic model states that heterogeneity of tumors is caused 
by known influences and relationships between other cells and the environment, a role 
for random phenomena is excluded [3]. In some cases, a pre-leukemic phase of ineffective 
production and dysplasia of the myeloid cell lineage, the myeolodysplastic syndrome (MDS), 
might precede evolution to AML. In these cases the steps to malignant evolution into AML 
can be researched more thoroughly: Walter et al. proposed a model for the development 
of secondary AML from MDS based on single nucleotide variant analysis performed at 
various time points during evolution of MDS to AML (summarized in figure 2)[4]. All of these 
hypotheses have provided the basis for better understanding cancer and consequently 
Figure 2. A model explaining clonal evolution (adapted from Walter et al. [4]). Based on Single 
nucleotide variant analysis of MDS (green cells) and secondary AML (purple) the following model was 
proposed for the evolution of MDS into AML. First (1) a single clone (green) is present. Cells in clone 2 
(red) are derived from a single cell from clone 1 since newly acquired variants are found in addition to 
the same single nucleotide variants found in nearly all AML cells. Finally, AML has developed showing 
various subclones evolved through serial (2,3) acquisition of single nucleotide variants. 
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added to the development of new therapeutics and as a result, survival rates in leukemia 
have increased over the last decades 
Nowadays, after induction and consolidation regimens complete remission can be 
established in 70-80% of adults with acute myeloid leukemia (AML) and even better results 
for acute lymphoid leukemia (ALL). Unfortunately, 5 year survival rates are significantly 
lower, for AML this is 30-40% and for ALL 40-50%.
The classification of acute (myeloid) leukemia 
Despite heterogeneity as described above, in clinical studies AML patients have been 
regarded as one homogenous group, randomized in two cohorts: one for the standard and 
one for the new (chemo)therapeutics. With our current knowledge, treatment regimens 
may differ for patients with a (very) good and poor risk profile (see www.hovon.nl for 
Dutch treatment guidelines). These risk stratifications are primarily based on molecular 
and genetic aberrancies. Thus, as a start, there should be consensus on how to classify 
acute leukemias in order to provide a standardized platform for testing different treatment 
options for distinct subgroups of AML. A struggle on one hand is the heterogeneity of acute 
leukemias and potentially numerous subgroups and on the other hand the need for large 
(homogenous) groups of patients for testing new (chemo)therapeutic regimens. 
In order to have a worldwide consensus on classification the WHO2008 provides guidelines 
for diagnosing different subgroups based on a combination of clinical, morphologic, 
and immunophenotypic features, and results obtained by molecular analysis and 
cytogenetics. Differentiation between AML and acute lymphoid leukemia (ALL) is important 
since ALL necessitates a different therapeutic regimen than leukemias from myeloid origin; 
for example, a longer maintenance treatment and intrathecal prophylaxis is needed for 
lymphoid leukemias.
In PART I of this thesis we evaluated the role of the WHO2008 guidelines in differentiating 
classification of myeloid and lymphoid leukemias by flow cytometry. In chapter 3 we 
describe two case reports highlighting the importance of immunophenotyping. The first 
report is a lymphoid leukemia at diagnosis which relapses as an immunophenotypic myeloid 
leukemia with the same complex cytogenetic aberrancies as at diagnosis. This subclone with 
a myeloid phenotype was already present at diagnosis and after chemotherapy following 
the ALL protocol. The other acute leukemia case describes a paradoxical appearance: 
morphology revealed a clear monocytoid picture with prominent vacuolization and 
erythrophagocytosis, whereas flow cytometry revealed a clear lymphoid phenotype. 
Besides the lymphoid markers, also MPO was found positive, thus classifying this case as 
a mixed phenotype acute leukaemia following the WHO2008 guidelines. The patient was 
treated with an AML chemotherapy regimen combined with intrathecal methotrexate 
prophylaxis, resulting in complete remission. Unfortunately the patient experienced a 
relapse (with the same phenotype) after 11 months, and further chemotherapy was not 
given. In about 2-4% of acute leukemias flow cytometry cannot unravel whether an acute 
leukemia should be assigned to the myeloid or lymphoid lineage. When expression of 
both myeloid and lymphoid markers is found, the acute leukemias are classified as mixed 
phenotype acute leukemias (MPAL), it is unclear whether MPAL benefit from an ALL or AML 
based treatment protocol. Moreover, acute leukemias with both lymphoid and myeloid 
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features have a poor prognosis and therefore may benefit from an intensified treatment 
scheme. International guidelines implementing these intensified schemes are lacking. For 
comparison of these different chemotherapy schemes a uniform classification has to be 
used. However, the last decades various guidelines have been used for classification of 
acute leukemias of ambiguous lineage. In chapter 4 we discussed the implications of the 
various guidelines and compared the latest WHO2008 guidelines with the former WHO2001 
guidelines in classification of MPAL. Noteworthy, according to the WHO2001 criteria 5.8% 
of all acute leukemias referred to our institute were classified as acute leukemias with 
both lymphoid and myeloid features (biphenotypic acute leukemia (WHO2001)), whereas 
according to the WHO2008 guidelines only 1.3% would have been classified as MPAL. In 
addition, clearly defined cut offs for positivity and negativity of certain immunophenotypic 
diagnostic markers are lacking in WHO2008; e.g. no cut off for cytoplasmic myeloperoxidase 
(cMPO), the hallmark of the myeloid lineage is defined. In chapter 5, we demonstrated 
that a 10% cut off is a secure lower limit for MPO expression by flow cytometry and can 
be used independently from the cytomorphology based Sudan Black analysis. Compared 
with a regular cut off of 20% (according to the former WHO2001 guidelines), this proposed 
cut off of 10% for cMPO expression would have changed the diagnosis into MPAL in only 
two cases in our cohort (1%). Nowadays, treatment schemes for MPAL are based on a 
lymphoid or myeloid based treatment scheme, the latter often combined with intrathecal 
methotrexate prophylaxis. Accordingly, it is necessary to distinguish between a myeloid 
or lymphoid lineage predominance within an acute leukemia with both characteristics. 
Classification of MPAL might be complemented by the use of other diagnostic tools, such 
as gene or microRNA expression profiling. In chapter 6 we demonstrated by microRNA 
arrays that MPAL did not segregate as a separate entity but showed microRNA expression 
profiles similar to that of either AML, B-ALL or T-ALL. This implies that MPAL might not 
be a unique clinical entity but can be traced back to their original genotypic lineage using 
microRNA expression. We hypothesize that microRNA classification of those leukemias with 
both lymphoid and myeloid characteristics could provide a more accurate classification 
as compared to immunophenotyping and is instrumental for therapy decision making. 
However, prospective studies are needed for implementation of microRNA arrays in clinical 
practice. 
In addition to microRNA arrays, the development of other mass data analysis on a gene or 
protein level (such as gene arrays, proteomics and mass cytometry [5]) will help to define 
more accurate signatures for acute leukemias and leukemic cells and thus more accurate 
definitions of subgroups of acute leukemias. In the near future these diagnostic tools 
might help defining (sub)groups for comparing different therapeutic schedules. Ideally, 
a personalized leukemic signature might lead to a personalized treatment: for instance a 
personalized immunotherapy which is discussed in PART III.
The development of AML: immunesurveillance
Most models describing the role of the immune system in cancer are deduced from the 
innate and adaptive immune response to foreign micro-organisms. One should be careful 
to extrapolate these models to acute leukemia. For instance, the process of a pre-malignant 
cell evolving into leukemia might take years such as is the case for MDS, whereas micro-
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organisms can cause fulminant infections within days. Furthermore, in contrast to micro-
organisms, leukemic cells are derived from previous non-malignant cells and thus express 
more self than non-self-antigens. Nonetheless, these models provide insights in the role 
of the immune system in the development of cancer and thus might provide a tool for the 
development of therapies. One interesting model trying to explain the development of 
leukemia is discussed in this thesis and is based on escape of the immune system. In this model 
the immune system is depicted as a balance (figure 3). A balanced immune system reacts in a 
balanced manner to micro-organisms and malignant cells (figure 3b). An overacting immune 
system (figure 3a) results in hyper inflammation and even worse, an immune response 
against normal cells and subsequently auto-immune diseases. In contrast, in case of hypo-
inflammation (figure 3c), the immune system leaves (pre)leukemic cells untouched resulting 
in outgrowth of leukemia. In other words, in order for leukemia to develop the leukemic 
cells must acquire escape mechanisms to prevent recognition by the immune system, this 
is researched in PART II of this thesis. However, this model can not be generally applied: for 
instance, chronic myeloid leukemia (CML) cells are able to activate BCR-ABL-specific T cells, 
however, these T cells were not able to proliferate [6]. Furthermore, it is evidenced that 
persistent antigen exposure can result in loss of high affinity leukemia reactive T cells or T 
cell tolerance [7-10]. Besides, many other immunosuppressive mechanisms are described 
involving the tumor environment such as regulatory and suppressor T cells and molecules 
expressed by the tumor cell itself such as indoleamine 2,3-dioxygenase (IDO) and Class II 
associated invariant chain peptide (CLIP) [11;12]. In PART II we have investigated the role 
of class II associated Invariant Chain peptide (CLIP) in antigen presentation via HLA class II 
by leukemic cells as a possible immune escape mechanism. Previously, we have shown that 
patients with a high CLIP expression on leukemic cells have a worse prognosis [12]. In this 
thesis we showed that CLIP expression on minimal residual disease can predict relapse more 
accurately (Chapter 8). The model explaining this difference in survival assumes that CLIP is 
preventing presentation of leukemia associated antigen (LAA) derived peptides by HLA-class 
II. However, CLIP expression is regulated by HLA-DM and HLA-DO; as such, CLIP expression 
might be the result of alterations in other pathways and molecules. CLIP expression implies 
that exogenous proteins are not efficiently presented by the leukemic cell onto HLA class 
II molecules. This assumption is substantiated by the finding that leukemic cells positive 
for CLIP have reduced CD4+ T cell activating capacity compared with the CLIP negative cells 
Figure 3. A simple (A) and complex (D) model explaining immunologic processes.  In (A) the immune 
system is represented as a balance. In A an over-reactive immune system will result in auto-immune 
diseases and an unresponsive (C) immune system will result in the development of cancer. When the 
immune system is balanced (B) no auto-immune diseases will develop and the immune system is 
capable of eliminating cancer. I
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within the same patients in an autologous setting (Chapter 9). These results have led to 
the assumption that analysis of CLIP can be used to predict which patient might be likely to 
experience a relapse. High CLIP expression results in a poor prognosis and warrants more 
intensive chemotherapy, or more preferably therapy directly targeting CLIP. The latter may 
entail potentiation of the antigen processing machinery, such as the proteasome and TAP. 
For instance, clinically applicable HDAC inhibitors enhance the expression of TAP subunits 
in tumor cells. By incubation of leukemic cells with HDAC inhibitors in vitro we found strong 
down modulation of CLIP (unpublished data). Another option might be to directly inhibit 
CLIP expression via modulation of HLA-DM/DO, for instance using PKC inhibitors [13]: in 
activated B cells PKC inhibition affects DO expression potentially leading to a decline in CLIP. 
In chapter 15 we investigate the role of R848 on monocyte derived dendritic cells (MoDC) 
and show down-modulation of CLIP. The role of TLR-ligands in affecting CLIP expression 
on leukemic cells should be further investigated; preliminary experiments showed that 
by incubation of leukemic cells with TLR-ligands CLIP was down regulated. However, due 
to presence of CLIP on non-malignant cells, such as B-cells one should be very careful in 
application of CLIP modulation in clinical practice in order to prevent auto-immunity.
Models for development of immunotherapeutic 
strategies
The immune-escape model provides a model for the development of cancer but can also 
provide a starting point for new treatment modalities such as immunotherapy (vaccination). 
After initial chemotherapy the bulk of leukemic cells are lysed, this is followed by 
consolidation therapy to attack remaining residual cells. In addition to consolidation therapy, 
immunotherapy can add to the recognition and lysis of residual leukemic cells and thereby 
might prevent relapse of AML. Immunotherapy aims at the induction of leukemic antigen 
specific T cells. In chapter 11 we show that PRAME-specific T cells efficiently recognize 
and lyse leukemic cells and thus are an attractive tool for development of additional 
immunotherapeutic strategies, such as adoptive T cell transfer or active immunotherapy 
aiming at the induction of PRAME or other LAA-specific T cells
The critical role of dendritic cells (DC) in induction, regulation and maintenance of primary 
immune responses, including specific antitumor responses, has been demonstrated. This has 
led to development of DC-based vaccination strategies as a way to actively induce antitumor 
immunity. Thus far, results are promising: T cell responses have been elicited by DC vaccines 
and DC vaccines have proved to have only few side effects [14;15]. Unfortunately, major 
clinical responses have only been reported in a minority of cancer patients. Partly this can 
be explained by the fact that DC-based vaccines have been administered to cancer patients 
who obtained a second complete remission (CR) after relapse and thus have a very poor 
prognosis; these results highlight the need for improvement of DC-based immunotherapeutic 
strategies. For the latter, lessons can be learnt from stem cell transplantations (SCT): whereas 
the patients’ immune system fails to control leukemic cells, donor immune cells can induce 
long term CR due to activation of donor T cells. These donor-derived T cells recognize either 
alloantigens that are expressed on normal and malignant cells or leukemia-specific antigens. 
However, SCT is not suitable for all patients, for instance those patient with high morbidity 
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or older patients, and has a high treatment-related mortality and morbidity (graft versus 
host disease). Passive immunotherapy might be effective in the short term; it does not offer 
long term immunity. In contrast, active DC-based immunotherapy aims at the induction of 
the LAA-specific T cells including memory T cells. The leukemic cell contains already known 
and not yet discovered LAA and thus provides an attractive source for loading onto DC and 
for development of personalized treatment regimens. Another option is to use DC cultured 
from leukemic cells: by culturing leukemic cells with a cytokine cocktail consisting of GM-
CSF and IL-4 differentiation into leukemic cell-derived DC is potentiated; this technique is 
exploited in chapter 12. In favor of this concept is that leukemic cells and leukemic cell-
derived DC processes and presents the same leukemic antigens by MHC-molecules. 
However, the leukemic cell-derived DC might harbor immune suppressive features and 
the antigen presenting machinery is less efficient as compared to normal non-leukemia 
derived DC. [16]. Another option is the use of MoDC loaded with leukemia-associated 
antigen sources. There are various ways to supply leukemic cells to the dendritic cells. For 
instance by repetitive freeze (liquid nitrogen)/ thaw (420C) cycles cellular integrity is lost 
and intracellular proteins and peptides can be provided to the DC for uptake and further 
processing. In chapter 13 we show that CML lysate-loaded DC are able to activate CML-
specific T cells. Another option is the induction of apoptosis by for instance, heat-shock, UV-
irradiation or chemotherapeutics to render leukemic cells suitable for loading onto MoDC. 
Beside the numerous antigen sources (e.g. lysate, blebs, RNA, peptides) even more options 
for adjuvants potentially enhancing the loading efficacy are becoming known. In chapter 
14 we have compared different DC-loading strategies for optimal immune responses. To 
shorten the list of numerous DC loading strategies to a researchable amount we focused 
on whole cell products: lysate and apoptotic cells. In innate immunity toll like receptors 
(TLR) are necessary to induce an optimal innate immune response and help the adaptive 
immune response. In contrast to lysate, by loading apoptotic cells in presence of TLR ligand 
more antigen is taken up by the DC (chapter 14). The addition of TLR ligands during loading 
of MoDC enhances the uptake of leukemic cell lysate and apoptotic cells. However, the 
sequential use of R848 and a conventional cytokine cocktail is counter indicated due to its 
adverse effects on MoDC maturation. 
During apoptosis of non-malignant cells highly immunogenic blebs are shed; the remaining 
apoptotic body is considered less immunogenic. We explored the immunogenicity of 
apoptotic blebs in leukemic cells in chapter 15 and show that bleb-loaded DC are more 
efficient in T cell activation than the apoptotic cell remnants. Further systematic studies 
comparing leukemic cell derived DC and MoDC loaded with leukemic cell-derived antigens 
sources are needed to evaluate the best DC source for inducing LAA specific T cells.
Future directions for development of immunotherapy 
Only a few studies are available comparing different DC loading strategies [17-20]. These 
comparitive studies revealed that different AML patients might benefit from different vaccine 
preparations. Furthermore, comparison of various studies with each other is complicated by 
different MoDC culturing and subsequent loading procedures. 
In this thesis, we show that LAA-specific T cells can efficiently recognize and lyse leukemic 
cells. Furthermore, for the development of active specific immunotherapy, DC-based 
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vaccines offer an interesting option. We show that leukemic cells can be differentiated 
into DC, whether or not after preceding expansion of leukemic cells. Furthermore, loading 
of MoDC loaded with blebs is favorable over loading with apoptotic cell remnants. And 
when loading the DC, one should be careful with the use of adjuvants such as TLR-L. 
These recommendations, which we provide in this thesis, offer a starting point for further 
research: these studies should focus on comparison of variations in DC culturing and loading 
possibilities. For example, AML-derived DC have not yet been compared side-by-side with 
MoDC loaded with whole cell derived antigens. 
Only a few LAA are known and these are not generally expressed in AML and thus hamper 
a LAA-specific in vitro read-out system [21]. In these cases results obtained from research 
using CML-cell loaded MoDC might be helpful: BCR-ABL is generally expressed in CML and 
phenotype and genotype are more homogenous compared with AML
When taking the stem cell model into account another challenge is faced in DC loading 
strategies: DC primed LAA specific T cells should ideally target leukemic cells and leukemia 
initiating stem cells. Therefore, in vitro research should focus on the development of 
leukemic stem cell loading strategies onto DC, for instance by loading of amplified RNA 
isolated from the leukemic stem cell.
Summary
In summary, in PART I we described the struggle with on one hand the heterogeneity 
of acute leukemias and potentially numerous subgroups and on the other hand the 
need for large (homogenous) groups of patients for testing new therapeutic regimens. 
Immunophenotyping plays an important role in definition of various subgroups. In 
future, results obtained from e.g. gene or microRNA array or mass cytometry might add 
to deciphering the genetic and protein signature of a leukemic cell and more accurate 
definition of subgroups. In PARTII we showed that leukemic cells exploit immune escape 
mechanisms such as expression of CLIP. These immune escape mechanisms provide a 
starting point for developing of immunotherapeutic interventions as described in PART III of 
this thesis. In this part we evaluated different DC-based loading strategies and made a start 
in finding the most optimal vaccine preparation and compare different adjuvants potentially 
enhancing DC-preparation and function. Diagnostic tools have to be developed that can 
direct personalized treatment schemes, such as immunotherapeutic vaccination strategies. 
Several steps have to be taken for preparation of dendritic cell based vaccines: ongoing 
research is needed in order to achieve consensus about which antigen loading strategy for 
MoDC combined with administration of optimal adjuvants is most suitable. This includes 
optimization of LAA processing and presentation pathways in order to achieve the best-
suited tailor-made vaccine preparation in each individual patient.
Reference List
1.  Kampen KR. The discovery and early understanding of leukemia. Leuk.Res. 2012;36:6-13.
2.  Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. 
N.Engl.J.Med. 2011;364:488-490.
Chapter 16
246
3.  Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future 
directions. Blood Rev. 2011;25:75-81.
4.  Walter MJ, Shen D, Ding L et al. Clonal architecture of secondary acute myeloid leukemia. 
N.Engl.J.Med. 2012;366:1090-1098.
5.  Bendall SC, Simonds EF, Qiu P et al. Single-cell mass cytometry of differential immune and 
drug responses across a human hematopoietic continuum. Science 2011;332:687-696.
6.  Rusakiewicz S, Madrigal A, Travers P, Dodi AI. BCR/ABL-specific CD8+ T cells can be 
detected from CML patients, but are only expanded from healthy donors. Cancer Immunol.
Immunother. 2009;58:1449-1457.
7.  Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by 
selective deletion of high-avidity leukemia-specific T cells. J.Clin.Invest 2003;111:639-647.
8.  Fujii S, Shimizu K, Koji F, Kawano F. Malignant counterpart of myeloid dendritic cell (DC) 
belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory 
potential. J.Leukoc.Biol. 2003;73:82-90.
9.  Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity 
and antigen-specific T cell function during tumor progression. J.Exp.Med. 2004;200:1581-
1592.
10.  Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. 
J.Immunol. 2003;171:6323-6327.
11.  Chamuleau ME, van de Loosdrecht AA, Hess CJ et al. High INDO (indoleamine 2,3-dioxygenase) 
mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. 
Haematologica 2008;93:1894-1898.
12.  Chamuleau ME, Souwer Y, Van Ham SM et al. Class II-associated invariant chain peptide 
expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 
2004;64:5546-5550.
13.  Roucard C, Thomas C, Pasquier MA et al. In vivo and in vitro modulation of HLA-DM and HLA-
DO is induced by B lymphocyte activation. J.Immunol. 2001;167:6849-6858.
14.  Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. 
Nat.Med. 2004;10:909-915.
15.  Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute 
myeloid leukemia. Cytotherapy. 2012;14:647-656.
16.  Rasaiyaah J, Noursadeghi M, Kellam P, Chain B. Transcriptional and functional defects of 
dendritic cells derived from the MUTZ-3 leukaemia line. Immunology 2009;127:429-441.
17.  Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells 
and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. 
Br.J.Haematol. 2005;129:340-349.
18.  Weigel BJ, Panoskaltsis-Mortari A, Diers M et al. Dendritic cells pulsed or fused with AML 
cellular antigen provide comparable in vivo antitumor protective responses. Exp.Hematol. 
2006;34:1403-1412.
19.  Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a 
source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
20.  Larmonier N, Merino D, Nicolas A et al. Apoptotic, necrotic, or fused tumor cells: an 
equivalent source of antigen for dendritic cell loading. Apoptosis. 2006;11:1513-1524.
21.  Greiner J, Schmitt M, Li L et al. Expression of tumor-associated antigens in acute myeloid 
leukemia: Implications for specific immunotherapeutic approaches. Blood 2006;108:4109-
4117.
Nederlandse samenvatting
Nederlandse samenvat-
ting
Nederlandse 
samenvatting
248
Nederlandse samenvatting
Introductie
Aan het begin van een nieuw leven is één stamcel verantwoordelijk voor het ontstaan van 
alle weefsels. Later in het leven dragen weefselspecifieke stamcellen zorg voor het in stand 
houden van de huid, bloed en inwendige organen. De twee belangrijkste eigenschappen 
van een stamcel zijn dat zij in staat zijn uit te rijpen naar verschillende gespecialiseerde 
celtypen en dat zij zichzelf kunnen vernieuwen. Bloedvormende of te wel hematopoëtische 
stamcellen zijn te vinden in het beenmerg en zorgen ervoor dat er voldoende bloedcellen 
worden gemaakt. De hematopoëtische  stamcel is de voorloper cel voor rode bloedcellen 
(erytrocyten), de witte bloedcellen (leukocyten,  verantwoordelijk voor de afweer) en de 
Figuur 1. Schematische weergave van de uitrijping van witte bloedcellen in gezonde toestand 
(A) en tijdens acute myeloïde leukemie (AML) (B). De hematopoëtische stamcel differentieert tot 
voorlopercellen die daarna verder uitrijpen tot bloedplaatjes (stolling), witte bloedcellen (afweer) 
en rode bloedcellen (A). Als er sprake is van acute leukemie dan verdringen de leukemische cellen de 
normale uitrijping en ontstaat er een tekort aan bloedplaatjes, witte bloedcellen en rode bloedcellen 
(B).
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bloedplaatjes (trombocyten,  verantwoordelijk voor de bloedstolling). De witte bloedcellen 
zijn te verdelen in myeloïde en lymfatische cellen. Een belangrijk verschil tussen de myeloïde 
en lymfatische afweercellen is dat de cellen van het myeloïde systeem een aspecifieke 
afweerreactie bewerkstelligen. De myeloïde cellen zijn het grove geschut: zij vallen 
bacteriën en virusgeïnfecteerde cellen op een aspecifieke manier aan. De afweercellen van 
de lymfatische reeks zijn verantwoordelijk voor de precieze en specifieke afweer en het 
ontstaan van een “afweer”geheugen, het principe waarop inenting of te wel vaccinatie is 
gebaseerd. 
Acute myeloïde leukemie (AML) is een maligniteit van de witte bloedcellen waarin een 
myeloïde voorlopercel transformeert naar een leukemische cel. Deze leukemische cel deelt 
ongecontroleerd en rijpt niet meer uit naar functionele witte bloedcellen. De leukemische 
cellen hopen zich op in het beenmerg en belemmeren daarmee uitgroei van gezonde 
bloedcellen (figuur  1). Dit heeft tot gevolg dat er weinig rode bloedcellen (bloedarmoede: 
anemie) en myeloïde bloedcellen (neutropenie) zullen worden gevormd. Bij neutropenie 
ontstaat er een grote kans op een infectie. Daarnaast zal een tekort aan bloedplaatjes 
(trombopenie) leiden tot een verslechterde bloedstelping, zich uitend in blauwe plekken bij 
gering trauma, gemakkelijk bloedend tandvlees en/of bloedneuzen. 
Figuur 2. Recidief en residuale ziekte na behandeling. Residuale leukemische cellen (A) kunnen na 
behandeling uitgroeien en een recidief van de leukemie veroorzaken (C). Indien alle leukemische 
cellen worden geëlimineerd na behandeling is een patiënt genezen (B)
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AML is een relatief zeldzame ziekte (2-3 gevallen per 100.000 inwoners per jaar in Nederland). 
Omdat mensen steeds ouder worden en de ziekte vooral voorkomt op hogere leeftijd, 
neemt het aantal gevallen van AML per jaar toe. Onbehandeld leidt AML tot de dood in 
enkele weken tot maanden. Omdat het een agressieve ziekte is, is intensieve behandeling 
met chemotherapie noodzakelijk. Als na therapie geen cellen meer worden gevonden in 
het beenmerg (complete remissie) betekent dit niet dat alle leukemiecellen zijn verdwenen. 
Een zeer kleine hoeveelheid leukemiecellen kan aan de therapie zijn ontsnapt: rest-  of ook 
wel residuale ziekte genoemd. Om te voorkomen dat de kleine hoeveelheid achtergebleven 
leukemiecellen weer uitgroeit  (“recidief”, figuur 2) is het noodzakelijk dat er een tweede 
chemotherapiekuur volgt. Zonodig kan dit gevolgd worden door een stamceltransplantatie 
van een familielid of een niet-verwante donor met (bijna) hetzelfde type witte bloedcellen. 
Complete remissie wordt bereikt bij 70-80% van de patiënten. Helaas ervaart 30-40% van 
de patiënten een recidief, ondanks intensieve chemotherapie en stamceltransplantatie. 
Met behulp van een betere classificatie en een beter begrip van de leukemische cel 
kunnen nieuwe therapieën worden ontwikkeld en dit wordt beschreven in dit proefschrift: 
Immunodiagnostiek en immuunsurveillance in een tijdperk van evoluerende AML 
behandelingen.  
Deel I van dit proefschrift focust op de diagnostiek en classificatie van acute leukemie. Deel 
2 onderzoekt mechanismen welke de leukemische cel gebruikt om het afweersysteem te 
ontwijken. In deel 3 worden tot slot nieuwe op de afweer gerichte (immunotherapeutische) 
behandelingsstrategieën bediscussieerd. 
DEEL I: Immuundiagnostiek van AML. 
Transformatie van een normale gezonde myeloïde voorloper cel naar een maligne 
leukemische cel kan gebeuren op elk moment gedurende differentiatie in de myeloïde lijn. 
Door te  kijken naar de cellen onder de microscoop (morfologie) kan worden gezien op welk 
punt in de uitrijping (differentiatie) naar een rijpe cel de myeloïde cel is getransformeerd 
naar een leukemische cel. Zo bestaat er bijvoorbeeld een “minimaal gedifferentieerde 
acute leukemie”; bij deze leukemie is er nog geen kenmerk van uitrijping zichtbaar onder 
de microscoop. Andere voorbeelden zijn de “acute myeloide leukemie met kenmerken van 
differentiatie” of de  “megakaryoblastaire acute leukemie” waarbij de leukemische cellen 
kenmerken vertonen van differentiatie of van voorlopercellen van bloedplaatjes. Bepaalde 
afwijkingen in de chromosomen zijn specifiek voor bepaalde typen leukemie, deze kunnen 
in kaart worden gebracht door middel van cytogenetisch onderzoek. 
Daarnaast kunnen met behulp van flowcytometrie de verschillende eiwitten in de 
celmembraan worden geanalyseerd, deze techniek wordt veelvuldig toegepast in de 
diagnostiek van acute leukemie zoals  in dit proefschrift is beschreven. 
Heterogeniteit van acute leukemie
Er zijn zeer veel verschillende acute leukemiën beschreven die zich onderscheiden op basis 
van hun morfologische, cytogenetische, moleculaire en flowcytometrische kenmerken; 
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geen enkele leukemie is daardoor hetzelfde. Voor de verschillende typen acute leukemie 
zijn verschillende behandelingen noodzakelijk. Een acute leukemie met bepaalde slecht 
prognostische afwijkingen moet bij voorkeur een intensievere behandeling krijgen inclusief 
een stamceltransplantatie. Waarschijnlijk zal in de toekomst de behandeling meer worden 
toegespitst op de individuele patiënt. 
Gemengd fenotype
Myeloïde en lymfatische leukemiecellen onderscheiden zich onder andere wat betreft 
verschillende eiwitten aan de buitenkant (celmembraan) en in de cel (cytoplasma). 
Deze verschillen kunnen in kaart worden gebracht met behulp van flowcytometrie. Het 
Figuur 3. Diagnostiek van acute leukemie. Bij het bepalen van het type acute leukemie wordt gekeken 
naar het uiterlijk van de cel onder de microscoop (morfologie), naar veranderingen in de chromosomen 
(cytogenetica) en afwijkingen in de opmaak van de celmembraan van de leukemiecel (flowcytometrie).
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onderscheid tussen een myeloïde of een lymfatische leukemiecel is zeer belangrijk omdat 
het de behandeling en de keuze van chemotherapie bepaalt. Op een acute myeloïde 
leukemie wordt regelmatig expressie van een lymfatisch  membraaneiwit gevonden. In 
sommige gevallen heeft de leukemische cel evenveel myeloïde als lymfatische kenmerken; 
het is dan onduidelijk of de leukemie een myeloïde of lymfatische oorsprong kent/heeft; in 
die gevallen wordt er gesproken van een acute leukemie met een gemengd fenotype. 
Beschrijving deel I van dit proefschrift
In deel I van dit proefschrift wordt de diagnostiek van leukemische cellen met een gemengd 
fenotype beschreven. Hoofdstuk 1 en 2 vormen een inleiding op het gehele proefschrift en 
op deel I van dit proefschrift. Met behulp van een flowcytometer kan van elke afzonderlijk cel 
worden bekeken welke eiwitten zich op het celmembraan bevinden; dit heet het fenotype 
van de cel. Daarnaast worden de eiwitten vergeleken die op een leukemische cel zitten met 
de genetische opmaak van de cel.
In hoofdstuk 3 worden de casus van twee patiënten beschreven met een bijzondere 
fenotypische opmaak van de leukemische cellen. De eerste patiënt presenteerde zich in 
eerste instantie met een acute lymfatische leukemie. Na chemotherapie ontstond er binnen 
2 jaar een recidief. De cytogenetica liet dezelfde complexe afwijkingen zien als bij diagnose. 
Het fenotype was echter totaal veranderd; er was nu sprake van een myeloïde leukemie. 
De tweede casus laat een volgens de morfologie typisch myeloïde leukemie zien, echter bij 
flowcytometrische analyse werd een lymfatische opmaak gevonden. Beide casus laten de 
belangrijke rol van flowcytometrie zien bij de diagnostiek van acute leukemiën. 
In hoofdstuk 4 zijn twee verschillende classificatiesystemen (de WHO2001 en de WHO2008) 
voor acute leukemiën met een gemengd fenotype met elkaar vergeleken. De aanpassing 
van het scoringssysteem heeft tot gevolg dat de diagnose van de leukemie (lymfatische, 
myeloide of gemengd fenotype) zou veranderen bij 30 van de 517 patiënten.
In hoofdstuk 5 worden de resultaten vergeleken van de morfologische kleuring Sudan black B 
met de flowcytometrische kleuring voor myeloperoxidase in 198 patiënten. Beide kleuringen 
tonen de aan- of afwezigheid  aan van het eiwit myeloperoxidase in de cel, de resultaten van 
de kleuring kunnen echter verschillen. Myeloperoxidase is de gouden standaard voor het 
aantonen van de myeloïde herkomst van de cel en daarom zeer belangrijk in de diagnostiek. 
De morfologie en de flowcytometrie gebruiken een andere drempel om een leukemie 
positief te noemen voor dit eiwit. Indien bij 10% van de leukemische cellen MPO positiviteit 
wordt gevonden met flowcytometrie, dan kan de acute leukemie als myeloperoxidase 
positief worden beschouwd. 
In hoofdstuk 6 wordt het genetische profiel (door middel van micro-RNA analyse) van 17 
patiënten met een acute leukemie met een gemengd fenotype onderzocht. Dit hoofdstuk 
laat zien dat er ongeacht de fenotypisch gemengde opmaak van de leukemische cellen 
een duidelijk lymfatische of myeloïde genetische opmaak bestaat. Onderzoek van de 
genetische opmaak van een acute leukemie met een gemengd fenotype kan op deze manier 
bijdragen om te bepalen of er sprake is van een myeloïde of lymfatische leukemie. De 
genetische analyse kan op deze manier helpen in het bepalen van de keuze van het juiste 
chemotherapieprotocol. 
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DEEL II: Het immuunsysteem en AML
Het afweersysteem in een notendop
De cellen van het afweersysteem beschermen de mens tegen bacteriën, virussen, parasieten 
en maligne cellen. Om goed te functioneren moeten de afweercellen onderscheid kunnen 
maken tussen “lichaamseigen” en “lichaamsvreemd”.  Evenals bacteriën en virussen zijn de 
cellen in het lichaam opgebouwd uit (onder andere) eiwitten; het DNA in de cel bepaalt hoe 
de eiwitten van de cel eruit zien. De eiwitten waaruit virussen en bacteriën zijn opgebouwd 
zijn anders (lichaamsvreemd) dan die van de menselijke cel (lichaamseigen). Ook een 
leukemiecel heeft, door veranderingen in het DNA, eiwitten die in gezonde cellen niet 
worden gevonden. Deze lichaamsvreemde eiwitcombinaties worden antigenen genoemd en 
het afweersysteem is in staat om een afweerreactie tegen deze antigenen te initiëren en 
bacteriën en virussen of maligne cellen op te ruimen. 
De cellen die verantwoordelijk zijn voor de aangeboren afweer vormen het grove geschut en 
herkennen “lichaamsvreemde ziekteverwekkers” op een aspecifieke manier. Myeloïde cellen 
die hiertoe behoren zijn de neutrofiele granulocyten en macrofagen, deze cellen herkennen 
ziektemakers zoals virussen en bacteriën via speciale receptoren. Deze receptoren herkennen 
Figuur 4. Antigeenspecifieke herkenning van AML cellen door leukemie-specifieke cytotoxische 
T-cellen. AML cellen presenteren verschillende eiwitten in het HLA-klasse I molecuul. Deze 
gepresenteerde eiwitten vormen een afspiegeling van de eiwitten die in de cel worden gevonden. Een 
AML cel zal zo leukemie-specifieke eiwitten presenteren die niet worden gevonden in normale cellen. 
De Cytotoxische T-cel herkent leukemie-specifieke eiwitten, ook wel antigenen genoemd (◊, ∆en ●). 
De antigenen worden gepresenteerd in het HLA-klasse I molecuul (I). De thymus zorgt ervoor dat er 
alleen T-cellen  bestaan die lichaamsvreemde eiwitten herkennen, T-cellen die lichaamseigen eiwitten 
herkennen worden in de thymus verwijderd.
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onderdelen van de virussen of bacteriën die veel voorkomen en zorgen er vervolgens voor 
dat deze worden opgeruimd. 
De cellen van de verworven afweer herkennen “lichaamsvreemd materiaal” op een specifieke 
manier en zijn verantwoordelijk voor een precisie-aanval. Daarnaast zijn zij verantwoordelijk 
voor het ontstaan van “geheugen”: op het moment dat een patiënt opnieuw te maken 
krijgt met dezelfde ziekteverwekker zal er direct een efficiënte immuunrespons ontstaan 
en wordt voorkomen dat een patiënt een tweede keer ziek wordt. Deze afweercellen heten 
lymfocyten: B-, T- en Natural Killer lymfocyten. 
Er zijn meerdere typen T-cellen te onderscheiden waaronder cytotoxische T-cellen en 
T-helper cellen. Cytotoxische T-cellen zijn in staat om geïnfecteerde cellen en leukemiecellen 
direct op te ruimen. Hierbij worden ze ondersteund en geactiveerd door  T-helper cellen.
De afweerreactie door antigeen-specifieke T-cellen 
Voor efficiënte herkenning door de T-cellen zorgen alle cellen in het menselijk lichaam 
ervoor dat zij een afspiegeling van alle eiwitten in de cel presenteren op de celmembraan 
aan de T-cellen. Hiertoe worden kleine stukjes van de eiwitten in de cel gepresenteerd op 
de celmembraan in zogenaamde HLA-klasse I moleculen. Een virusgeïnfecteerde cel zal zo 
bijvoorbeeld stukjes viruseiwit (antigenen) presenteren op het HLA-klasse I molecuul.  Ook 
leukemiecellen presenteren stukjes leukemie-specifieke antigenen in het HLA-molecuul. 
T-cellen die dit stukje virus- of leukemie-eiwit herkennen zullen vervolgens de geïnfecteerde 
cel opruimen. 
T-cellen ontstaan uit de oorspronkelijke hematopoëtische stamcel in het beenmerg. 
Vervolgens verhuizen de jonge, voorloper T-cellen naar de thymus (zwezerik) waar alleen 
Figuur 5. Samenspel van lymfocyten en dendritische cellen (DC). De DC activeert de T-helper cel en 
de cytotoxische T-cel. De naïeve T-helper cel groeit uit tot een effector T-helper cel. De T-helper cel 
activeert vervolgens de DC en helpt bij activatie van de  cytotoxische T-cel.
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die T-cellen worden geselecteerd die een lichaamsvreemd eiwit herkennen. T-cellen die 
lichaamseigen eiwitten herkennen worden in de thymus verwijderd en op deze manier 
wordt er een afweerreactie tegen lichaamseigen eiwitten voorkomen. Elke T-cel die de 
thymus passeert kan maar één specifiek lichaamsvreemd eiwit herkennen, er zijn miljoenen 
verschillende T-cellen die elk specifiek zijn voor een ander eiwit (zie figuur 4). 
Er zijn verschillende leukemie-specifieke eiwitten (leukemie-geassocieerde antigenen, LAA) 
bekend. Deze stukjes eiwit worden voornamelijk gevonden in leukemische cellen en niet 
in gezonde cellen.
Activatie van T-cellen door antigeenpresenterende cellen
Bovenstaande suggereert dat ons lichaam in staat is om leukemiecellen te herkennen en op 
te ruimen. Tumorcellen of geïnfecteerde cellen zijn echter niet goed uitgerust om T-cellen 
te activeren, hiervoor zijn professionele antigeen presenterende cellen noodzakelijk. Een 
voorbeeld van een antigeen presenterende cel is de dendritische cel (DC). De DC herkent 
bacteriën, geïnfecteerde of maligne cellen en neemt vervolgens de hele cel (of stukjes 
hiervan) in zich op en presenteert de eiwitten in HLA-klasse I moleculen aan T -cellen. 
Als bijvoorbeeld een leukemie-specifieke T-cel het gepresenteerde antigeen herkent zal 
deze worden geactiveerd en gaat de T-cel zich delen. Op deze manier ontstaat er een leger 
aan geactiveerde T-cellen dat maligne cellen herkent en op kan ruimen. Ook worden na 
activatie geheugen-T-cellen gevormd, deze memory T-cellen zijn in staat om bij een volgend 
contact  met hetzelfde antigeen een efficiënte immuunrespons te bewerkstelligen en zo 
te voorkomen dat een patiënt opnieuw ziek wordt.  Het samenspel tussen de DC en de 
verschillende T-cellen is weergegeven in figuur 5. 
Ontsnappen aan het immuunsysteem: CLIP expressie op AML cellen.
Presentatie van antigenen op HLA moleculen is een complex proces waarin vele verschillende 
moleculen en processen in verschillende compartimenten van de cel zijn betrokken, 
in figuur 6 staat dit proces vereenvoudigd weergegeven. Een belangrijk verschil tussen 
T-helper  en cytotoxische T-cellen is dat T-helper cellen antigeen herkennen gepresenteerd 
in HLA klasse II en cytotoxische T-cellen antigenen gepresenteerd in HLA klasse I. 
Leukemische cellen proberen op verschillende wijze de antigeenpresentatie op HLA klasse 
I en II minder optimaal te laten verlopen en daarmee te ontsnappen aan herkenning door 
T-cellen: “immuunescape”. Een voorbeeld van een dergelijk immuunescape-mechanisme 
is de expressie van CLIP op leukemische cellen. In het proces van antigeenpresentatie op 
HLA klasse II wordt normaal gesproken het eiwit CLIP uitgewisseld voor een te presenteren 
antigeen. Gebeurt dit niet dan zal CLIP aanwezig blijven in het HLA molecuul; dit voorkomt 
dat de cel wordt herkend door de T-helper cel (figuur 6A). 
Op gezonde cellen wordt ook CLIP expressie gevonden, hiermee wordt voorkomen dat het 
immuunsysteem geoveractiveerd wordt en zorgt CLIP expressie voor een evenwichtige 
immuunrespons. In het geval van leukemie gebruikt de leukemische cel CLIP om te 
ontsnappen aan het immuunsysteem, er wordt veel CLIP gepresenteerd in plaats van 
leukemie-specifieke antigenen. Het gevolg is dat T-helper cellen niet worden geactiveerd 
en er een suboptimale antileukemische immuunrespons plaatsvindt (figuur 6A). Indien 
CLIP wel wordt uitgewisseld voor een antigeen zal de T-helpercel worden geactiveerd en 
zal er een antileukemische immuunrespons plaats kunnen vinden (figuur 6B)
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Figuur 6 De rol van CLIP in antigeenpresentatie door antigeenpresenterende cellen. In het proces van 
antigeenpresentatie op HLA klasse II moet het molecuul CLIP uitgewisseld worden met een antigeen 
(een eiwit in de cel specifiek voor de leukemische cel, B). Gebeurt dit niet, dan kan de T-helpercel 
(rood) cel niet worden geactiveerd en kan de cytotoxische T-cel niet optimaal zijn functie uitvoeren (A). 
Hierdoor zullen AML cellen (groen) niet goed worden herkend. 
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Beschrijving deel II van dit proefschrift
Presentatie van CLIP door leukemische cellen wordt bediscussieerd in deel 2 van dit 
proefschrift. De aanwezigheid van CLIP op een leukemische cel kan bestudeerd worden met 
behulp van flowcytometrie. Hoofdstuk 8 laat zien dat de aanwezigheid van CLIP op residuale 
leukemische cellen een minder gunstige prognose oplevert. In de meeste patiënten is maar 
een deel van de cellen positief voor CLIP, het andere deel brengt CLIP niet tot expressie; in 
hoofdstuk 9 wordt beschreven dat de CLIP+ fractie van leukemische cellen niet in staat is om 
T-helper cellen te activeren, terwijl CLIP- cellen van dezelfde patiënt dit wel goed kunnen. 
DEEL III: immuuntherapie
Immuuntherapie richt zich op het induceren van een afweerreactie tegen residuale 
tumorcellen welke ontsnapt zijn aan chemotherapie en later kunnen zorgen voor een recidief 
van de leukemie (figuur 7). Hoofdstuk 10 vormt de inleiding van deel III van het proefschrift.
Immuuntherapie met leukemie-specifieke T-cellen
Door de acute leukemie wordt de uitrijping van gezonde normale bloedcellen verdrongen 
en is het immuunsysteem minder functioneel. Daarnaast heeft chemotherapie een negatief 
effect op de gezonde cellen van het immuunsysteem. Immuuntherapie kan bestaan uit 
het toedienen van leukemie-specifieke T-cellen. De behandeling met leukemie-specifieke 
T-cellen heeft effect zolang de levensduur van de cellen duurt. Het voordeel is dat de 
T-cellen hun functie kunnen uitoefenen zonder hulp van andere immuuncellen. Hoofdstuk 
11 laat zien dat leukemie-specifieke T-cellen AML cellen kunnen herkennen en opruimen. 
Cytotoxische T-cellen die een leukemie-specifiek antigeen herkennen kunnen worden 
geïsoleerd bij leukemiepatiënten of gekweekt in het laboratorium uit naïeve T-cellen. Een 
T-celkloon is een verzameling van identieke T-cellen die allen hetzelfde antigeen herkennen 
in context van het HLA molecuul. Voor het isoleren van de leukemie-specifieke T-cellen wordt 
in het laboratorium gebruik gemaakt van een flowcytometer. Daarna worden de leukemie-
specifieke T-cellen geëxpandeerd in het laboratorium. Deze techniek wordt toegepast in 
hoofdstuk 11 van dit proefschrift. 
Immuuntherapie met DC vaccins.  
Een andere vorm van immuuntherapie is vaccinatie; hierbij wordt geprobeerd om een 
cytotoxische T-cel- en memory T-celreactie te induceren. Voor vaccinatie is het belangrijk dat 
alle immuuncellen hun werk goed kunnen doen en dat er een goede T-cel respons kan worden 
opgewekt in het lichaam van de patiënt. Vaccinatie kan daarom pas worden toegepast als de 
patiënt in complete remissie is en helemaal is hersteld van de chemotherapie. 
Een vorm van vaccinatie bij leukemie zijn DC-vaccins. Deze DC kunnen worden verkregen uit 
gezonde DC-voorlopers uit het bloed van de patiënt. Een andere optie is om de leukemiecel in 
het laboratorium te kweken tot een AML-afgeleide DC (AML-DC) met behulp van een cocktail 
van verschillende hulpstoffen. Een probleem bij het huidige protocol om leukemische DC te 
maken is dat er vaak te weinig leukemische DC worden verkregen. Hoofdstuk 12 laat zien dat 
met een combinatie van verschillende hulpstoffen eerst het aantal leukemische cellen kan 
worden vergroot en dat de geëxpandeerde cellen vervolgens kunnen worden gekweekt tot 
een antigeen presenterende cel. 
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Bij het gebruik van gezonde DC als vaccin moeten de DC worden beladen met leukemie-
specifieke antigenen (figuur 8). Dit kan door de DC verschillende preparaten aan te bieden 
met daarin leukemie-specifiek antigeen. Een voorbeeld van een dergelijke werkwijze is het 
lyseren van leukemische cellen. Lyseren gebeurt door cellen afwisselend op 42˚C en -80˚C te 
brengen. De cel valt zo uiteen en er blijven kleine fragmenten van de cel over. Hierin zitten 
normale eiwitten maar ook eiwitten specifiek voor de leukemische cel. In het laboratorium 
worden de DC en het lysaat samengevoegd en zal de DC het lysaat opnemen en verwerken. 
Hierna zal de DC de antigenen in het HLA-molecuul kunnen presenteren aan de T-cellen. 
Het principe van dendritische celvaccinatie staat weergegeven in figuur 8.
Het maken van een DC vaccin wordt beschreven in hoofdstuk 13, 14 en 15 van dit 
proefschrift. Er worden verschillende strategieën met elkaar vergeleken en deze 
hoofdstukken laten zien dat lysaten maar ook cellen die in het proces van “dood gaan” 
zitten, zogenaamde apoptotische cellen, geschikt zijn als antigeenbron voor belading 
op een DC. In het geheel van apoptotische celmateriaal kunnen ook weer verschillende 
fracties worden onderscheiden. Hier wordt verder op in gegaan in hoofdstuk 15. Daarnaast 
kunnen er allerlei hulpstoffen worden gebruikt om de belading efficiënter te laten verlopen, 
in hoofdstuk 14 worden verschillende van deze  cocktails onderzocht. Er zijn zeer veel 
variaties mogelijk in de bereiding van DC vaccins. In de differentiatie van monocyten 
Figuur 7. Recidief en residuale ziekte na behandeling. Residuale leukemische cellen (A) kunnen na 
behandeling uitgroeien en een recidief van de leukemie veroorzaken (C). Indien alle leukemische 
cellen worden geëlimineerd na behandeling is een patiënt genezen (B). Immuuntherapie richt zich op 
eliminatie van residuale leukemische cellen om zo een recidief te voorkomen.
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tot DC kunnen verschillende cocktails van hulpstoffen worden gebruikt. En ook in het 
bereiden van leukemische cellen tot antigeenbron voor belading op DC kunnen zeer veel 
variaties worden aangebracht. Daarnaast kan tijdens de belading van DC gebruik worden 
gemaakt van weer andere hulpstoffen om de belading efficiënter te kunnen laten verlopen. 
In alle wetenschappelijke artikelen die tot nu toe hierover zijn gepubliceerd worden 
veel verschillende bereidingsstrategieën gebruikt; dit maakt het vergelijken van deze 
verschillende studies zeer ingewikkeld.  Er zijn daarom grotere studies nodig waar deze 
verschillende strategieën worden vergeleken. 
Figuur 8. Het principe van dendritische cel (DC) vaccinatie. Voorloper cellen van de DC  worden 
geïsoleerd uit het bloed. Vervolgens worden deze gekweekt in het laboratorium tot DC. De DC 
worden beladen met antigeen. Dit kan worden verkregen uit leukemische cellen door het induceren 
van celdood gereguleerd door de cel zelf (apoptose) of het direct kapot maken van de cel (lyseren). 
Dit materiaal wordt daarna aangeboden aan de DC, de DC neemt het materiaal op en verwerkt 
het en presenteert de antigenen op de MHC klasse I en II moleculen. Deze DC kunnen vervolgens 
teruggegeven worden aan de patiënt: vaccinatie. Nadat het vaccin is toegediend migreren de DC naar 
de lymfklieren waar zij naïeve T-cellen kunnen activeren.
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Conclusie
Bij acute leukemiën is het belangrijk of deze een myeloïde of lymfatische behandeling 
moeten krijgen;  deel I van het proefschrift laat zien dat onderzoek naar genetische 
kenmerken kan helpen in het onderscheiden van de myeloïde of lymfatische oorsprong van 
een acute leukemie
Naast verbetering van diagnostiek en het in kaart brengen van de verschillende 
eigenschappen van de cel is het belangrijk om de verschillende eigenschappen van de cel 
te begrijpen. Het beter begrijpen van verschillende immuunescape mechanismen van de 
leukemische cellen kan helpen bij het ontwikkelen van nieuwe immuuntherapeutische 
strategieën. In deel II van dit proefschrift wordt beschreven dat leukemische cellen het CLIP-
eiwit gebruiken om te ontsnappen aan herkenning door T-cellen. CLIP expressie kan in het 
laboratorium worden beïnvloed door allerlei hulpstoffen en medicijnen. In deel III worden 
verschillende immuuntherapeutische behandelingsstrategieën besproken. Een probleem 
bij het ontwikkelen van nieuwe (immuun-) therapeutische strategieën is de heterogeniteit 
van leukemie, elke leukemie is anders en zelfs binnen één patiënt worden veel variaties 
gevonden in de leukemische cellen. Verschillende leukemiën hebben daarom verschillende 
behandelingen nodig. Aan de andere kant zijn er grote homogene patiënten groepen 
nodig om het effect van verschillende behandelingen met elkaar te kunnen vergelijken. Dit 
contrast maakt het ontwikkelen van nieuwe therapeutische strategieën ingewikkeld. In de 
toekomst zal mogelijk met een op maat gemaakt vaccin worden voorkomen dat residuale 
leukemische cellen na behandeling uitgroeien en een recidief veroorzaken. 
Samenvatting
DEEL I: diagnostiek van leukemie
- Leukemie is een ziekte van de witte bloedcellen. Acute myeloïde leukemie 
(AML) ontstaat uit de myeloïde voorlopercel, acute lymfatische leukemie uit de 
lymfatische voorlopercel. 
- Door leukemie wordt de uitrijping van gezonde cellen verdrongen en ontstaat er 
een tekort aan witte en rode bloedcellen en bloedplaatjes (figuur 1). 
- Diagnostiek van AML gebeurt door naar uiterlijke kenmerken te kijken onder de 
microscoop (morfologie), genetische afwijkingen en fenotypische afwijkingen in de 
eiwitten in de celmembraan en in de cel (flowcytometrie) (figuur 3). 
- Met behulp van flowcytometrie kunnen de verschillende eiwitten in en op de cel 
van elke afzonderlijke cel in kaart worden gebracht. Met behulp van flowcytometrie 
kan er worden gedifferentieerd tussen myeloïde leukemie en lymfatische leukemie. 
- In sommige gevallen heeft de leukemische cel evenveel lymfatische als myeloïde 
kenmerken, in dat geval spreekt men van een acute leukemie met een gemengd 
fenotype.
- Elke leukemie is anders en ook binnen één patiënt hebben leukemische cellen 
verschillende eigenschappen: dit wordt heterogeniteit van acute leukemie 
genoemd. 
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DEEL II: Het immuunsysteem en AML
- De cellen van het immuunsysteem beschermen de mens tegen bacteriën, virussen, 
parasieten en maligne cellen. 
- De cellen van het immuunsysteem worden zodanig gevormd dat zij onderscheid 
kunnen maken tussen lichaamsvreemd (zoals bacteriën, virusgeïnfecteerde en 
maligne cellen) en lichaamseigen (gezonde cellen) materiaal.
- De immuuncellen kunnen worden verdeeld in de myeloïde en de lymfatische cellen. 
- De myeloïde cellen zijn verantwoordelijk voor de aangeboren afweer en herkennen 
“lichaamsvreemde ziekteverwekkers” op een aspecifieke manier, hiertoe behoren 
onder andere de macrofagen.
- De lymfatische cellen zijn verantwoordelijk voor de verworven afweer en het 
herkennen van “lichaamsvreemd materiaal” op een specifieke manier, hiertoe 
behoren de T-cellen.
- Cytotoxische T-cellen herkennen lichaamsvreemde eiwitten (antigenen) met hun 
T-cel receptor als stukjes hiervan worden gepresenteerd door een geïnfecteerde 
cel of tumorcel in het HLA molecuul. Elke cel van het menselijk lichaam laat een 
afspiegeling zien van alle eiwitten in de cel in het HLA-molecuul op het celmembraan 
(figuur 4).
- T-helper cellen zijn noodzakelijk voor een goede functie van cytotoxische T-cellen 
(figuur 5). 
- Leukemie cellen zijn slecht in staat om T-cellen te activeren. Dendritische cellen 
(DC) daarentegen kunnen  leukemiecellen herkennen en de leukemische antigenen 
efficiënt presenteren aan de T-cellen.  
- Expressie van CLIP door leukemische cellen zorgt ervoor dat T-helper cellen niet 
meer kunnen worden geactiveerd en dat vervolgens de cytotoxische T-celrespons 
suboptimaal verloopt. Dit is een immuun-escape mechanisme van de leukemische 
cel (figuur 6). 
DEEL III: immuuntherapie bij AML. 
- Immuuntherapie richt zich op het induceren van een immuunrespons tegen 
residuale leukemiecellen welke ontsnapt zijn aan chemotherapie en later kunnen 
zorgen voor een recidief van de leukemie (figuur 7)
- Bij actieve immuuntherapie probeert men een T-cel respons te induceren tegen de 
leukemie cellen, dit kan met behulp van DC vaccinatie. 
- Gezonde voorlopers van DC kunnen worden verkregen uit het bloed van een 
patiënt of donor. Deze cellen kunnen worden gekweekt tot DC in het laboratorium. 
Vervolgens wordt het vaccin teruggeven aan de patiënt (figuur 8)
- De DC moeten daarvoor worden beladen met antigeen: de DC neemt het antigeen 
op, verwerkt het en presenteert dit op zijn HLA molecuul. Als er een exacte match 
is met de T-cel receptor van een naïeve T-cel zal de T-cel worden geactiveerd en zal 
de T-cel uitgroeien tot een leukemie-specifieke T-cel kloon. 
- Uiteindelijk kan er zo een persoonlijk vaccin ontwikkeld worden voor de individuele 
patiënt. 
